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Checklists and Illustrative Financial Statements for Health Care Entities

FSP Section 11,000
Checklists and Illustrative Financial
Statements for Health Care Entities
Letter to Customers
Dear Valued Customer,
The following checklists and illustrative materials have been developed by the AICPA Accounting and
Auditing Publications Staff to serve as nonauthoritative practice aids for use by preparers of financial
statements and by practitioners who audit, review, or compile financial statements. The auditor’s and
accountant’s report checklists address those requirements most likely to be encountered when reporting on financial statements of a commercial corporation prepared in conformity with U.S. generally
accepted accounting principles.
Relevant financial statement reporting and disclosure guidance issued through September 30, 2009, has
been considered in the development of this edition of the checklist. The accounting guidance in this
checklist has been conformed to reflect reference to FASB Accounting Standards Codificatione as it existed on September 30, 2009.
Any guidance issued subsequent to September 30, 2009, has not been included in this checklist; therefore, if your entity has a fiscal year-end after September 30, 2009, you need to consider the applicability
of such guidance. In determining the applicability of newly issued guidance, its effective date also
should be considered.
Recognizing that many entities have December 31 year-ends and in an effort to assist those users, this
checklist includes guidance issued through September 30, 2009, which may become effective by December 31, 2009. This guidance is discussed in each section of the checklist when applicable. Additional
questions appear and are indicated with an “A” or “B” reference. As determined by the effective date
or early implementation decision
●

entities for which this guidance has not been implemented should consider all questions with
an “A” reference (for example, question 1A, question 2A, and so on) and should place an “N/
A” mark by questions with a “B” reference.

●

entities for which this guidance has been implemented should consider all questions with a
“B” reference (for example, question 1B, question 2B, and so on) and should place an “N/A”
mark by questions with an “A” reference.

Therefore, based upon the year-end of the entities and the decision to early implement (if allowed), the
appropriate additional questions should be answered when provided.
We hope you find this checklist helpful as you perform your audit and compilation and review engagements. We would greatly appreciate your feedback on this checklist. You may e-mail these comments to A&APublications@aicpa.org or write to
A&A Publications
AICPA
220 Leigh Farm Road
Durham, NC 27707-8110

FSP §11,000
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Description
.01 Health care entities may be classified by sponsorship or legal structure within the following broad
categories:
Not-for-profit business-oriented. These are essentially self-sustaining from fees charged for goods and services.
The fees charged by such entities generally are intended to help the entity maintain its self-sustaining status
rather than to maximize profits for the owner’s benefit. Such entities often are exempt from federal income
taxes and may receive contributions of relatively small amounts from resource providers that do not expect
commensurate or proportionate pecuniary returns.
Not-for-profit nonbusiness-oriented. These are voluntary health and welfare entities as defined in Financial
Accounting Standards Board (FASB) Statement No. 117, Financial Statements of Not-for-Profit Organizations.
Such entities are within the scope of AICPA Audit and Accounting Guide Not-for-Profit Entities, rather than
that of Audit and Accounting Guide Health Care Entities.
Governmental. Often called public health care entities, the entities are owned and operated by federal, state,
city, or county governments or other political subdivisions.
Investor- (or operator-) owned. These entities operate as stock corporations, partnerships, or sole proprietorships.
.02 Health care entities include, but are not limited to, the following:
●

Clinics, medical group practices, individual practitioners and practice associations, and other
ambulatory care entities

●

Continuing care retirement communities

●

Health maintenance organizations and similar prepaid health care plans

●

Home health agencies

●

Hospitals

●

Nursing homes that provide skilled, intermediate, and less intensive levels of health care

●

Parent companies, holding companies, and other entities that primarily plan, organize, and
oversee health care services

Applicability of These Checklists
.03 These checklists, and the illustrative financial statements included herein, follow the guidance contained in AICPA Audit and Accounting Guide Health Care Entities (with conforming changes as of August
1, 2009), referred to as “the guide.” These checklists and illustrative financial statements should be used for
not-for-profit business-oriented and investor-owned health care entities. These checklists do not apply to not-forprofit nonbusiness-oriented health care entities. For these types of entities, follow the guidance in AICPA Audit
and Accounting Guide Not-for-Profit Entities and the AICPA’s Checklists and Illustrative Financial Statements Not-for-Profit Entities.
.04 Not-for-profit health care providers that receive federal financial assistance may be required to have
an audit conducted in accordance with Office of Management and Budget (OMB) Circular A-133, Audits of
States, Local Governments, and Non-Profit Organizations. FSP section 11,300 includes guidance for auditors’
reports for audits performed under OMB Circular A-133.
.05 Although the guide also applies to state and local government-owned health care providers, these
checklists do not include disclosures or sample financial statements of government-owned providers. Chapter
1 of the guide discusses the application of generally accepted accounting principles (GAAP) to governmental
health care providers.

FSP §11,000.01
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Legislation and Regulation
.06 Significant aspects of health care entity operations are affected by government legislation and regulation with many states adopting laws governing the granting of licenses, as well as scope of services to be
rendered. In addition, many independent entities and governmental agencies, including Medicare and Medicaid, evaluate programs and services of health care entities to determine compliance with set standards.

Basic Financial Statements
.07 The financial reporting for not-for-profit business-oriented entities and investor-owned health care
enterprises generally is consistent except for transactions that clearly are not applicable. For example, notfor-profit business-oriented entities, by their nature, do not have shareholders’ equity. On the other hand,
investor-owned health care enterprises typically do not receive contributions.
.08 The basic financial statements of health care providers generally consist of a statement of financial
position or balance sheet, a statement of activities or income statement or statement of operations, a statement of changes in net assets (equity), a statement of cash flows, and notes to the financial statements. The
titles of the financial statements will depend upon the business form of the provider (that is, not-for-profit
and investor-owned). See the following chart:
Basic Financial Statements
Not-for-Profit
Business-Oriented Entity

Investor-Owned Entity

Balance Sheet/Statement of Financial Position

Balance Sheet

Statement of Operations/Statement of Activities

Statement of Operations/Income Statement

Statement of Changes in Net Assets

Statement of Changes in Equity

Statement of Cash Flows

Statement of Cash Flows

General
.09 This publication includes the following information:
●

Financial Statements and Notes Checklist (FSP section 11,100)—For use by preparers of financial statements and by practitioners who audit or compile them as they evaluate the adequacy
of disclosures.

●

Auditors’ Reports Checklist (FSP section 11,200)—For use by auditors in reporting on audited
financial statements.

●

Auditors’ Reports Checklist for Audits Performed in Accordance With Government Auditing
Standards and OMB Circular A-133 (FSP section 11,300).

●

Illustrative Financial Statement Formats (FSP section 11,400)—Formats commonly used to
present financial statements for both not-for-profit business-oriented and investor-owned health care
entities.

.10 This checklist is intended to be used in connection with engagements of nonpublic entities and is
not intended to be used in connection with audits of public entities that are required to be audited under
standards set by the Public Company Accounting Oversight Board (PCAOB).
.11 These checklists are applicable to not-for-profit business-oriented and investor-owned health care entities.
Although financial reporting for these types of entities is generally consistent, there are requirements that
apply to only not-for-profit business-oriented entities and those that apply to only investor-owned enterprises. Symbols have been used to indicate the applicability of presentation and disclosure requirements to

FSP §11,000.11
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these types of entities. Not-for-profit business-oriented entities should complete all disclosure items denoted
with a star (.). Investor-owned entities should complete all disclosure items denoted with a diamond (l).
.12 These checklists and illustrative materials have been developed by the AICPA Accounting and Auditing Publications staff to serve as nonauthoritative practice aids for use by preparers of financial statements and by practitioners who audit or compile them. The auditor’s and accountant’s report checklists
address those requirements most likely to be encountered when reporting on financial statements of a notfor-profit business-oriented and investor-owned health care entity prepared in conformity with U.S. GAAP. They
do not include reporting requirements relating to other matters such as internal control or agreed-upon
procedures. The financial statement and notes checklist includes disclosure considerations applicable to notfor-profit business-oriented and investor-owned health care entities in preparing financial statements in conformity with U.S. GAAP.
.13 Users of the financial statements and notes checklist should remember that it is a disclosure checklist
only and not a comprehensive U.S. GAAP application or measurement checklist. Accordingly, application
and measurement issues related to preparing financial statements in conformity with U.S. GAAP are not
included in the checklist.
.14 The checklists and illustrative financial statements should be used by, or under the supervision of,
persons having adequate technical training and proficiency in the application of U.S. GAAP, generally accepted auditing standards, and other relevant technical guidance.
.15 In some cases, this checklist uses the term common practice or provides additional practice tips to
describe a disclosure item. In such cases, although there is no authoritative guidance to support such a
disclosure for nonpublic entities, it has become a common practice (sometimes due to Securities and
Exchange Commission [SEC] requirements) that such disclosures are made. Entities should evaluate
whether such items warrant disclosure in their financial statements.
.16 Relevant financial statement reporting and disclosure guidance issued through September 30, 2009,
has been considered in the development of this edition of the checklist. This includes relevant guidance
issued up to and including the following:
●

FASB Accounting Standards Updates issued through September 30, 2009

●

Statement on Auditing Standards No. 116, Interim Financial Information (AICPA, Professional
Standards, vol. 1, AU sec. 722)

●

Interpretation No. 19, “Financial Statements Prepared in Conformity With International Financial Reporting Standards as Issued by the International Accounting Standards Board,”
of AU section 508, Reports on Audited Financial Statements (AICPA, Professional Standards, vol.
1, AU sec. 9508 par. .93–.97)

●

Statement of Position 09-1, Performing Agreed-Upon Procedures Engagements That Address the
Completeness, Accuracy, or Consistency of XBRL-Tagged Data (AICPA, Technical Practice Aids,
AUD sec. 14,440)

●

Statements on Standards for Attestation Engagements No. 15, An Examination of an Entity’s
Internal Control Over Financial Reporting That Is Integrated With an Audit of Its Financial Statements (AICPA, Professional Standards, vol. 1, AT sec. 501)

●

Interpretation No. 7, “Reporting on the Design of Internal Control,” of AT section 101, Attest
Engagements (AICPA, Professional Standards, vol. 1, AT sec. 9101 par. .59–.69)

●

PCAOB Auditing Standard No. 6, Evaluating Consistency of Financial Statements (AICPA,
PCAOB Standards and Related Rules, Auditing Standards)

.17 Any guidance issued subsequent to September 30, 2009, has not been included in this checklist;
therefore, if your entity has a fiscal year-end after September 30, 2009, you need to consider the applicability
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of such guidance. In determining the applicability of newly issued guidance, its effective date should also
be considered.
.18 Recognizing that many entities have December 31 year-ends and in an effort to assist those users,
questions are also included in this checklist if the guidance was issued on or before September 30, 2009, and
will become effective for entities with fiscal year-ends on or before December 31, 2009.
.19 Because such questions may not be applicable for September 30, 2009, year-ends, they are separately
identified with an “A” or “B” designation in the checklist (for example, question 1A and question 1B).
Throughout the checklist information is presented to assist entities in making decisions, based on a consideration of the effective date of the guidance or early implementation decision made by the entity, as to which
questions are applicable, ensuring that the appropriate additional questions are answered when provided.
.20 These checklists contain numerous references to authoritative accounting and auditing guidance.
Abbreviations and acronyms used in such references include the following:
AAG-NPO5

AICPA Audit and Accounting Guide Not-for-Profit Entities (with conforming
changes as of May 1, 2009)

APB5

Accounting Principles Board Opinion

AU5

Reference to a section number in AICPA Professional Standards for U.S. auditing standards that are applicable to nonissuers

AUD5

Reference to a section number in AICPA Technical Practice Aids, Statements of
Position—Auditing and Attestation

EITF5

FASB Emerging Issues Task Force consensus

FASB ASC5

Reference to a topic, subtopic, section, or paragraph in Financial Accounting
Standards Board Accounting Standards Codificatione

PCAOB AU5

Reference to a section number in AICPA PCAOB Standards and Related Rules
for interim auditing standards, as amended, of the PCAOB that are applicable
to issuers

SFAS5

FASB Statement of Financial Accounting Standards

SOP5

AICPA Statement of Position

.21 The accounting guidance in this checklist has been conformed to reflect reference to FASB ASC as it
existed on September 30, 2009.
.22 On June 30, 2009, FASB issued FASB Statement No. 168, The FASB Accounting Standards Codificatione and the Hierarchy of Generally Accepted Accounting Principles—a replacement of FASB Statement No. 162,
which is codified at FASB ASC 105, Generally Accepted Accounting Principles. On the effective date of this
statement, FASB ASC is the authoritative source of U.S. accounting and reporting standards for nongovernmental entities, in addition to guidance issued by the SEC. At that time, FASB ASC supersedes all thenexisting, non-SEC accounting and reporting standards for nongovernmental entities. Once effective, all other
nongrandfathered, non-SEC accounting literature not included in FASB ASC is nonauthoritative. This statement is effective for financial statements issued for interim and annual periods ending after September 15,
2009. See the FASB Web site at www.fasb.org for further information.

Instructions
.23 Within these checklists are a number of questions or statements that are accompanied by references
to applicable authoritative guidance. The financial statements and notes checklist is organized into nine
discrete sections. Disclosures listed in the “General,” “Statement of Financial Position/Balance Sheet,”
“Statement of Activities/Income Statement/Statement of Operations/Statement of Changes in Net Assets,”
“Statement of Cash Flows,” and “Summary of Significant Accounting Policies” sections are common to most
not-for-profit business-oriented and investor-owned health care entities. Those listed in the “Other Financial

FSP §11,000.23
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Statement Disclosures Continuing Care Retirement Communities” and “OMB Circular A-133 Presentation
Requirements” sections are required when circumstances dictate.
.24 The checklists provide spaces for checking off or initialing each question or point to indicate that it
has been considered. Carefully review the topics listed and consider whether they represent potential disclosure items for the reporting entity for which you are preparing or auditing financial statements. Users
should check or initial
●

Yes—If the disclosure is required and has been made appropriately.

●

No—If the disclosure is required but has not been made.

●

N/A (Not Applicable)—If the disclosure is not applicable to the entity.

.25 It is important that the effect of any “No” response be considered on the auditor’s or accountant’s
report. For audited financial statements, a “No” response that is material to the financial statements may
warrant a departure from an unqualified opinion as discussed in paragraphs .20–.64 of AU section 508. If a
“No” response is indicated, the authors recommend that a notation be made in the margin to explain why
the disclosure was not made (for example, because the item was not considered to be material to the financial statements).
.26 Users may find it helpful to use the right margin for certain other remarks and comments as appropriate, including the following:
a.

For each disclosure for which a “Yes” is indicated, a notation as to where the disclosure is
located in the financial statements and a cross-reference to the applicable working papers where
the support to a disclosure may be found

b.

For items marked as “N/A,” the reasons for which they do not apply in the circumstances of
the particular report

c.

For each disclosure for which a “No” response is indicated, a notation as to why the disclosure
was not made (for example, because the item was not considered to be material to the financial
statements)

.27 Recognizing that many entities have December 31 year-ends and in an effort to assist those users,
this checklist includes guidance issued through September 30, 2009, that may become effective by December
31, 2009. This guidance is discussed in each section of the checklist where applicable. Additional questions
appear and are indicated with an “A” or “B” reference. As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented should consider all questions
indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A”
mark in question indicated with a “B” reference. Entities for which the guidance has been implemented
should consider all questions indicated by a “B” reference (for example, question 1B and question 2B) and
place an “N/A” mark by questions indicated with an “A” reference. Therefore, based upon your entities
year-end and decision to early implement or not (if allowed), the appropriate additional questions should
be answered when provided.
.28 These checklists and illustrative materials have been prepared by the AICPA staff. They have not
been reviewed, approved, disapproved, or otherwise acted on by any senior technical committee of the
AICPA and do not represent official positions or pronouncements of the AICPA.
.29 The use of these or any other checklists requires the exercise of individual professional judgment.
These checklists are not substitutes for the original authoritative guidance. Users of these checklists and
illustrative materials are urged to refer directly to applicable authoritative guidance when appropriate. The
checklists and illustrative materials may not include all disclosures and presentation items promulgated, nor
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do they represent minimum standards or requirements. Additionally, users of the checklists and illustrative
materials are encouraged to tailor them as required to meet specific circumstances of each particular engagement. As an additional resource, users may call the AICPA Technical Hotline at (877) 242-7212.

Recognition
.30 The AICPA gratefully appreciates the invaluable assistance Dave Arman and Anne Mundinger provided in updating and maintaining the guidance in this checklist. The AICPA gratefully acknowledges those
who reviewed and otherwise contributed to the development of this edition of the checklist, Dennis Ridge
and Chris Cole.
.31 We hope you find this checklist helpful as you perform your audit and compilation and review
engagements. We would greatly appreciate your feedback on this checklist. You may e-mail these comments
to darman@aicpa.org or write to
Dave Arman, CPA
AICPA
220 Leigh Farm Road
Durham, NC 27707-8110
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FSP Section 11,100
Financial Statements and Notes Checklist
.01 Checklist Questionnaire. This financial statement disclosure checklist is organized into sections. Carefully review the topics listed and consider whether they represent potential disclosure items for the entity
for which you are preparing or auditing financial statements. Place a check mark by the topics or sections
that are applicable and complete those sections of the checklist. Other sections may be marked “N/A” or
left blank. For example, if the entity had a business combination, place a check mark by the section “Business
Combinations” and complete that section of the checklist. On the other hand, if the entity did not have a
business combination, do not place a check mark by “Business Combinations” and skip that section when
completing the checklist.
Place U by Sections
Applicable
I.

II.

III.

General
A.
Titles and References
B.
Comparative Financial Statements
C.
Consolidated Financial Statements
D.
Risks and Uncertainties
Statement of Financial Position/Balance Sheet
A.
General
B.
Cash and Cash Equivalents
C.
Investments
D.
Receivables and Loans
E.
Inventories
F.
Beneficial Interests Held by Others
G.
Property and Equipment and Supplies
H.
Deferred Income Tax Assets and Liabilities
I.
Other Assets and Deferred Charges
J.
Intangible Assets and Goodwill
K.
Current Liabilities
L.
Notes Payable and Other Debt
M.
Shareholders’ Equity
N.
Changes in Shareholders’ Equity
O.
Restricted Resources
Statement of Activities/Income Statement/Statement of Operations/Statement of Changes in Net Assets
A.
General
B.
Revenue
C.
Income Taxes
D.
Extraordinary Items
E.
Advertising Costs
F.
Donated or Contributed Services
G.
Donated Materials and Facilities
H.
Fund-Raising
I.
Contributions/Pledges
J.
Expenses
K.
Wills
L.
Endowments

FSP §11,100.01
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Place U by Sections
Applicable

IV.
V.

VI.
VII.

VIII.

IX.

M.
Earnings Per Share
N.
Comprehensive Income
Statement of Cash Flows
Summary of Significant Accounting Policies
A.
Accounting Policies
B.
Certain Significant Estimates
Interim Reporting
Other Financial Statement Disclosures
A.
Business Combinations
A1.
Business Combinations (Subject to FASB Statement No. 141(R))
B.
Accounting Changes and Error Corrections
C.
Commitments and Contingencies
D.
Current Vulnerability Due to Certain Concentrations
E.
Employee Stock Ownership Plans
F.
Employers’ Disclosures for Defined Benefit Pension and Other Postretirement Plans
G.
Environmental Remediation Liabilities
H.
Financial Instruments
I.
Guarantees
J.
Foreign Currency Matters
K.
Long-Lived Assets and Disposal Groups to Be Disposed Of
L.
Impaired Loans
M.
Impairment of Long-Lived Assets to Be Held and Used
N.
Leases—Lessors
O.
Leases—Lessees
P.
Nonmonetary Transactions
Q.
Postemployment Benefits
R.
Related-Party Transactions and Economic Dependency
S.
Research and Development Arrangements
T.
Exit or Disposal Activities
U.
Segment Reporting
V.
Stock Compensation Plans
W.
Subsequent Events
X.
Accounting for Servicing of Financial Assets
Y.
Troubled Debt Restructurings—Creditors
Z.
Troubled Debt Restructurings—Debtors
AA.
Asset Retirement Obligations
BB.
Fair Value Measurements
Continuing Care Retirement Communities
A.
Refundable Advance Fees
B.
Obligations to Provide Future Services and Use of Facilities to Current
Residents
C.
Other
OMB Circular A-133 Presentation Requirements

FSP §11,100.01
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I.

General
Yes
A.

No

N/A

Titles and References

.l 1. For a full presentation in conformity with accounting principles
generally accepted in the United States (U.S. GAAP), are the following financial statements presented:
a.

Statement of financial position (balance sheet)?

b.

Statement of activities (statement of income operations/income statement)?

c.

Statement of cash flows?

d.

Statement of changes in net assets (equity)?
Practice Tip

The statement of changes in net assets (equity) may be combined with the statement of activities.
[FASB ASC 954-225-45-1]
e.

Notes to the financial statements?
[FASB ASC 954-205-45-1]

.l 2. Is each financial statement suitably titled?
[Common Practice]
.l 3. Does each statement include a reference to the notes, which are
an integral part of the financial statements?
[Common Practice]
B.

Comparative Financial Statements

.l 1. If changes have occurred in the manner of or basis for presenting
corresponding items for two or more periods, has information
been disclosed that will explain the change (for example, any
change in practice that affects comparability of financial statements must be disclosed)?
[FASB ASC 205-10-50-1]
.l 2. Has the entity disclosed appropriate explanations of changes related to any differences in the manner of or basis for presenting
corresponding items for two or more periods?
[FASB ASC 205-10-45-3]
.l 3. If comparative statements are presented, are the notes and other
disclosures included in the financial statements of the preceding
year(s) repeated, or at least referred to, to the extent that they
continue to be of significance?
[FASB ASC 205-10-45-4 ]
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C.

Consolidated Financial Statements

Notes: In March 2008, the Financial Accounting Standards Board (FASB)
issued Statement No. 160, Noncontrolling Interests in Consolidated Financial
Statements—an amendment of ARB No. 51, to establish accounting and reporting standards for the noncontrolling interests in a subsidiary and for
the deconsolidation of a subsidiary, areas for which limited guidance previously existed. FASB Statement No. 160 clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity
that should be reported as equity in the consolidated financial statements.
This statement amended authoritative accounting literature to change the
term minority interest to noncontrolling interest. FASB Statement No. 160
does not change the requirements in FASB Interpretation No. 46 (revised
December 2003), Consolidation of Variable Interest Entities.
FASB Statement No. 160 changes the way the consolidated income statement is presented. It requires consolidated net income to be reported at
amounts that include the amounts attributable to both the parent and the
noncontrolling (minority) interest. It also requires disclosure, on the face
of the consolidated statement of income, of the amounts of consolidated
net income attributable to the parent and to the noncontrolling interest.
FASB Statement No. 160 establishes a single method of accounting for
changes in a parent’s ownership interest in a subsidiary that do not result
in deconsolidation and clarifies that all of those transactions are equity
transactions if the parent retains its controlling financial interest in the
subsidiary.
FASB Statement No. 160 requires expanded disclosures in the consolidated financial statements that clearly identify and distinguish between
the interests of the parent’s owners and the interests of the noncontrolling
owners of a subsidiary. Those expanded disclosures include a reconciliation of the beginning and ending balances of the equity attributable to the
parent and the noncontrolling owners and a schedule showing the effects
of changes in a parent’s ownership interest in a subsidiary on the equity
attributable to the parent. These provisions are effective for fiscal years,
and interim periods within those fiscal years, beginning on or after December 15, 2008 (that is, January 1, 2009, for entities with calendar yearends). FASB Statement No. 160 should be applied prospectively as of the
beginning of the fiscal year in which the statement is initially adopted.
Presentation and disclosure requirements should be applied retrospectively for all periods presented.
This checklist has been updated to include the presentation and disclosure
requirements of FASB Statement No. 160.
As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented should consider
all questions indicated with an “A” reference (for example, question 1A
and question 2A) and should place an “N/A” mark in questions indicated
with a “B” reference. Entities for which the guidance has been implemented should consider all questions indicated by a “B” reference (for example, question 1B and question 2B) and place an “N/A” mark by questions indicated with an “A” reference. Therefore, based upon your entity’s
(continued)
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year-end and decision to early implement or not (if allowed), the following
additional questions will be answered when provided in this section
(check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and
open effective date information discussed in FASB Accounting Standards
Codification (ASC) 810-10-65-1.
******
FASB Statement No. 164, Not-for-Profit Entities: Mergers and Acquisitions—Including an amendment of FASB Statement No. 142, issued in May
2009, provides standards for the information a not-for-profit entity provides in its financial reports about a combination with one or more other
not-for-profit entities, businesses, or nonprofit activities. FASB Statement
No. 164 also amends FASB Statement No. 160 to make it that statement’s
amendments to Accounting Research Bulletin No. 51, Consolidated Financial
Statements, fully applicable by not-for-profit organizations. This checklist
does not contain questions for display and disclosure of noncontrolling
interests in accordance with the amended standards of ARB No. 51 because FASB Statement No. 164’s provisions cannot be adopted early.
Until the effective date of FASB Statement No. 164, FASB Statement No.
160 does not apply to not-for-profit organizations, nor do its amendments
to other standards when applied by not-for-profit organizations. Not-forprofit organizations continue to apply the guidance in ARB No. 51, as codified primarily in FASB ASC 810 and FASB ASC 958-810, before the
amendments made by FASB Statement No. 160, the guidance in Statement
of Position 94-3, Reporting of Related Entities by Not-for-Profit Organizations
(AICPA, Technical Practice Aids, ACC sec. 10,610), as codified in FASB ASC
958 and other applicable standards until the FASB issues interpretative
guidance.

Practice Tip
The purpose of consolidated statements is to present, primarily for the benefit of the shareholders and creditors of the parent entity, the results of operations and the financial position of a parent entity and subsidiaries essentially as if the group were a single entity with one or more branches or divisions. There is a
presumption that consolidated statements are more meaningful than separate statements and that they are
usually necessary for a fair presentation when one of the entities in the group directly or indirectly has a
controlling financial interest in the other entities.
In some cases parent entity statements may be needed, in addition to consolidated statements, to indicate
adequately the position of bondholders and other creditors or preferred stockholders of the parent. Consolidating statements, in which one column is used for the parent entity and other columns for particular
subsidiaries or groups of subsidiaries, often are an effective means of presenting the pertinent information.
[FASB ASC 810-10-10-1; FASB ASC 810-10-45-11]
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. 1. If consolidated financial statements are presented:
a.

Is the consolidation policy disclosed?
[FASB ASC 810-10-50-1]

b.

In instances in which the financial reporting periods of subsidiaries differ from that of the parent, is recognition given
to the effect of intervening events that materially affect financial position or the results of operations?
[FASB ASC 810-10-45-12]

c.

Are restrictions made by entities outside of the reporting
entity on distributions from the controlled not-for-profit organization to the reporting organization and any resulting
unavailability of the net assets of the controlled not-forprofit organization for use by the reporting organization
disclosed?
[FASB ASC 958-810-50-1]

l 2. Has the entity disclosed the consolidation policy, if consolidated
statements are presented?
[FASB ASC 810-10-50-1; FASB ASC 235-10-50-4]
Practice Tip
(FASB Statement No. 160) With regard to question 3B, if a parent deconsolidates a subsidiary through a
nonreciprocal transfer to owners, such as a spinoff, the accounting guidance in FASB ASC 845-10 applies.
[“Pending Content” in FASB ASC 810-10-40-5]
l 3B.

l 4B.

(FASB Statement No. 160) Has the entity disclosed the following, as a parent, if a subsidiary has been deconsolidated:
a.

The amount of any gain or loss recognized in accordance with FASB ASC 810-10-40-5?

b.

The portion of any gain or loss related to the remeasurement of any retained investment in the former subsidiary to its fair value?

c.

The caption in the income statement in which the gain
or loss is recognized unless separately presented on the
face of the income statement?
[“Pending Content” in FASB ASC 810-10-50-1B]

(FASB Statement No. 160) Has the entity disclosed the following, if the entity is a parent with one or more less-thanwholly owned subsidiaries:
a.

Separately, on the face of the consolidated financial
statements, both of the following:
i.

The amounts of consolidated net income and consolidated comprehensive income?

ii. The related amounts on each attributable to the
parent and the noncontrolling interest?
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b.

No

N/A

Either in the notes or on the face of the consolidated
income statement, amounts attributable to the parent
for any of the following, if reported in the consolidated
financial statements:
i.

Income from continuing operations?

ii. Discontinued operations?
iii. Extraordinary items?
c.

Either in the consolidated statement of changes in equity, if presented, or in the notes to consolidated financial statements, a reconciliation at the beginning and
the end of the period of the carrying amount of total
equity (net assets), equity (net assets) attributable to the
parent, and equity (net assets) attributable to the noncontrolling interest? (See FASB ASC 810-10-50-1A and
FASB ASC 810-10-55-4(G) for example disclosures.)

d.

In notes to the consolidated financial statements, a separate schedule that shows the effects of any changes in
a parent’s ownership interest in a subsidiary on the equity attributable to the parent?
[“Pending Content” in FASB ASC 810-10-50-1A]

.l 5.

Has the entity eliminated for presentation material intra-entity transactions and accounts, including any intra-entity
profit or loss on assets that remain within the consolidated
group?
[FASB ASC 810-10-45 par. 1 and 6]

.l 6.

If the financial reporting periods of any subsidiaries are different from that of the parent, are intervening events that materially affect financial position or results of operations disclosed?
[FASB ASC 810-10-45-12]

.l 7.

If a parent company reports a change to (or the elimination
of) a previously existing difference between the parent’s reporting period and the reporting period of a consolidated entity in the parent’s consolidated financial statements as described in FASB ASC 810-10-45-13, has the change been
reported as a change in accounting principle in accordance
with the provisions of FASB ASC 250, Accounting Changes and
Error Corrections, excluding retrospective application if it is
impracticable to do so?
[FASB ASC 810-10-45-13]
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.l 8.

If the organization is the parent company of, or an equity
method investor in, a for-profit entity that early adopted SOP
07-1, Clarification of the Scope of the Audit and Accounting Guide
Investment Companies and Accounting by Parent Companies
and Equity Method Investors for Investments in Investment Companies (AICPA, Technical Practice Aids, ACC sec. 10,930), prior
to fiscal years beginning on or after December 15, 2007, and
the subsidiary has not elected to rescind its early adoption of
SOP 07-1 as permitted by paragraph 11 of FASB Staff Position
(FSP) SOP 07-1-1, Effective Date of AICPA Statement of Position
07-1, do the financial statements include the disclosures required by paragraphs .50–.53 of SOP 07-1 if investment company accounting is retained in the consolidated financial
statements?
[SOP 07-1 par. D-2 (ACC 10,930.D2)]

Consolidation of Variable Interest Entities
Notes: In June 2009, FASB issued Statement No. 167, Amendments to
FASB Interpretation No. 46(R). Among other things, FASB Statement
No. 167 amends FASB Interpretation No. 46(R), Consolidation of Variable Interest Entities (revised December 2003)—an interpretation of ARB
No. 51, to require an entity to perform an analysis to determine
whether the entity’s variable interest or interests give it a controlling
financial interest in a variable interest entity (VIE) and to provide
enhanced disclosures that will provide more transparent information
about an entity’s involvement in a VIE.
FASB Statement No. 167 is effective as of the beginning of each reporting entity’s first annual reporting period that begins after November 15, 2009 (that is, January 1, 2010, for entities with calendar
year-ends), for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter. Earlier
application is prohibited.
This checklist has not been updated to include the presentation and
disclosure requirements of FASB Statement No. 167.
Readers can refer to the full text of this statement on the FASB Web
site at www.fasb.org.
******
In December 2007, FASB issued Statement No. 141 (revised 2007),
Business Combinations, to improve the relevance, representational
faithfulness, and comparability of the information that a reporting
entity provides in its financial reports about a business combination
and its effects. FASB Statement No. 141(R) supersedes FASB Statement No. 141, Business Combinations, but retains the fundamental requirements in FASB Statement No. 141 that the acquisition method
of accounting (formerly called the purchase method in FASB Statement No. 141) be used for all business combinations and that an acquirer be identified for each business combination.
(continued)
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Among many other significant amendments to existing pronouncements precipitated by FASB Statement No. 141(R), this statement redefines goodwill in FASB Statement No. 142, Goodwill and Other Intangible Assets, to mean an asset representing the future economic
benefits arising from other assets acquired in a business combination
that are not individually identified and separately recognized.
FASB Statement No. 141(R) applies to all transactions or other events
in which an entity (the acquirer) obtains control of one or more businesses (the acquiree), including those sometimes referred to as true
mergers or mergers of equals and combinations achieved without the
transfer of consideration, for example, by contract alone or through
the lapse of minority veto rights. This statement applies to all business entities, including mutual entities that previously used the pooling-of-interests method of accounting for some business combinations. It does not apply to the following:
a.

The formation of a joint venture

b.

The acquisition of an asset or a group of assets that does not
constitute a business

c.

A combination between entities or businesses under common control

d.

A combination between not-for-profit entities or the acquisition of a for-profit business by a not-for-profit entity

This statement applies prospectively to business combinations for
which the acquisition date is on or after the beginning of the first
annual reporting period beginning on or after December 15, 2008
(that is, January 1, 2009, for entities with calendar year-ends). An entity may not apply it before that date.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 141(R).
As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented
should consider all questions indicated with an “A” reference (for
example, question 1A and question 2A) and should place an “N/A”
mark in questions indicated with a “B” reference. Entities for which
the guidance has been implemented should consider all questions indicated by a “B” reference (for example, question 1B and question
2B) and place an “N/A” mark by questions indicated with an “A”
reference. Therefore, based upon your entity’s year-end and decision
to early implement or not (if allowed), the following additional questions will be answered when provided in this section (check one that
applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 805-1065-1.
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Practice Tip
A VIE may issue voting equity interests, and the entity that holds a majority voting interest also may be the
primary beneficiary of the VIE. If so, the disclosures in question 8A are not required.
[FASB ASC 810-10-50-3]
l8A. If the entity is a primary beneficiary of a VIE, has the entity disclosed all of the following (unless the primary beneficiary also
holds a majority voting interest):
a.

The nature, purpose, size, and activities of the VIE?

b.

The carrying amount and classification of consolidated assets
that are collateral for the VIE’s obligations?

c.

Lack of recourse if creditors (or beneficial interest holders) of
a consolidated VIE have no recourse to the general credit of
the primary beneficiary?
[FASB ASC 810-10-50-3]
Practice Tips

(FASB Statement No. 141(R)) The primary beneficiary of a VIE that is a business should disclose items
required by FASB ASC 805, Business Combinations. The primary beneficiary of a VIE that is not a business
should disclose the amount of gain or loss recognized on the initial consolidation of the VIE.
[“Pending Content” in FASB ASC 810-10-50-3]
******
(FASB Statement No. 141(R)) A VIE may issue voting equity interests, and the entity that holds a majority
voting interest also may be the primary beneficiary of the VIE. If so, the disclosures in question 8B are not
required.
[“Pending Content” in FASB ASC 810-10-50-3]
l 8B.

l 9.

FSP §11,100.01

(FASB Statement No. 141(R)) If the entity is a primary beneficiary of a VIE, has the entity disclosed all of the following
(unless the primary beneficiary also holds a majority voting
interest):
a.

The nature, purpose, size, and activities of the VIE?

b.

The carrying amount and classification of consolidated
assets that are collateral for the VIE’s obligations?

c.

Lack of recourse if creditors (or beneficial interest holders) of a consolidated VIE have no recourse to the general credit of the primary beneficiary?
[“Pending Content” in FASB ASC 810-10-50-3]

Have the following disclosures been made if the entity holds
a significant variable interest in a VIE but is not the primary
beneficiary:
a.

The nature of its involvement with the VIE and when
that involvement began?

b.

The nature, purpose, size, and activities of the VIE?
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The enterprise’s maximum exposure to loss as a result
of its involvement with the VIE?
[FASB ASC 810-10-50-4]
Practice Tip

The disclosures required by FASB ASC 860, Transfers and Servicing, about a VIE should be included in the
same note to the financial statements as the information required by the “Variable Interest Entities” subsections of FASB ASC 810. Further, information about VIEs may be reported in the aggregate for similar entities
if separate reporting would not add material information.
[FASB ASC 810-10-50-5]
l 10. If the entity does not apply the guidance in the “Variable Interest
Entities” subsections of FASB ASC 810 to one or more VIEs or
potential VIEs because of the condition described in FASB ASC
810-10-15-17(c), is the following information disclosed:
a.

The number of entities to which this guidance is not being
applied and the reason why the information required to apply this guidance is not available?

b.

The nature, purpose, size (if available), and activities of the
entity(ies) and the nature of the enterprise’s involvement
with the entity(ies)?

c.

The reporting enterprise’s maximum exposure to loss because of its involvement with the entity(ies)?

d.

The amount of income, expense, purchases, sales, or other
measure of activity between the reporting enterprise and
the entity(ies) for all periods presented?
[FASB ASC 810-10-50-6]

Notes: In December 2008, FASB issued FSP FAS 140-4 and FIN 46(R)8, Disclosures by Public Entities (Enterprises) about Transfers of Financial
Assets and Interests in Variable Interest Entities. The objective of this
FSP is to require public entities to provide additional disclosures
about transfers of financial assets. It also amend FASB Interpretation
No. 46(R) to require public enterprises, including sponsors that have
a variable interest in a VIE, to provide additional disclosures about
their involvement with VIEs. Further, it amends FASB Interpretation
No. 46(R) to required disclosure by (a) a nontransferor sponsor of a
qualifying special purpose entity (QSPE) that holds a variable interest in the QSPE and (b) a nontransferor servicer of a QSPE that holds
a significant variable interest in the QSPE. Note that this FSP does
not change the existing disclosure requirements for nonpublic entities.
This FSP applies to public entities that are subject to the disclosure
requirements of FASB Statement No. 140, Accounting for Transfers and
Servicing of Financial Assets and Extinguishment of Liabilities—a replacement of FASB Statement No. 125, and public enterprises that are subject to the disclosure requirements of FASB Interpretation No. 46(R)
as amended by this FSP.
(continued)
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This FSP is effective for the first reporting period (interim or annual)
ending after December 15, 2008 (that is, December 31, 2008, for entities with calendar year-ends), and for interim and annual reporting
periods thereafter. Earlier application is encouraged.
Readers can refer to the full text of both the FSP and the statement
on the FASB Web site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 860-1065-2.
Readers should be aware that this FSP was superseded by FASB
Statement No. 167 and by FASB Statement No. 166, Accounting for
Transfers of Financial Assets—an amendment of FASB Statement No. 140.
Both FASB Statement No. 167 and FASB Statement No. 166 are effective as of the beginning of each reporting entity’s first annual reporting period that begins after November 15, 2009 (that is, January 1,
2010, for entities with calendar year-ends), for interim periods within
that first annual reporting period, and for interim and annual reporting periods thereafter. Earlier application is prohibited.
This checklist has not been updated to include the presentation and
disclosure requirements of FASB Statement No. 166 or FASB Statement No. 167.
Readers can refer to the full texts of these statements on the FASB
Web site at www.fasb.org.
******
In December 2007, FASB issued Statement No. 141(R) to improve the
relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial reports
about a business combination and its effects. FASB Statement No.
141(R) supersedes FASB Statement No. 141 but retains the fundamental requirements in FASB Statement No. 141 that the acquisition
method of accounting (formerly called the purchase method in FASB
Statement No. 141) be used for all business combinations and that an
acquirer be identified for each business combination.
Among many other significant amendments to existing pronouncements precipitated by FASB Statement No. 141(R), this statement redefines goodwill in FASB Statement No. 142 to mean an asset representing the future economic benefits arising from other assets
acquired in a business combination that are not individually identified and separately recognized.
FASB Statement No. 141(R) applies to all transactions or other events
in which an entity (the acquirer) obtains control of one or more businesses (acquiree), including those sometimes referred to as true
mergers or mergers of equals and combinations achieved without the
transfer of consideration, for example, by contract alone or through
the lapse of minority veto rights. This statement applies to all busi(continued)

FSP §11,100.01

No

N/A

21

Financial Statements and Notes Checklist

Yes

No

N/A

ness entities, including mutual entities that previously used the pooling-of-interests method of accounting for some business combinations. It does not apply to the following:
a.

The formation of a joint venture

b.

The acquisition of an asset or a group of assets that does not
constitute a business

c.

A combination between entities or businesses under common control

d.

A combination between not-for-profit entities or the acquisition of a for-profit business by a not-for-profit entity

This statement applies prospectively to business combinations for
which the acquisition date is on or after the beginning of the first
annual reporting period beginning on or after December 15, 2008
(that is, January 1, 2009, for entities with calendar year-ends). An entity may not apply it before that date.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 141(R).
As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented
should consider all questions indicated with an “A” reference (for
example, question 1A and question 2A) and should place an “N/A”
mark in questions indicated with a “B” reference. Entities for which
the guidance has been implemented should consider all questions indicated by a “B” reference (for example, question 1B and question
2B) and place an “N/A” mark by questions indicated with an “A”
reference. Therefore, based upon your entity’s year-end and decision
to early implement or not (if allowed), the following additional questions will be answered when provided in this section (check one that
applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 805-1065-1.

Practice Tips
(Issuers Only) The entity should determine, in light of the facts and circumstances, how much detail it
should provide to satisfy the disclosure requirements of FASB ASC 810-10-50, how much emphasis it places
on different aspects of the requirements, and how it aggregates information to display its overall involvements with VIEs with different risk characteristics. The entity must strike a balance between obscuring important information as a result of too much aggregation and overburdening financial statements with excessive detail that may not assist financial statement users to understand the reporting entity’s financial
position.
(continued)
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The public entity disclosures required in the “Variable Interest Entities” subsection of FASB ASC 810-10-50
may be provided in more than one note to financial statements, as long as the objectives in FASB ASC 81010-50-8 are met. If the disclosures are provided in more than one note to financial statements, the reporting
entity should provide a cross reference to the other notes to financial statements that provide the disclosures
prescribed in the “Variable Interest Entities” subsection of FASB ASC 810-10-50 for similar VIEs.
[“Pending Content” in FASB ASC 810-10-50 par. 10–11]
******
(Issuers Only) The entity should consider the overall objectives in question 11 in providing disclosures. To
achieve those objectives, the entity may need to supplement the disclosures required in FASB ASC 810-1050, depending on the facts and circumstances surrounding the VIE and the reporting entity’s interest in that
VIE.
[“Pending Content” in FASB ASC 810-10-50-8]
l 11. (Issuers Only) Has the entity made disclosures that provide financial statement users with information regarding all of the following:
a.

The significant judgments and assumptions made by a reporting entity in determining whether it must do any of the
following:
i.

Consolidate a VIE?

ii. Disclose information about its involvement with a VIE?
b.

The nature of restrictions on a consolidated VIE’s assets reported by a reporting entity in its statement of financial position, including the carrying amounts of such assets?

c.

The nature of, and changes in, the risks associated with a
reporting entity’s involvement with the VIE?

d.

How a reporting entity’s involvement with the VIE affects
the entity’s financial position, financial performance, and
cash flows?
[“Pending Content” in FASB ASC 810-10-50-8]

l 12. (Issuers Only) If reporting disclosures in aggregate, which may
be more useful, has the entity disclosed how similar entities are
aggregated and distinguish between
a.

VIEs that are not consolidated because the reporting entity
is not the primary beneficiary but has a significant variable
interest or is the sponsor that holds a variable interest?

b.

VIEs that are consolidated?
[“Pending Content” in FASB ASC 810-10-50-9]
Practice Tip

(Issuers Only) A VIE may issue voting equity interests, and the reporting entity that holds a majority voting
interest also may be the primary beneficiary of the VIE. If so, the disclosures in questions 13 and 14A are
required if the activities of the VIE are primarily related to securitizations or other forms of asset-backed
financings or single-lessee leasing arrangements.
[“Pending Content” in FASB ASC 810-10-50-13]
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l 13.

No
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(Issuers Only) If the entity is a primary beneficiary of a VIE,
an entity that holds a significant variable interest in a VIE but
is not the primary beneficiary, or an entity that is a sponsor
that holds a variable interest in a VIE have the following disclosures been made:
a.

Its methodology for determining whether the entity is
(or is not) the primary beneficiary of a VIE, including,
but not limited to, significant judgments and assumptions made?

b.

If the conclusion to consolidate a VIE has changed in
the most recent financial statements the primary factors
that caused the change and the effect on the entity’s financial statements?

c.

Whether the entity has provided financial or other support during the periods presented to the VIE that it was
not previously contractually required to provide, including both of the following:
i.

The type and amount of support?

ii. The primary reasons for providing the support?
d.

Qualitative and quantitative information about the reporting entity’s involvement with the VIE, including
but not limited to the nature, purpose, size, and activities of the VIE, including how the VIE is financed?
[“Pending Content” in FASB ASC 810-10-50-12]

l 14A. (Issuers Only) If the entity is the primary beneficiary of a VIE,
have the following disclosures been made:
a.

The carrying amount and classification of the VIE’s assets and liabilities in the statement of financial position
that are consolidated in accordance with the guidance
in the “Variable Interest Entities” subsections of FASB
ASC 810-10, including qualitative information about
the relationship(s) between those assets and associated
liabilities?

b.

Lack of recourse if creditors (or beneficial interest holders) of a consolidated VIE have no recourse to the general credit of the primary beneficiary?

c.

Terms of arrangements, giving consideration to both
explicit arrangements and implicit variable interests,
that could require the reporting entity to provide financial support to the VIE, including events or circumstances that could expose the reporting entity to a loss?
[“Pending Content” in FASB ASC 810-10-50-14]
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Practice Tip
(FASB Statement No. 141(R)) (Issuers Only) With respect to question 14B, the primary beneficiary of a VIE
that is a business should disclose items required by FASB ASC 805. The primary beneficiary of a VIE that is
not a business should disclose the amount of gain or loss recognized on the initial consolidation of the VIE.
[“Pending Content” in FASB ASC 805-10-50-14]
14B. (FASB Statement No. 141(R)) (Issuers Only) If the entity is
the primary beneficiary of a VIE, have the following disclosures been made:
a.

The carrying amount and classification of the VIE’s assets and liabilities in the statement of financial position
that are consolidated in accordance with the guidance
in the “Variable Interest Entities” subsections of FASB
ASC 810-10, including qualitative information about
the relationship(s) between those assets and associated
liabilities?

b.

Lack of recourse if creditors (or beneficial interest holders) of a consolidated VIE have no recourse to the general credit of the primary beneficiary?

c.

Terms of arrangements, giving consideration to both
explicit arrangements and implicit variable interests,
that could require the reporting entity to provide financial support to the VIE, including events or circumstances that could expose the reporting entity to a loss?
[“Pending Content” in FASB ASC 810-10-50-14]
Practice Tip

(Issuers Only) With regard to question 15(c), the entity should provide qualitative and quantitative information to allow financial statement users to understand the differences between the two amounts (liability
and maximum exposure to loss).
[“Pending Content” in FASB ASC 810-10-50-15]
l 15. (Issuers Only) Has the entity made the following disclosures if it
holds a significant variable interest or is a sponsor that holds a
variable interest in a VIE, but is not the VIE’s primary beneficiary:
a.

The carrying amount and classification of the assets and liabilities in the reporting entity’s statement of financial position that relate to the reporting entity’s variable interest in
the VIE.

b.

The reporting entity’s maximum exposure to loss as a result
of its involvement with the VIE, including the following:
i.

How the maximum exposure is determined?

ii. The significant sources of the reporting entity’s exposure to the VIE?
iii. If a maximum exposure cannot be identified, has that
fact been disclosed?
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Yes
c.

No

N/A

A tabular comparison of the carrying amount of the liability
(as required by item (a)) and the reporting entity’s maximum exposure to loss (as required by item (b)).
[“Pending Content” in FASB ASC 810-10-50-15]

l 16. (Issuers Only) If the entity has not applied the guidance in the
“Variable Interest Entities” subsections of FASB ASC 810-10-50 to
one or more VIEs or potential VIEs because of the condition described in FASB ASC 810-10-15-17(c) (see preceding practice tip),
has all of the following information been disclosed:
a.

The number of legal entities to which that guidance is not
being applied?

b.

The reason why the information required to apply that
guidance is not available?

c.

The nature, purpose, size (if available), and activities of the
legal entities?

d.

The nature of the reporting entity’s involvement with the
legal entities?

e.

The reporting entity’s maximum exposure to loss because of
its involvement with the legal entities?

f.

The amount of income, expense, purchases, sales, or other
measure of activity between the reporting entity and the legal entities for all periods presented?
[“Pending Content” in FASB ASC 810-10-50-16]

l 17. (Issuers Only) If the entity is either a nontransferor sponsor or a
nontransferor servicer, (as defined in FASB ASC 810-10-50-17),
have they disclosed information that provides financial statement
users with an understanding of its involvement with the QSPE?
[“Pending Content” in FASB ASC 810-10-50-17]
Practice Tip
(Issuers Only) Disclosures may be reported in the aggregate for similar entities if separate reporting would
not provide more useful information to financial statement users. The reporting entity should disclose how
similar entities are aggregated. In determining whether to aggregate QSPEs, the reporting entity should
consider quantitative and qualitative information about the different risk and reward characteristics of each
QSPE and the importance of each QSPE to the reporting entity.
[“Pending Content” in FASB ASC 810-10-50-18]
l 18. (Issuers Only) If the entity is either a nontransferor sponsor (see
FASB ASC 810-10-50-8(a)) or a nontransferor servicer (see FASB
ASC 810-10-50-8(b)) of a QSPE, have the following been disclosed:
a.

The nature, purpose, size, and activities of the QSPE, including how the entity is financed?

b.

The carrying amount and classification of the assets and liabilities recognized in the statement of financial position related to the entity’s involvement with the QSPE?
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Yes
c.

Terms of arrangements that could require the reporting entity to provide financial support to the QSPE, including
events or circumstances that could expose the entity to loss?
(All available evidence should be considered. See FASB
ASC 810-10-50-19(c) for specific examples of evidence to
consider).

d.

The entity’s maximum exposure to loss as a result of its involvement with the QSPE, including how the maximum exposure is determined and the significant sources of the reporting entity’s exposure to the QSPE? (If the entity’s
maximum exposure to loss as a result of its involvement
with the QSPE cannot be quantified, that fact should be disclosed.)

e.

Whether the entity has provided financial or other support
during the periods presented to the QSPE that it was not
previously contractually required to provide, including
both of the following:
i.

The type and amount of support?

ii. The primary reasons for providing the support?
[“Pending Content” in FASB ASC 810-10-50-19]
D.

Risks and Uncertainties
Note: In April 2008, FASB issued FSP FAS 142-3, Determination of the
Useful Life of Intangible Assets, to improve the consistency between the
useful life of a recognized intangible asset under FASB Statement No.
142 and the period of expected cash flows used to measure the fair
value of the asset under FASB Statement No. 141(R) and other U.S.
GAAP. This FSP applies to recognized intangible assets that are accounted for pursuant to FASB Statement No. 142 and applies regardless of the nature of the transaction that resulted in the recognition
of the intangible asset, that is, whether acquired in a business combination or otherwise.
Among other significant provisions, FSP FAS 142-3 will add criterion
as to whether disclosure related to the estimated useful life of an intangible asset should be required under FASB ASC 275-10-50-8.
FSP FAS 142-3 is effective for financial statements issued for fiscal
years beginning after December 15, 2008 (that is, January 1, 2009, for
entities with calendar year-ends), and interim periods within those
fiscal years. Early adoption is prohibited.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 142-3.
Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 350-1065-1.
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Yes

No

N/A

Practice Tips
The 4 areas of disclosure prescribed by FASB ASC 275-10-50-1, in question 1, are not mutually exclusive.
The information required by some may overlap. Accordingly, the disclosures required by FASB ASC 27510-50 may be combined in various ways, grouped together, or placed in diverse parts of the financial statements, or included as part of the disclosures made pursuant to other U.S. GAAP requirements.
[FASB ASC 275-10-50-1]
******
Whether an estimate meets the criteria for disclosure under FASB ASC 275, Risks and Uncertainties, does not
depend on the amount that has been reported in the financial statements but rather on the materiality of the
effect that using a different estimate would have had on the financial statements. Simply because an estimate
resulted in the recognition of a small financial statement amount, or no amount, does not mean that disclosure is not required under FASB ASC 275-10.
[FASB ASC 275-10-50-14]
.l 1. Has the entity made disclosures about the risks and uncertainties
existing as of the date of the financial statements in the following
areas:
a.

Nature of operations?

b.

Use of estimates in the preparation of financial statements?

c.

Certain significant estimates?

d.

Current vulnerability due to certain concentrations?
[FASB ASC 275-10-50-1]

.l 2. Has the entity disclosed a description of the major products or
services the entity sells or provides and it principal markets, including the locations of those markets?
[FASB ASC 275-10-50-2]
.l 3. If the entity operates in more than one business, have the disclosures made indicated the relative importance of its operations in
each business and the basis for this determination (assets, revenues, and earnings)?
[FASB ASC 275-10-50-2]
.l 4. Do the financial statements include an explanation that the preparation of financial statements in conformity with U.S. GAAP requires the use of managements’ estimates?
[FASB ASC 275-10-50-4]
.l 5. If, based on known information available to the entity before the
issuance of the financial statements, it is reasonably possibly that
estimates in the financial statements will change in the near term
(as defined by the FASB ASC glossary as a period of time not to
exceed one year from the date of the financial statements) and the
effects will be material, is there discussion (including an estimate
of the effect of the change in condition, situation, or set of circumstances that existed at the date of the financial statements) in the
financial statements of these facts and circumstances?
[FASB ASC 275-10-50-6]
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Yes

No

N/A

Practice Tip
(FSP FAS 142-3) In determining whether disclosure about an estimate of the useful life of an intangible asset
is required under FASB ASC 275-10-50-8 (see the “Summary of Significant Accounting Policies” section, part
B, “Certain Significant Estimates”), the criterion in item (b) of that paragraph should be considered met if
the effect of either of the following would be material to the financial statements, either individually or in
aggregate by major intangible asset class:
●

A change in the useful life of an intangible

● A change in the expected likelihood of renewal or extension of an intangible asset
[“Pending Content” in FASB ASC 275-10-50-15A]

II.

Statement of Financial Position/Balance Sheet
A.

General

.l 1. For classified balance sheets, are assets and liabilities segregated
into current and noncurrent classifications with totals presented
for current assets and current liabilities?
[FASB ASC 210-10-05–5; FASB 210-10-45-5; FASB ASC 470-1045-2; FASB ASC 70-10-45-15]
.l 2. Are assets not expected to be realized during the current operating cycle classified as noncurrent?
[FASB ASC 210-10-45 par. 3–4]
. 3. Does the statement of financial position/balance sheet report total assets, liabilities, and net assets, as well as separate amounts
for each of the three classes of net assets, with captions used to
describe their meanings as explained in FASB ASC 958-210-45?
[FASB ASC 958-210-45-1]
. 4. Has the not-for-profit entity disclosed in the notes to the financial
statements relevant information about the liquidity or maturity
of assets and liabilities, including restrictions on the use of particular items, unless that information is provided on the face of the
statement of financial position?
[FASB ASC 958-210-50-1]
. 5. Does the entity provide information about liquidity by one or
more of the following presentations:
a.

Sequencing assets according to their nearness of conversion
to cash and sequencing liabilities according to the nearness
of their maturity and resulting use of cash?

b.

Classifying assets and liabilities as current and noncurrent?

c.

Disclosing in notes to financial statements relevant information about the liquidity or maturity of assets and liabilities, including restrictions on the use of particular assets?
[FASB ASC 958-210-45-8]

. 6. Has the not-for-profit entity disclosed all of the following, if present, in the notes to financial statements:
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a.

Unusual circumstances, such as special borrowing arrangements, requirements imposed by resource providers that
cash be held in separate accounts, and known significant liquidity problems?

b.

The fact that the not-for-profit has not maintained appropriate amounts of cash and cash equivalents to comply with
donor-imposed restrictions?

c.

Information about significant limits resulting from contractual agreements with suppliers, creditors, and other, including the existence of loan covenants?
[FASB ASC 958-210-50-2]

No

N/A

. 7. Has the not-for-profit entity disclosed all of the following, if present, in the notes to financial statements if not provided on the
face of the statement of financial position:
a.

A description of the kind of asset whose use is limited?

b.

Information about the nature and amount of limitations on
the use of cash and cash equivalents?

c.

Contractual limitations on the use of particular assets?

d.

Information about the nature and amounts of different
types of permanent restrictions?

e.

Information about the nature and amounts of different
types of temporary restrictions?
[FASB ASC 958-210-50-3; FASB ASC 958-210-45 par. 6, 7(a),
7(b), 9 and 10]

.l 8. Are valuation allowances for assets shown as deductions from
their related assets with appropriate disclosure?
[FASB ASC 310-10-45-3]
B.

Cash and Cash Equivalents

.l 1. Has the entity made disclosures related to any restrictions on
cash?
[Common Practice]
.l 2. Is any cash restricted as to withdrawal or use for other than current operations excluded from current assets? (See FASB ASC
954-305-45-1 for additional detail.)
[FASB ASC 210-10-45-4]
.l 3. Are personal funds of patients, residents, and others under an
agency arrangement reported as unrestricted assets and corresponding liabilities in the balance sheet/statement of financial
position?
[FASB ASC 954-305-45-4]
.l 4. If a concentration of credit risk arises from deposits in excess of
federally insured limits, is it disclosed?
[FASB ASC 958-320-50-3]
.l 5. Are bank overdrafts reclassified to and presented separately in
current liabilities?
[Common Practice]
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Yes

No

N/A

.l 6. Are held checks (those written before but not released until after
the balance sheet date) reclassified to accounts payable?
[Common Practice]
.l 7. Are internally designated funds reported separately from externally designated funds, in accordance with FASB ASC 958-21045-4? (If the form of the assets is not evident from the description
on the balance sheet, the form of the assets should be disclosed
in the notes to the financial statements.)
[FASB ASC 954-210-50-2]
C.

Investments
Practice Tip

FASB ASC 320, Investments—Debt and Equity Securities, as discussed in following questions, does not apply
to investments in equity securities that, absent the election of the fair value option in FASB ASC 825-10-251, would be required to be accounted for under the equity method, nor to investments in consolidated
subsidiaries.
[FASB ASC 320-10-15-7]

Notes: In April 2009, FASB issued FSP FAS 115-2 and FAS 124-2,
Recognition and Presentation of Other-Than-Temporary Impairments. This
FSP amends the other-than-temporary impairment guidance in U.S.
GAAP for debt securities to make the guidance more operational
and to improve the presentation and disclosure of other-than-temporary impairments on debt and equity securities in the financial
statements. This FSP does not amend existing recognition and measurement guidance related to other-than-temporary impairments of
equity securities. This FSP incorporates other-than-temporary impairment guidance for debt securities from Securities and Exchange
Commission (SEC) Staff Accounting Bulletin Topic 5M and other authoritative literature, modifies and expands it to address the unique
features of debt securities, and clarifies the interaction of the factors
that should be considered when determining whether a debt security
is other than temporarily impaired.
The FSP is effective for interim and annual reporting periods ending
after June 15, 2009 (that is, December 31, 2009, for entities with calendar year-ends), with early adoption permitted for periods
ending after March 15, 2009. This FSP does not require disclosures
for earlier periods presented for comparative purposes at initial
adoption. In periods after initial adoption, this FSP requires comparative disclosures only for periods ending after initial adoption.
This checklist has not been updated to include the presentation and
disclosure requirements of FSP FAS 115-2 and FAS 124-2.
Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 320-1065-1.
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No

N/A

Practice Tip
The disclosures in this FASB ASC 320-10-50 are required for all interim and annual periods. Major security
types should be based on the nature and risks of the security. In determining whether disclosure for a
particular security type is necessary and whether it is necessary to further separate a particular security type
into greater detail, an entity should consider all of the following:
●

Shared activity or business sector

●

Vintage

●

Geographic concentration

●

Credit quality

●

Economic characteristic

[“Pending Content” in FASB ASC 320-10-50 par. 1A–1B]
l 1. Has the entity disclosed all of the following, for securities classified as available for sale, by major security type, as of each date
for which a statement of financial position is presented:
a.

Amortized cost basis?

b.

Aggregate fair value?

c.

Total other-than-temporary impairment recognized in accumulated other comprehensive income (OCI)?

d.

Total gains for securities with net gains in accumulated
OCI?

e.

Total losses for securities with net losses in accumulated
OCI?

f.

Information about the contractual maturities of those securities as of the date of the most recent statement of financial
position reported?
[“Pending Content” in FASB ASC 320-10-50-2]

l 2. Has the entity disclosed any investments in available-for-sale securities and trading securities separately from similar assets that
are subsequently measured using another measurement attribute
on the face of the statement of financial position and, in doing so,
does the entity
a.

present the aggregate of those fair value and non-fair-value
amounts in the same line item and parenthetically disclose
the amount of fair value included in the aggregate amount?

b.

present two separate line items to display the fair value and
non-fair-value carrying amounts?
[FASB ASC 320-10-45-1]
Practice Tip

Maturity information may be combined in appropriate groupings. Securities not due at a single maturity
date, such as mortgage-backed securities, may be disclosed separately rather than allocated over several
maturity groupings; if allocated, the basis for allocation also should be disclosed.
(continued)
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Yes

No

N/A

Investments in mutual funds that invest only in U.S. government debt securities may be shown separately
rather than grouped with other equity securities in the disclosures by major security type required by FASB
ASC 942-320-50-2 related to depository and lending entities and the required investment disclosures.
[FASB ASC 320-10-50 par. 3–4]
l 3. Has the entity made the following disclosures for securities classified as held-to-maturity by major security type as of each date
for which a statement of financial position is presented:
a.

Amortized cost basis?

b.

Aggregate fair value?

c.

Gross unrecognized holding gains?

d.

Gross unrecognized holding losses?

e.

Net carrying amount?

f.

Total other-than-temporary impairment recognized in accumulated OCI?

g.

Gross gains and losses in accumulated OCI for any derivatives that hedged the forecasted acquisition of the held-tomaturity securities?

h.

Information about the contractual maturities of those securities as of the date of the most recent statement of financial
position presented?
[“Pending Content” in FASB ASC 320-10-50-5]

.l 4. If the entity presents a classified statement of financial position,
are all individual held-to-maturity securities, individual available-for-sale securities, and individual trading securities reported
as either current or noncurrent, as appropriate, under the current
asset and current liability provisions of FASB ASC 210-10?
[FASB ASC 320-10-45-2]
.l 5. For all investments in an unrealized loss position, including
those that fall within the scope of FASB ASC 325-40, for which
other-than-temporary impairments have not been recognized in
earnings (including investments for which a portion of an otherthan-temporary impairment has been recognized in OCI), does
an entity disclose the following in its interim and annual financial statements:
a.

As of each date for which a statement of financial position
is presented, quantitative information, aggregated by category of investment—each major security type that the entity
discloses in accordance with FASB ASC 320-10 and costmethod investments—in tabular form
i.
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Yes

No

N/A

Practice Tip
The reference point for determining how long an investment has been in a continuous unrealized loss position is the balance sheet date of the reporting period in which the impairment is identified. The continuous
unrealized loss position ceases upon either of the following:
●

The recognition of the total amount by which amortized cost basis exceeds fair value as an otherthan-temporary impairment in earnings

●

The investor becoming aware of a recovery of fair value up to (or beyond) the cost of the investment
during the period.

[“Pending Content” in FASB ASC 320-10-50-8]
ii.
b.

the aggregate amount of unrealized losses (that is, the
amount by which cost exceeds fair value)?

As of the date of the most recent statement of financial position, additional information (in narrative form) that provides sufficient information to allow financial statement
users to understand the quantitative disclosures and the information that the entity considered (both positive and negative) in reaching the conclusion that the impairment or impairments are not other than temporary? (See “Pending
Content” in FASB ASC 320-10-50-6 for example disclosures.)
[“Pending Content” in FASB ASC 320-10-50-6]

.l 6. Has the entity disclosed, for interim and annual periods in which
an other-than-temporary impairment of a debt security is recognized and only the amount related to a credit loss was recognized in earnings, by major security type, the methodology and
significant inputs used to measure the amount related to credit
loss? (Examples include default rates, delinquency rates, percentage of nonperforming assets, loan-to-collateral-value ratios,
third-party guarantees, current levels of subordination, vintage,
geographic concentration and credit ratings.)
[“Pending Content” in FASB ASC 320-10-50-8A]
.l 7. Has the entity disclosed, in tabular format, a rollforward of the
amount related to credit losses recognized in earnings in accordance with FASB ASC 320-10-35-34D, for interim and annual
periods, including, at a minimum,
a.

the beginning balance of the amount related to credit losses
on debt securities held by the entity at the beginning of the
period for which a portion of an other-than-temporary impairment was recognized in OCI?

b.

additions for the amount related to the credit loss for which
an other-than-temporary impairment was not previously
recognized?

c.

reductions for securities sold during the period (realized)?
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d.

reductions for securities for which the amount previously
recognized in OCI was recognized in earnings because the
entity intends to sell the security or more likely than not
will be required to sell the security before recovery of its
amortized cost basis?

e.

if the entity does not intend to sell the security and it is not
more likely than not that the entity will be required to sell
the security before recovery of its amortized cost basis, additional increases to the amount related to the credit loss for
which an other-than-temporary impairment was previously
recognized?

f.

reductions for increases in cash flows expected to be collected that are recognized over the remaining life of the security?

g.

the ending balance of the amount related to credit losses on
debt securities held by the entity at the end of the period
for which a portion of an other-than-temporary impairment
was recognized in OCI?
[“Pending Content” in FASB ASC 320-10-50-8B]

l 8. Has the entity disclosed the following for each period for which
an income statement is presented:
a.

The proceeds from sales of available-for-sale securities and
gross realized gains and losses that have been included in
earnings as a result of those sales?

b.

The basis on which the cost of a security sold or the amount
reclassified out of accumulated OCI into earnings was determined (that is, specific identification, average cost, or
other method used)?

c.

The gross gains and losses included in earnings from transfers of securities from the available-for-sale category to the
trading category?

d.

The amount of the net unrealized holding gain or loss on
available-for-sale securities for the period that has been included in accumulated OCI and the amount of gains and
losses reclassified out of accumulated OCI into earnings for
the period?

e.

The portion of trading gains and losses for the period that
relates to trading securities still held at the reporting date?
[FASB ASC 320-10-50-9]

l 9. Has the entity disclosed the following for any sales of or transfers
from securities classified as held-to-maturity for each period for
which an earnings statement is presented:
a.

Net carrying amount of the sold or transferred security?

b.

The net gain or loss in accumulated OCI for any derivative
that hedged the forecasted acquisition of the held-to-maturity security?

c.

Related realized or unrealized gain or loss?
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d.

No

N/A

The circumstances leading to the decision to sell or transfer
the security?
[FASB ASC 320-10-50-10]

.l 10. Has the entity disclosed its accounting policy for the premium
paid (time value) to acquire an option that is classified as held to
maturity or available for sale, if applicable?
[FASB ASC 815-10-50-9]
.l 11. For the most recent period for which a statement of financial position is presented, does the entity disclose the nature of and carrying amount for every individual investment or group of investments that represents a significant concentration of market
risk?
[FASB ASC 958-320-50-3]
Practice Tip
With regard to question 11, market risk may result from the nature of the investments, a lack of diversity
industry, currency, or geographic location.
[FASB ASC 958-320-50-3]
. 12. For each period for which a statement of financial position is presented, has the not-for-profit entity disclosed he aggregate carrying amount of investments by major types, for example, equity
securities, U.S. Treasury securities, corporate debt securities,
mortgage-backed securities, oil and gas properties, and real estate?
[FASB ASC 958-320-50-2]
. 13. Are realized gains and losses; unrealized gains and losses; dividend, interest, and other similar investment income; and other
than temporary impairment losses reported in the statement of
activities as increases or decreases in unrestricted net assets or in
temporarily restricted net assets or in permanently restricted net
assets, depending on the existence of or lack of donor restrictions
or law?
[FASB ASC 958-320-45 par. 1–2]
. 14. Have the following investment returns been included in the performance indicator:
a.

Dividend, interest, and other similar investment income?

b.

Realized gains and losses?

c.

Unrealized gains and losses on trading securitites (as defined in FASB ASC 320)?

d.

Other than temporary impairment losses?
[FASB ASC 954-320-45-1]
Practice Tips

With regard to question 14, unrealized gains and losses on other than trading securities should be excluded
from the performance indicator.
[FASB ASC 954-320-45-1]
(continued)
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No

N/A

For examples of other items that should be reported separately from the performance indicator, see FASB
ASC 954-225-45-7.
[FASB ASC 954-225-45-7]
. 15.

Have gains and investment income that are limited to specific
uses by donor-imposed restrictions reported as increases in unrestricted net assets, if (a) the restrictions are met in the same
reporting period as the gains and income are recognized, provided that the not-for-profit entity has a similar policy for reporting contributions received, (b) reports consistently from period to period, and (c) discloses it accounting policy.
[FASB ASC 958-320-45-3]

. 16.

For cost-method investments, does the entity disclose the following additional information, if applicable, as of each date for
which a statement of financial position is presented in its annual financial statements:

. 17.

a.

The composition of investment return including, at a minimum, investment income, net realized gains or losses on
investments reported at other than fair value, and net
gains or losses on investments reported at fair value?

b.

A reconciliation of investment return to amounts reported
in the statement of activities if investment return is separated into operating and nonoperating amounts?

c.

A description of the policy used to determine the amount
that is included in the measure of operations and a discussion of circumstances leading to a change, if any, in
that policy?
[FASB ASC 958-320-50-1]

For each period for which a statement of financial position is
presented, are the following disclosures made on the face of the
financial statements or in the notes thereto:
a.

The basis for determining the carrying amount for other
investments?

b.

The method(s) and significant assumptions used to estimate the fair values of investments other than financial
instruments if those other investments are reported at fair
value?

c.

The information required by FASB ASC 320-10-50-6(a),
question 5 of the preceding, if the not-for-profit entity
holds cost-method investments that are in an unrealized
loss position for which impairment losses have not been
recognized?

d.

The information required by FASB ASC 325-20-50-1, in
question 12?
[FASB ASC 958-325-50-2]
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. 18.

No

N/A

For the most recent period for which a statement of financial
position is presented, does the not-for-profit entity disclose the
nature of and carrying amount for every individual investment
or group of investments that represents a significant concentration of market risk (market risk may result from the nature of
the investments, a lack of diversity of industry, currency, or geographic location)?
[FASB ASC 958-320-50-3]
Practice Tip

Information about realized and unrealized gains and losses and about historical costs of investments may
be useful in some circumstances. For example, if a state adopted a law that allows a not-for-profit entity to
spend only realized gains or if a not-for-profit entity pays taxes on realized gains and losses, information
that distinguishes between realized and unrealized amounts may be useful. FASB ASC 958-320-50 does not
preclude disclosing that information.
[FASB ASC 958-320-50-5]
.l 19.

. 20.

For cost-method investments, does the entity disclose the following additional information, if applicable, as of each date for
which a statement of financial position is presented in its annual
financial statements:
a.

The aggregate carrying amount of all cost-method investments?

b.

The aggregate carrying amount of cost-method investments that the entity did not evaluate for impairment (see
FASB ASC 325-20-35)?

c.

The fact that the fair value of a cost-method investment is
not estimated if there are no identified events or changes
in circumstances that may have a significant adverse effect
on the fair value of the investment, and
i.

the entity determined, in accordance with paragraphs 16–19 of FASB ASC 825-10-50, that it is not
practicable to estimate the fair value of the investment;

ii.

the entity is exempt from estimating fair value under
FASB ASC 825; or

iii.

the entity is exempt from estimating interim fair values because it does not meet the FASB ASC definition of a publicly traded company?
[“Pending Content” in FASB ASC 325-20-50-1]

Are cash flows from purchases, sales, and maturities of available-for-sale securities and held-to-maturity securities classified
as cash flows from investing activities and reported gross for
each security classification in the statement of cash flows?
[FASB ASC 320-10-45-11]
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. 21.

Are cash flows from purchases, sales, and maturities of trading
securities classified as cash flows based on the nature and purpose for which the securities were acquired (generally, operating activities) in the statement of cash flows?
[FASB ASC 320-10-45-11]

.l 22.

Has the entity made following disclosures for investments in
common stock accounted for by the equity method:
a.

The name of each investee and their percentage of ownership of common stock?

b.

The accounting policies of the investor with respect to investments in common stock?

c.

The difference between the amount at which an investment is carried and the amount of underlying equity in net
assets, and the accounting treatment of this difference?

d.

For investments in common stock for which a quoted market price is available, the aggregate value of each identified investment based on the quoted market price? (This is
not required for investments in common stock of subsidiaries.)

e.

For investments in common stock, corporate joint ventures, or other investments which are in the aggregate material in relation to the financial position or results of operations of an investor, summarized information as to
assets, liabilities, and results of operation of the investees
as appropriate?

f.

Material effects of conversions of outstanding convertible
securities, exercises or contingent issuances?
[FASB ASC 323-10-50-3]
.l 23.

.l 24.

.l 25.

If the entity holds 20 percent or more of the voting stock of a
significant investee corporation but does not account for the investment using the equity method, are the following disclosed:
a.

The name of such investee?

b.

The reasons why the equity method is not considered appropriate?
[FASB ASC 323-10-50-3(a)(2)]

If the entity holds less than 20 percent of the voting stock of a
significant investee corporation and accounts for the investment
using the equity method, are the following disclosed:
a.

The name of such investee?

b.

The reasons why the equity method is considered appropriate?
[FASB ASC 323-10-50-3(a)(2)]

Upon loss of significant influence, has the investor recorded the
proportionate share of an investee’s equity adjustments for
other comprehensive income (OCI) as offset against the carrying
value of the investment at the time significant influence is lost?
[FASB ASC 323-10-35-39]
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.l 26.

No

N/A

To the extent that the offset results in a carrying value of the
investment that is less than zero has the investor (a) reduced the
carrying value of the investment to zero and (b) recorded the
remaining balance in income?
[FASB ASC 323-10-35-39]
Practice Tip

FASB ASC 323-10-35-39 does not provide guidance for entities that have historically not recorded their proportionate share of an investee’s equity adjustments for OCI. These entities should refer to the correction-oferror guidance in FASB ASC 250-10-45-2.
[FASB ASC 323-10-35-39]
.l 27.

D.

When previous losses have reduced the common stock investment account to zero (as discussed in paragraphs 27–28 of FASB
ASC 323-10-35), is the selected policy disclosed for determining
the amount of equity losses?
[Common Practice]

Receivables and Loans
Notes: In December 2008, FASB issued FSP FAS 140-4 and FIN 46(R)8 to amend FASB Statement No. 140 to require public entities (enterprises) to provide additional disclosures about transfers of financial
assets. It also amends FASB Interpretation No. 46(R) to require public
enterprises, including sponsors that have a variable interest in a VIE,
to provide additional disclosures about their involvement with VIEs.
Additionally, this FSP requires certain disclosures to be provided by
a public enterprise that is (a) a sponsor of a QSPE that holds a variable interest in the QSPE but was not the transferor (nontransferor) of
financial assets to the QSPE and (b) a servicer of a QSPE that holds a
significant variable interest in the QSPE but was not the transferor
(nontransferor) of financial assets to the QSPE. The disclosures required by this FSP are intended to provide greater transparency to
financial statement users about a transferor’s continuing involvement
with transferred financial assets and an enterprise’s involvement with
VIEs and QSPEs.
This FSP applies to public entities that are subject to the disclosure
requirements of FASB Statement No. 140 and public enterprises that
are subject to the disclosure requirements of FASB Interpretation No.
46(R) as amended by this FSP.
This FSP is effective for the first reporting period (interim or annual)
ending after December 15, 2008 (that is, December 31, 2008, for entities with calendar year-ends), with earlier application encouraged.
This FSP applies to each annual and interim reporting period thereafter. An entity (enterprise) is encouraged, but not required, to disclose comparative information in periods earlier than the effective
date for disclosures that were not previously required for public entities (enterprises) by FASB Statement No. 140 and FASB Interpretation No. 46(R). In periods after initial adoption, comparative dis(continued)
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closures for those disclosures that were not previously required for
public entities (enterprises) by FASB Statement No. 140 and FASB Interpretation No. 46(R) are required only for periods subsequent to the
effective date.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 140-4 and FIN 46(R)-8.
Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 860-1065-2.
Readers should be aware that this FSP was superseded by FASB
Statement No. 166 and FASB Statement No. 167. Both FASB Statement No. 167 and FASB Statement No. 166 are effective as of the beginning of each reporting entity’s first annual reporting period that
begins after November 15, 2009 (that is, January 1, 2010, for entities
with calendar year-ends), for interim periods within that first annual
reporting period, and for interim and annual reporting periods thereafter. Earlier application is prohibited.
This checklist has not been updated to include the presentation and
disclosure requirements of FASB Statement No. 166 or FASB Statement No. 167.
Readers can refer to the full texts of these statements on the FASB
Web site at www.fasb.org.
.l 1.

Are charity care revenue and receivables excluded from the financial statements?
[FASB ASC 954-605-25-10]

.l 2.

Are differences between the estimates originally reported and
subsequent revisions, including final settlements:
a.

Included in the statement of activities/income statement
in the period the revisions are made and disclosed, if material?

b.

Reported in the current period unless they meet the criteria for prior-period adjustments?
[FASB ASC 954-605-35-1]

.l 3.

Has the entity disclosed the differences between original estimates and subsequent revisions (including final settlements)
under retrospective-rate setting methods?
[FASB ASC 954-605-50-2]

.l 4.

Are amounts due from third-party payors for retroactive adjustments of items (such as final settlements or appeals) reported
separately in the financial statements?
[FASB ASC 954-310-45-1]

. 5.

When displaying total assets and total liabilities, are interfund
assets and liabilities eliminated?
[FASB ASC 954-210-45-3]

FSP §11,100.01

No

N/A

41

Financial Statements and Notes Checklist

Yes
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N/A

Practice Tip
FASB ASC 958-320 does not preclude display of interfund items in a statement of financial position; rather,
its requirement to display total assets and liabilities results in certain practical limits on how interfund items
are displayed in a financial statement. For example, because receivables and payables between fund groups
are not entity assets or liabilities, a statement of financial position shall clearly label and arrange those interfund items to eliminate their amounts when displaying total assets or liabilities.
[FASB ASC 958-320-50-5]
. 6. Do entities that receive unconditional promises to give disclose
the following:
a.

The amounts of promises receivable in less than one year,
in one to five years, and in more than five years?

b.

The amount of any allowance for uncollectible promises receivable?
[FASB ASC 958-310-50-1]
Practice Tips

As illustrated in FASB ASC 958-605-55-22, the allowance for uncollectible promises to give does not include
amounts determined to be uncollectible when the contributions receivable were initially measured.
[FASB ASC 958-310-50-2]
If unconditional promises to give are subsequently measured at fair value, the disclosures in the following
paragraphs should also be made in the notes to financial statements:
●

Disclosures required by paragraphs 1–2 of FASB ASC 820-10-50 in the format described in FASB
ASC 820-10-50-8

●

Disclosures required by paragraphs 28–31 of FASB ASC 825-10-50

●

Disclosures required by FASB ASC 825-10-50-32, if an election to report unconditional promises to
give is made after initial recognition pursuant to FASB ASC 825-10-25-4(e).

[FASB ASC 958-310-50-3]
. 7.

Do entities that receive conditional promises to give disclose the
following:
a.

The total of the amounts promised?

b.

A description and amount for each group of promises having similar characteristics (such as amount of promises conditioned on establishing new programs, completing a new
building, and raising matching gifts by a specified date)?
[FASB ASC 958-310-50-4]

.l 8.

Are allowances for uncollectible receivables shown as deductions
from the related receivables?
[FASB ASC 310-10-45-4; FASB ASC 310-10-50-14; FASB ASC 954310-45-1]

.l 9.

Are accounts and notes receivable from officers, employees, and
affiliated entities shown separately with appropriate disclosures,
and not included under a general heading such as notes receivable or accounts receivable?
[FASB ASC 310-10-45-13; FASB ASC 850-10-50-2]
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.l 10. Are unbilled receivables shown separately from billed receivables?
[Common Practice]
.l 11. Are unbilled costs and fees under cost-plus-fixed fee contracts
shown as receivables rather than advances or inventory?
[FASB ASC 912-310-25-1]
.l 12. For each period for which results of operations are presented,
has the entity disclosed the activity in the total allowance for
credit losses related to loans, including
a.

the balance in the allowance at the beginning and end of
each period?

b.

additions charged to operations?

c.

direct write-downs charged against the allowance?

d.

recoveries of amounts previously charged off?
[FASB ASC 310-10-50-12]

.l 13. Are unearned discounts (other than cash or quantity discounts
and the like), finance charges, and interest included in the face
amounts of receivables shown as a deduction from the related
receivables?
[FASB ASC 310-10-45-8]
.l 14. If a note is noninterest bearing or has an inappropriate stated
interest rate,
a.

is the discount or premium presented as a deduction from
or addition to the face amount of the note?

b.

does the disclosure include the effective interest rate and
face amount of the note?

c.

is amortization of discount or premium reported as interest
in the income statement?

d.

are issue costs reported on the balance sheet as deferred
charges?
[FASB ASC 835-30-45 par. 1A and 2–3]

.l 15. Does the accounting policy note disclosure include the following:
a.

The basis of accounting for loans, trade receivables, and
lease financings, including those classified as held for sale?

b.

The method used in determining the lower of cost or fair
value of nonmortgage loans held for sale (that is aggregate
or individual asset basis)?

c.

The method for recognizing interest income on loan and
trade receivables, including a statement about the entity’s
policy for treatment of related fees and costs, including the
method of amortizing net deferred fees or costs?

d.

The classification and method of accounting for interestonly strips, loans, other receivables, or retained interests in
securitizations that can be contractually prepaid or otherwise settled in a way that the holder would not recover
substantially all of its recorded investment?
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e.

In addition to the loss contingencies disclosures required by
FASB ASC 450-20, a description of the accounting policies
and methodology the entity used to estimate its allowance
for loan losses, allowance for doubtful accounts, and any
liability for off-balance sheet credit losses, and related
charges for loan, trade receivable or other credit losses, including a description of the factors that influenced management’s judgment?

f.

The policy for placing loans (and trade receivables if applicable) on nonaccrual status (or discontinuing accrual of interest) and recording payments received on nonaccrual
loans (and trade receivables if applicable), and the policy
for resuming accrual of interest?

g.

The policy for charging off uncollectible loans and trade receivables?

h.

The policy for determining past due or delinquency status
(that is, whether past due status is based on how recently
payments have been received or contractual terms)?
[FASB ASC 310-10-50 par. 2, 6, and 9]

No

N/A

.l 16. Has the entity disclosed the aggregate amount of gains or losses
on sales of loans or trade receivables (including adjustments to
record loans held for sale at the lower of cost or fair value) separately in the financial statements or in the notes to the financial
statements?
[FASB ASC 860-20-50-5]
.l 17. Loans or trade receivables may be presented on the balance sheet
as aggregated amounts. However, are the following exceptions
disclosed:
a.

Are loans or trade receivables held for sale presented on the
balance sheet in a separate category?

b.

Are major categories of loans or trade receivables presented
separately either in the balance sheet or in the notes to the
financial statements?

c.

Are the allowance for credit losses, the allowance for
doubtful accounts, and, as applicable, any unearned income, any unamortized premiums and discounts, and any
net unamortized deferred fees and costs, disclosed in the
financial statements?
[FASB ASC 310-10-45 par. 2–4]

.l 18. Are foreclosed and repossessed assets classified as a separate balance-sheet amount or included in other assets on the balance
sheet with separate disclosures in the notes to the financial statements?
[FASB ASC 310-10-45-3; FASB ASC 310-10-50-11]
.l 19. Are certain returned or repossessed assets, such as inventory,
subsequently to be utilized by the entity in operations, not classified separately?
[FASB ASC 310-10-45-3]
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.l 20. Is the valuation allowance for loans prior to foreclosure not carried over as a separate element of the cost basis in the foreclosed
asset for purposes of accounting for the long-lived asset under
FASB ASC 360, Property, Plant, and Equipment, after foreclosure?
[FASB ASC 310-40-40-10]
.l 21. Is the recorded investment in loans (and trade receivables if applicable) on nonaccrual status as of each balance sheet date disclosed in the notes to the financial statements?
[FASB ASC 310-10-50-7]
.l 22. Is the recorded investment in loans (and trade receivables if applicable) past due 90 days or more and still accruing disclosed?
[FASB ASC 310-10-50-7]
.l 23. Insurance subsidiaries may be required to deposit securities with
state regulatory authorities. If so, is the carrying amount of securities deposited disclosed?
[FASB ASC 944-320-50-1]
.l 24. Is the carrying amount of loans, trade receivables, securities and
financial instruments that serve as collateral for borrowings disclosed pursuant to ASC 860-30-50-1(b) for public entities and
pursuant to FASB ASC 860-30-50-4(b) for nonpublic entities?
[“Pending Content” in FASB ASC 310-10-50-5]
.l 25. Do the notes to financial statements describe how prepayments
are considered in the determination of contractual cash flows
and cash flows expected to be collected?
[FASB ASC 310-30-50-1]
.l 26. Is information about loans meeting the scope criteria of FASB
ASC 310-30 included in the disclosures required by FASB ASC
310-10-50-15(a) and 15(b) if the condition in paragraphs 18–34 of
FASB ASC 320-10-35 or FASB ASC 450-20-25-2(a), as discussed
in paragraphs 8(a) and 10(a) of FASB ASC 310-30-35 is met?
[FASB ASC 310-10-50-18]
.l 27. For each balance sheet presented, has the entity disclosed the following information about loans within the scope of FASB ASC
310-30:
a.

FSP §11,100.01

Separately for both those loans that are accounted for as
debt securities and those loans that are not accounted for as
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i.

the outstanding balance and related carrying amount
at the beginning and end of the period?

ii.

the amount of accretable yield at the beginning and
end of the period, reconciled for additions, accretion,
disposals of loans, and reclassifications to or from
nonaccretable difference during the period?

iii.

for loans acquired during the period, the contractually
required payments receivable, cash flows expected to
be collected, and fair value at the acquisition date?
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iv.

b.

No

N/A

for those loans within the scope of FASB ASC 310-30
for which the income recognition model is not applied
in accordance with FASB ASC 310-30-35-3, the carrying amount at the acquisition date for loans acquired
during the period and the carrying amount of all
loans at the end of the period?

Further, for those loans that are not accounted for as debt
securities, has the entity disclosed
i.

the amount of (a) any expense recognized pursuant to
FASB ASC 310-30-35-10(a) and (b) any reductions of
the allowance recognized pursuant to FASB ASC 31030-35-10(b)(1). For each period for which an income
statement is presented?

ii.

the amount of the allowance for uncollectible accounts
at the beginning and end of the period?
[FASB ASC 310-30-50-2]

.l 28. For financial instruments, are significant concentrations of credit
risk arising from receivables disclosed?
[FASB ASC 954-310-50-2]
E.

Inventories

Practice Tip
The following disclosure represents an SEC requirement under Regulation S-X, Rule 5-02, Balance Sheets, for
public entities. Although this is not required for nonpublic entities, it has become common practice for
entities to implement this disclosure.
.l 1. Are the major classes of inventory disclosed (for example, finished goods, work in process, and raw materials)?
[Common Practice]
Practice Tip
Disclosures required of entities using last in, first out (LIFO) of annual income, profit, or loss of any inventory basis other than LIFO may be made only in the notes to the financial statements or in a supplementary
schedule and should be excluded from the face of the financial statements. (However, the SEC requires in
Regulation S-X that, if the LIFO inventory method is used, public entities state parenthetically or in a note
to financial statements the excess of replacement or current cost over stated LIFO value, if material.)
.l 2. Have amounts at which current assets are stated supplemented
by information that reveals, for the various classifications of inventory items, the basis upon which their amounts are stated,
and where practicable, indication of the method of determining
the cost (for example, is the method of determining inventory
cost like LIFO and first in, first out disclosed)?
[FASB ASC 210-10-50-1]
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Yes

No

N/A

.l 3. Has the basis of stating inventories been consistently applied and
disclosed in the financial statements (for example, lower of cost
or market)?
[FASB ASC 330-10-50-1]
Practice Tip
Whenever a significant change is made in the basis of stating inventory, there should be disclosure of the
nature of the change and, if material, the effect on income. A change of such basis may have an important
effect upon the interpretation of the financial statements both before and after that change, and hence, in the
event of a change, a full disclosure of its nature and of its effect, if material, upon income should be made.
[FASB ASC 330-10-50-1]
.l 4.

Are valuation allowances for inventory losses shown as a deduction from the related inventory?
[FASB ASC 310-10-45-4]

.l 5.

If substantial and unusual losses have resulted from the application of the rule of lower of costs or market has disclosure been
made (normally as a charge separately identified from the consumed inventory costs described as cost of goods sold)?
[FASB ASC 330-10-50-2]

.l 6.

If goods are stated above cost, has that fact been fully disclosed?
[FASB ASC 330-10-50-3]

.l 7.

If goods are stated at sales prices, has that fact been fully disclosed?
[FASB ASC 330-10-50-4]

.l 8.

Are net losses on firm purchase commitments for goods for inventory disclosed separately in the income statement?
[FASB ASC 330-10-50-5]

F.

Beneficial Interests in Assets Held by Others
. 1.

If the entity transferred assets to a recipient entity in an equity
transaction, has it disclosed the following information (as required by FASB ASC 958-605-50-6 for each period for which a
statement of financial position is presented):
[FASB ASC 958-20-50-1]
a.

The identity of the recipient entity to which the transfer was
made?

b.

Whether variance power was granted to the recipient entity
and, if so, a description of the terms of the variance power?

c.

The terms under which amounts will be distributed to the
resource provider or its affiliate?

d.

The aggregate amount recognized in the statement of financial position for those transfers and whether that amount is
recorded as an interest in the net assets of the recipient entity or as another asset (for example, as a beneficial interest
in assets held by others or a refundable advance)?
[FASB ASC 958-605-50-6]
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G.

No

N/A

Property and Equipment and Supplies
. 1.

.l 2.

.l 3.

.l 4.
. 5.

. 6.

Are the following policies related to property and equipment disclosed by the not-for-profit entity, in the notes to financial statements:
a.

The capitalization policy adopted?

b.

The capitalization policy for collections (capitalization, prospective capitalization, or no capitalization)?

c.

The basis of valuation of property, plant, and equipment—for example, cost for purchased items and fair value
for contributed items?
[FASB ASC 958-360-50-1]

For depreciable assets, do the financial statements include disclosure of
a.

depreciation expense for each period?

b.

balances of major classes of depreciable assets by nature or
function?

c.

accumulated depreciation, either by major classes of assets
or in total?

d.

the method or methods used in computing depreciation for
each major class of depreciable assets?
[FASB ASC 360-10-50-1]

Is the following information concerning interest costs disclosed:
a.

For accounting periods in which no interest is capitalized,
the amount of interest cost incurred and charged to expense
during the period?

b.

For an accounting period in which some interest cost is capitalized, the total amount of interest cost incurred during
the period and the amount thereof that has been capitalized?
[FASB ASC 835-20-50-1]

Are material commitments for property expenditures disclosed?
[FASB ASC 440-10-50-1]
Have separate disclosures been made for the following:
a.

Nondepreciable assets?

b.

Property and equipment not held for use in operations, for
example, items held for sale or for investment purposes or
construction in process?

c.

Improvements to leased facilities and equipment?
[FASB ASC 958-360-50-2]

Has disclosure been made regarding the liquidity of property,
plant, and equipment, including information about limitations on
their use, such as
a.

property, plant, and equipment pledged as collateral or otherwise subject to lien?

FSP §11,100.01

48

Health Care Entities

Yes

H.

b.

donor or legal limitations on the use of or proceeds from
the disposal of plant, property, and equipment?

c.

property, plant, and equipment acquired with restricted assets if title may revert to another party, such as a resource
provider?

d.

the terms of exchange transactions (other than lease transactions), such as federal contracts, in which the resource
provider retains legal title during the term of the arrangement but it is probable that the not-for-profit entity will be
permitted to keep the assets when the arrangement terminates?
[FASB ASC 958-360-50 par. 3–4]

. 7.

If not presented separately on the face of the statement of financial position pursuant to FASB ASC 958-360-45-4, has the amount
capitalized for works of art, historical treasures, and similar assets that do not meet the definition of a collection, been disclosed?
[FASB ASC 958-360-50-5]

. 8.

If the not-for-profit entity does not recognize and capitalize its
collections or capitalizes collections prospectively, has it disclosed its collections, including their relative significance and its
stewardship policies for those collections? (If collection items not
capitalized are deaccessed during the period, it also shall describe the items given away, damaged, destroyed, lost, or otherwise deaccessed during the period or disclose their fair value.)
[FASB ASC 958-360-50-6]

Deferred Income Tax Assets and Liabilities
l 1.

Are the components of the net deferred tax liability or asset recognized in the balance sheet disclosed as follows:
a.

The total of all deferred tax liabilities (measured as described in FASB ASC 740-10-30-5(b))?

b.

The total of all deferred tax assets (measured as described
in (c) and (d) of FASB ASC 740-10-30-5)?

c.

The total valuation allowance recognized for deferred tax
assets (measured as described in FASB ASC 740-10-30-5(e))?
[FASB ASC 740-10-50-2]

l 2.

Is the net change during the year in the valuation allowance disclosed?
[FASB ASC 740-10-50-2]

l 3.

Are deferred tax assets and liabilities classified as current or noncurrent based on the classification of the related asset or liability?
[FASB ASC 740-10-45-4]

l 4.

Are deferred tax assets not related to an asset or liability for financial reporting (see paragraphs 25–26 of FASB ASC 740-10-25),
including those related to carryforwards, classified according to
the expected reversal date of the temporary difference?
[FASB ASC 740-10-45-9]
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l 5.

I.

No

N/A

For each particular tax-paying component of the reporting entity
and within each particular tax jurisdiction:
a.

Are all current deferred tax liabilities and assets offset and
presented as a single amount?

b.

Are all noncurrent deferred tax liabilities and assets offset
and presented as a single amount?
[FASB ASC 740-10-45-6]

l 6.

Is the valuation allowance for each particular tax jurisdiction allocated between current and noncurrent deferred tax assets for
that jurisdiction on a pro rata basis?
[FASB ASC 740-10-45-5]

l 7.

(Issuers Only) Has the entity disclosed the types of temporary
differences and carryforwards that give rise to a significant portion of deferred tax liabilities and deferred tax assets (before valuation allowances) and if the entity is not subject to income taxes
because its income is taxed directly to its owners, is that fact and
the net difference between the tax bases and reported amounts of
the enterprises’ assets and liabilities disclosed?
[FASB ASC 740-10-50 par. 6–7 and 16]

l 8.

(Nonissuers Only) Has the entity disclosed the types of temporary differences and carryforwards that give rise to a significant
portion of deferred tax liabilities and deferred tax assets (before
valuation allowances)?
[FASB ASC 740-10-50-8]

Other Assets and Deferred Charges

.l 1.

Has the entity made the following disclosures for computer software to be sold, leased, or otherwise marketed:
a.

The amount of unamortized computer software costs included in each balance sheet presented?
[FASB ASC 985-20-50-1(a)]

b.

The amount charged to expense for amortization of these
costs and for amounts written down to net realizable value
disclosed in each income statement presented?
[FASB ASC 985-20-50-1(b)]

c.

The amount of research and development expense incurred
for computer software to be sold, leased, or otherwise marketed charged to expense in each period for which an income statement is presented?
[FASB ASC 985-20-50-2; FASB ASC 730-10-50-1]

.l 2.

Is any payment by an S Corporation to the IRS to retain its fiscal
year for tax purposes classified as an asset (deposit)?
[FASB ASC 740-10-55-71]

.l 3.

Have investments in life insurance been reported at amounts that
can be realized as of the statement-of-financial-position date and
calculated in accordance with FASB ASC 325-30?
[FASB ASC 325-30-35-1]

.l 4.

Are investments in life insurance reported using one of the following measurements:
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.l 5.

a.

Transaction price plus all initial direct external costs, which
is then tested for impairment?
[FASB ASC 325-30-30-1C; FASB ASC 325-30-35-10]

b.

Fair value?
[FASB ASC 325-30-30-2; FASB ASC 325-30-35-12]

If the entity chooses to report using measurement (a) or (b) in
question 4, do the financial statements include all of the following disclosures required by FASB ASC 325-30-45 and FASB ASC
325-30-50 in questions 6–16?

Presentation on the Statement of Financial Position
.l 6.

To accomplish separate reporting, has the entity reported its investments that are remeasured at fair value on the face of the
statement of financial position separately from those accounted
for under the investment method by
a.

displaying separate line items on the statement of financial
position for the fair value method and investment method
carrying amounts?

b.

presenting the aggregate of those fair value method and investment method carrying amounts and parenthetically disclose the amount of those investments accounted for under
the fair value method included in the aggregate amount?
[FASB ASC 325-30-45-1]

Presentation in the Income Statement
.l 7.

To accomplish separate reporting, has the entity reported the investment income from its investments in life settlement contracts
that are remeasured at fair value on the face of the income statement separately from the investment income from those accounted for under the investment method by
a.

displaying separate line items on the income statement for
the investment income from the investments in life settlement contracts that are accounted for under the fair value
method and investment method?

b.

presenting the aggregate of the investment income in life
settlement contracts and parenthetically disclose the investment income from those investments accounted for under
the fair value method that are included in the aggregate
amount?
[FASB ASC 325-30-45-2]

Presentation in the Statement of Cash Flows
.l 8.

Has the entity classified cash receipts and cash payments related
to life settlement contracts pursuant to FASB ASC 230, Statement
of Cash Flows, based on the nature and purpose for which the life
settlements were acquired?
[FASB ASC 325-30-45-3]
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Yes

No

N/A

Disclosure Requirements
.l 9.

Has the entity disclosed its accounting policy for life settlement
contracts including the classification of cash receipts and cash
disbursements in statement of cash flows? (Note: The disclosure
requirements in FASB ASC 325-30-50 do not eliminate disclosure
requirements included in elsewhere in FASB ASC, including
other disclosure requirements on the use of fair value.)
[FASB ASC 325-30-50 par. 2–3]

Investment Method
.l 10. Has the entity disclosed the following for life settlements contracts accounted for under the investment method based on the
remaining life expectancy for each of the first five succeeding
years from the date of the statement of financial position and
thereafter, as well as in the aggregate:
a.

The number of life settlement contracts?

b.

The carrying value of the life settlement contracts?

c.

The face value (death benefits) of the life insurance policies
underlying the contracts?
[FASB ASC 325-30-50-4]

.l 11. Has the entity disclosed the life insurance premiums anticipated
to be paid for each of the five succeeding fiscal years to keep the
life settlement contracts in force as of the date of the most recent
statement of financial position presented?
[FASB ASC 325-30-50-5]
.l 12. If the entity becomes aware of new or updated information that
causes it to change its expectations on the timing of the realization of proceeds from the investments in life settlement contracts,
has the investor disclosed the nature of the information and the
related effect on the timing of the realization of proceeds from
the life settlement contracts, including disclosing significant
changes to the amounts disclosed in accordance with FASB ASC
325-30-50-4? (Note: The investor is required to actively seek out
new or updated information to update the assumptions used in
determining the remaining life expectancy of the life settlement
contracts.)
[FASB ASC 325-30-50-6]
Fair Value Method
.l 13. Has the entity disclosed the method(s) and significant assumptions used to estimate the fair value of investments in life settlement contracts, including any mortality assumptions?
[FASB ASC 325-30-50-7]
.l 14. Has the entity disclosed the following for life settlement contracts
accounted for under the fair value method based on remaining
life expectancy for each of the first five succeeding years from the
date of the statement of financial position and thereafter, as well
as in the aggregate:
a.

The number of life settlement contracts?

b.

The carrying value of the life settlement contracts?
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c.

The face value (death benefits) of the life insurance policies
underlying the contracts?
[FASB ASC 325-30-50-8]

.l 15. Has the entity disclosed the reasons for changes in its expectation
of the timing of the realization of the investments in life settlement contracts, including disclosing significant changes to the
amounts disclosed in accordance with FASB ASC 325-30-50-8?
[FASB ASC 325-30-50-9]
.l 16. Has the investor disclosed the following for each reporting period presented in the income statement:
a.

The gains or losses recognized during the period on investments sold during the period?

b.

The unrealized gains or losses recognized during the period
on investments that are still held at the date of the statement of financial position?
[FASB ASC 325-30-50-10]

Other Matters
.l 17. Has the policyholder disclosed when contractual restrictions on
the ability to surrender a policy exist?
[FASB ASC 325-30-50-1]
J.

Intangible Assets and Goodwill
Notes: In April 2008, FASB issued FSP FAS 142-3 to improve the consistency between the useful life of a recognized intangible asset under
FASB Statement No. 142 and the period of expected cash flows used
to measure the fair value of the asset under FASB Statement No.
141(R) and other U.S. GAAP. This FSP applies to recognized intangible assets that are accounted for pursuant to FASB Statement No. 142
and applies regardless of the nature of the transaction that resulted in
the recognition of the intangible asset, that is, whether acquired in a
business combination or otherwise.
Among other significant provisions, FSP FAS 142-3 provides that, in
determining the useful life of the intangible asset for amortization
purposes, an entity should consider the period of expected cash flows
used to measure the fair value of the recognized intangible asset, adjusted for the entity-specific factors in paragraph 11 of FASB Statement No. 142. This FSP contains several disclosures requirements in
addition to the required disclosures in paragraphs 44–45 of FASB
Statement No. 142, including information that enables users of financial statements to assess the extent to which the expected future cash
flows associated with the intangible asset are affected by the entity’s
intent or ability to renew or extend the arrangement, or both.
FSP FAS 142-3 is effective for financial statements issued for fiscal
years beginning after December 15, 2008 , (that is, January 1, 2009, for
entities with calendar year-ends), and interim periods within those
fiscal years. Early adoption is prohibited.
This checklist has been updated to include the presentation and disclosure requirements of FASP FAS 142-3.
(continued)
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As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should
consider all questions indicated with an “A” reference (for example,
question 1A and question 2A) and should place an “N/A” mark in
questions indicated with a “B” reference. Entities for which the guidance has been implemented should consider all questions indicated
by a “B” reference (for example, question 1B and question 2B) and
place an “N/A” mark by questions indicated with an “A” reference.
Therefore, based upon your entity’s year-end and decision to early
implement or not (if allowed), the following additional questions will
be answered when provided in this section (check one that applies for
your entity):
pppA pppB
Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 350-1065-1.
******
In December 2007, FASB issued Statement No. 141(R) to improve the
relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial reports
about a business combination and its effects. FASB Statement No.
141(R) supersedes FASB Statement No. 141 but retains the fundamental requirements in FASB Statement No. 141 that the acquisition
method of accounting (formerly called the purchase method in FASB
Statement No. 141) be used for all business combinations and that an
acquirer be identified for each business combination.
Among many other significant amendments to existing pronouncements precipitated by FASB Statement No. 141(R), this statement redefines goodwill in FASB Statement No. 142 to mean an asset representing the future economic benefits arising from other assets
acquired in a business combination that are not individually identified and separately recognized.
FASB Statement No. 141(R) applies to all transactions or other events
in which an entity (the acquirer) obtains control of one or more businesses (the acquiree), including those sometimes referred to as true
mergers or mergers of equals and combinations achieved without the
transfer of consideration, for example, by contract alone or through
the lapse of minority veto rights. This statement applies to all business entities, including mutual entities that previously used the pooling-of-interests method of accounting for some business combinations. It does not apply to the following:
a.

The formation of a joint venture

b.

The acquisition of an asset or a group of assets that does not
constitute a business
(continued)

FSP §11,100.01

54

Health Care Entities

Yes

c.

A combination between entities or businesses under common
control

d.

A combination between not-for-profit entities or the acquisition of a for-profit business by a not-for-profit entity.

No

N/A

This statement applies prospectively to business combinations for
which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008 (that
is, January 1, 2009, for entities with calendar year-ends). An entity
may not apply it before that date.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 141(R).
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should
consider all questions indicated with an “A” reference (for example,
question 1A and question 2A) and should place an “N/A” mark in
questions indicated with a “B” reference. Entities for which the guidance has been implemented should consider all questions indicated
by a “B” reference (for example, question 1B and question 2B) and
place an “N/A” mark by questions indicated with an “A” reference.
Therefore, based upon your entity’s year-end and decision to early
implement or not (if allowed), the following additional questions will
be answered when provided in this section (check one that applies for
your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 805-1065-1.

Practice Tip
Entities that report segment information in accordance with FASB ASC 280, Segment Reporting, should provide the following information about goodwill in total and for each reportable segment and should disclose
any significant changes in the allocation of goodwill by reportable segment. If any portion of goodwill has
not yet been allocated to a reporting unit at the date the financial statements are issued, that unallocated
amount and the reasons for not allocating that amount should be disclosed.
[FASB ASC 350-20-50-1]
l 1.
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Yes
l 2.

Is the aggregate amount of goodwill impairment losses presented as a separate line item in the income statement before
the subtotal income from continuing operations (or similar caption) unless a goodwill impairment loss is associated with a
discontinued operation?
[FASB ASC 350-20-45-2]

l 3.

Is a goodwill impairment loss associated with a discontinued
operation included (on a net-of-tax basis) within the results of
discontinued operations?
[FASB ASC 350-20-45-3]

l 4A.

Has the entity disclosed any changes in the carrying amount
of goodwill during the period, including the following (see
example 3 in FASC ASC 350-20-55-24):

l 4B.

a.

The aggregate amount of goodwill acquired?

b.

The aggregate amount of impairment losses recognized?

c.

The amount of goodwill included in the gain or loss on
disposal of all or a portion of a reporting unit?
[FASB ASC 350-20-50-1]

No

N/A

(FASB Statement No. 141(R)) Has the entity disclosed any
changes in the carrying amount of goodwill during the period, including the following, (see example 3 in FASC ASC
350-20-55-24):
a.

The gross amount and accumulated impairment losses
at the beginning of the period?

b.

Additional goodwill recognized during the period, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for
sale in accordance with FASB ASC 360-10-45-9?

c.

Adjustments resulting from the subsequent recognition
of deferred tax assets during the period in accordance
with paragraphs 2–4 of FASB ASC 805-740-25 and
FASB ASC 805-740-45-2?

d.

Goodwill included in a disposal group classified as
held for sale in accordance with FASB ASC 360-10-45-9
and goodwill derecognized during the period without
having previously been reported in a disposal group
classified as held for sale?

e.

Impairment losses recognized during the period in accordance with FASB ASC 350-10?

f.

Net exchange differences arising during the period in
accordance with FASB ASC 830, Foreign Currency Matters?

g.

Any other changes in the carrying amounts during the
period?
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h.

l 5.

No

N/A

The gross amount and accumulated impairment losses
at the end of the period?
[“Pending Content” in FASB ASC 350-20-50-1]

For each goodwill impairment loss recognized, has the entity
disclosed following information disclosed in the notes to the
financial statement that include the period in which the impairment loss is recognized:
a.

A description of the facts and circumstances leading to
the impairment?

b.

The amount of the impairment loss and the method of
determining the fair value of the associated reporting
unit (whether based on quoted market prices, prices of
comparable businesses, a present value or other valuation technique, or a combination thereof)?

c.

If a recognized impairment loss is an estimate that has
not yet been finalized (refer to paragraphs 18–19 of
FASB ASC 350-20-35), that fact and the reasons therefore and, in subsequent periods, the nature and amount
of any significant adjustments made to the initial estimate of the impairment loss?
[FASB ASC 350-20-50-2]

.l 6.

At a minimum, are all intangible assets aggregated and presented as a separate line item in the statement of financial
position? (This requirement does not preclude presentation of
individual intangible assets or classes of intangible assets as
separate line items.)
[FASB ASC 350-30-45-1]

.l 7.

Are amortization expense and impairment losses for intangible assets presented in income statement line items within
continuing operations as deemed appropriate for each entity?
[FASB ASC 350-30-45-2]
Practice Tips

The information in question 8A also should be disclosed separately for each material business combination
or in the aggregate for individually immaterial business combinations that are material collectively if the
aggregate fair values of intangible assets acquired, other than goodwill, are significant.
[“Pending Content” in FASB ASC 350-30-50-1]
******
(FSP FAS 142-3) For intangible assets acquired either individually or with a group of assets (in either an
asset acquisition or business combination) and recognized under FASB Statement No. 142, the following
disclosure should be made in addition to those in question 8B:
●

For intangible assets with renewal or extension terms, the weighted-average period before the next
renewal or extension (both explicit and implicit), by major intangible asset class.
[“Pending Content” in FASB ASC 350-30-50-1]
.l 8A. For intangible assets acquired either individually or with a
group of assets, has the entity disclosed all of the following in
the notes to financial statements in the period of acquisition:
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Yes
a.

No

N/A

For intangible assets subject to amortization, all of the following:
i.

The total amount assigned and the amount assigned
to any major intangible asset class?

ii.

The amount of any significant residual value, in total
and by major intangible asset class?

iii.

The weighted-average amortization period, in total
and by major intangible asset class?

b.

For intangible assets not subject to amortization, the total
amount assigned and the amount assigned to any major intangible asset class?

c.

The amount of research and development assets acquired
and written off in the period and the line item in the income statement in which the amounts written off are aggregated?
[FASB ASC 350-30-50-1]

.l 8B. (FSP FAS 142-3) For intangible assets acquired either individually or with a group of assets (in either an asset acquisition or
business combination), has the entity disclosed all of the following in the notes to financial statements in the period of acquisition:
a.

For intangible assets subject to amortization, all of the following:
i.

The total amount assigned and the amount assigned
to any major intangible asset class?

ii.

The amount of any significant residual value, in total
and by major intangible asset class?

iii.

The weighted-average amortization period, in total
and by major intangible asset class?

b.

For intangible assets not subject to amortization, the total
amount assigned and the amount assigned to any major intangible asset class?

c.

The amount of research and development assets acquired
and written off in the period and the line item in the income statement in which the amounts written off are aggregated?

d.

For intangible assets with renewal or extension terms, the
weighted-average period before the next renewal or extension (both explicit and implicit), by major intangible asset
class?
[“Pending Content” in FASB ASC 350-30-50-1]

.l 9A. Has the entity disclosed the following information in the financial statements or the notes to financial statements for each period for which a statement of financial position is presented:
a.

For intangible assets subject to amortization, all of the following:
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b.

i.

The gross carrying amount and accumulated amortization, in total and by major intangible asset class?

ii.

The aggregate amortization expense for the period?

iii.

The estimated aggregate amortization expense for
each of the five succeeding fiscal years?

For intangible assets not subject to amortization, the total
carrying amount and the carrying amount for each major
intangible asset class?
[FASB ASC 350-30-50-2]

.l 9B. (FSP FAS 142-3) Has the entity disclosed the following information in the financial statements or the notes to financial statements for each period for which a statement of financial position
is presented:
a.

.l 10.

For intangible assets subject to amortization, all of the following:
i.

The gross carrying amount and accumulated amortization, in total and by major intangible asset class?

ii.

The aggregate amortization expense for the period?

iii.

The estimated aggregate amortization expense for
each of the five succeeding fiscal years?

b.

For intangible assets not subject to amortization, the total
carrying amount and the carrying amount for each major
intangible asset class?

c.

The entity’s accounting policy on the treatment of costs incurred to renew or extend the term of a recognized intangible asset?

d.

For intangible assets that have been renewed or extended
in the period for which a statement of financial position is
presented, both of the following:
i.

For entities that capitalize renewal or extension costs,
the total amount of costs incurred in the period to
renew or extend the term of a recognized intangible
asset, by major intangible asset class?

ii.

The weighted-average period before the next renewal or extension (both explicit and implicit), by
major intangible asset class?
[“Pending Content” in FASB ASC 350-30-50-2]

For each impairment loss recognized related to an intangible asset, is the following information disclosed in the notes to the financial statements that include the period in which the impairment loss is recognized:
a.

A description of the impaired intangible asset and the facts
and circumstances leading to the impairment?

b.

The amount of the impairment loss and the method for determining fair value?
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Yes
c.

The caption in the income statement in which the impairment loss is aggregated?

d.

If applicable, the segment in which the impaired intangible
asset is reported under FASB ASC 280, Segment Reporting?
[FASB ASC 350-30-50-3]

No

N/A

.l 11B. (FSP FAS 142-3) For recognized intangible assets, has the entity
disclosed information that enables users of financial statements
to assess the extent to which the expected future cash flows associated with the asset are affected by the entity’s intent or ability (or both intent and ability) to renew or extend the arrangement?
[“Pending Content” in FASB ASC 350-30-50-4]
K.

Current Liabilities
Practice Tip

The SEC requires that public entities disclose separately significant categories of debt such as those in question 1 [Regulation S-X, Article 5]. Although not required for nonpublic entities, such separate disclosure is
common practice.
.l 1. Are significant categories of current liabilities, such as accounts
payable, accrued expenses, deferred revenue, interest payable,
and amounts due to officers and employees segregated and presented separately?
[Common Practice]
.l 2. If a classified balance sheet is presented, is a total for current liabilities shown?
[FASB ASC 210-10-45-5]
.l 3. Are short term obligations expected to be refinanced reclassified
to long term liabilities?
[FASB ASC 470-10-45-13]
.l 4. If the reporting entity has not accrued compensated absences
(FASB ASC 710, Compensation—General, including sabbatical
leaves described in the FASB ASC glossary and FASB ASC 71010-25-5) because the amount cannot be reasonably estimated, is
that fact disclosed?
[FASB ASC 710-10-50-1]
.l 5. Are borrowings outstanding under revolving credit agreements
that include both a subjective acceleration clause and a requirement to maintain a lock-box arrangement, whereby remittances
from the borrower’s customers reduce the debt outstanding, classified as short term obligations?
[FASB ASC 470-10-45-5]
L.

Notes Payable and Other Debt

.l 1. Are major categories of debt (notes payable to banks, mortgages
payable, notes to related parties) identified on the balance sheet
or in the notes to the financial statements?
[Common Practice]
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Yes

No

N/A

.l 2. Are interest rates, maturities, conversion features, and other significant terms (for example, subordinated features) of long term
debt disclosed?
[FASB ASC 470-10-50-5]
.l 3. Are terms and conditions provided in loan agreements and bond
indentures (such as assets pledged as collateral and covenants to
reduce debt, maintain working capital, and restrict dividends) disclosed?
[FASB ASC 440-10-50-1]
Practice Tip
Some long term loans require compliance with certain covenants that must be met on a quarterly or semiannual basis. If a covenant violation occurs that would otherwise give the lender the right to call the debt, a
lender may waive its call right arising from the current violation for a period greater than one year while
retaining future covenant requirements. Unless facts and circumstances indicate otherwise, the borrower
should classify the obligation as noncurrent, unless both of the following conditions exist:
●

A covenant violation that gives the lender the right to call the debt has occurred at the balance sheet
date or would have occurred absent a loan modification.

●

It is probable that the borrower will not be able to cure the default (comply with the covenant) at
measurement dates that are within the next 12 months.

See example 1 in FASB ASC 470-10-55-2 for an illustration of this classification guidance.
[FASB ASC 470-10-45-1]
.l 4. Has the entity disclosed the following for each of the five years
following the latest balance sheet presented:
a.

The aggregate amount of payments for unconditional purchase obligations that meet the criteria set forth in FASB
ASC 440-10-50-2 and that have been recognized in the purchaser’s balance sheet?

b.

The combined aggregate amount of maturities and sinking
fund requirements for all long term borrowings?
[FASB ASC 440-10-50-4; FASB ASC 470-10-50-1]

.l 5. If a note is noninterest bearing or has an inappropriate stated interest rate,
a.

is the discount or premium presented as a direct deduction
from or addition to the face amount of the note?

b.

is the effective interest rate disclosed?

c.

is the face amount of the note disclosed?

d.

is amortization of the discount or premium reported as interest in the income statement?

e.

are issue costs reported as deferred charges?
[FASB ASC 835-30-45 par. 1A and 2–3]

.l 6. Are current portions of debt obligations presented as current liabilities?
[FASB ASC 210-10-45-9]
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No

N/A

.l 7. If short term obligations have been excluded from current liabilities pursuant to FASB ASC 470-10-45-14, do disclosures include
a.

a general description of the financing agreement?

b.

terms of any new obligation incurred or expected to be incurred, or equity securities issued, or expected to be issued,
as a result of the refinancing?
[FASB ASC 470-10-50-4]

.l 8. Are long term debt agreements subject to a subjective acceleration
clause disclosed unless the likelihood of the acceleration of the
due date is remote?
[FASB ASC 470-10-45-2; FASB ASC 470-10-50-3]
.l 9. Are long term obligations that are or will be callable by the creditor, either because the debtor’s violation of the debt agreement at
the balance-sheet date makes the obligation callable or because the
violation, if not cured within a specified grace period, will make
the obligation callable, classified as current unless either of the following conditions is met:
a.

The creditor has waived or subsequently lost the right to demand repayment for more than one year (or operating cycle,
if longer) from the balance-sheet date?

b.

The obligation contains a grace period within which the
debtor may cure the violation, and it is probable that the violation will be cured within that period, thus preventing the
violation from becoming callable?
[FASB ASC 470-10-45-11]

.l 10. If an obligation under question 9 is included in long term liabilities (or in the case of an unclassified balance sheet is included as
a long term liability in the disclosure of debt maturities), are the
circumstances disclosed?
[FASB ASC 470-10-50-2]
.l 11. If the reporting entity has borrowed funds in the form of participating mortgage loans, are the following disclosed in the financial
statements:
a.

The aggregate amount of participating mortgage obligations
at the balance-sheet date, with separate disclosure of the aggregate participation liabilities and related debt discounts?

b.

Terms of the participations by the lender in either the appreciation in the market value of the mortgaged real estate project or the results of operations of the mortgaged real estate
project, or both?
[FASB ASC 470-30-50-1]

.l 12. For insurance-related assessments,
a.

if amounts relating to insurance-related assessments have
been discounted pursuant to the provisions of paragraphs
9–10 of FASB ASC 405-30-30, has the entity disclosed in the
financial statements the undiscounted amounts of the liability and any related asset for premium tax offsets or policy
surcharges as well as the discount rate used?
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b.

No

N/A

if amounts have not been discounted, has the entity disclosed in the financial statements the amounts of the liability, any related asset for premium tax offsets or policy surcharges, the periods over which the assessments are
expected to be paid, and the period over which the recorded
premium tax offsets or policy surcharges are expected to be
realized?
[FASB ASC 405-30-50-1]
Practice Tip

Disclosure is not required for a loss contingency involving an unasserted claim or assessment if there has
been no manifestation by a potential claimant of an awareness of a possible claim or assessment unless both
of the following conditions are met:
●

It is considered probable that a claim will be asserted.

●

There is a reasonable possibility that the outcome will be unfavorable.

Further, disclosure of noninsured or underinsured risks in encouraged but not required.
[FASB ASC 450-20-50 par. 6–7]
The Basis for Conclusions of the original standard (FASB Statement No. 5, Accounting for Contingencies) indicated that disclosure was not required because of the problems involved in developing operational criteria
for disclosure of noninsured or underinsured risks. Nonetheless, a 1987 AICPA report, Disclosure Concerning
Insurance Coverage, stated that disclosure of these risks should be encouraged rather than simply not discouraged. Questions 13–14 that follow are nonauthoritative suggestions from that report. The AICPA noted
that disclosure of this kind is experimental. Therefore, its location in a financial report would depend on the
judgment of preparers of the report.
.l 13. For publicly held entities and entities with public accountability,
such as governments, are circumstances disclosed in which
a.

b.

they are exposed to risks of future material loss related to
i.

torts?

ii.

theft of, damage to, expropriation of, or destruction of
assets?

iii.

business interruption?

iv.

errors or omissions?

v.

injuries to employees?

vi.

acts of God?

those risks have not been transferred to unrelated third parties through insurance? (Encouraged, but not required.)

.l 14. In considering those matters to be disclosed that relate to certain
uninsured risks of future material loss as described in FASB ASC
720-20, has the entity considered the following:
a.
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Yes
b.

Comparison of current insurance coverage by major categories of risk to coverage in prior periods, without necessarily
quantifying such coverage or change in coverage?

c.

Recent claims experience?

d.

A description of the reporting entity’s risk management programs? (Encouraged, but not required.)

No

N/A

. 15. Does the not-for-profit entity report tax-exempt obligations that
were issued for its benefit as liabilities if the entity is responsible
for repayment?
[FASB ASC 954-470-25-1]
M.

Shareholders’ Equity
Notes: In May 2008, FASB issued FSP APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion
(Including Partial Cash Settlement). This FSP requires an issuer to separately account for the liability and equity components of convertible
debt instruments within its scope. Convertible debt instruments, including instruments within the scope of this FSP, consist of a liability
component with a below-market interest coupon (the debt instrument)
and an equity component (the conversion option). Convertible debt
instruments within the scope of this FSP are required to be separated
into its liability and equity components, with each component accounted for pursuant to other U.S. GAAP applicable to that component.
This FSP applies to convertible debt instruments that, by their stated
terms, may be settled in cash (or other assets) upon conversion, including partial cash settlement, unless the embedded conversion option is required to be separately accounted for as a derivative under
FASB Statement No. 133, Accounting for Derivative Instruments and
Hedging Activities. Other scope limitations apply. This FSP is effective
for financial statements issued for fiscal years beginning after December 15, 2008 (that is, January 1, 2009, for entities with calendar yearends), and interim periods within those fiscal years. Early adoption is
not permitted.
This checklist has been updated to include the presentation and disclosure requirements of FSP APB 14-1.
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 470-2065-1.

l 1. For each class of stock, do disclosures include the number of
shares authorized, issued, and outstanding, and par or stated
value per share?
[FASB ASC 505-10-50-3]
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Yes

No

N/A

l 2. Are classes of capital stock presented in order of priority in liquidation?
[Common Practice]
l 3. Do the financial statements include a description, in summary
form, sufficient to explain the pertinent rights and privileges of
the various securities outstanding, including
a.

possible conversion prices and dates as well as other significant terms for each convertible instrument? (For example,
the entity is obligated to issue X shares and as the market
price of the common stock decreases, the entity is obligated
to issue an additional X shares for each $1 decrease in the
stock price.)

b.

have the terms of the transaction been disclosed in the footnotes to the financial statements, including the excess of the
aggregate fair value of the instruments that the holder
would receive at conversion over the proceeds received and
the period over which the discount is amortized?
[FASB ASC 505-10-50 par. 3 and 7–8]

l 4. Has the entity considered disclosure of information about derivative instruments entered into in connection with the issuance of
the contingently convertible securities that may be useful in terms
of fully explaining the potential impact of the contingently convertible securities? That information might include the terms of
those derivative instruments, including the terms of settlement,
how those instruments relate to the contingently convertible securities, and the number of shares underlying the derivative instruments. One example is the purchase of a call option such that
the terms of the purchased call option would be expected to substantially offset changes in value of the written call option embedded in the convertible security. Derivative instruments are also
subject to additional disclosure information, as required by FASB
ASC 815, Derivatives and Hedging.
[FASB ASC 505-10-50-10]
Practice Tip
(FSP APB 14-1) Incremental disclosures may be required for debt with conversion and other options. See
FASB ASC 470-20-10-2 and paragraphs 2–6 of FASB ASC 470-20-50.
[“Pending Content” in FASB ASC 505-10-50-10A]
l 5. Do disclosures include the number of shares issued upon conversion, exercise, or satisfaction of required conditions during at least
the most recent annual fiscal period and any subsequent interim
period presented?
[FASB ASC 505-10-50-3]
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Yes

No

N/A

l 6. For preferred stock that has a preference in involuntary liquidation considerably in excess of par or stated value of the shares, is
the liquidation preference disclosed in the equity section of the
balance sheet in the aggregate, either parenthetically or “in short,”
rather than on a per share basis or in the notes to the financial
statements?
[FASB ASC 505-10-50-4]
l 7. Are the following disclosed on the face of the balance sheet or in
the notes to the financial statements:
a.

The aggregate or per-share amounts at which preferred
stock may be called or are subject to redemption through
sinking-fund operations or otherwise?

b.

The aggregate and per-share amounts of arrearages in cumulative preferred dividends?
[FASB ASC 505-10-50-5]

l 8. For redeemable stock, do disclosures include the amount of redemption requirements, separately by issue or combined, for all
issues of capital stock that are redeemable at fixed or determinable
prices on fixed or redeemable dates in each of the five years following the date of the latest balance sheet?
[FASB ASC 505-10-50-11]
l 9. Do disclosures for contingently convertible securities include the
significant quantitative and qualitative terms of the conversion
features to enable users of the financial statements to understand
the circumstances of the contingency and the potential impact of
conversion, including
a.

events or changes in circumstances that would cause the
contingency to be met and any significant features necessary
to understand the conversion rights and the timing of those
rights (for example, the periods in which (1) the contingency
might be met and (2) the securities may be converted if the
contingency is met)?

b.

the conversion price and the number of shares into which
the security is potentially convertible?

c.

events or changes in circumstances, if any, that could adjust
or change the contingency, conversion price, or number of
shares, including significant terms of those changes?

d.

the manner of settlement upon conversion and any alternative settlement methods (for example, cash, shares, or a combination)?
[FASB ASC 505-10-50-6]

l 10. Do disclosures indicate whether the shares that would be issued
if the contingently convertible securities were converted are included in the calculation of diluted earnings per share (EPS), and
the reasons why or why not?
[FASB ASC 505-10-50-9]
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Yes
l 11. Are appropriations of retained earnings for loss contingencies
clearly identified and included in shareholders’ equity?
[FASB ASC 505-10-45-3]
l 12. Has the entity disclosed any restrictions on the payment of dividends?
[FASB ASC 440-10-50-1]
l 13. After completion of a quasi-reorganization, is a new retained
earnings account established and dated with the date being disclosed in subsequent financial statements until it is no longer
deemed significant?
[FASB ASC 852-20-50-2]
l 14. Are the carrying basis, cost and number of shares of any treasury
stock held by the reporting entity disclosed?
[Common Practice]
l 15. If treasury stock is purchased for purposes other than retirement
or if ultimate disposition has not yet been decided is its cost:
a.

Shown separately as a deduction from the total of capital
stock, additional paid-in capital, and retained earnings? or

b.

Accorded the accounting treatment appropriate for retired
stock?
[FASB ASC 505-30-45-1]

l 16. If state laws relating to acquisition of stock restrict the availability
of retained earnings for payment of dividends or other significant
effects, is appropriate disclosure made?
[FASB ASC 505-30-50-2]
l 17. If treasury shares are purchased at a stated price significantly in
excess of the current market price of the shares, is the allocation
of the amounts paid and the accounting treatment for such
amounts disclosed?
[FASB ASC 505-30-50 par. 3–4]
l 18. If the pension asset or liability that is recognized pursuant to
FASB ASC 715-30-25-1, results in a temporary difference, as defined in the FASB ASC glossary, are the deferred tax effects of any
temporary differences recognized in income tax expense or benefit
for the year and allocated to various financial statement components, including OCI, pursuant to FASB ASC 740-20-45?
[FASB ASC 715-30-25-3]
N.

Changes in Shareholders’ Equity
l 1. Are changes in the separate accounts of shareholders’ equity disclosed?
[FASB ASC 505-10-50-2]
l 2. Are changes in the number of shares of equity securities disclosed?
[FASB ASC 505-10-50-2]
3. If prior-period adjustments have been recorded during the current
year, are the resulting effects (both gross and net of applicable income taxes and including the amounts of income tax applicable to
the prior period adjustments) appropriately disclosed?
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Yes
a.

For single-period statements, does the disclosure indicate the
effects of such restatement on the balance of retained earnings at the beginning of the period and on the net income of
the immediately preceding period?

b.

If financial statements of more than one period are presented, does disclosure include the effects for each of the
periods presented in the statements?
[FASB ASC 250-10-50 par. 8–9]

No

N/A

Note: See part B, “Accounting Changes and Error Corrections,” of the
“Other Financial Statement Disclosures” section of this checklist for additional disclosures.
O.

Restricted Resources
. 1. Are cash or other assets received with a donor-imposed restriction
that limits their use to long-term purposes reported separately
from assets that are unrestricted and available for current use?
[FASB ASC 958-210-45-6]
. 2. Is property and equipment that is donor-restricted reported as
temporarily or permanently restricted assets?
[FASB ASC 958-605-45-3]

III.

Statement of Activities/Income Statement/Statement of
Operations/Statement of Changes in Net Assets
A.

General
. 1. Does the statement of activities/operations or statement of
changes in net assets report the amount of change in net assets
for the period for the entity as a whole (using a descriptive term
such as change in net assets or change in equity), and does that
amount articulate to the net assets reported in the statement of
financial position?
[FASB ASC 958-225-45 par. 1–2]
. 2. Does the statement of activities/operations or the statement of
changes in net assets report the amount of change in permanently restricted net assets, temporarily restricted net assets, and
unrestricted net assets for the period?
[FASB ASC 958-225-45-1]
. 3. Does the statement of activities/operations report the following:
a.

Revenues as increases in unrestricted net assets, unless the
use of the assets received is limited by donor-imposed restrictions?

b.

Expenses as decreases in unrestricted net assets? Events
that simultaneously increase one class of net assets and decrease another (reclassifications), including expiration of
donor-imposed restrictions, separately from revenues, expenses, gains, and losses?
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Yes
c.

Events that simultaneously increase one class of net assets
and decrease another (reclassifications), including expiration of donor-imposed restrictions, separately from revenues, expenses, gains, and losses?

d.

Gains and losses as increases or decreases in unrestricted
net assets unless a donor or law temporarily or permanently restrict their use?
[FASB ASC 958-225-45]

No

N/A

. 4. Are revenues and expenses (arising from ongoing activities associated with health care services) displayed as gross amounts?
[FASB ASC 958-225-45-14]
. 5. If the entity elects to report investment revenues net of related
expenses, does the entity disclose the amount of expenses, either
on the face of the statement of activities or in the notes to the
financial statements?
[FASB ASC 958-225-45-14]
. 6. If the entity reports an intermediate measure of operations (for
example, excess or deficit of operating revenues over expenses),
is this intermediate measure reported only in a financial statement that, at a minimum, reports the change in unrestricted net
assets for the period? (Example 1 in FASB ASC 958-225-55-5 illustrates a statement of unrestricted revenues, expenses, and
other changes in unrestricted net assets that subdivides all transactions and other events and circumstances to make an operating
and nonoperating distinction.)
[FASB ASC 958-225-45-10]
. 7. If the entity’s use of the term operations is not apparent from the
details provided on the face of the statement of activities, does a
note to financial statements describe the nature of the reported
measure of operations or the items excluded from operations?
[FASB ASC 958-225-50-1(a)]
Practice Tip
Pursuant to FASB ASC 958-225-50-1, in question 7, because terms such as operating income are used with
different meanings, if an intermediate measure of operations is reported and its use is not apparent from the
details provided on the face of the statement, a note to the financial statements shall describe the nature of
the reported measure of operations or the items excluded from operations.
[FASB ASC 958-225-50-2]
. 8. If the entity reports net gains and losses on its statement of activities/operations, do these net amounts result from peripheral or
incidental transactions or from events largely beyond the control
of the entity and its management?
[FASB ASC 958-225-45 par. 15 and 17]
. 9. Is management’s policy for providing charity care, as well as the
level of charity care provided, disclosed?
[FASB ASC 954-605-50-3]
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Yes

No

N/A

Practice Tip
With respect to question 9, such disclosures are generally made in the notes to financial statements and are
measured based on the provider’s rates, costs, units of services, or other statistical measure.
. 10. Does the statement of activities/operations include a performance indicator that reports results of operations and that is
clearly labeled with a descriptive term such as revenues over expenses, revenues and gains over expenses and losses, earned income,
or performance earnings?
[FASB ASC 954-225-45-4]
. 11. Do the notes to the financial statements include a description of
the nature and composition of the performance indicator?
[FASB ASC 954-225-50-1]
. 12. Does the not-for-profit entity report the performance indicator
in a statement that also presents the total changes in unrestricted
net assets? (Note: Other changes in net assets may be presented
separately or in the same statement.)
[FASB ASC 954-225-45-4]
. 13. Does the entity report the following items separately from the
performance indicator:
a.

Transactions with owners acting in that capacity?

b.

Equity transfers involving other entities that control the reporting entity, are controlled by the reporting entity, or are
under common control with the reporting entity?

c.

Receipt of restricted contributions, including temporary restrictions (such as time or purpose) or permanent restrictions?

d.

Contributions of (and assets released from donor restrictions related to) long-lived assets?

e.

Items that are required to be reported in or reclassified
from other comprehensive income, such as minimum pension liabilities in accordance with FASB ASC 715-30-25-3;
foreign currency translation adjustments and the effective
portion of the gain or loss on derivative instruments designated and qualifying as cash flow hedging instruments
pursuant to paragraphs 1–2 of FASB ASC-954-815-25?

f.

Items that are required to be reported separately under
specialized not-for-profit standards. These include extraordinary items, the effect of discontinued operations, and the
cumulative effect of accounting changes; and unrealized
gains and losses on investments not restricted by donors
or by law (except for those investments classified as trading securities) and investment returns restricted by donors
or by law, as required by FASB ASC 954-320-45-1?
[FASB ASC 954-225-45-7]
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Yes
.l 14. For investments in common stock accounted for by the equity
method, is the investor’s share of earnings shown as a single
amount except for investee extraordinary items and prior-period adjustments that are material to the investor?
[FASB ASC 323-10-45 par. 1–2]
.l 15. Are total research and development costs charged to expense
disclosed for each period for which a statement of activities/
income statement is presented?
[FASB ASC 730-10-50-1]
.l 16. If the entity accounts for its obligation under a research and development arrangement as a contract to perform research and
development for others, is there disclosure of
a.

the terms of significant agreements under the research and
development arrangement as of the date of each balance
sheet or statement of financial position, or both, presented?

b.

the amount of compensation earned or costs incurred under such contracts for each period for which a statement of
revenues and expenses (statement of operations) is presented?
[FASB ASC 730-20-50-1]

l 17. Are the following excluded from the determination of net income or results of operations under all circumstances:
a.

Adjustments or charges or credits resulting from transactions in the entity’s own capital stock?

b.

Transfers to and from accounts properly designated as appropriated retained earnings?

c.

Adjustments made pursuant to a quasi-reorganization?
[FASB ASC 505-10-25-2]

l 18. Are net assets released from restriction, such as those related to
the fulfillment of time or purpose restrictions, reported separately in the financial statements or disclosed in the notes?
[FASB ASC 958-205-45-9]
B.

Revenue

.l 1.

Are the important components of income, such as sales or other
sources of revenue, cost of sales, selling and administrative expenses, interest expense and income taxes, separately disclosed
on the face of the income statement?
[Common Practice]

.l 2.

Is revenue classified based on the type of service (such as patient
or resident) rendered or contracted to be rendered?
[FASB ASC 954-605-45-1]

.l 3.

Is patient service revenue reported net of provisions for contractual and other adjustments?
[FASB ASC 954-605-45-2]

.l 4.

Do disclosures include methods of revenue recognition?
[FASB ASC 954-605-25]
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Yes
.l 5.

With regard to contractual adjustments and third-party settlements, does the entity identify and explain the estimated
amounts payable or receivable?
[FASB ASC 954-405-50-1]

.l 6.

Is significant revenue earned under capitation arrangements reported separately?
[FASB ASC 954-605-45-3]

.l 7.

With regard to contractual adjustments and third-party settlements, does the provider identify and explain the estimated
amounts that are receivable?
[FASB ASC 954-310-50-1]

.l 8.

Do disclosures include methods of revenue recognition?
[FASB ASC 954-605-50-1]

.l 9.

Is the amount of revenue and expense recognized from advertising barter transactions disclosed for each income statement
period presented?
[FASB ASC 605-20-50-1]

No

N/A

.l 10. If the entity engages in advertising barter transactions for which
the fair value is not determinable within the limits of paragraphs 15–18 of FASB ASC 605-20-25, is information regarding
the volume and type of advertising surrendered and received
(such as the number of equivalent pages, the number of
minutes, or the overall percentage of advertising volume) disclosed for each income statement period presented?
[FASB ASC 605-20-50-1]
.l 11. Does a vendor disclose the following in regard to revenue arrangements with multiple deliverables:
a.

Its accounting policy for recognition of revenue from multiple-deliverable arrangements (for example, whether deliverables are separable into units of accounting)?

b.

The description and nature of such arrangements, including performance, cancellation, termination, or refund-type
provisions?
[FASB ASC 605-25-50-1]
Practice Tip

Question 12 is based on the presumption that cash consideration (including a sales incentive) given by a
vendor to a customer is a reduction of the selling prices of the vendor’s products or services. That presumption is overcome and the consideration should be characterized as a cost incurred (question 13) if, and to the
extent that, both of the conditions in FASB ASC 605-50-45-2 are met.
.l 12.

Has the entity characterized as a reduction of revenue any cash
consideration (including a sales incentive) given to a customer
when recognized in the entity’s income statement?
[FASB ASC 605-50-45-2]
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.l 13.

If the entity provides a customer with a sales incentive or other
consideration which consists of a free product or service (for example, a gift certificate from the vendor or a free airline ticket
that will be honored by another, unrelated entity), or anything
other than cash (including credits that the customer can apply
against trade amounts owed to the vendor) or equity instruments (see FASB ASC 605-50-55-43), has the cost of the consideration been characterized as an expense (as opposed to a reduction of revenue) when recognized in the entity’s income
statement?
[FASB ASC 605-50-45-3]

.l 14.

If the entity is a service provider and provides incentives to a
third-party manufacturer or reseller that ultimately benefits the
service provider’s customer, has this fact been disclosed?
[FASB ASC 605-50-50-1]

Notes: In December 2007, FASB issued Emerging Issues Task Force
(EITF) Issue No. 07-1, “Accounting for Collaborative Agreements Related to the Development and Commercialization if Intellectual Property.” The objective of this issue is to define collaborative arrangements and to establish reporting requires for transactions between
participants in a collaborative arrangement and between participants
in the arrangement and third parties. FASB Statement No. 167, Amendments to FASB Interpretation No. 46(R). Among other things, EITF Issue
No. 07-1 changes income statement classification of costs and revenue
generated by participants in a collaborative arrangement from transactions with third parties, as opposed to applying the equity method
of accounting under Accounting Principles Board (APB) Opinion No.
18, The Equity Method of Accounting for Investments in Common Stock.
The EITF also requires enhanced disclosures.
EITF Issue No. 07-1 is effective for financial statements issued for fiscal
years beginning after December 15, 2008 (that is, January 1, 2009, for
entities with calendar year-ends), and interim periods within those fiscal years. The guidance should be applied retrospectively to all prior
periods presented for all collaborative arrangements existing as of the
effective date.
This checklist has been updated to include the presentation and disclosure requirements of EITF Issue No. 07-1.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions indicated with a “B” reference. Entities for which the guidance
has been implemented should consider all questions indicated by a
“B” reference (for example, question 1B and question 2B) and place an
“N/A” mark by questions indicated with an “A” reference. Therefore,
based upon your entity’s year-end and decision to early implement or
(continued)
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Yes

No

N/A

not (if allowed), the following additional questions will be answered
when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the issue on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 808-1065-1.
.l 15B. (EITF Issue No. 07-1) If the entity is a participant in a collaborative arrangement, has it disclosed all following in the period in
which a collaborative arrangement is entered into (which may be
an interim period) and all annual periods thereafter:
a.

Information about the nature and purpose of its collaborative arrangements?

b.

Its rights and obligations under the collaborative arrangements?

c.

The accounting policy for collaborative arrangements in accordance with FASB ASC 235-10?

d.

The income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants for each period an income statement is presented?
[“Pending Content” in FASB ASC 808-10-50-1]

.l 16.

Is the accounting policy decision regarding the presentation of
taxes within the scope of FASB ASC 605-45-15-2(e), either on a
gross basis (included in revenues and costs) or a net basis (excluded from revenues), disclosed pursuant to FASB ASC 235-10?
[FASB ASC 605-45-50-3]

.l 17.

For any such taxes that are reported on a gross basis, does the
entity disclose the amounts of those taxes in interim and annual
financial statements for each period for which an income statement is presented if those amounts are significant? (Note: The
disclosure of those taxes can be done on an aggregate basis.)
[FASB ASC 605-10-50-4]

C.

Income Taxes
Notes: In December 2007, FASB issued Statement No. 141(R) to improve the relevance, representational faithfulness, and comparability
of the information that a reporting entity provides in its financial reports about a business combination and its effects. FASB Statement
No. 141(R) supersedes FASB Statement No. 141 but retains the fundamental requirements in FASB Statement No. 141 that the acquisition
method of accounting (formerly called the purchase method in FASB
Statement No. 141) be used for all business combinations and that an
acquirer be identified for each business combination.
(continued)
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This statement applies prospectively to business combinations for
which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008 (that
is, January 1, 2009, for entities with calendar year-ends). An entity may
not apply it before that date.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 141(R).
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions indicated with a “B” reference. Entities for which the guidance
has been implemented should consider all questions indicated by a
“B” reference (for example, question 1B and question 2B) and place an
“N/A” mark by questions indicated with an “A” reference. Therefore,
based upon your entity’s year-end and decision to early implement or
not (if allowed), the following additional questions will be answered
when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 805-1065-1.
******
In September 2009, FASB issued Accounting Standards Update (ASU)
No. 2009-006, Implementation Guidance on Accounting for Uncertainty in
Income Taxes and Disclosure Amendments for Nonpublic Entities. The
amendments apply only to nonpublic entities as defined in FASB ASC
740-10-20.
The amendments to FASB ASC in this ASU provide implementation
guidance, through examples, on how to apply the standards for uncertainty in income taxes. In addition, the ASU eliminates for nonpublic entities the disclosures required by both FASB ASC 740-10-5015(a) (which requires a tabular reconciliation of the total amount of
unrecognized tax benefits at the beginning and end of the periods presented) and FASB ASC 740-10-50-15(b) (which requires the disclosure
of the total amount of unrecognized tax benefits that, if recognized,
would affect the effective tax rate).
For entities that are currently applying the guidance for accounting
and uncertainty in income taxes, this guidance and the disclosure
amendments are effective for financial statements issued for interim
and annual periods ending after September 15, 2009 (that is, December
31, 2009, for entities with calendar year-ends). For those entities that
have deferred the application of accounting for uncertainty in income
taxes in accordance with FASB ASC 740-10-65-1(e), the guidance and
disclosure amendments are effective upon adoption of those standards.
(continued)
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This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2009-006.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions indicated with a “B” reference. Entities for which the guidance
has been implemented should consider all questions indicated by a
“B” reference (for example, question 1B and question 2B) and place an
“N/A” mark by questions indicated with an “A” reference. Therefore,
based upon your entity’s year-end and decision to early implement or
not (if allowed), the following additional questions will be answered
when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the ASU on the FASB Web site at
www.fasb.org.
l 1A. Has the entity disclosed the following:

l 1B.

a.

The amounts and expiration dates of operating loss and tax
credit carryforwards for tax purposes?

b.

Any portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be
allocated to reduce goodwill or other noncurrent intangible
assets of an acquired entity or directly to contributed capital?
[FASB ASC 740-10-50-3]

(FASB Statement No. 141(R)) Has the entity disclosed the following:
a.

The amounts and expiration dates of operating loss and tax
credit carryforwards for tax purposes?

b.

Any portion of the valuation allowance for deferred tax assets for which subsequently recognized tax benefits will be
credited directly to contributed capital?
[“Pending Content” in FASB ASC 740-10-50-3]

l 2A. Has the entity disclosed the following significant components of
income tax expense attributable to continuing operations for
each year presented:
a.

Current tax expense (or benefit)?

b.

Deferred tax expense (or benefit) (exclusive of the effects of
other components in this list)?

c.

Investment tax credits?

d.

Government grants (to the extent recognized as a reduction
of income tax expense)?

e.

The benefits of operating loss carryforwards?
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l 2B.

f.

Tax expense that results from allocating certain tax benefits
directly to contributed capital?

g.

Adjustments of a deferred tax liability or asset for enacted
changes in tax laws or rates or a change in the tax status of
the reporting entity?

h.

Adjustments of the beginning-of-the-year balance of a valuation allowance because of a change in circumstances that
causes a change in judgment about the realizability of the
related deferred tax asset in future years?
[FASB ASC 740-10-50-9]

(FASB Statement No. 141(R)) Has the entity disclosed the following significant components of income tax expense attributable to
continuing operations for each year presented:
a.

Current tax expense (or benefit)?

b.

Deferred tax expense (or benefit) (exclusive of the effects of
other components in this list)?

c.

Investment tax credits?

d.

Government grants (to the extent recognized as a reduction
of income tax expense)?

e.

The benefits of operating loss carryforwards?

f.

Tax expense that results from allocating certain tax benefits
directly to contributed capital?

g.

Adjustments of a deferred tax liability or asset for enacted
changes in tax laws or rates or a change in the tax status of
the reporting entity?

h.

Adjustments of the beginning-of-the-year balance of a valuation allowance because of a change in circumstances that
causes a change in judgment about the realizability of the
related deferred tax asset in future years (for example, any
acquisition-date income tax benefits or expenses recognized
from changes in the acquirer’s valuation allowance for its
previously existing deferred tax assets as a result of a business combination [see FASB ASC 805-740-30-3])?
[“Pending Content” in FASB ASC 740-10-50-9]

l 3.

Are the amount of income tax expense or benefit allocated to
continuing operations and the amounts separately allocated to
other items (in accordance with the intraperiod tax allocation
provisions of paragraphs 2–14 of FASB ASC 740-20-45 and FASB
ASC 852-740-45-3) disclosed for each year for which those items
are presented?
[FASB ASC 740-10-50-10]

l 4.

(Issuers Only) If the reporting entity is a public enterprise, is
there a reconciliation in both percentages and dollar amounts of
the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations?
[FASB ASC 740-10-50-12]
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l 5.

No

N/A

(Nonissuers Only) Is there disclosure of the nature of significant
items required to reconcile the reported amount of income tax
expense attributable to continuing operations for the year to the
amount of income tax expense that would result from applying
domestic federal statutory tax rates to pretax income from continuing operations?
[FASB ASC 740-10-50-13]

l 6A. Has the entity disclosed the following at the end of each annual
reporting period presented:
a.

A tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period,
which include, at a minimum
i.

the gross amounts of the increases and decreases in
unrecognized tax benefits as a result of tax positions
taken during a prior period?

ii.

the gross amounts of increases and decreases in unrecognized tax benefits as a result of tax positions
taken during the current period?

iii.

the amounts of decreases in the unrecognized tax
benefits relating to settlements with taxing authorities?

iv.

reductions to unrecognized tax benefits as a result of
a lapse of the applicable statute of limitations?

b.

The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate?

c.

The total amounts of interest and penalties recognized in
the statement of operations and the total amounts of interest and penalties recognized in the statement of financial
position?

d.

For positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly
increase or decrease within 12 months of the reporting date,
has the following been disclosed:

e.

i.

The nature of the uncertainty?

ii.

The nature of the event that could occur in the next
12 months that would cause the change?

iii.

An estimate of the range of the reasonably possible
change or a statement that an estimate of the range
cannot be made?

A description of tax years that remain subject to examination by major tax jurisdictions?
[FASB ASC 740-10-50-15]
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Practice Tip
The FASC ASC glossary, as amended by FASB ASU No. 2009-006, defines tax position as
a position in a previously filed tax return or a position expected to be taken in a future tax return that
is reflected in measuring current or deferred income tax assets and liabilities for interim or annual periods. A tax position can result in a permanent reduction of income taxes payable, a deferral of income
taxes otherwise currently payable to future years, or a change in the expected realizability of deferred
tax assets. The term tax position also encompasses, but is not limited to:
a.

A decision not to file a tax return

b.

An allocation or a shift of income between jurisdictions

c.

The characterization of income or a decision to exclude reporting taxable income in a tax return

d.

An entity’s status, including its status as a pass-through entity or a tax-exempt not-for-profit
entity
[FASB ASC glossary]
l 6B.

(ASU No. 2009-006) Has the entity disclosed the following at
the end of each annual reporting period presented:
a.

The total amounts of interest and penalties recognized
in the statement of operations and the total amounts of
interest and penalties recognized in the statement of financial position?

b.

For positions for which it is reasonably possible that the
total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date,

c.

l 7B.

the nature of the uncertainty?

ii.

the nature of the event that could occur in the
next 12 months that would cause the change?

iii.

an estimate of the range of the reasonably possible change or a statement that an estimate of the
range cannot be made?

A description of tax years that remain subject to examination by major tax jurisdictions?
[“Pending Content” in FASB ASC 740-10-50-15]

(ASU No. 2009-006) (Issuers Only) In addition to the items in
question 6B, has the entity also disclosed the following at the
end of each annual reporting period presented:
a.
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A tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the
period, which should include at a minimum
i.

the gross amounts of the increases and decreases
in unrecognized tax benefits as a result of tax positions taken during a prior period?

ii.

the gross amounts of increases and decreases in
unrecognized tax benefits as a result of tax positions taken during the current period?
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b.

iii.

the amounts of decreases in the unrecognized tax
benefits relating to settlements with taxing authorities?

iv.

reductions to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations?

No

N/A

The total amount of unrecognized tax benefits that, if
recognized, would affect the effective tax rate?
[“Pending Content” in FASB ASC 740-10-50-15A]

l 8.

(Issuers Only) If the entity is not subject to income tax because it income is taxed directly to its owners, has that fact
and the net difference between the tax bases and the reported
amounts of the entity’s assets and liabilities been disclosed?
[FASB ASC 740-10-50-16]

l 9.

If the entity is a member of a group that files a consolidated
tax return, are the following items disclosed in its separately
issued financial statements:
a.

The aggregate amount of current and deferred tax expense for each income statement presented and the
amount of any tax-related balances due to or from affiliates as of the date of each balance sheet presented?

b.

The principal provisions of the method by which the
consolidated amount of current and deferred tax expense is allocated to members of the group and the nature and effect of any changes in that method (and in
determining related balances to or from affiliates) during the years for which the disclosures in item (a) are
presented?
[FASB ASC 740-10-50-17]

l 10.

Has the entity disclosed its policy on classification of interest
and penalties in accordance with FASB ASC 740-10-45-25 in
the footnotes to the financial statements?
[FASB ASC 740-10-50-19]

l 11.

If the entity presents a classified statement of financial position, does the entity classify a liability associated with an unrecognized tax benefit as a current liability (or the amount of
a net operating loss carryforward or amount refundable is reduced) to the extent the enterprise anticipates payment (or
receipt) of cash within one year or the operating cycle, if
longer? Furthermore, has the liability for unrecognized tax
benefits (or reduction in amounts refundable) not been combined with deferred tax liabilities or assets?
[FASB ASC 740-10-45-11]

l 12.

Is a liability that has been recognized as a result of applying
FASB ASC 740-10-25-17 not classified as a deferred tax liability unless it arises from a taxable temporary difference?
[FASB ASC 740-10-45-12]
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l 13.

If the entity’s tax exempt status is in question by the IRS, is
the potential impact disclosed?
[FASB ASC 958-450-50-1]

l 14.

If the entity is an S corporation, partnership, or proprietorship, is the reason that no income tax expense is recorded disclosed?
[Common Practice]

.l 15.

Is the accounting policy decision regarding the presentation
of taxes within the scope of FASB ASC 605-45-15-2(e), either
on a gross basis (included in revenues and costs) or a net basis (excluded from revenues), disclosed pursuant to FASB
ASC 235–10?
[FASB ASC 605-45-50-3]

.l 16.

For any such taxes that are reported on a gross basis, does the
entity disclose the amounts of those taxes in interim and annual financial statements for each period for which an income
statement is presented if those amounts are significant? (Note:
The disclosure of those taxes can be done on an aggregate
basis.)
[FASB ASC 605-10-50-4]

.l 17.

Are disclosures appropriate regarding the provider’s tax-exempt status and any other significant tax matters?
[FASB ASC 954-740-50-1]

D.

No

N/A

Extraordinary Items
1.

Has the nature and financial effects of each event or transaction that is unusual in nature or occurs infrequently, but not
both, been disclosed on the face of the income statement, or
alternatively, in notes to the financial statements?
[FASB ASC 225-20-50-3]

2.

Have extraordinary items been disclosed separately and included in the determination of net income for the interim period or periods in which they occurred?
[FASB ASC 225-20-50-4]
Practice Tip

FASB ASC 270-10-45-11A requires that extraordinary items, gains or losses from disposal of a component of
an entity, and unusual or infrequently occurring items not be prorated over the balance of the fiscal year.
[FASB ASC 225-20-50-4]
.l 3. Are extraordinary items (as described in FASB ASC 225-10-45-2)
segregated and shown (including applicable income taxes) following income before extraordinary items and before net income?
[FASB ASC 225-20-45-10]
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.l 4. Is the caption extraordinary items used to identify separately the
effects of events and transactions, other than disposals of components of an entity, that meet the criteria for classification as
extraordinary as discussed in paragraphs 1–6 of FASB ASC 22520-45?
[FASB ASC 225-20-45-11]
.l 5. Are descriptive captions and amounts presented for individual
extraordinary events or transactions, preferably on the face of the
income statement if practicable?
[FASB ASC 225-20-45-11]
.l 6. Are the nature of each extraordinary event or transaction and the
principle items entering into the determination of extraordinary
gains or losses described?
[FASB ASC 225-20-45-11]
l 7. Are income taxes applicable to any extraordinary items disclosed
on the face of the income statement (preferable) or disclosed in
the notes to the financial statements?
[FASB ASC 225-20-45-11]
.l 8. Are material events or transactions that are either unusual in nature or of infrequent occurrence, but not both (and therefore not
meeting the criteria for extraordinary items)
a.

reported as a separate component of income from continuing operations?

b.

accompanied by disclosure of the nature and financial effects of each event?
[FASB ASC 225-20-45-16]

.l 9. If any extraordinary items that were reported in prior periods are
adjusted during the current period, are the adjustments separately disclosed as to year of origin, nature, and amount and classified separately on the current period as an extraordinary item?
[FASB ASC 225-20-45-13]
E.

Advertising Costs

.l 1. Has the entity made disclosures related to advertising which include
a.

the accounting policy for reporting advertising including
whether such costs are expensed as incurred or the first
time the advertising takes place?

b.

a description of direct-response-advertising reported as assets (if any), the related accounting policy, and the amortization method and period?

c.

the amount charged to advertising expense for each statement of income presented, with separate disclosure of
amounts, if any, representing a write-down of capitalized
advertising costs to net realizable value?

d.

the amount of advertising reported as assets in each balance
sheet presented?
[FASB ASC 720-35-50-1; FASB ASC 340-20-50-1]
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F.

Donated or Contributed Services
. 1. If the not-for-profit entity receives contributed services, does it
disclose the following:

G.

a.

A description of the programs or activities for which those
services were used, including the nature and extent of contributed services received for the period and the amount
recognized as revenues for the period?

b.

The fair value of contributed services received but not recognized, if practicable? (Encouraged, but not required.)

c.

Nonmonetary information such as the number and trends
of donated hours received or service outputs provided by
volunteer efforts? (Encouraged, but not required.)

d.

Dollar amount of contributions raised by volunteers? (Encouraged, but not required.)
[FASB ASC 720-35-50-1; FASB ASC 340-20-50-1]

Donated Materials and Facilities
. 1. If donated materials merely pass through the entity to its charitable beneficiaries, and the entity is only an agent or intermediary
for the donors, has that donation been excluded from contribution revenues?
[FASB ASC 958-605-55-13]

H.

Fund-Raising
. 1. Has the not-for-profit disclosed the following related to fundraising:
a.

The types of activities for which joint costs have been incurred?

b.

A statement that such costs have been allocated?

c.

The total amount allocated during the period and the portion allocated to each functional expense category?
[FASB ASC 958-720-50-2]

. 2. If the entity includes within its financial statements a ratio of
fund-raising expenses to amounts raised, has it disclosed how
that ration was computed?
[FASB ASC 958-205-50-3]
I.

Contributions/Pledges
. 1. Does the entity distinguish between contributions received with
permanent restrictions, those received with temporary restrictions, and those received without donor-imposed restrictions, so
that they are reported as support increasing permanently restricted net assets, temporarily restricted net assets, or unrestricted net assets, respectively?
[FASB ASC 958-605-45 par. 3–4]
. 2. If donor-restricted contributions whose restrictions are met in the
same reporting period are reported as unrestricted support, pursuant to FASB ASC 958-605-45-4, is such treatment consistent
from period to period and is the policy disclosed?
[FASB ASC 958-360-50-1]
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. 3. Does the entity report receipt of unconditional promises to give
with payments due in future periods as restricted support, unless
explicit donor stipulations or circumstances surrounding the receipt of the promise make clear that the donor intended the contribution to be used to support activities of the current period?
[FASB ASC 958-605-45-5]
. 4. Has the entity disclosed whether or not it implies a time restriction that expires over the useful life of the donated assets if those
long-lived assets are received without stipulations about how
long the donated asset must be used or are acquired with gifts of
cash or other assets restricted for those acquisitions?
[FASB ASC 958-360-50-1]
. 5. Has the non-for-profit entity made disclosure if it reports contributions with donor-imposed restrictions as unrestricted support,
in accordance with FASB ASC 958-605-45-4?
[FASB ASC 958-605-50-2]
. 6. In addition to disclosures required by FASB ASC 450-20-50, has
the entity disclosed in the notes to financial statements a schedule
of unconditional promises to give that shows the total amount
separated into amounts payable in each of the next five years, the
aggregate amount due in more than five years, and for unconditional promises to give that are reported using present value
techniques, the unamortized discount?
[FASB ASC 958-405-50-1]
. 7. Does an entity that receives unconditional promises to give measured using present value techniques report the subsequent accrual of the interest element recognized as contribution income
(FASB ASC 958-310-35-6) as an increase in either temporarily restricted or permanently restricted net assets if the underlying
promise to give is donor restricted?
[FASB ASC 958-310-45-2]
J.

Expenses
. 1. Does the entity provide information about expenses reported by
their functional classification (such as major classes of program
services and supporting services) either in the statement of activities or in notes to financial statements?
[FASB ASC 958-205-45-6]

.l 2. For deferred compensation agreements, are estimated amounts to
be paid properly accrued?
[FASB ASC 710-10-25-9]
. 3. Has the not-for-profit disclosed the following other expenses:
a.

Total fund-raising expenses?

b.

Total program expenses and information about why total
program expenses disclosed in the notes do not articulate
with the statement of activities? (Pursuant to FASB ASC
958-720-45-5, this disclosure is only required if the components of total program expenses are not evident from the
details provided on the face of the statement of activities.)
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c.

The amount of income tax expense and the nature of the
activities that generated the taxes? (Only required if the notfor-profit incurs income tax expense.)
[FASB ASC 958-720-50-1]

.l 4. With regard to contractual adjustments and third-party settlements, does the provider identify and explain the estimated
amounts that are receivable?
[FASB ASC 954-405-50-1]
.l 5. Are interest costs associated with product financing arrangements identified separately?
[FASB ASC 470-40-25-4]
.l 6. Are disclosures included in the financial statements of the total
research and development costs charged to expense in each period for which an income statement is presented?
[FASB ASC 730-10-50-1]
.l 7. Have all nonrefundable advance payments made for goods or
services that will be used or rendered for future research and development activities pursuant to an executory contractual arrangement been deferred and capitalized, and recognized as an
expense as the goods are delivered or the related services are performed?
[FASB ASC 730-20-25-13; FASB ASC 730-20-35-1]
. 8. If the entity has capitalized costs incurred for a computer software product to be sold, leased, or otherwise marketed, are the
following disclosed in the financial statements:
a.

Unamortized computer software costs included in each balance sheet presented?

b.

The total amount charged to expense in each income statement presented for amortization of capitalized computer
software costs and for amounts written down to net realizable value?
[FASB ASC 985-20-50-1]

.l 9. Are research and development costs incurred for a computer
software product to be sold, leased, or otherwise marketed disclosed either separately or as part of the total research and development costs for each period presented?
[FASB ASC 985-20-50-2]
.l 10. If shipping and handling costs for a seller of goods are significant
and are not included in cost of sales (that is, if those costs are
accounted for together or separately on other income statement
line items), does the entity disclose both the amount(s) of such
costs and the line item(s) on the income statement that include
them?
[FASB ASC 605-45-50-2]
. 11. Has the entity disclosed the following information in the notes to
the financial statements in the period(s) in which business interruption insurance recoveries are recognized:
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K.

a.

The nature of the event resulting in business interruption
losses?

b.

The aggregate amount of business interruption insurance
recoveries recognized during the period and the line item(s)
in the statement of operations in which those recoveries are
classified (including amounts reported as an extraordinary
item pursuant to FASB ASC 225-20)?
[FASB ASC 225-30-50-1]

No

N/A

Wills
. 1. If the entity receives a promise to give conditioned on a future
uncertain event that is contained in a will and the will has been
declared valid by the probate court, has the entity disclosed the
conditional promise to give?
[FASB ASC 958-605-55-51]

L.

Endowments
Note: In August 2008, FASB issued FSP FAS 117-1, Endowments of Notfor-Profit Organizations: Net Asset Classification of Funds Subject to an
Enacted Version of the Uniform Prudent Management of Institutional
Funds Act, and Enhanced Disclosures for All Endowment Funds, to provide guidance on the net asset classification of donor-restructed endownment funds for a not-for-profit organization that is subject to an
enacted version of the Uniform Prudent Management of Institutional
Funds Act of 2006 (UPMIFA). This FSP also improves disclosures
about an organization’s endowment funds (both donor-restriced endowment funds and board-designated endowment funds), whether
or not the organization is subject to UPMIFA.
The provisions of this FSP are effective for fiscal years ending after
December 15, 2008 (that is, December 31, 2008, for entities with calendar year-ends), with early adoption permitted provided that the
annual financial statements for that fiscal year have not been previously issued.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 117-1.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should
consider all questions indicated with an “A” reference (for example,
question 1A and question 2A) and should place an “N/A” mark in
questions indicated with a “B” reference. Entities for which the guidance has been implemented should consider all questions indicated
by a “B” reference (for example, question 1B and question 2B) and
place an “N/A” mark by questions indicated with an “A” reference.
Therefore, based upon your entity’s year-end and decision to early
implement or not (if allowed), the following additional questions will
be answered when provided in this section (check one that applies for
your entity):
pppA pppB
(continued)

FSP §11,100.01

86

Health Care Entities

Yes

Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 958-20565-1.
. 1B. (FSP FAS 117-1) Has the not-for-profit entity disclosed information to enable the users of financial statements to understand all
of the following about its endowment funds (both donor restricted and board designated):
a.

Net asset classification?

b.

Net asset composition?

c.

Changes in net asset composition?

d.

Spending policies?

e.

Related investment policies?
[“Pending Content” in FASB ASC 958-205-50-1A]

. 2B. (FSP FAS 117-1) Has the not-for-profit disclosed the following for
each period for which it presents financial statements:
a.

A description of the governing board’s interpretation of the
law or laws that underlie the not-for-profit entity’s net asset
classification of donor-restricted endowment funds?

b.

A description of the not-for-profit entity’s policy or policies
for the appropriation of endowment assets for expenditure
(its endowment spending policy or policies)?

c.

A description of the not-for-profit entity’s endowment investment policies, including all of the following:
i.

Return objectives and risk parameters?

ii.

How return objectives relate to the not-for-profit entity’s endowment spending policy or policies?

iii.

The strategies employed for achieving return objectives?

d.

The composition of the not-for-profit entity’s endowment by
net asset class at the end of the period, in total and by type
of endowment fund, showing donor-restricted endowment
funds separately from board-designated endowment funds?

e.

A reconciliation of the beginning and ending balance of the
not-for-profit entity’s endowment, in total and by net asset
class, including, at a minimum, all of the following line
items that apply:
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Investment return, separated into investment income
(for example, interest, dividends, rents) and net appreciation or depreciation of investments?

ii.

Contributions?

iii.

Amounts appropriated for expenditure?
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iv.

Reclassifications?

v.

Other changes?
[“Pending Content” in FASB ASC 958-205-50-1B]

No

N/A

. 3. Has the not-for-profit disclosed, for each period for which a statement of financial position is presented, the aggregate amount of
the deficiencies for all donor-restricted endowment funds for
which the fair value of the assets at the reporting date is less than
the level required by donor stipulations or law?
[FASB ASC 958-205-50-2]
. 4. If the governing board determines that the relevant law requires
the entity to retain permanently some portion of gains on investment assets of endowment funds, is that amount reported as an
increase in permanently restricted net assets?
[FASB ASC 958-205-45-21]
. 5. In the absence of such a law or a donor’s explicit or clear implicit
permanent restriction, is net appreciation reported as unrestricted
if the endowment’s income is unrestricted, or temporarily restricted if the endowment’s income is temporarily restricted by
the donor?
[FASB ASC 958-205-45-34]
M.

Earnings Per Share
Practice Tip

The guidance in FASB ASC 260, Earnings per Share, requires presentation of EPS by all entities that have
issued common stock or potential common stock (that is, securities such as options, warrants, convertible
securities, or contingent stock agreements) if those securities trade in a public market either on a stock
exchange (domestic or foreign) or in the over-the-counter market, including securities quoted only locally or
regionally. FASB ASC 260 also requires presentation of EPS by an entity that has made a filing or is in the
process of filing with a regulatory agency in preparation for the sale of those securities in a public market.
[FASB ASC 260-10-15-2]

Notes: In March 2008, FASB issued Statement No. 160 to establish
accounting and reporting standards for the noncontrolling interests
in a subsidiary and for the deconsolidation of a subsidiary, areas for
which limited guidance previously existed. In addition to the overview of this statement provided in a note appearing in this checklist,
readers should be aware that FASB Statement No. 160 clarifies that, if
an entity has an outstanding noncontrolling interest (minority interest), amounts for both comprehensive income attributable to the parent and comprehensive income attributable to the noncontrolling interest in a less-than-wholly-owned subsidiary are reported on the face
of the financial statement in which comprehensive income is presented in addition to presenting consolidated comprehensive income.
Additionally, if an entity has an outstanding noncontrolling interest,
the components of OCI attributable to the parent and noncontrolling
interest in a less-than wholly-owned subsidiary are required to be disclosed as part of its equity reconciliation. FASB Statement No. 160 is
(continued)
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effective for fiscal years, and interim periods within those fiscal years,
beginning on or after December 15, 2008 (that is, January 1, 2009, for
entities with calendar year-ends). Earlier adoption is prohibited.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 160.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should
consider all questions indicated with an “A” reference (for example,
question 1A and question 2A) and should place an “N/A” mark in
questions indicated with a “B” reference. Entities for which the guidance has been implemented should consider all questions indicated
by a “B” reference (for example, question 1B and question 2B) and
place an “N/A” mark by questions indicated with an “A” reference.
Therefore, based upon your entity’s year-end and decision to early
implement or not (if allowed), the following additional questions will
be answered when provided in this section (check one that applies for
your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 810-1065-1.
l 1.

If the entity has a simple capital structure (only common
stock outstanding), are basic per-share amounts for income
from continuing operations and for net income presented on
the face of the income statement for all periods for which an
income statement or summary of earnings is presented?
[FASB ASC 260-10-45 par. 2 and 7]

l 2.

If the entity has other than a simple capital structure, are basic and diluted per-share amounts for income from continuing operations and for net income presented on the face of
the income statement with equal prominence for all periods
for which an income statement or summary of earnings is
presented? (Note: If diluted EPS data are reported for at least
one period, they should be reported for all periods presented,
even if they are the same amounts as basic EPS.)
[FASB ASC 260-10-45 par. 2 and 7]

l 3.

If discontinued operations, extraordinary items, or the cumulative effect of accounting changes are reported in the period, are the basic and diluted per share amounts for those
line items presented on the face of the income statement or in
the notes?
[FASB ASC 260-10-45-3]
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l 4.

If per share amounts not required to be presented by FASB
ASC 260-10 are disclosed, are they disclosed only in the notes
and do the disclosures indicate whether the per share
amounts are pretax or net of tax?
[FASB ASC 260-10-45-5]

l 5.

Are the following disclosed for each period for which an income statement is presented:
a.

A reconciliation of the numerators and denominators of
the basic and diluted per share computations for income from continuing operations?

b.

The effect that has been given to preferred dividends in
arriving at income available to common shareholders’
in computing basic EPS?

c.

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would have
been antidilutive for the period(s) presented?
[FASB ASC 260-10-50-1]

l 6.

For the latest period for which an income statement is presented, do disclosures include a description of any transaction that occurs after the end of the most recent period but
before the financial statements are issued or are available to
be issued (as discussed in FASB ASC 855-10-25) that would
have changed materially the number of common shares or
potential common shares outstanding at the end of the period
if the transaction had occurred before the end of the period?
[FASB ASC 260-10-50-2]

l 7.

If the number of common shares outstanding increases as a
result of a stock dividend or stock split (see FASB ASC 50520) or decreases as a result of a reverse stock split, the computations of basic and diluted EPS should be adjusted retroactively for all periods presented to reflect that change in
capital structure. If per-share computations reflect such
changes in the number of shares, is that fact disclosed?
[FASB ASC 260-10-55-12]

l 8.

If changes in common stock resulting from stock dividends,
stock splits, or reverse stock splits occur after the close of the
period but before the financial statements are issued or are
available to be issued (as discussed in FASB ASC 855-10-25),
the per-share computations for those and any prior-period financial statements presented should be based on the new
number of shares. If per-share computations reflect such
changes in the number of shares, is that fact disclosed?
[FASB ASC 260-10-55-12]

No

N/A
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l 9.

When prior EPS amounts have been restated in compliance
with an accounting standard requiring restatement, is the effect of the restatement, expressed in per share terms, disclosed in the period of restatement?
[FASB ASC 260-10-55-16]

l 10B. (FASB Statement No. 160) For purposes of computing EPS in
consolidated financial statements (both basic and diluted), if
one or more less-than-wholly-owned subsidiaries are included in the consolidated group, has the income attributable
to the noncontrolling interest in subsidiaries been excluded
from income from continuing operations and net income?
[“Pending Content” in FASB ASC 260-10-45-11A]
N.

Comprehensive Income
Notes: In March 2008, FASB issued Statement No. 160 to establish
accounting and reporting standards for the noncontrolling interests
in a subsidiary and for the deconsolidation of a subsidiary, areas for
which limited guidance previously existed. In addition to the overview of this statement provided in a note appearing in this checklist,
readers should be aware that FASB Statement No. 160 clarifies that, if
an entity has an outstanding noncontrolling interest (minority interest), amounts for both comprehensive income attributable to the parent and comprehensive income attributable to the noncontrolling interest in a less-than-wholly-owned subsidiary are reported on the face
of the financial statement in which comprehensive income is presented in addition to presenting consolidated comprehensive income.
Additionally, if an entity has an outstanding noncontrolling interest,
the components of OCI attributable to the parent and noncontrolling
interest in a less-than wholly-owned subsidiary are required to be disclosed as part of its equity reconciliation. FASB Statement No. 160 is
effective for fiscal years, and interim periods within those fiscal years,
beginning on or after December 15, 2008 (that is, January 1, 2009, for
entities with calendar year-ends). Earlier adoption is prohibited.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 160.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should
consider all questions indicated with an “A” reference (for example,
question 1A and question 2A) and should place an “N/A” mark in
questions indicated with a “B” reference. Entities for which the guidance has been implemented should consider all questions indicated
by a “B” reference (for example, question 1B and question 2B) and
place an “N/A” mark by questions indicated with an “A” reference.
Therefore, based upon your entity’s year-end and decision to early
implement or not (if allowed), the following additional questions will
be answered when provided in this section (check one that applies for
your entity):
pppA pppB
(continued)
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Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 810-1065-1.
******
In April 2009, FASB issued FSP 115-2 and FAS 124-2 to determine
whether the holder on an investment in a debt or equity security for
which changes in fair value are not regularly recognized in earnings
(such as securities classified as held-to-maturity or available-for-sale)
should recognize a loss in earnings when the investment is impaired.
This FSP amends the other-than-temporary impairment guidance in
U.S. GAAP for debt securities to make the guidance more operational
and to improve the presentation and disclosure of other-than-temporary impairments on debt and equity securities in the financial statements. This FSP does not amend existing recognition and measurement guidance related to other-than-temporary impairments of
equity securities.
FSP FAS 115-2 and FAS 124-2 is effective for interim and annual reporting periods ending after June 15, 2009 (that is, December 31, 2009,
for entities with calendar year-ends), with early adoption permitted
for periods ending after March 15, 2009. Earlier adoption for periods
ending before March 15, 2009, is not permitted. If an entity elects to
adopt early either FSP FAS 157-4 or FSP FAS 107-1 and APB 28-1,
Interim Disclosures about Fair Value of Financial Instruments, then entity
is also required to adopt early this FSP. Additionally, if an entity
elects to adopt early this FSP, it is required to adopt FSP FAS 157-4.
This FSP does not require disclosures for earlier periods presented for
comparative purposes at initial adoptions. In periods after initial
adoption, this FSP requires comparative disclosures only for periods
ending after initial adoption.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 115-2 and FAS 124-2.
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 320-1065-1.
l 1.

Are all components of comprehensive income reported in the
financial statements in the period in which they are recognized?
[FASB ASC 220-10-45-5]

l 2.

Is a total amount for comprehensive income displayed in the
financial statement where the components of OCI are reported?
[FASB ASC 220-10-45-5]
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l 3B.

(FASB Statement No. 160) If the entity has an outstanding
noncontrolling interest, are amounts for both comprehensive
income attributable to the parent and comprehensive income
attributable to the noncontrolling interest reported on the face
of the financial statement in which comprehensive income is
presented in addition to presenting consolidated comprehensive income?
[“Pending Content” in FASB ASC 220-10-45-5; “Pending Content” in FASB ASC 810-10-50-1A]

l 4.

Is an amount for net income displayed and included as a
component of comprehensive income?
[FASB ASC 220-10-45-6]

l 5.

Are items included in OCI classified separately based on their
nature, including

FSP §11,100.01

a.

foreign currency translation adjustments?

b.

gains and losses on foreign currency transactions that
are designated as, and are effective as, economic
hedges of a net investment in a foreign entity, commencing as of the designation date [see FASB ASC 83020-35-3(a)]?

c.

gains and losses on intraentity foreign currency transactions that are of a long term investment nature (that
is, settlement is not planned or anticipated in the foreseeable future), when the entities to the transaction are
consolidated, combined, or accounted for by the equity
method in the reporting entity’s financial statements
[see FASB ASC 830-20-35-3(b)]?

d.

gains and losses (effective portion) on derivative instruments that are designated as, and qualify as, cash flow
hedges [see FASB ASC 815-20-35-1(c)]?

e.

unrealized holding gains and losses that result from a
debt security being transferred into the available-forsale category from the held-to-maturity category [see
FASB ASC 320-10-35-10(c)]?

f.

subsequent decreases (if not an other-than-temporary
impairment) or increases in the fair value of availablefor-sale securities previously written down as impaired
[see FASB ASC 320-10-35-18])?

g.

gains or losses associated with pension or other postretirement benefits (that are not recognized immediately
as a component of net periodic benefit cost) [see FASB
ASC 715-20-50-1(j)]?

h.

prior service costs or credits associated with pension or
other postretirement benefits [see FASB ASC 715-20-501(j)]?

No

N/A
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i.

No

N/A

transition assets or obligations associated with pension
or other postretirement benefits (that are not recognized immediately as a component of net periodic benefit cost) [see FASB ASC 715-20-50-1(j)]?
[“Pending Content” in FASB ASC 220-10-45-13; “Pending Content” in FASB ASC 220-10-55-2]

l 6.

Are reclassification adjustments made to avoid double counting in comprehensive income of items that are displayed as
part of net income for a period that also had been displayed
as part of OCI in that period or other periods presented on
the face of the financial statement in which comprehensive
income is reported or disclosed in the notes?
[FASB ASC 220-10-45-15]

l 7.

Are comprehensive income and its components displayed in
a financial statement that is displayed with the same prominence as the other financial statements? (Note: FASB ASC
220-10 encourages but does not require that the components
of OCI and total comprehensive income be displayed below
the total for net income in a statement that reports results of
operations or in a separate statement of comprehensive income that begins with net income.)
[FASB ASC 220-10-45 par. 8–9]

l 8B.

(FASB Statement No. 160) If the entity has an outstanding
noncontrolling interest, are the components of OCI attributable to the parent and noncontrolling interest in a less-thanwholly-owned subsidiary disclosed as part of its equity reconciliation?
[“Pending Content” in FASB ASC 220-10-45-8; “Pending Content” in FASB ASC 810-10-50-1A]

l 9.

Are the components of OCI displayed either net of related tax
effects, or before related tax effects with one amount shown
for the aggregate tax effect related to the total of OCI items?
[FASB ASC 220-10-45-11]

l 10.

Is the amount of income tax expense or benefit allocated to
each component of OCI (including reclassification adjustments) displayed on the face of the statement in which those
components are displayed or disclosed in the notes to the financial statements?
[FASB ASC 220-10-45-12]

l 11.

Is the total of OCI for a period transferred to a component of
equity that is displayed separately from retained earnings
and additional paid-in-capital in the balance sheet with a descriptive title such as “accumulated OCI?”
[FASB ASC 220-10-45-14]

l 12.

Are accumulated balances for each classification within accumulated OCI disclosed on the face of the balance sheet, in the
statement of changes in shareholders’ equity, or in the notes?
[FASB ASC 220-10-45-14]
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IV.

l 13.

Has the enterprise reported a total for comprehensive income
in condensed financial statements of interim periods?
[FASB ASC 220-10-45-18]

l 14.

Has the entity displayed as a separate classification within
OCI the net gain or loss on derivative instruments designated
and qualifying as cash flow hedging instruments that are reported in comprehensive income pursuant to FASB ASC 81520-25-65 and FASB ASC 815-30-35-3?
[FASB ASC 815-30-45-1]

l 15.

As part of the disclosures of accumulated OCI, pursuant to
FASB ASC 220-10-45-14, has the entity separately disclosed
the beginning and ending accumulated derivative gain or
loss, the related net change associated with current period
hedging transactions, and the net amount of any reclassification into earnings?
[FASB ASC 815-30-50-2]

No

N/A

Statement of Cash Flows

.l 1.

Does the statement of cash flows report net cash provided or used
by the operating, investing, and financing activities and the effect of
those flows on cash and cash equivalents during the period in a manner that reconciles beginning and ending cash and cash equivalents?
[FASB ASC 230-10-45-24]

.l 2.

Is the accounting policy for determining which items are treated as
cash equivalents disclosed?
[FASB ASC 230-10-50-1]

.l 3.

If the direct method of reporting net cash flow from operating activities is used, do cash flows from operating activities separately report
a. cash received from customers?
b. interest and dividends received?
c. other operating cash receipts?
d. cash paid to employees and suppliers?
e. interest paid?
f.

income taxes paid and, separately, the cash that would have been
paid for income taxes if increases in the value of equity instruments issued under share-based payment arrangements that are
not recognizable as a cost of goods or services for accounting purposes also had not been deductible in determining taxable income (FASB ASC 230-10-45-14(e))?

g. other operating cash payments (if any)?
[FASB ASC 230-10-45-25]
Practice Tip
FASB ASC 230-10-45-25 encourages reporting entities to use the direct method of reporting cash flows. The
sample financial statements in FSP section 11,400 illustrate a statement of cash flows prepared using the
direct method.
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.l 4.

If the direct method is used, is a separate reconciling schedule provided to reconcile net income to net cash flow from operating activities?
[FASB ASC 230-10-45-30]

.l 5.

If the direct method of reporting net cash flow from operating activities is not used, is the net cash flow from operating activities reported indirectly by adjusting net income to reconcile it to net cash
flow from operating activities?
[FASB ASC 230-10-45-28]

.l 6.

Is the reconciliation of net income to net cash flow from operating
activities, including separate reporting of all major classes of reconciling items, presented?
[FASB ASC 230-10-45-29]

.l 7.

If the indirect method of reporting net cash flow from operating
activities is used, are amounts of interest paid (net of amounts capitalized) and income taxes paid during the period provided in related disclosures?
[FASB ASC 230-10-50-2]

.l 8.

Are investing and financing activities that affect recognized assets
or liabilities, but that do not result in cash receipts or cash payments
in the period, disclosed?
[FASB ASC 230-10-50-3]

.l 9.

Are cash receipts and cash payments for the following transactions
classified as cash flows from operating activities:
a.

Cash receipts from sales of goods or services, including receipts from collection or sale of accounts and both short and
long term notes receivable from customers arising from those
sales?

b.

Cash receipts from returns on loans, other debt instruments of
other entities, and equity securities—interest and dividends?

c.

All other cash receipts that do not stem from transactions defined as investing or financing activities, such as amounts received to settle lawsuits; proceeds of insurance settlements except for those that are directly related to investing or
financing activities, such as from destruction of a building;
and refunds from suppliers?

d.

Cash payments to acquire materials for manufacture or goods
for resale, including principal payments on accounts and both
short and long term notes payable to suppliers for those materials or goods?

e.

Cash payments to other suppliers and employees for other
goods or services?

No

N/A
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f.

Cash payments to governments for taxes, duties, fines, and
other fees or penalties and the cash that would have been paid
for income taxes if increases in the value of equity instruments
issued under share-based payment arrangements that are not
included in the cost of goods or services recognizable for financial reporting purposes also had not been deductible in
determining taxable income?

g.

Cash payments to lenders and other creditors for interest?

h.

All other cash payments that do not stem from transactions
defined as investing or financing activities, such as payments
to settle lawsuits, cash contributions to charities, and cash refunds to customers?
[FASB ASC 230-10-45 par. 16–17]

.l 10. Are cash receipts and cash payments for the following transactions
classified as cash flows from investing activities:
a.

Receipts from collections or sales of loans?

b.

Receipts from sales of property, plant, and equipment?

c.

Loans to others?

d.

Cash flows from purchases, sales, and maturities of availablefor-sale securities?

e.

Payments to acquire property, plant, and equipment?

f.

Receipts from sales of equity instruments of other enterprises
exclusive of those carried in the trading account?

g.

Payments to acquire equity instruments of other enterprises,
exclusive of those carried in the trading account?
[FASB ASC 230-10-45 par. 12–13; FASB ASC 310-10-45-11]

.l 11. Are cash receipts and cash payments for the following transactions
classified as cash flows from investing activities:
a.

Proceeds from issuing debt?

b.

Issuance of equity instruments?

c.

Payment of dividends?

d.

Repayments for amounts borrowed?

e.

Purchases of treasury stock?

f.

Other principal payments to creditors who have extended
long term debt?

g.

Proceeds received from derivative instruments and distributions to counterparties of derivative instruments that include
financing elements at inception?

h.

Cash retained as a result of the tax deductibility of increases
in the value of equity instruments issued under share-based
payment arrangements that are not included in the cost of
goods or services that is recognizable for financial reporting
purposes? For this purpose, excess tax benefits should be determined on an individual award (or a portion thereof) basis?
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i.

No

N/A

Payments for debt issue costs?
[FASB ASC 230-10-45 par. 14–15]

.l 12. Are cash payments made to settle an asset retirement obligation
classified in the statement of cash flows as an operating activity?
[FASB ASC 230-10-45-17(e)]
.l 13. Except for certain items whose turnover is quick, amounts are large,
and maturities are short, are cash receipts and cash payments from
investing and financing activities shown separately on the statement of cash flows?
[FASB ASC 230-10-45 par. 8–9 and 26]
.l 14. If an other-than-insignificant financing element is present at inception, other than a financing element inherently included in an atthe-market derivative instrument with no prepayments (that is, the
forward points in an at-the-money forward contract), does the borrower report all cash inflows and outflows associated with that derivative instrument as financing activities?
[FASB ASC 230-10-45-27]
Practice Tip
If there are only a few noncash transactions, it may be convenient to include them on the same page as the
statement of cash flows. Otherwise, the transactions may be reported elsewhere in the financial statements,
clearly referenced to the statement of cash flows.
[FASB ASC 230-10-50-6]

V.

Summary of Significant Accounting Policies
Practice Tips

As you evaluate the completeness of the significant accounting policies, consider whether additions or revisions are required in response to recently issued accounting guidance. Also consider whether disclosures
of accounting policies covered in other sections of this checklist are included.
If the accounting policy disclosures called for in sections such as these are not included in notes elsewhere
in the financial statements, they should be included in the summary of accounting policies.
[FASB ASC 235-10-50-4]
******
Financial statement disclosure of accounting policies should not duplicate details (for example, composition
of inventories or of plant assets) presented elsewhere as part of the financial statements. In some cases, the
disclosure of accounting policies should refer to related details presented elsewhere as part of the financial
statements; for example, changes in accounting policies during the period should be described with crossreference to the disclosure required by FASB ASC 250.
[FASB ASC 235-10-50-5]
A.

Accounting Policies

.l 1. Is a description of all significant accounting policies of the reporting entity presented as either a separate summary preceding the
notes to the financial statements or as the initial note?
[FASB ASC 235-10-50-6]
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Yes

No

N/A

.l 2. Do the summary or notes identify and describe all significant accounting principles followed by the reporting entity and the
methods of applying those principles that materially affect the
determination of financial position, cash flows, and results of operations?
[FASB ASC 235-10-50-3]
.l 3. Do those principles and methods identified in question 2 include
all instances in which there
a.

is a selection from existing acceptable alternatives?

b.

are principles and methods peculiar to the industry in
which the reporting entity operates, even if such principles
and methods are predominantly followed in that industry?

c.

are unusual or innovative applications of U.S. GAAP?
[FASB ASC 235-10-50-3]

.l 4. Is a description of the method for recognizing interest income on
loan and trade receivables, including a statement about the entity’s policy for treatment of related fees and costs, including the
method of amortizing net deferred fees or costs included in the
notes to the financial statements?
[FASB ASC 310-20-50-1]
B.

Certain Significant Estimates

.l 1. If known information available before the financial statements
are issued indicates that: (a) it is at least reasonably possible that
the effect on the financial statements of a condition, situation, or
set of circumstances that existed the date of the financial statements will change in the near term due to one or more future
confirming events, and (b) the effect of the change would be material to the financial statements:
a.

Is disclosure made of the nature of the uncertainty, including an indication that it is at least reasonably possible that a
change in the estimate will occur in the near term?

b.

If the estimate involves a loss contingency covered by FASB
Statement No. 5, does the disclosure include an estimate of
the possible range of loss, or state that such an estimate cannot be made?

c.

Does the disclosure describe the factors that cause the estimate to be sensitive to change?
[FASB ASC 275-10-50 par. 8–9]
Practice Tip

For public entities, additional disclosures regarding concentration of credit risk may be required by applicable SEC rules and regulations (for example, Item 303 of Regulation S-K, Management’s Discussion and
Analysis of Financial Conditions and Results of Operations). For banks and bank holding companies subject to
the requirements of SEC Regulation S-X, Rule 9-03, and SEC Industry Guide 3, additional disclosures may
be required.
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VI.

No

N/A

Interim Reporting

Notes: In March 2008, FASB issued Statement No. 161, Disclosures
about Derivative Instruments and Hedging Activities—an amendment of
FASB Statement No. 133, to enhance the current disclosure framework
in FASB Statement No. 133. This statement has the same scope as
FASB Statement No. 133 and, accordingly, applies to all entities.
This statement changes the disclosure requirements for derivative instruments and hedging activities. Entities are required to provide enhanced disclosures about (a) how and why an entity uses derivative
instruments, (b) how derivative instruments and related hedged
items are accounted for under FASB Statement No. 133 and its related interpretations, and (c) how derivative instruments and related
hedged items affect an entity’s financial position, financial performance, and cash flows.
FASB Statement No. 161 is effective for financial statements issued
for fiscal years and interim periods beginning after November 15,
2008 (that is, January 1, 2009, for entities with calendar year-ends).
Early application is encouraged. This statement encourages but does
not require disclosures for earlier periods presented for comparative
purposes at initial adoption. In years after initial adoption, it requires
comparative disclosures only for periods subsequent to initial adoption.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 161.
As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented
should consider all questions indicated with an “A” reference (for
example, question 1A and question 2A) and should place an “N/A”
mark in questions indicated with a “B” reference. Entities for which
the guidance has been implemented should consider all questions indicated by a “B” reference (for example, question 1B and question
2B) and place an “N/A” mark by questions indicated with an “A”
reference. Therefore, based upon your entity’s year-end and decision
to early implement or not (if allowed), the following additional questions will be answered when provided in this section (check one that
applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 815-1065-1.
******
In April 2009, FASB issued FSP 107-1 and APB 28-1 to require disclosures about fair value of financial instruments for interim reporting
(continued)
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periods of publicly traded entities as well as in annual financial statements. This FSP also amends APB Opinion No. 28, Interim Financial
Reporting, to require those disclosures in summarized financial information at interim reporting periods. This FSP applies to all financial
instruments within the scope of FASB Statement No. 107, Disclosures
about Fair Value of Financial Instruments, held by publicly traded companies, as defined by APB Opinion No. 28.
FSP FAS 107-1 and APB 28-1 is effective for interim reporting periods
ending after June 15, 2009 (that is, December 31, 2009, for entities
with calendar year-ends), with early adoption permitted for periods
ending after March 19, 2009. An entity may early adopt this FSP only
if it also elects to early adopt FSP FAS 157-4 and FSP FAS 115-2 and
FAS 124-2. This FSP does not require disclosures for earlier periods
presented for comparative purposes at initial adoptions. In periods
after initial adoption, this FSP requires comparative disclosures only
for periods ending after initial adoption.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 107-1 and APB 28-1.
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 825-1065-1.
******
In April 2009, FASB issued FSP 115-2 and FAS 124-2 to determine
whether the holder on an investment in a debt or equity security for
which changes in fair value are not regularly recognized in earnings
(such as securities classified as held-to-maturity or available-for-sale)
should recognize a loss in earnings when the investment is impaired.
This FSP amends the other-than-temporary impairment guidance in
U.S. GAAP for debt securities to make the guidance more operational and to improve the presentation and disclosure of other-thantemporary impairments on debt and equity securities in the financial
statements. This FSP does not amend existing recognition and measurement guidance related to other-than-temporary impairments of
equity securities.
FSP FAS 115-2 and FAS 124-2 is effective for interim and annual reporting periods ending after June 15, 2009 (that is, December 31,
2009, for entities with calendar year-ends). Earlier adoption for periods ending before March 15, 2009, is not permitted. If an entity elects
to adopt early either FSP FAS 157-4 or FSP FAS 107-1 and APB 28-1,
then entity is also required to adopt early this FSP. Additionally, if
an entity elects to adopt early this FSP, it is required to adopt FSP
FAS 157-4. This FSP does not require disclosures for earlier periods
presented for comparative purposes at initial adoptions. In periods
after initial adoption, this FSP requires comparative disclosures only
for periods ending after initial adoption.
(continued)
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This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 115-2 and FAS 124-2.
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 320-1065-1.
l 1A.

(Issuers Only) If the entity reports summarized financial information at interim dates (including reports on fourth quarters), has the following, at a minimum, been disclosed:
a.

Sales or gross revenues, provision for income taxes, extraordinary items (including related income tax effects),
net income, and comprehensive income?

b.

Basic and diluted EPS data for each period presented,
determined in accordance with the provisions of FASB
ASC 260?

c.

Seasonal revenue, costs, or expenses?

d.

Significant changes in estimates or provisions for income taxes?

e.

Disposal of a component of an entity and extraordinary, unusual, or infrequently occurring items?

f.

Contingent items?

g.

Changes in accounting principles or estimates?

h.

Significant changes in financial position?

i.

All of the following information about reportable operating segments determined according to the provisions of FASB ASC 280, including provisions related to
restatement of segment information in previously issued financial statements:
i.

Revenues from external customers?

ii. Intersegment revenues?
iii. A measure of segment profit or loss?
iv. Total assets for which there has been a material
change from the amount disclosed in the last annual report?
v. A description of differences from the last annual report in the basis of segmentation or in the measurement of segment profit or loss?
vi. A reconciliation of the total of the reportable segments’ measures of profit or loss to the entity’s consolidated income before income taxes, extraordinary items, and discontinued operations?
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Yes

No

N/A

Practice Tip
If an entity allocates items such as income taxes and extraordinary items to segments, the entity may choose
to reconcile the total of the segments’ measures of profit or loss to consolidated income after those items.
Significant reconciling items should be separately identified and described in that reconciliation.
[FASB ASC 270-10-50-1(i)(6)]
j.

All of the following information about defined benefit
pension plans and other defined benefit postretirement
benefit plans, disclosed for all periods presented pursuant to the provisions of FASB ASC 715-20:
i.

The amount of net periodic benefit cost recognized,
for each period for which a statement of income is
presented, showing separately the service cost
component, the interest cost component, the expected return on plan assets for the period, the gain
or loss component, the prior service cost or credit
component, the transition asset or obligation component, and the gain or loss recognized due to a
settlement or curtailment?

ii. The total amount of the employer’s contributions
paid, and expected to be paid, during the current
fiscal year, if significantly different from amounts
previously disclosed pursuant to FASB ASC 71520-50-1? Estimated contributions may be presented
in the aggregate combining contributions required
by funding regulations or laws, discretionary contributions, and noncash contributions.
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k.

The information about the use of fair value to measure
assets and liabilities recognized in the statement of financial position pursuant to paragraphs 1–6 of FASB
ASC 820-10-50?

l.

The information about derivative instruments as required by FASB ASC 815-10-50, 815-20-50, 815-25-50,
815-30-50, and 815-35-50?

m.

The information about fair value of financial instruments as required by FASB ASC 825-10-50?

n.

The information about certain investments in debt and
equity securities as required by FASB ASC 320-10-50
and FASB ASC 942-320-50?

o.

The information about other-than-temporary impairments as required by FASB ASC 320-10-50, 325-25-50,
and 958-320-50?
[“Pending Content” in FASB ASC 270-10-50-1]
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Yes

No

N/A

Practice Tip
If summarized financial data are regularly reported on a quarterly basis, the foregoing information with
respect to the current quarter and the current year-to-date or the last 12 months to date should be furnished
together with comparable data for the preceding year.
[“Pending Content” in FASB ASC 270-10-50-1]
l 1B.

(FASB Statement No. 161) (Issuers Only) If the publicly
traded entity reports summarized financial information at interim dates (including reports on fourth quarters), has the following, at a minimum, been disclosed:
a.

Sales or gross revenues, provision for income taxes, extraordinary items (including related income tax effects),
net income, and comprehensive income?

b.

Basic and diluted EPS data for each period presented,
determined in accordance with the provisions of FASB
ASC 260?

c.

Seasonal revenue, costs, or expenses?

d.

Significant changes in estimates or provisions for income taxes?

e.

Disposal of a component of an entity and extraordinary, unusual or infrequently occurring items?

f.

Contingent items?

g.

Changes in accounting principles or estimates?

h.

Significant changes in financial position?

i.

All of the following information about reportable operating segments determined according to the provisions of FASB ASC 280, including provisions related to
restatement of segment information in previously issued financial statements:
i.

Revenues from external customers?

ii. Intersegment revenues?
iii. A measure of segment profit or loss?
iv. Total assets for which there has been a material
change from the amount disclosed in the last annual report?
v. A description of differences from the last annual report in the basis of segmentation or in the measurement of segment profit or loss?
vi. A reconciliation of the total of the reportable segments’ measures of profit or loss to the entity’s consolidated income before income taxes, extraordinary items, and discontinued operations?
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No
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Practice Tip
(FASB Statement No. 161) If an entity allocates items such as income taxes and extraordinary items to
segments, the entity may choose to reconcile the total of the segments’ measures of profit or loss to consolidated income after those items. Significant reconciling items should be separately identified and described
in that reconciliation.
[FASB ASC 270-10-50-1(i)(6)]
j.

All of the following information about defined benefit pension plans and other defined benefit postretirement benefit
plans, disclosed for all periods presented pursuant to the
provisions of FASB ASC 715-20:
i.

The amount of net periodic benefit cost recognized, for
each period for which a statement of income is presented, showing separately the service cost component,
the interest cost component, the expected return on plan
assets for the period, the gain or loss component, the
prior service cost or credit component, the transition asset or obligation component, and the gain or loss recognized due to a settlement or curtailment?

ii. The total amount of the employer’s contributions paid,
and expected to be paid, during the current fiscal year,
if significantly different from amounts previously disclosed pursuant to FASB ASC 715-20-50-1. Estimated
contributions may be presented in the aggregate combining all of the following: (1) contributions required by
funding regulations or laws, (2) discretionary contributions, and (3) noncash contributions?
k.

The information about the use of fair value to measure assets and liabilities recognized in the statement of financial
position pursuant to paragraphs 1–6 of FASB ASC 820-1050?

l.

The information about derivative instruments as required
by FASB ASC 815-10-50, 815-20-50, 815-25-50, 815-30-50,
and 815-35-50?
[“Pending Content” in FASB ASC 270-10-50-1]

l 2. If the reporting entity is a publicly traded company and if interim
financial data and disclosures are not separately reported for the
fourth quarter, are accounting changes made during the fourth
quarter, disposals of segments of a business, extraordinary, unusual, or infrequently occurring items recognized in the fourth
quarter, and the aggregate effect of year-end adjustments that are
material to the results of that quarter disclosed in a note to the
financial statements?
[FASB ASC 270-10-50-2]
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No

N/A

l 3. Has the disclosure of the impact of the financial results for interim periods of the matters discussed in paragraphs 12–16 of
FASB ASC 270-10-45 and paragraphs 5–6 of FASB ASC 270-10-50
been made?
[FASB ASC 270-10-50-3]
l 4. Has balance sheet and cash flow data been published for the interim periods? (Encouraged, but not required)
[FASB ASC 270-10-50-4]
l 5. Have extraordinary items been disclosed separately and including in the determination of net income for the period in which
the occurred?
[FASB ASC 270-10-50-5]
Practice Tip
The disclosures in question 6 should be repeated in interim and annual reports until the contingencies have
been removed, resolved, or have become immaterial. The significance of a contingency or uncertainty
should be judged in relation to annual financial statements. Disclosures of such items should include, but
not be limited to, those matters that form the basis of a qualification of an independent auditor’s report.
[FASB ASC 270-10-50-6]
6.

VII.

Have contingencies and other uncertainties that could be expected to affect the fairness of presentation of financial data at
an interim date been disclosed in the same manner required for
annual reports?
[FASB ASC 270-10-50-6]

Other Financial Statement Disclosures
A.

Business Combinations
Notes: For entities for which FASB Statement No. 141(R) is applicable, complete part A1, “Business Combinations (Subject to FASB
Statement 141(R)).”.
Because FASB Statement No. 141(R) is to be applied prospectively,
based on the transition guidance, and because FASB used a target
effective date of December 31, 2008, when authoring FASB ASC,
FASB Statement No. 141 was not codified and included in FASB
ASC. FASB ASC 805, Business Combinations, was created using only
FASB Statement No. 141(R) and related content. As noted, it excluded content from FASB Statement No. 141 and related standards.
To maintain a consistent presentation, FASB ASC 805 presents all
content as pending content even though some content applies to
business combinations before the effective date of FASB Statement
No. 141(R). Accordingly, for business combinations applicable before the effective date in FASB ASC 805-10-65-1, users need to access
FASB Statement No. 141 and any other relevant standards. This decision results in this section of the checklist containing references to
(continued)
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pre-FASB Statement No. 141(R) guidance, which has not been codified.
In December 2007, FASB issued Statement No. 141(R) to improve the
relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial reports
about a business combination and its effects. FASB Statement No.
141(R) supersedes FASB Statement No. 141 but retains the fundamental requirements in FASB Statement No. 141 that the acquisition
method of accounting (formerly called the purchase method in FASB
Statement No. 141) be used for all business combinations and that
an acquirer be identified for each business combination.
Among many other significant amendments to existing pronouncements precipitated by FASB Statement No. 141(R), this statement redefines goodwill in FASB Statement No. 142 to mean an asset representing the future economic benefits arising from other assets
acquired in a business combination that are not individually identified and separately recognized.
FASB Statement No. 141(R) applies to all transactions or other events
in which an entity (the acquirer) obtains control of one or more businesses (the acquiree), including those sometimes referred to as true
mergers or mergers of equals and combinations achieved without the
transfer of consideration, for example, by contract alone or through
the lapse of minority veto rights. This statement applies to all business entities, including mutual entities that previously used the
pooling-of-interests method of accounting for some business combinations. It does not apply to the following:
a.

The formation of a joint venture

b.

The acquisition of an asset or a group of assets that does not
constitute a business

c.

A combination between entities or businesses under common control

d.

A combination between not-for-profit entities or the acquisition of a for-profit business by a not-for-profit entity
This statement applies prospectively to business combinations for
which the acquisition date is on or after the beginning of the first
annual reporting period beginning on or after December 15, 2008
(that is, January 1, 2009, for entities with calendar year-ends). An
entity may not apply it before that date.
Part A1, “Business Combinations (Subject to FASB Statement No.
141(R)),” of this checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 141(R).
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 805-1065-1.
******
(continued)
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No
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Note that FASB Statement No. 141 does not apply to combinations
between not-for-profit organizations, nor does it apply to the acquisition of a for-profit business by a not-for-profit entity. See the following discussion regarding FASB Statement No. 164. For mergers
and acquisitions occurring prior to the effective date of FASB Statement No. 164, not-for-profit organizations should follow the guidance in paragraphs 1.15–.18 of Audit and Accounting Guide Not for
Profit Entities and in Accounting Principles Bulletin No. 16, Business
Combinations, as amended by pronouncements prior to the issuance
of FASB Statement No. 141 and complete questions 1–2.
******
In April 2009, FASB issued Statement No. 164 to improve the relevance, representational faithfulness, and comparability of the information that a not-for-profit entity provides in its financial reports
about a combination with one or more other not-for-profit entities,
businesses or nonprofit activities. and its effects. The statement also
improves the relevance, representation faithfulness, and comparability of the information a not-for-profit entity provides about goodwill
and other intangible assets after an acquisition and changes in the
noncontrolling interest in subsidiaries after a merger or acquisition.
This statement applies prospectively to mergers for which the
merger date is on or after the beginning of an initial reporting period
beginning on or after December 15, 2008 (that is, January 1, 2010, for
entities with calendar year-ends) or acquisitions for which the acquisition date is on or after the beginning of the first annual reporting
period beginning on or after December 15, 2009 (that is, January 1,
2010, for calendar year-ends). An entity may not apply it before that
date.
This checklist has not been updated to include the presentation and
disclosure requirements of FASB Statement No. 164.
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
. 1. If a combination occurred during the period and met the specified conditions for a pooling-of-interests, do the statements and
notes include the required disclosures? (Note: Not-for-profit organizations are, under certain circumstances, permitted to use
the pooling-of-interests method, even though they generally do
not issue common stock.)
[AAG-NPO 1.15–.18; APB 16 par. 45–48 and 63–65]
. 2. If a business combination does not meet the specified conditions
for a pooling-of-interests,
a.

is the combination accounted for by the purchase method?
[APB 16 par. 66–88 and 90–94; SFAS 38; FIN 4 concerns research and development activities of an acquired subsidiary]
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b.

do the statements and notes include the required disclosures?
[APB 16 par. 78 and 95–96]

l 3. Do the notes to the financial statements of a combined entity disclose the following information in the period in which a material
business combination is completed:
a.

The name and a brief description of the acquired entity and
the percentage of voting equity interests acquired?

b.

The primary reasons for the acquisition, including a description of the factors that contributed to a purchase price
that results in recognition of goodwill?

c.

The period for which the results of operations of the acquired entity are included in the income statement of the
combined entity?

d.

The cost of the acquired entity and, if applicable, the number of shares of equity interests (such as common shares,
preferred shares, or partnership interests) issued or issuable, the value assigned to those interests, and the basis for
determining that value?

e.

A condensed balance sheet disclosing the amount assigned
to each major asset and liability caption of the acquired entity at the acquisition date?

f.

Contingent payments, options, or commitments specified in
the acquisition agreement and the accounting treatment
that will be followed should any such contingency occur?

g.

The amount of purchased research and development assets
acquired and written off in the period (refer to paragraph
42 of FASB Statement No. 141) and the line item in the income statement in which the amounts written off are aggregated?

h.

For any purchase price allocation that has not been finalized, that fact and the reasons therefore?

i.

In subsequent periods, the nature and amount of any material adjustment made to the initial allocation of the purchase price?
[SFAS 141 par. 51]

l 4. Is the following information disclosed in the notes to the financial statements in the period in which a material business combination is completed if the amounts assigned to goodwill or to
other intangible assets acquired are significant in relation to the
total cost of the acquired entity:
a.
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For intangible assets subject to amortization,
i.

the total amount assigned and the amount assigned to
a major intangible asset class?

ii.

the amount of any significant residual value, in total
and by major intangible asset class?
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iii.

the weighted-average amortization period, in total
and by major intangible asset class?
b.
For intangible assets not subject to amortization the total
amount assigned and the amount assigned to any major intangible asset class?
c.
For goodwill,
i.
the total amount of goodwill and the amount that is
expected to be deductible for tax purposes?
ii.
the amount of goodwill by reportable segment (if the
combined entity is required to disclose segment information in accordance with FASB Statement No. 131),
unless not practicable?
[SFAS 141 par. 52]
l 5. If a series of individually immaterial business combinations completed during the period are material in the aggregate, is the following disclosed:
a.
The number of entities acquired and a brief description of
those entities?
b.
The aggregate cost of the acquired entities, the number of
equity interests, (such as common shares, preferred shares,
or partnership interests) issued or issuable, and the value
assigned to those interests?
c.
The aggregate amount of any contingent payments, options, or commitments and the accounting treatment that
will be followed should any contingency occur (if potentially significant in relation to the aggregate cost of the acquired entities)?
d.
The information described in question 2, if the aggregate
amount assigned to goodwill or to other intangible assets
acquired is significant in relation to the aggregate cost of
the acquired entities?
[SFAS 141 par. 53]
l 6. If the combined entity is a public business enterprises, is the following supplemental information on a pro forma basis for the
period in which a material business combinations occurs (or for
the period in which a series of individually immaterial business
combinations occur that are material in the aggregate) disclosed:
a.
Results of operations for the current period as though the
business combination or combinations had been completed
at the beginning of the period unless the acquisition was at
or near the beginning of the period?
b.
Results of operations for the comparable period as though
the business combination or combinations had been completed at the beginning of that period if comparative financial statements are presented?
[SFAS 141 par. 54]
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l 7. Does the supplemental pro forma information display revenue,
income before extraordinary items and the cumulative effect of
accounting changes, net income, and earnings per share at a minimum? (Note: In determining the pro forma amounts, income
taxes, interest expense, preferred share dividends, and depreciation and amortization of assets shall be adjusted to the accounting base recognized for each in recording the combination. Pro
forma information related to results of operations of periods
prior to the combination shall be limited to the results of operations for the immediately preceding period.)
[SFAS 141 par. 55]
l 8. Does the supplemental pro forma information disclose the nature and amount of material, nonrecurring items included in the
reported pro forma results of operations, if any?
[SFAS 141 par. 55]
l 9. In the period in which an extraordinary gain is recognized related to a business combination, do the notes to the financial
statements disclose the information required by paragraph 11 of
APB Opinion No. 30, Disclosure of Lease Commitments by Lessees?
[SFAS 141 par. 56]
l 10. If a material business combination is completed after the balance
sheet date but before the financial statements are issued, is the
information required by questions 1–2 disclosed if practicable?
[SFAS 141 par. 57]
Interim Financial Information
l 11. For summarized interim financial information of a public business enterprise is the following information disclosed if a material business combination is completed during the current year
up to the date of the most recent interim statement of financial
position presented:
a.
The name and a brief description of the acquired entity and
the percentage of voting equity interests acquired?
b.
The primary reasons for the acquisition, including a brief
description of the factors that contributed to a purchase
price that results in recognition of goodwill?
c.
The period for which the results of operations of the acquired entity are included in the income statement of the
combined entity?
d.
The cost of the acquired entity and, if applicable, the number of shares of equity interests (such as common shares,
preferred shares, or partnership interests) issued or issuable, the value assigned to those interests, and the basis for
determining that value?
e.
Supplemental pro forma information that discloses the results of operations for the current interim period and the
current year up to the date of the most recent interim statement of financial position presented (and for the corresponding periods in the preceding year) as though the business combination had been completed as of the beginning
of the period reported on?
f.
The nature and amount of any material, nonrecurring items
included in the reported pro forma results of operations?
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g.

Do the pro forma information disclosures in item (e) display at a minimum, revenue, income before extraordinary
items and the cumulative effect of accounting changes (including those on an interim basis), net income and earnings
per share?
[SFAS 141 par. 58]
l 12. If, as part of a business combination accounted for as a purchase,
a material liability is recognized by the combined company for
costs incurred to (a) exit an activity, (b) involuntarily terminate
employees of an acquired company, or (c) relocate employees of
an acquired company,
a.
are the following disclosures made for the period in which
a purchase business combination occurs:
i.
If the plans to exit an activity or involuntarily terminate (relocate) employees of the acquired company
are not final as of the balance sheet date, a description
of any unresolved issues, the types of additional liabilities that may result in an adjustment to the purchase price allocation, and how any adjustment will
be reported?
ii.
A description of the type and amount of liabilities assumed in the purchase price allocation for costs to exit
an activity or involuntary terminate (relocate) employees?
iii. A description of the major actions comprising the plan
to exit an activity or involuntarily terminate (relocate)
employees of an acquired company?
iv. A description of activities of the acquired company
that will not be continued, including the method of
disposition, and the anticipated date of completion
and description of employee group(s) to be terminated (relocated)?
b.
are the following disclosures made for all periods presented subsequent to the acquisition date in which a purchase business combination occurred, until a plan to exit an
activity or involuntarily terminate or relocate employees of
an acquired company is fully executed:
i.
A description of the type and amount of exit costs,
involuntary employee termination costs, and relocation costs paid and charged against the liability?
ii.
The amount of any adjustment to the liability account
and whether the corresponding entry was an adjustment of the costs of the acquired company or included
in the determination of net income for the period?
[EITF 95-3]
l 13. Are the following disclosures made for business combinations
between parties with a preexisting relationship:
a.
The nature of the preexisting relationship?
b.
The measurement of the settlement amount of the preexisting relationship, if any, and the valuation method used to
determine the settlement amount?
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c.

The amount of any settlement gain or loss recognized and
its classification in the statement of operations?
[EITF 04-1]
l 14. Amounts previously recognized as goodwill should not be reclassified as an identifiable intangible asset, however, previously
recognized goodwill should be tested for impairment by applying the consensuses in step 2 of a goodwill impairment test. As a
result of the application of EITF Issue No. 04-1, “Accounting for
Preexisting Relationships between the Parties to a Business Combination,” is any effect on a goodwill impairment charge reported in operating income?
[EITF 04-1]
A1. Business Combinations (Subject to FASB Statement No. 141(R))
Notes: In December 2007, FASB issued Statement No. 141(R) to improve the relevance, representational faithfulness, and comparability
of the information that a reporting entity provides in its financial
reports about a business combination and its effects. FASB Statement
No. 141(R) supersedes FASB Statement No. 141 but retains the fundamental requirements in FASB Statement No. 141 that the acquisition method of accounting (formerly called the purchase method in
FASB Statement No. 141) be used for all business combinations and
that an acquirer be identified for each business combination. Note
that FASB Statement No. 141(R) does not apply to combinations between not-for-profit organizations, nor does it apply to the acquisition of a for-profit business by a not-for-profit entity. See the following discussion regarding FASB Statement No. 164. For mergers and
acquisitions occurring prior to the effective date of FASB Statement
No. 164, not-for-profit organizations should follow the guidance in
paragraphs 1.15–.18 of Audit and Accounting Guide Not-for-Profit
Entities in Accounting Princples Bulletin No. 16 as amended by pronouncements prior to the issuance of FASB Statement No. 141(R)
and complete questions 1–2 of section A, “Business Combinations.”
Among many other significant amendments to existing pronouncements precipitated by FASB Statement No. 141(R), this statement
redefines goodwill in FASB Statement No. 142 to mean an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified
and separately recognized.
FASB Statement No. 141(R) applies to all transactions or other events
in which an entity (the acquirer) obtains control of one or more businesses (the acquiree), including those sometimes referred to as true
mergers or mergers of equals and combinations achieved without the
transfer of consideration, for example, by contract alone or through
the lapse of minority veto rights. This statement applies to all business entities, including mutual entities that previously used the
pooling-of-interests method of accounting for some business combinations. It does not apply to the following:
a.

The formation of a joint venture
(continued)
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b.

The acquisition of an asset or a group of assets that does not
constitute a business

c.

A combination between entities or businesses under common control

d.

A combination between not-for-profit entities or the acquisition of a for-profit business by a not-for-profit entity

No

N/A

This statement applies prospectively to business combinations for
which the acquisition date is on or after the beginning of the first
annual reporting period beginning on or after December 15, 2008
(that is, January 1, 2009, for entities with calendar year-ends). An
entity may not apply it before that date.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 141(R).
As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented
should consider all questions indicated with an “A” reference (for
example, question 1A and question 2A) and should place an “N/A”
mark in questions indicated with a “B” reference. Entities for which
the guidance has been implemented should consider all questions
indicated by a “B” reference (for example, question 1B and question
2B) and place an “N/A” mark by questions indicated with an “A”
reference. Therefore, based upon your entity’s year-end and decision
to early implement or not (if allowed), the following additional
questions will be answered when provided in this section (check one
that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 805-1065-1.
******
In April 2009, FASB amended FASB Statement No. 141(R) through
the issuance of FSP FAS 141(R)-1, Accounting for Assets Acquired and
Liabilities Assumed in a Business Combination That Arise from Contingencies. The FSP amends the initial recognition and measurement, subsequent measurement and accounting, and disclosure of assets and
liabilities arising from contingencies in a business combination. The
FSP is effective for assets or liabilities arising from contingencies in
business combinations for which the acquisition date is on or after
the beginning of the first annual reporting period beginning on or
after December 15, 2008 (that is, January 1, 2009, for entities with
calendar year-ends). As indicated in FASB ASC 270-10-50, the disclosures also apply to interim periods.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 141(R)-1.
(continued)
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As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented
should consider all questions indicated with an “A” reference (for
example, question 1A and question 2A) and should place an “N/A”
mark in questions indicated with a “B” reference. Entities for which
the guidance has been implemented should consider all questions
indicated by a “B” reference (for example, question 1B and question
2B) and place an “N/A” mark by questions indicated with an “A”
reference. Therefore, based upon your entity’s year-end and decision
to early implement or not (if allowed), the following additional
questions will be answered when provided in this section (check one
that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
******
FASB Statement No. 141(R) and FSP FAS 141(R)-1 require disclosures that enable users of its financial statements to evaluate
a.

the nature and financial effect of a business combination that
occurs either during the current reporting period, or after
the reporting date but before the financial statements are issued or are available to be issued (see FASB ASC 855-10-25).

b.

the financial effects of adjustments recognized in the current
reporting period that relate to business combinations that
occurred in the current or previous reporting periods.
******

In April 2009, FASB issued Statement No. 164 to improve the relevance, representational faithfulness, and comparability of the information that a not-for-profit entity provides in its financial reports
about a combination with one or more other not-for-profit entities,
businesses or nonprofit activities. and its effects. The statement also
improves the relevance, representation faithfulness, and comparability of the information a not-for-profit entity provides about goodwill
and other intangible assets after an acquisition and changes in the
noncontrolling interest in subsidiaries after a merger or acquisition.
This statement applies prospectively to mergers for which the merger
date is on or after the beginning of an initial reporting period beginning
on or after December 15, 2008 (that is, January 1, 2010, for entities with
calendar year-ends) or acquisitions for which the acquisition date is on
or after the beginning of the first annual reporting period beginning on
or after December 15, 2009 (that is, January 1, 2010, for calendar yearends). An entity may not apply it before that date.
This checklist has not been updated to include the presentation and
disclosure requirements of FASB Statement No. 164.
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
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Practice Tip
(FASB Statement No. 141(R)) The acquirer should disclose information that enables users of its financial
statements to evaluate the nature and financial effect of a business combination that occurs either during the
current reporting period or after the reporting date but before the financial statements are issued or are
available to be issued.
[“Pending Content” in FASB ASC 805-10-50-1]
l 1B.

(FASB Statement No. 141(R)) For each business combination
that occurs during the reporting period, has the entity disclosed
a.

the name and a description of the acquiree?

b.

the acquisition date?

c.

the percentage of voting equity interests acquired?

d.

the primary reasons for the business combination and
a description of how the acquirer obtained control of
the acquiree?

e.

for transactions that are recognized separately from the
acquisition of assets and assumptions of liabilities in
the business combination (see FASB ASC 805-10-25-20),
all of the following:

f.

g.

i.

A description of each transaction?

ii.

How the acquirer accounted for each transaction?

iii.

The amounts recognized for each transaction and
the line item in the financial statements in which
each amount is recognized?

iv.

If the transaction is the effective settlement of a
preexisting relationship, the method used to determine the settlement amount?

for separately recognized transactions required in item
(e),
i.

the amount of acquisition-related costs, the
amount recognized as an expense, and the line
item or items in the income statement in which
those expenses are recognized?

ii.

the amount of any issuance costs not recognized
as an expense and how they were recognized?

in a business combination achieved in stages, both of
the following:
i.

The acquisition-date fair value of the equity interest in the acquiree held by the acquirer immediately before the acquisition date?
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ii.

h.

No

N/A

The amount of any gain or loss recognized as a
result of remeasuring to fair value the equity interest in the acquiree held by the acquirer before
the business combination (see FASB ASC 805-1025-10) and the line item in the income statement
in which that gain or loss is recognized?

(Issuers Only) if the acquirer is a public business entity,
are all of the following disclosed:
i.

The amounts of revenue and earnings of the acquiree since the acquisition date included in the
consolidated income statement for the reporting
period?

ii.

The revenue and earnings of the combined entity
for the current reporting period as though the acquisition date for all business combinations that
occurred during the year had been as of the beginning of the annual reporting period (supplemental pro forma information)?

iii.

If comparative financial statements are presented, the revenue and earnings of the combined entity for the comparable prior reporting
period as though the acquisition date for all business combinations that occurred during the current year had occurred as of the beginning of the
comparable prior annual reporting period (supplemental pro forma information)?
[“Pending Content” in FASB ASC 805-10-50-2]
Practice Tips

(FASB Statement No. 141(R)) If disclosure of any of the information required by item (h) is impracticable,
the acquirer should disclose that fact and explain why the disclosure is impracticable.
[“Pending Content” in FASB ASC 805-10-50-2(h)]
******
(FASB Statement No. 141(R)) If the acquisition date of a business combination is after the reporting date but
before the financial statements are issued or are available to be issued, the acquirer should disclose the
information required by question 1B unless the initial accounting for the business combination is incomplete
at the time the financial statements are issued or are available to be issued. In that situation, the acquirer
should describe which disclosures could not be made and the reason why they could not be made.
[“Pending Content” in FASB ASC 805-10-50-4]
******
(FASB Statement No. 141(R)) If the acquisition date of a business combination is in the previous reporting
period, the acquirer should disclose information that enables users of its financial statements to evaluate the
financial effects of adjustments recognized in the current reporting period related to that prior business
combination.
[“Pending Content” in FASB ASC 805-10-50-5]
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l 2B.

(FASB Statement No. 141(R)) For individually immaterial
business combinations occurring during the reporting period
that are material collectively, has the entity disclosed the information required by items (e)–(g) in question 1B in the aggregate?
[“Pending Content” in FASB ASC 805-10-50-3]

l 3B.

(FASB Statement No. 141(R)) If the initial accounting for a
business combination is incomplete (see paragraphs 13–14 of
FASB ASC 805-10-25) and the amounts recognized in the financial statements have been determined only provisionally,
has the entity disclosed the following information for each
material business combination (or, in the aggregate for individually immaterial business combinations that are material
collectively):

l 4B.

a.

The reasons why the initial accounting is incomplete?

b.

The assets, liabilities, equity interests, or items of consideration for which the initial accounting is incomplete?

c.

The nature and amount of any measurement period adjustments recognized during the reporting period in accordance with FASB ASC 805-10-25-17?
[“Pending Content” in FASB ASC 805-10-50-6]

No

N/A

(FASB Statement No. 141(R) and FSP FAS 141(R)-1) With respect to identifiable assets and liabilities and any noncontrolling interest, has the entity disclosed all of the following for
each business combination that occurs during the reporting
period:
a.

b.

For indemnification assets, all of the following:
i.

The amount recognized as of the acquisition
date?

ii.

A description of the arrangement and the basis
for determining the amount of the payment?

iii.

An estimate of the range of outcomes (undiscounted) or, if a range cannot be estimated, that
fact and the reasons why a range cannot be estimated? (If the maximum amount of the payment
is unlimited, the entity should disclose that fact.)

For acquired receivables not subject to the requirements
of FASB ASC 310-30, all of the following (provided by
major class of receivable, such as loans, direct financing
leases in accordance with FASB ASC 840-30, and any
other class of receivables):
i.

The fair value of the receivables?

ii.

The gross contractual amounts receivable?

iii.

The best estimate at the acquisition date of the
contractual cash flows not expected to be collected?
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c.

The amounts recognized as of the acquisition date for
each major class of assets acquired and liabilities assumed (see example 5 in FASB ASC 805-10-55-37)?

d.

For contingencies, in the footnote that describes the
business combination,

e.

i.

for assets and liabilities arising from contingencies recognized at the acquisition date (which
may be aggregated for assets or liabilities arising
from contingencies that are similar in nature), (1)
the amounts recognized at the acquisition date
and the measurement basis applied (that is, at
fair value or at an amount recognized in accordance with FASB ASC 450, Contingencies, and
FASB ASC 450-20-25), and (2) the nature of the
contingencies?

ii.

for contingencies that are not recognized at the
acquisition date, the disclosures required by
FASB ASC 450 if the criteria for disclosures
therein are met (which may be aggregated for assets and liabilities arising from contingencies that
are similar in nature)?

For each business combination in which the entity
holds less than 100 percent of the equity interests in the
acquiree,
i.

the fair value of the noncontrolling interest in the
acquiree at the acquisition date?

ii.

the valuation technique(s) and significant inputs
used to measure the fair value of the noncontrolling interest?
[“Pending Content” in FASB ASC 805-20-50-1]

l 5B.

(FASB Statement No. 141(R)) For individually immaterial
business combinations occurring during the reporting period
that are material collectively, has the entity disclosed the information required by question 4B in the aggregate?
[“Pending Content” in FASB ASC 805-20-50-2]

l 6B.

(FASB Statement No. 141(R)) If the acquisition date of a business combination is after the reporting date but before the financial statements are issued or are available to be issued (as
discussed in FASB ASC 855-10-25), has the entity disclosed
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a.

the information required by question 4B (FASB ASC
805-20-50-1)?

b.

if the initial accounting for the business combination is
incomplete at the time the financial statements are issued or are available to be issued, a description of
which disclosures could not be made and the reason
why they could not be made?
[“Pending Content” in FASB ASC 805-20-50 par. 3–4]

No

N/A
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l 7B.

No

N/A

(FASB Statement No. 141(R)) With respect to goodwill, has
the entity disclosed all of the following information for each
business combination that occurs during the reporting period:
a.

A qualitative description of the factors that make up
the goodwill recognized, such as expected synergies
from combining operations of the acquiree and the acquirer, intangible assets that do not qualify for separate
recognition, or other factors?

b.

The acquisition-date fair value of the total consideration transferred and the acquisition-date fair value of
each major class of consideration, such as the following:

c.

i.

Cash?

ii.

Other tangible or intangible assets, including a
business or subsidiary of the acquirer?

iii.

Liabilities incurred, for example, a liability for
contingent consideration?

iv.

Equity interests of the acquirer, including the
number of instruments or interests issued or issuable and the method of determining the fair
value of those instruments or interests?

For contingent consideration arrangements, all of the
following:
i.

The amount recognized as of the acquisition
date?

ii.

A description of the arrangement and the basis
for determining the amount of the payment?

iii.

An estimate of the range of outcomes (undiscounted) or, if a range cannot be estimated, that
fact and the reasons why a range cannot be estimated? If the maximum amount of the payment
is unlimited, the acquirer should disclose that
fact.

d.

The total amount of goodwill that is expected to be deductible for tax purposes?

e.

If the acquirer is required to disclose segment information in accordance with FASB ASC 280-10, the amount
of goodwill by reportable segment? (If the assignment
of goodwill to reporting units required by paragraphs
41–44 of FASB ASC 350-20-35 has not been completed
as of the date the financial statements are issued or are
available to be issued, the acquirer should disclose that
fact.)

f.

In a bargain purchase (see paragraphs 2–4 of FASB
ASC 805-30-25), both of the following:
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i.

The amount of any gain recognized in accordance with FASB ASC 805-30-25-2 and the line
item in the income statement in which the gain is
recognized?

ii.

A description of the reasons why the transaction
resulted in a gain?
[“Pending Content” in FASB ASC 805-30-50-1]

l 8B.

(FASB Statement No. 141(R)) For individually immaterial
business combinations occurring during the reporting period
that are material collectively, has the entity disclosed the information required by question 7B in the aggregate?
[“Pending Content” in FASB ASC 805-30-50-2]

l 9B.

(FASB Statement No. 141(R)) If the acquisition date of a business combination is after the reporting date but before the financial statements are issued or are available to be issued (as
discussed in FASB ASC 855-10-25), has the entity disclosed
a.

the information required by questions 1B, 4B, and 7B?

b.

if the initial accounting for the business combination is
incomplete at the time the financial statements are issued or are available to be issued, a description of
which disclosures could not be made and the reason
why they could not be made?
[“Pending Content” in FASB ASC 805-10-50-4, FASB
ASC 805-20-50-3, and FASB ASC 805-30-50-3]

l 10B. (FASB Statement No. 141(R)) With respect to adjustments
that relate to business combinations that occurred in the current or previous reporting periods, has the entity disclosed
the following information for each material business combination:
a.

b.
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For each reporting period after the acquisition date until the entity collects, sells, or otherwise loses the right
to a contingent consideration asset, or until the entity
settles a contingent consideration liability or the liability is cancelled or expires, all of the following:
i.

Any changes in the recognized amounts, including any differences arising upon settlement?

ii.

Any changes in the range of outcomes (undiscounted) and the reasons for those changes?

iii.

The fair value disclosures required by paragraphs 1–3 of FASB ASC 820-10-50?

A reconciliation of the carrying amount of goodwill at
the beginning and end of the reporting period as required by FASB ASC 350-20-50-1?
[“Pending Content” in FASB ASC 805-30-50-4]

No

N/A
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Practice Tip
(FASB Statement No. 141(R)) Paragraphs 1–5 of FASB ASC 805-50-45 provide guidance on financial statement presentation in the period of transfer and for periods before the transfer of assets and liabilities between entities under common control. Question 11B addresses incremental disclosures related to such a
transaction. The receiving entity also should consider whether additional disclosures are required in accordance with FASB ASC 850-10-50, which provides guidance on related party transactions and certain common control relationships.
[“Pending Content” of FASB ASC 805-50-50 par. 1–4]
l 11B. (FASB Statement No. 141(R)) If the entity is the receiving entity in transactions between entities under common control,
has the following been disclosed for the period in which the
transfer of assets and liabilities or exchange of equity interests
has occurred:
a.

The name and brief description of the entity included
in the reporting entity as a result of the net asset transfer or exchange of equity interests?

b.

The method of accounting for the transfer of net assets
or exchange of equity interests?
[“Pending Content” in FASB ASC 805-50-50-3]
Practice Tip

(FASB Statement No. 141(R)) FASB ASC 805-740-30-3 describes a situation in which an acquirer reduces its
valuation allowance for deferred tax assets as a result of a business combination. FASB ASC 740-10-50-9(h)
requires disclosure of adjustments of the beginning-of-the-year balance of a valuation allowance because of
a change in circumstances that causes a change in judgment about the realizability of the related deferred
tax asset in future years. That would include, for example, any acquisition date income tax benefits or expenses recognized from changes in the acquirer’s valuation allowance for its previously existing deferred
tax assets as a result of a business combination.
[“Pending Content” in FASB ASC 805-740-50-1]
B.

Accounting Changes and Error Corrections
Practice Tip

In determining materiality for the purpose of reporting the correction of an error, amounts should be related
to the estimated income for the full fiscal year and also to the effect on the trend of earnings. Changes that
are material with respect to an interim period but not material with respect to the estimated income for the
full fiscal year or to the trend of earnings should be separately disclosed in the interim period.
[FASB ASC 250-10-45-27]
Change in Accounting Principle
.l 1. Is the following disclosed in the fiscal period in which a change
in accounting principle is made (not required for subsequent periods):
a.

The nature of and reason for the change in accounting principle, including an explanation of why the newly adopted
accounting principle is preferable?

FSP §11,100.01

122

Health Care Entities

Yes
b.

c.

The method of applying the change, including all of the following:
i.

A description of the prior-period information that has
been retrospectively adjusted, if any?

ii.

The effect of the change on income from continuing
operations, net income (or other appropriate captions
of changes in the applicable net assets or performance
indicator), any other affected financial statement line
item, and any affected per-share amounts for the current period and any prior periods retrospectively adjusted? Presentation of the effect on financial statement subtotals and totals other than income from
continuing operations and net income (or other appropriate captions of changes in the applicable net assets
or performance indicator) is not required.

iii.

The cumulative effect of the change on retained earnings or other components of equity or net assets in the
statement of financial position as of the beginning of
the earliest period presented?

iv.

If retrospective application to all prior periods is impracticable, disclosure of the reasons therefore, and a
description of the alternative method used to report
the change (see paragraphs 5–7 of FASB ASC 250-1045)?

If indirect effects of a change in accounting principle are
recognized,
i.

a description of the indirect effects of a change in accounting principle, including the amounts that have
been recognized in the current period, and the related
per-share amounts, if applicable?

ii.

unless impracticable, the amount of the total recognized indirect effects of the accounting change and the
related per-share amounts, if applicable, that are attributable to each prior period presented?
[FASB ASC 250-10-50-1]

.l 2. If a change in accounting principle has no material effect in the
period of change but is reasonably certain to have a material effect in later periods, are the disclosures required by question 1a
provided whenever the financial statements of the period of
change are presented?
[FASB ASC 250-10-50-1]
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N/A

.l 3. In the fiscal year in which a new accounting principle is adopted,
does financial information reported for interim periods after the
date of adoption include disclosure of the effect of the change on
income from continuing operations, net income (or other appropriate captions of changes in the applicable net assets or performance indicator), and related per-share amounts, if applicable,
for those postchange interim periods?
[FASB ASC 250-10-50-3]
Practice Tip
(Issuers Only) A change in accounting principle made in an interim period should be reported by retrospective application in accordance with FASB ASC 250-10-45-5. However, the impracticability exception in FASB
ASC 250-10-45-9 may not be applied to prechange interim periods of the fiscal year in which the change is
made. When retrospective application to prechange interim periods is impracticable, the desired change may
only be made as of the beginning of a subsequent fiscal year.
[FASB ASC 250-10-45-14]
l 4.

(Issuers Only) If a public company that regularly reports interim
information makes an accounting change during the fourth quarter of its fiscal year and does not report the data specified by
FASB ASC 270-10-50-1, in a separate fourth-quarter report or in
its annual report, does the entity include disclosure of the effects
of the accounting change on interim-period results, as required
by FASB ASC 250-10-50-1, in a note to the annual financial statements for the fiscal year in which the change is made?
[FASB ASC 250-10-45-15]

Change in Accounting Estimate
.l 5.

Is the effect on income from continuing operations, net income
(or other appropriate captions of changes in the applicable net
assets or performance indicator), and any related per-share
amounts of the current period disclosed for a change in estimate
that affects several future periods, such as a change in service
lives of depreciable assets? Disclosure of those effects is not necessary for estimates made each period in the ordinary course of
accounting for items such as uncollectible accounts or inventory
obsolescence; however, if the effect of a change in the estimate is
material, is it disclosed?
[FASB ASC 250-10-50-4]

.l 6.

When an entity effects a change in estimate by changing an accounting principle, are the disclosures required by questions 1–3
made?
[FASB ASC 250-10-50-4]

.l 7.

If a change in estimate does not have a material effect in the period of change but is reasonably certain to have a material effect
in later periods, is a description of that change in estimate disclosed whenever the financial statements of the period of change
are presented?
[FASB ASC 250-10-50-4]
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Change in the Reporting Entity
.l 8.

When there has been a change in the reporting entity, do the financial statements of the period of the change describe the nature of the change and the reason for it?
[FASB ASC 250-10-50-6]

.l 9.

Is the effect of the change on income before extraordinary items,
net income (or other appropriate captions of changes in the applicable net assets or performance indicator), other comprehensive income, and any related per-share amounts disclosed for all
periods presented?
[FASB ASC 250-10-50-6]

.l 10. If a change in reporting entity does not have a material effect in
the period of change but is reasonably certain to have a material
effect in later periods, is the nature of and reason for the change
disclosed whenever the financial statements of the period of
change are presented?
[FASB ASC 250-10-50-6]
Practice Tip
FASB ASC 805-10-50, FASB ASC 805-20-50, FASB ASC 805-30-50, and FASB ASC 805-740-50 describe the
manner of reporting and the disclosures required for a business combination.
[FASB ASC 250-10-50-6]
.l 11. If a change in reporting entity results in financial statements that
are, in effect, the statements of a different reporting entity, has
the change been retrospectively applied to all periods presented?
[FASB ASC 250-10-45-21]
Correction of an Error in Previously Issued Financial Statements
.l 12. When financial statements are restated to correct an error, does
the entity disclose that its previously issued financial statements
have been restated, along with a description of the nature of the
error? Does the entity also disclose the following:
a.

The effect of the correction on each financial statement line
item and any per-share amounts affected for each prior
period presented?

b.

The cumulative effect of the change on retained earnings or
other appropriate components of equity or net assets in the
statement of financial position, as of the beginning of the
earliest period presented?
[FASB ASC 250-10-50-7]

.l 13. In addition, does the entity make the following disclosures of
prior-period adjustments and restatements (see also FASB ASC
205-10-45 and FASB ASC 205-10-50-1):
a.
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For single period financial statements, the effects (including
applicable income taxes) of such restatement on the balance
of retained earnings at the beginning of the period and on
the net income of the immediately preceding period?
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b.

C.

No
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For multiple-period financial statements, the effects (including applicable income taxes) for each of the periods included in the statements, in total and by class, of the correction on change in net assets for each of the periods
presented?
[FASB ASC 250-10-50-9]

Commitments and Contingencies
Notes: In June 2008, FASB issued a proposed Statement of Financial
Accounting Standards titled Disclosure of Certain Loss Contingencies—an amendment of FASB Statements No. 5 and 141(R) that would
replace the disclosure requirements in FASB Statement No. 5 for loss
contingencies that are recognized as liabilities in a statement of financial position and for unrecognized loss contingencies that would
be recognized as liabilities if the criteria for recognition in paragraph
8 of FASB Statement No. 5 were met. Loss contingencies that are (or
would be) recognized as asset impairments would continue to be
disclosed in accordance with FASB Statement No. 5. This proposed
statement would also amend FASB Statement No. 141(R) to require
the disclosures included in this statement for loss contingencies recognized in a business combination. This proposed statement would
not change the recognition and measurement guidance for loss contingencies contained in FASB Statement No. 5 and in FASB Statement No. 141(R).
On September 24, 2008, FASB decided on a plan for redeliberations
and directed the staff to prepare an alternative model that will attempt to address the concerns that certain constituents raised about
this proposed statement. This alternative model will be field tested
along with the model in the exposure draft. The board also decided
that any final statement on this topic will be effective no sooner than
for fiscal years ending after December 15, 2009 (that is, December 31,
2009, for entities with calendar year-ends).
FASB began redeliberation of disclosure of certain loss contingencies
at the August 19, 2009 meeting. They plan to continue redeliberations in a future meeting. FASB did not rule out the possibility that
final guidance on this project could be effective for fiscal years ending after December 15, 2009 (that is, December 31, 2009, for entities
with calendar year-ends).
This checklist has not been updated to include the presentation and
disclosure requirements of this proposed statement. Readers may
continue to check the status of this proposed statement on the FASB
Web site at www.fasb.org.
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.l 1. Is disclosure made of the nature of estimated loss contingencies
accrued when (a) information available prior to issuance of the
financial statements indicates that it is probable that an asset has
been impaired or a liability incurred at the date of the financial
statements and (b) the amount of loss can be reasonably estimated?
[FASB ASC 450-20-25-2; FASB ASC 450-20-50-1]
.l 2. If necessary to keep the financial statements from being misleading, are the amounts of contingencies accrued as described in
question 1 disclosed?
[FASB ASC 450-20-50-1]
.l 3. If the criteria in FASB ASC 275-10-50-8 (see the “Summary of Significant Accounting Policies” section, part B, “Certain Significant
Estimates”) are met, has the entity disclosed that it is at least reasonably possible that a change in an entity’s estimate of its liability could occur in the near term? (FASB ASC 450-20-55-36 illustrates this disclosure for an entity involved in litigation.)
[FASB ASC 450-20-50-2; FASB ASC 275-10-50-9]
.l 4. For loss contingencies not accrued because one or both of the
conditions described in question 1 are not met or if an exposure
to loss exists in excess of the amount accrued for a loss contingency, do disclosures indicate the
a.

nature of the contingency?

b.

estimate of possible loss or range of loss, or a statement that
such estimate cannot be made?
[FASB ASC 450-20-50 par. 3–4 ]
Practice Tips

Disclosure is preferable to accrual when a reasonable estimate of loss cannot be made. For example, disclosure should be made of any loss contingency that meets the condition in FASB ASC 450-20-25-2(a), question
1, but that is not accrued because the amount of loss cannot be reasonably estimated. Disclosure also should
be made of some loss contingencies that do not meet the condition in FASB ASC 450-20-25-2(a), question 1,
namely, those contingencies for which there is a reasonable possibility that a loss may have been incurred
even though information may not indicate that it is probable that an asset had been impaired or a liability
had been incurred at the date of the financial statements.
[FASB ASC 420-10-50-5]
******
Disclosure is not required of a loss contingency involving an unasserted claim or assessment if there has
been no manifestation by a potential claimant of an awareness of a possible claim or assessment unless both
of the following conditions are met:
●

It is considered probable that a claim will be asserted.

●

There is a reasonable possibility that the outcome will be unfavorable.

Further, disclosure of noninsured or underinsured risks in encouraged but not required.
[FASB ASC 450-20-50 par. 6–7]
******
(continued)
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Disclosure of a loss, or a loss contingency, arising after the date of an entity’s financial statements but before
those financial statements are issued, as described in paragraphs 6–7 of FASB ASC 450-20-25, may be necessary to keep the financial statements from being misleading if an accrual is not required. If disclosure is
deemed necessary, the financial statements should include both of the following:
●

The nature of the loss or loss contingency

●

An estimate of the amount or range of loss or possible loss or a statement that such an estimate
cannot be made

Occasionally, in the case of a loss arising after the date of the financial statements if the amount of asset
impairment or liability incurrence can be reasonably estimated, disclosure may best be made by supplementing the historical financial statements with pro forma financial data giving effect to the loss as if it had
occurred at the date of the financial statements. It may be desirable to present pro forma statements, usually
a balance sheet only, in columnar form on the face of the historical financial statements.
[FASB ASC 450-20-50 par. 9–10]
.l 5.

Are the nature and amount of guarantees disclosed (for example, guarantees of indebtedness of others, guarantees to repurchase receivables (or, in some cases, the related property) that
have been sold or otherwise assigned) even though the possibility of loss may be remote?
[FASB ASC 460-10-50 par. 2–3]

.l 6.

Are gain contingencies adequately disclosed with care to avoid
any misleading implications about likelihood of realization?
[FASB ASC 450-30-50-1]

.l 7.

Has the entity disclosed the following items:

8.

a.

Unused letters of credit?

b.

Long term leases?

c.

Assets pledged as securities for loans?

d.

Pension plans?

e.

The existence of cumulative preferred stock dividends in
arrears?
[FASB ASC 440-10-50-1]

Have any unconditional purchase obligations, exhibiting all of
the following characteristics been disclosed in accordance with
FASB ASC 440-10-50-4, question 10, (if not on the balance sheet)
or in accordance with FASB ASC 440-10-50-6, question 11 (if recorded on the balance sheet):
a.

It is noncancelable, or cancelable only in any of the following circumstances:
i.

Upon the occurrence of some remote contingency?

ii.

With the permission of the other party?

iii.

If a replacement agreement is signed between the
same parties?
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iv.

.l 9.

Upon payment of a penalty in an amount such that
continuation of the agreement appears reasonably assured?

b.

It was negotiated as part of arranging financing for the facilities that will provide the contracted goods or services
or for costs related to those goods or services (for example,
carrying costs for contracted goods)? A purchaser is not
required to investigate whether a supplier used an unconditional purchase obligation to help secure financing, if the
purchaser would otherwise be unaware of that fact.

c.

It has a remaining term in excess of one year?
[FASB ASC 440-10-50-2]

For long term unconditional purchase obligations that are not
recorded in the purchaser’s balance sheet, are the following disclosed:
a.

Nature and term of the obligations?

b.

Amount of the fixed and determinable portion of the obligations as of the date of the latest balance sheet presented
in the aggregate and, if determinable, for each of the next
five years?

c.

Nature of any variable components of the obligation?

d.

Amounts of purchases under the obligations for each year
for which an income statement is presented?
[FASB ASC 440-10-50-4]

.l 10.

If an unconditional purchase obligation is subject to the requirements of both FASB ASC 440-10 and FASB ASC 815-10, has the
entity complied with those disclosure requirements of FASB
ASC, including question 8? (See also part I of the “Other Financial Statement Disclosures” section herein.)
[FASB ASC 440-10-50-7]

.l 11.

For unconditional purchase obligations that meet the criteria of
FASB ASC 440-10-50-2 and that have been recognized on the
purchaser’s balance sheet, has the entity disclosed for each of
the 5 years following the date of the latest balance sheet presented the aggregate amount of payments?
[FASB ASC 440-10-50-6]

. 12.

Have issues of noncompliance with donor-imposed restrictions
been disclosed if (a) there is a reasonable possibility that a material contingent liability has been incurred or (b) there is at
least a reasonable possibility that the noncompliance could lead
to a material loss of revenue or cause the entity to be unable to
continue as a going concern?
[FASB ASC 958-450-50-2]

. 13.

If the noncompliance (see question 12) results from the not-forprofit entity’s failure to maintain an appropriate composition of
assets in amount needed to comply with donor restrictions,
have the amounts and circumstances been disclosed?
[FASB ASC 958-450-50-3]
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.l 14.

If the entity is a provider of prepaid health care services, is the
basis for accruing health care costs disclosed?
[FASB ASC 954-405-50-1]

.l 15.

If the entity is a provider of prepaid health care services, are
significant business and contractual arrangements with hospitals, physicians, and other associated entities disclosed?
[FASB ASC 954-405-50-2]

.l 16.

Has the health care entity disclosed their program of medical
malpractice insurance coverages?
[FASB ASC 954-450-50-1]

.l 17.

If the health care entity discounts accrued malpractice claims,
has it disclosed the amount of accrued malpractice claims that
are discounted and the interest rate or rates used to discount
those claims?
[FASB ASC 954-450-50-2]

.l 18.

With regards to retrospectively rated premiums, has the entity
disclosed the following:

.l 19.

.l 20.

.l 21.

a.

That it is under a retrospectively rated policy?

b.

That premiums are accrued based on the ultimate cost of
the experience to date of a group of entities?
[FASB ASC 954-720-50-1]

No

N/A

With regards to medical malpractice claims insured with captive insurance companies, has the entity disclosed the following:
a.

That it is insured under a retrospectively rated policy of a
multiprovider captive insurance entity?

b.

That premiums are accrued based on the captive insurance
entity’s experience to date?
[FASB ASC 954-720-50-2]

For entities that are insured by a multiprovider captive insurance entity, have the following been disclosed:
a.

That it is ensured by such an entity?

b.

Its ownership percentage in the captive entity?

c.

The method for accounting for its investment in, and the
operations of, the captive entity?
[FASB ASC 954-720-50-3]

If the health care entity is party to stop-loss insurance have the
nature, amounts, and effects of significant stop-loss insurance
contracts disclosed?
[FASB ASC 954-450-50-4]
Practice Tip

Stop-loss insurance premiums should be included in reported health care costs. Stop-loss insurance recoveries should be reported as reductions to health care costs.
[FASB ASC 954-720-45-1]
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.l 22. Is the existence of trust funds and whether they are irrevocable
disclosed?
[FASB ASC 954-810-50-1]
.l 23. Is a portion of the trust funds (the amount of assets expected to
be liquidated to pay malpractice claims classified as current liabilities) classified as a current asset in a classified balance sheet/
statement of financial position?
[FASB ASC 954-810-45-4]
.l 24. Is the balance of the trust funds, if any, classified as a noncurrent
asset in a classified balance sheet/statement of financial position?
[FASB ASC 954-810-45-4]
.l 25. Are trust fund revenue and administrative expenses included in
the statement of activities/income statement?
[FASB ASC 954-810-45-4]
.l 26. Are estimated losses to the trust fund from asserted and unasserted claims reported?
[FASB ASC 954-450-25-3]
D.

Current Vulnerability Due to Certain Concentrations

.l 1. If the entity has concentrations that exist at the date of the financial statements, those concentrations make the entity vulnerable to
the risk of a near term severe impact, and it is at least reasonably
possible that the events that could cause the severe impact will
occur in the near term, have the concentrations been disclosed,
including information that is adequate to inform users of the general nature of the risk associated with the concentration?
[FASB ASC 275-10-50 par. 16 and 20]
Practice Tip
Concentrations, including known group concentrations, described in the following list require disclosure if
they meet the criteria of FASB ASC 275-10-50-16 (question 1). (Group concentrations exist if a number of
counterparties or items that have similar economic characteristics collectively expose the reporting entity to
a particular kind of risk.) Some concentrations may fall into more than one of the following categories:
●

Concentrations in the volume of business transacted with a particular customer, supplier, lender, grantor, or
contributor. The potential for the severe impact can result, for example, from total or partial loss of
the business relationship. For purposes of FASB ASC 275-10, it is always considered at least reasonably possible that any customer, grantor, or contributor will be lost in the near term.

●

Concentrations in revenue from particular products, services, or fund-raising events. The potential for the
severe impact can result, for example, from volume or price changes or the loss of patent protection
for the particular source of revenue.

●

Concentrations in the available sources of supply of materials, labor, or services, or of licenses or other rights
used in the entity’s operations. The potential for the severe impact can result, for example, from
changes in the availability to the entity of a resource or a right.

●

Concentrations in the market or geographic area in which an entity conducts its operations. The potential
for the severe impact can result, for example, from negative effects of the economic and political
forces within the market or geographic area. For purposes of FASB ASC 275-10, it is always considered at least reasonably possible that operations located outside an entity’s home country will be
disrupted in the near term.
(continued)
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The concentrations of financial instruments, and other concentrations not described in the preceding list,
may be required to be disclosed pursuant to other guidance included in FASB ASC. If adequate information
about concentrations is presented in other parts of the financial statements in accordance with other guidance included in FASB ASC, that information need not be repeated.
[FASB ASC 275-10-50 par. 18–19]
.l 2. For those concentrations of labor subject to collective bargaining
agreements and concentrations of operations located outside the
reporting entity’s home country that (a) exist at the date of the
financial statements and (b) make the reporting entity vulnerable
to the risk of a near term severe impact, where it is at least reasonably possible that the events that could cause the severe impact
will occur in the near term, are the following disclosed:
a.

The percentage of labor force covered by a collective agreement and the percentage of the labor force covered by a collective bargaining agreement that will expire in one year?

b.

For operations located outside the reporting entity’s home
country, the carrying amounts of net assets and the geographic areas in which they are located?
[FASB ASC 275-10-50-20]
Practice Tip

FASB ASC 275-10-50 does not prohibit entities from also stating in disclosures of concentrations related to
customers, grantors, or contributors or operations located outside the entity’s home country that the entity
does not expect that the business relationship will be lost or does not expect that the foreign operations will
be disrupted if such is the case.
[FASB ASC 275-10-50-20]
.l 3. Certain loan products have contractual terms that expose entities
to risks and uncertainties that fall into one or more categories, as
discussed in FASB ASC 275-10-50-1. If they meet the requirements
of FASB ASC 275-10-50-16, are other concentrations disclosed?
[FASB ASC 310-10-50-25; FASB ASC 275-10-50-16]
Practice Tip
The guidance in FSP SOP 94-6-1, Terms of Loan Products That May Give Rise to a Concentration of Credit Risk,
addresses the adequacy of disclosures for all lending products (including both secured and unsecured loans)
and the effect of changes in market or economic conditions on the adequacy of those disclosures. An entity
should provide the disclosures required by FASB ASC 825-10 for products that are determined to represent
a concentration of credit risk. Examples of possible shared characteristics on which significant concentrations
may be determined are in FASB ASC 825-10-55-1.
[FASB ASC 825-10-50 par. 20–21; FASB ASC 825-10-55-1]
E.

Employee Stock Ownership Plans
l 1. For any employee stock ownership plans (ESOPs) sponsored by
the entity, do the financial statements include disclosure of
a.

a description of the plan?
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b.

the basis for determining contributions?

c.

the employee groups covered?

d.

the nature and effect of significant matters affecting comparability of information for all periods presented?

e.

for leveraged ESOPs and pension reversion ESOPs, the basis
for releasing shares and how dividends on allocated and unallocated shares are used?
[FASB ASC 718-40-50-1(a)]

l 2. A description of the accounting policies followed for ESOP transactions, including
a.

the method of measuring compensation?

b.

the classification of dividends on ESOP shares?

c.

the treatment of ESOP shares for EPS computation?
[FASB ASC 718-40-50-1(b)]

l 3. If the entity has both old ESOP shares for which it does not adopt
the guidance in FASB ASC 718-40 [see FASB ASC 105-10-70-2(c)],
and new ESOP shares for which the guidance in FASB ASC 71840 is required, are the accounting policies set forth in question 2
disclosed for both blocks of shares?
[FASB ASC 718-40-50-1(b)]
l 4. Is the amount of compensation cost recognized during the period
disclosed?
[FASB ASC 718-40-50-1(c)]
l 5. Is the number of allocated shares, committed-to-be-released
shares, and suspense shares held by the ESOP at the balance-sheet
date disclosed? (Note: This disclosure should be made separately
for shares accounted for under FASB ASC 718-40 and for grandfathered employee stock ownership plan shares [see FASB ASC
105-10-70-2(c)].)
[FASB ASC 718-40-50-1(d)]
l 6. Is the fair value of unearned ESOP shares at the balance-sheet date
for shares accounted for under FASB ASC 718-40 disclosed?
[FASB ASC 718-40-50-1(e)]
l 7. Is disclosure made of the existence and nature of any repurchase
obligation, including disclosure of the fair value (see FASB ASC
718-40-30-4) of the shares allocated as of the balance-sheet date,
which are subject to a repurchase obligation?
[FASB ASC 718-40-50-1(f)]
l 8. The amount and treatment in the EPS computation of the tax benefit related to dividends paid to any employee stock ownership
plan, if material.
[FASB ASC 718-40-50-1(g)]
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l 9. If the reporting entity issues shares or sells treasury shares to an
ESOP or if a leveraged ESOP buys outstanding shares on the market rather than from the employer, has a corresponding charge to
unearned ESOP shares, a contra-equity account presented as a
separate item in the balance sheet, been reported?
[FASB ASC 718-40-45-2]
l 10. If the ESOP used assets from a terminated defined benefit pension
plan to purchase employer shares, has a corresponding charge to
unearned ESOP shares, a contra-equity account presented as a
separate item in the balance sheet, been reported?
[FASB ASC 718-40-25-4]
l 11. If the employer sponsors an ESOP with an indirect loan, is the
outside loan reported as a liability and the receivable from the
ESOP not reported on the employer’s balance sheet?
[FASB ASC 718-40-25-9(b)]
l 12. If the employer sponsors an ESOP with an employer loan, is the
employer’s note receivable from the ESOP not reported in the employer’s balance sheet?
[FASB ASC 718-40-25-9(e)]
l 13. If any grandfathered shares (FASB ASC 105-10-70-2[c]) are still being accounted for in accordance with SOP 76-3, Accounting Practices for Certain Employee Stock Ownership Plans (AICPA, Technical
Practice Aids, ACC sec. 10,130), is still being followed for ESOP
shares purchased before December 31, 1992, and if the reporting
entity has guaranteed the debt of an ESOP or made a commitment
to make future contributions to the ESOP sufficient to meet debt
service requirements, are the compensation element and the interest element of annual contributions reported separately and are
the interest rate and debt terms disclosed in the notes to the financial statements?
[SOP 76-3 par. 10 (ACC 10,130.10)]
F.

Employers’ Disclosures for Defined Benefit Pension and Other Postretirement Plans

Notes: In September 2006, FASB issued Statement No. 158, Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans—an amendment of FASB Statements No. 87, 88, 106, and 132(R). FASB Statement No.
158 requires, among other provisions, an employer to recognize the overfunded or underfunded status of a defined benefit postretirement plan
(other than a multiemployer plan) as an asset or liability in its statement of
financial position and to recognize changes in that funded status in the
year in which the changes occur through comprehensive income. This
statement also requires an employer to measure the funded status of a plan
as of the date of its year-end statement of financial position, with limited
exceptions.
(continued)
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The requirement to measure plan assets and benefit obligations as of the
date of the employer’s fiscal year-end statement of financial position (see
paragraphs 5–6 and 9 of FASB Statement No. 158) is effective for fiscal
years ending after December 15, 2008 (that is, December 31, 2008, for entities with calendar year-ends). If in the last quarter of the preceding fiscal
year an employer enters into a transaction that results in a settlement or
experiences an event that causes a curtailment of the plan, the related gain
or loss pursuant to FASB Statement No. 88 or FASB Statement No. 106 is
required to be recognized in earnings or changes in unrestricted net assets
of that quarter.
Earlier application of the recognition or measurement date provisions is
encouraged; however, early application must be for all of an employer’s
benefit plans. Retrospective application of the statement is not permitted.
This checklist has been updated to include the presentation and disclosure
requirements of FASB Statement No. 158.
Readers can refer to the full text of FASB Statement No. 158 on the FASB
Web site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and
open effective date information discussed in FASB ASC 715-20-65-1.
******
In December 2008, FASB issued FSP FAS 132(R)-1, Employers’ Disclosures
about Postretirement Benefit Plan Assets, to provide guidance on an employer’s disclosures about plan assets of a defined benefit pension or other
postretirement plan. One objective is to disclose information about fair
value measurements of plan assets that would be similar to the disclosures
required by FASB Statement No. 157, Fair Value Measurements.
The disclosures about plan assets required by this FSP should be provided
for fiscal years ending after December 15, 2009 (that is, December 31, 2009,
for entities with calendar year-ends). Upon initial application, the provisions of this FSP are not required for earlier periods presented for comparative purposes. Earlier application is permitted.
This FSP also includes a technical amendment to FASB Statement No.
132(R) that requires a nonpublic entity to disclose net periodic benefit cost
for each annual period for which a statement of income is presented. This
amendment was effective upon issuance.
This checklist has been updated to include the presentation and disclosure
requirements of FSP FAS 132(R)-1.
As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented should consider
all questions indicated with an “A” reference (for example, question 1A
and question 2A) and should place an “N/A” mark in questions indicated
with a “B” reference. Entities for which the guidance has been implemented should consider all questions indicated by a “B” reference (for example, question 1B and question 2B) and place an “N/A” mark by questions indicated with an “A” reference. Therefore, based upon your entity’s
year-end and decision to early implement or not (if allowed), the following
(continued)
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additional questions will be answered when provided in this section (check
one that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and
open effective date information discussed in FASB ASC 715-20-65-2.

Practice Tip
Not-for-profit entities should make the following substitutions when applying the disclosure requirements
of FASB ASC 715-20-50 in the following questions:
●

The references to the neoft gain or loss, net prior service cost or credit, and net transition asset or
obligation recognized in other comprehensive income in FASB ASC 715-20-50-1(i) and FASB ASC
715-20-50-5(h) shall instead be to such amounts recognized as changes in unrestricted net assets
arising from a defined benefit plan but not yet included in net periodic benefit cost.

●

The references to reclassification adjustments other comprehensive income in FASB ASC 715-20-501(i) and FASB ASC 715-20-50-5(h) shall instead be to reclassifications to net periodic benefit cost of
amounts previously recognized as changes in unrestricted net assets arising from a defined benefit
plan but not included in net periodic benefit cost when they arose.

●

The references to the net gain or loss, net prior service cost or credit, and net transition asset or
obligation recognized in accumulated other comprehensive income in the following paragraphs
shall instead be to such amounts that have been recognized as changes in unrestricted net assets
arising from a defined benefit plan but not yet reclassified as components of net periodic benefit
cost:
— FASB ASC 715-20-50-5(i)
— FASB ASC 715-20-50-1(j)
— FASB ASC 715-20-50-5(n)
— FASB ASC 715-20-50-1(s)

●

The references to results of operations (including items of other comprehensive income) in FASB
ASC 715-20-50-1 and FASB ASC 715-20-50-5 shall instead be to changes in unrestricted net assets
and the references to a statement of income in those paragraphs shall instead be to a statement of
activities.

[FASB ASC 958-715-50-1]
l 1A.

(Issuers Only) If an employer sponsors one or more defined
benefit pension plans or one or more defined benefit postretirement plans has the following information been provided,
separately for pension plans and other postretirement benefit
plans:
a.

A reconciliation of beginning and ending balances of
the benefit obligation showing separately, if applicable,
the effects during the period attributable to each of the
following:
i.

Service cost?

FSP §11,100.01

136

Health Care Entities

Yes

b.

ii.

Interest cost?

iii.

Contributions by plan participants?

iv.

Actuarial gains and losses?

v.

Foreign currency rate changes (the effects of foreign currency exchange rate changes that are to
be disclosed are those applicable to plans of a foreign operation whose functional currency is not
the reporting currency pursuant to FASB ASC
830-10-45)?

vi.

Benefits paid?

vii.

Plan amendments?

viii.

Business combinations?

ix.

Divestitures?

x.

Curtailments, settlements, and special and contractual termination benefits?

A reconciliation of beginning and ending balances of
the fair value of plan assets showing separately, if applicable, the effects during the period attributable to
each of the following:
i.

Actual return on plan assets?

ii.

Foreign currency exchange rate changes?

iii.

Contributions by the employer?

iv.

Contributions by plan participants?

v.

Benefits paid?

vi.

Business combinations?

vii.

Divestitures?

viii.

Settlements?

c.

The funded status of the plans and the amounts recognized in the statement of financial position showing
separately the assets and current and noncurrent liabilities recognized?

d.

The following information about plan assets:
i.

FSP §11,100.01
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assets held as of the measurement date used for
each statement of financial position presented?
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ii.

A narrative description of investment policies
and strategies, including target allocation percentages or range of percentages for each major
category of plan assets presented on a weightedaverage basis as of the measurement date(s) of
the latest statement of financial position presented, if applicable, and other factors that are
pertinent to an understanding of the policies or
strategies such as investment goals, risk management practices, permitted and prohibited investments including the use of derivatives, diversification, and the relationship between plan assets
and benefit obligations?

iii.

A narrative description of the basis used to determine the overall expected long term rate-of-return-on-assets assumption, such as the general
approach used, the extent to which the overall
rate-of-return-on-assets assumption was based
on historical returns, the extent to which adjustments were made to those historical returns in
order to reflect expectations of future returns,
and how those adjustments were determined?

iv.

Disclosure of additional asset categories and additional information about specific assets within
a category is encouraged if that information is expected to be useful in understanding the risks associated with each asset category and the overall
expected long term rate of return on assets?

e.

For defined benefit pension plans, the accumulated
benefit obligation?

f.

The benefits (as of the date of the latest statement of
financial position presented) expected to be paid in
each of the next five fiscal years, and in the aggregate
for the five fiscal years thereafter? The expected benefits should be estimated based on the same assumptions used to measure the entity’s benefit obligation at
the end of the year and should include benefits attributable to estimated future employee service.

g.

The employer’s best estimate, as soon as it can reasonably be determined, of contributions expected to be
paid to the plan during the next fiscal year beginning
after the date of the latest statement of financial position presented. Estimated contributions may be presented in the aggregate combining all of the following:
i.

Contributions required by funding regulations or
laws?

ii.

Discretionary contributions?

iii.

Noncash contributions?

No

N/A
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h.

i.

The service cost component?

ii.

The interest cost component?

iii.

The expected return on plan assets for the period?

iv.

The gain or loss component?

v.

The prior service cost or credit component?

vi.

The transition asset or obligation component?

vii.

The gain or loss recognized due to settlements or
curtailments?

i.

Separately the net gain or loss and net prior service cost
or credit recognized in OCI for the period pursuant to
FASB ASC 715-30-35-11, FASB ASC 715-30-35-21, FASB
ASC 715-60-35-16, and FASB ASC 715-60-35-25, and reclassification adjustments of OCI for the period, as
those amounts, including amortization of the net transition asset or obligation, are recognized as components
of net periodic benefit cost?

j.

The amounts in accumulated OCI that have not yet
been recognized as components of net periodic benefit
cost, showing separately the net gain or loss, net prior
service cost or credit, and net transition asset or obligation?

k.

On a weighted-average basis, all of the following assumptions used in the accounting for the plans, specifying in a tabular format, the assumptions used to determine the benefit obligation and the assumptions
used to determine net benefit cost:

l.
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The amount of net benefit cost recognized, showing
separately all of the following:

i.

Assumed discount rates?

ii.

Rates of compensation increase (for pay-related
plans)?

iii.

Expected long term rates of return on plan assets?

The assumed health care cost trend rate(s) for the next
year used to measure the expected cost of benefits covered by the plan (gross eligible charges), and a general
description of the direction and pattern of change in the
assumed trend rates thereafter, together with the ultimate trend rate(s) and when that rate is expected to be
achieved?
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m.

The effect of a one percentage point increase and the
effect of a one percentage point decrease in the assumed health care cost trend rates on the aggregate of
the service and interest cost components of net periodic
postretirement health care benefit costs and the accumulated postretirement benefit obligation (APBO) for
health care benefits? Measuring the sensitivity of the
APBO and the combined service and interest cost components to a change in the assumed health care cost
trend rates requires remeasuring the APBO as of the
beginning and end of the year.

n.

If applicable, the amounts and types of securities of the
employer and related parties included in plan assets,
the approximate amount of future annual benefits of
plan participants covered by insurance contracts, including annuity contracts issued by the employer or related parties, and any significant transactions between
the employer or related parties and the plan during the
period?

o.

If applicable, any alternative method used to amortize
prior service amounts or net gains and losses pursuant
to FASB ASC 715-30-35-13 and FASB ASC 715-30-35-25
or FASB ASC 715-60-35-18 and FASB ASC 715-60-3531?

p.

If applicable, any substantive commitment, such as past
practice or a history of regular benefit increases, used
as the basis for accounting for the benefit obligation?

q.

If applicable, the cost of providing special or contractual termination benefits recognized during the period
and a description of the nature of the event?

r.

An explanation of any significant change in the benefit
obligation or plan assets not otherwise apparent in the
other disclosures required by FASB ASC 715-20?

s.

The amounts in accumulated OCI expected to be recognized as components of net periodic benefit cost over
the fiscal year that follows the most recent annual statement of financial position presented, showing separately the net gain or loss, net prior service cost or
credit, and net transition asset or obligation?

t.

The amount and timing of any plan assets expected to
be returned to the employer during the 12 month period, or operating cycle if longer, that follows the most
recent annual statement of financial position presented?
[“Pending Content” in FASB ASC 715-20-50-1]

No

N/A
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l 1B.

(FSP FAS 132(R)-1) (Issuers Only) If an employer sponsors
one or more defined benefit pension plans or one or more
defined benefit postretirement plans has the following information been provided, separately for pension plans and other
postretirement benefit plans:
a.

b.

c.
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A reconciliation of beginning and ending balances of
the benefit obligation showing separately, if applicable,
the effects during the period attributable to each of the
following:
i.

Service cost?

ii.

Interest cost?

iii.

Contributions by plan participants?

iv.

Actuarial gains and losses?

v.

Foreign currency rate changes (the effects of foreign currency exchange rate changes that are to
be disclosed are those applicable to plans of a foreign operation whose functional currency is not
the reporting currency pursuant to FASB ASC
830-10-45)?

vi.

Benefits paid?

vii.

Plan amendments?

viii.

Business combinations?

ix.

Divestitures?

x.

Curtailments, settlements, and special and contractual termination benefits?

A reconciliation of beginning and ending balances of
the fair value of plan assets showing separately, if applicable, the effects during the period attributable to
each of the following:
i.

Actual return on plan assets?

ii.

Foreign currency exchange rate changes (see the
preceding practice tip)?

iii.

Contributions by the employer?

iv.

Contributions by plan participants?

v.

Benefits paid?

vi.

Business combinations?

vii.

Divestitures?

viii.

Settlements?

The funded status of the plans and the amounts recognized in the statement of financial position showing
separately the assets and current and noncurrent liabilities recognized?

No

N/A
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Have disclosures been made to provide users of financial statements with an understanding of the following
(see FASB ASC 715-20-50-1 for example disclosures):
i.

For each major category of plan assets (which
should include but is not limited to equity securities, debt securities, real estate, and all other assets), the percentage of the fair value of total plan
assets held as of the measurement date used for
each statement of financial position presented?

ii.

The major categories of plan assets?

iii.

The inputs and valuation techniques used to
measure the fair value of plan assets?

iv.

The effect of fair value measurements using significant unobservable inputs (level 3) on changes
in plan assets for the period?

v.

Significant concentrations of risk within plan assets?

e.

For defined benefit pension plans, the accumulated
benefit obligation?

f.

The benefits (as of the date of the latest statement of
financial position presented) expected to be paid in
each of the next five fiscal years, and in the aggregate
for the five fiscal years thereafter? The expected benefits should be estimated based on the same assumptions used to measure the entity’s benefit obligation at
the end of the year and should include benefits attributable to estimated future employee service.

g.

The employer’s best estimate, as soon as it can reasonably be determined, of contributions expected to be
paid to the plan during the next fiscal year beginning
after the date of the latest statement of financial position presented. Estimated contributions may be presented in the aggregate combining all of the following:

h.

No

i.

Contributions required by funding regulations or
laws?

ii.

Discretionary contributions?

iii.

Discretionary contributions?

The amount of net benefit cost recognized, showing
separately all of the following:
i.

The service cost component?

ii.

The interest cost component?

iii.

The expected return on plan assets for the period?

iv.

The gain or loss component?

v.

The prior service cost or credit component?

vi.

The transition asset or obligation component?
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The gain or loss recognized due to settlements or
curtailments?

i.

Separately the net gain or loss and net prior service cost
or credit recognized in OCI for the period pursuant to
FASB ASC 715-30-35-11, FASB ASC 715-30-35-21, FASB
ASC 715-60-35-16, and FASB ASC 715-60-35-25, and reclassification adjustments of OCI for the period, as
those amounts, including amortization of the net transition asset or obligation, are recognized as components
of net periodic benefit cost?

j.

The amounts in accumulated OCI that have not yet
been recognized as components of net periodic benefit
cost, showing separately the net gain or loss, net prior
service cost or credit, and net transition asset or obligation?

k.

On a weighted-average basis, all of the following assumptions used in the accounting for the plans, specifying in a tabular format, the assumptions used to determine the benefit obligation and the assumptions
used to determine net benefit cost:
i.

Assumed discount rates?

ii.

Rates of compensation increase (for pay-related
plans)?

iii.

Expected long term rates of return on plan assets?

l.

The assumed health care cost trend rate(s) for the next
year used to measure the expected cost of benefits covered by the plan (gross eligible charges), and a general
description of the direction and pattern of change in the
assumed trend rates thereafter, together with the ultimate trend rate(s) and when that rate is expected to be
achieved?

m.

The effect of a one-percentage-point increase and the
effect of a one-percentage-point decrease in the assumed health care cost trend rates on the aggregate of
the service and interest cost components of net periodic
postretirement health care benefit costs and the APBO
for health care benefits? Measuring the sensitivity of
the APBO and the combined service and interest cost
components to a change in the assumed health care cost
trend rates requires remeasuring the APBO as of the
beginning and end of the year.

No

N/A
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n.

If applicable, the amounts and types of securities of the
employer and related parties included in plan assets,
the approximate amount of future annual benefits of
plan participants covered by insurance contracts, including annuity contracts issued by the employer or related parties, and any significant transactions between
the employer or related parties and the plan during the
period?

o.

If applicable, any alternative method used to amortize
prior service amounts or net gains and losses pursuant
to FASB ASC 715-30-35-13 and FASB ASC 715-30-35-25
or FASB ASC 715-60-35-18 and FASB ASC 715-60-3531?

p.

If applicable, any substantive commitment, such as past
practice or a history of regular benefit increases, used
as the basis for accounting for the benefit obligation?

q.

If applicable, the cost of providing special or contractual termination benefits recognized during the period
and a description of the nature of the event?

r.

An explanation of any significant change in the benefit
obligation or plan assets not otherwise apparent in the
other disclosures required by FASB ASC 715-20?

s.

The amounts in accumulated OCI expected to be recognized as components of net periodic benefit cost over
the fiscal year that follows the most recent annual statement of financial position presented, showing separately the net gain or loss, net prior service cost or
credit, and net transition asset or obligation?

t.

The amount and timing of any plan assets expected to
be returned to the employer during the 12 month period, or operating cycle if longer, that follows the most
recent annual statement of financial position presented?
[“Pending Content” in FASB ASC 715-20-50-1]

No

N/A

Practice Tips
The disclosures required by FASB ASC 715-20 should be aggregated for all of an employer’s defined benefit
pension plans and for all of an employer’s other defined benefit postretirement plans unless disaggregating
in groups is considered to provide useful information or is otherwise required by FASB ASC 715-20-50-3
and FASB 715-20-50-4.
[FASB ASC 715-20-50-2]
******
(continued)
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Disclosures about pension plans with assets in excess of the accumulated benefit obligation generally may
be aggregated with disclosures about pension plans with accumulated benefit obligations in excess of assets.
The same aggregation is permitted for other postretirement benefit plans. If aggregate disclosures are presented, an employer should disclose both of the following:
●

The aggregate benefit obligation and aggregate fair value of plan assets for plans with benefit obligations in excess of plan assets as of the measurement date of each statement of financial position
presented

●

The aggregate pension accumulated benefit obligation and aggregate fair value of plan assets for
pension plans with accumulated benefit obligations in excess of plan assets
[FASB ASC 715-20-50-3]
l 2A.

FSP §11,100.01

(Nonissuers Only) If the entity sponsors one or more defined
benefit pension plans or one or more other defined benefit
postretirement plans, has the following information been disclosed, separately for pension plans and other postretirement
benefit plans:
a.

The benefit obligation, fair value of plan assets, and
funded status of the plan?

b.

Employer contributions, participant contributions, and
benefits paid?

c.

Plan assets, including the following information:
i.

For each major category of plan assets (which
should include but is not limited to equity securities, debt securities, real estate, and all other assets), the percentage of the fair value of total plan
assets held as of the measurement date used for
each statement of financial position presented?

ii.

A narrative description of investment policies
and strategies, including target allocation percentages or range of percentages for each major
category of plan assets presented on a weightedaverage basis as of the measurement date(s) of
the latest statement of financial position presented, if applicable, and other factors that are
pertinent to an understanding of the policies or
strategies such as investment goals, risk management practices, permitted and prohibited investments including the use of derivatives, diversification, and the relationship between plan assets
and benefit obligations?
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iii.

A narrative description of the basis used to determine the overall expected long term rate-of-return-on-assets assumption, such as the general
approach used, the extent to which the overall
rate-of-return-on-assets assumption was based
on historical returns, the extent to which adjustments were made to those historical returns in
order to reflect expectations of future returns and
how those adjustments were determined?

iv.

Disclosure of additional asset categories and additional information about specific assets within
a category is encouraged if that information is expected to be useful in understanding the risks associated with each asset category and the overall
expected long term rate of return on assets?

d.

For defined benefit pension plans, the accumulated
benefit obligation?

e.

The benefits (as of the date of the latest statement of
financial position presented) expected to be paid in
each of the next five fiscal years, and in the aggregate
for the five fiscal years thereafter? The expected benefits should be estimated based on the same assumptions used to measure the entity’s benefit obligation at
the end of the year and should include benefits attributable to estimated future employee service.

f.

The employer’s best estimate, as soon as it can reasonably be determined, of contributions expected to be
paid to the plan during the next fiscal year beginning
after the date of the latest statement of financial position presented? Estimated contributions may be presented in the aggregate combining any of the following:
i.

Contributions required by funding regulations or
laws?

ii.

Discretionary contributions?

iii.

Noncash contributions?

g.

The amounts recognized in the statements of financial
position, showing separately the postretirement benefit
assets and current and noncurrent postretirement benefit liabilities?

h.

Separately, the net gain or loss and net prior service
cost or credit recognized in OCI for the period pursuant
to FASB ASC 715-30-35-11, 715-30-35-21, 715-60-35-16,
and 715-60-35-25 and reclassification adjustments of
OCI for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost?

No

N/A
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i.

The amounts in accumulated OCI that have not yet
been recognized as components of net periodic benefit
cost, showing separately the net gain or loss, net prior
service cost or credit, and net transition asset or obligation?

j.

On a weighted-average basis, all of the following assumptions used in the accounting for the plans, specifying in a tabular format, the assumptions used to determine the benefit obligation and the assumptions
used to determine net benefit cost:
i.

Assumed discount rates (refer to FASB ASC 71530-35-45 for a discussion of representationally
faithful disclosure)?

ii.

Rates of compensation increase (for pay-related
plans)?

iii.

Expected long term rates of return on plan assets?

k.

The assumed health care cost trend rate(s) for the next
year used to measure the expected cost of benefits covered by the plan (gross eligible charges), and a general
description of the direction and pattern of change in the
assumed trend rates thereafter, together with the ultimate trend rate(s) and when that rate is expected to be
achieved?

l.

If applicable, the amounts and types of securities of the
employer and related parties included in plan assets,
the approximate amount of future annual benefits of
plan participants covered by insurance contracts, including annuity contracts, issued by the employer or
related parties, and any significant transactions between the employer or related parties and the plan during the period?

m.

The nature and effect of significant nonroutine events,
such as amendments, combinations, divestitures, curtailments, and settlements?

n.

The amounts in accumulated OCI expected to be recognized as components of net periodic benefit cost over
the fiscal year that follows the most recent annual statement of financial position presented, showing separately the net gain or loss, net prior service cost or
credit, and net transition asset or obligation?

o.

The amount and timing of any plan assets expected to
be returned to the employer during the 12 month period, or operating cycle if longer, that follows the most
recent annual statement of financial position presented?
[“Pending Content” in FASB ASC 715-20-50-5]

No

N/A
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l 2B.

No

N/A

(FSP FAS 132(R)-1) (Nonissuers Only) If the entity sponsors
one or more defined benefit pension plans or one or more
other defined benefit postretirement plans, has the following
information been disclosed, separately for pension plans and
other postretirement benefit plans:
a.

The benefit obligation, fair value of plan assets, and
funded status of the plan?

b.

Employer contributions, participant contributions, and
benefits paid?

c.

Have disclosures been made to provide users of financial statements with an understanding of the following
(see FASB ASC 715-20-50-5(c) for example disclosures):
i.

How investment allocation decisions are made,
including the factors that are pertinent to an understanding of investment policies and strategies?

ii.

The major categories of plan assets?

iii.

The inputs and valuation techniques used to
measure the fair value of plan assets?

iv.

The effect of fair value measurements using significant unobservable inputs (level 3) on changes
in plan assets for the period?

v.

Significant concentrations of risk within plan assets?

d.

For defined benefit pension plans, the accumulated
benefit obligation?

e.

The benefits (as of the date of the latest statement of
financial position presented) expected to be paid in
each of the next five fiscal years, and in the aggregate
for the five fiscal years thereafter? The expected benefits should be estimated based on the same assumptions used to measure the entity’s benefit obligation at
the end of the year and should include benefits attributable to estimated future employee service.

f.

The employer’s best estimate, as soon as it can reasonably be determined, of contributions expected to be
paid to the plan during the next fiscal year beginning
after the date of the latest statement of financial position presented? Estimated contributions may be presented in the aggregate combining any of the following:
i.

Contributions required by funding regulations or
laws?

ii.

Discretionary contributions?

iii.

Noncash contributions?

FSP §11,100.01

148

Health Care Entities

Yes

FSP §11,100.01

g.

The amounts recognized in the statements of financial
position, showing separately the postretirement benefit
assets and current and noncurrent postretirement benefit liabilities?

h.

Separately, the net gain or loss and net prior service
cost or credit recognized in OCI for the period pursuant
to FASB ASC 715-30-35-11, 715-30-35-21, 715-60-35-16,
and 715-60-35-25 and reclassification adjustments of
OCI for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost?

i.

The amounts in accumulated OCI that have not yet
been recognized as components of net periodic benefit
cost, showing separately the net gain or loss, net prior
service cost or credit, and net transition asset or obligation?

j.

On a weighted-average basis, all of the following assumptions used in the accounting for the plans, specifying in a tabular format, the assumptions used to determine the benefit obligation and the assumptions
used to determine net benefit cost:
i.

Assumed discount rates (refer to FASB ASC 71530-35-45 for a discussion of representationally
faithful disclosure)?

ii.

Rates of compensation increase (for pay-related
plans)?

iii.

Expected long term rates of return on plan assets?

k.

The assumed health care cost trend rate(s) for the next
year used to measure the expected cost of benefits covered by the plan (gross eligible charges), and a general
description of the direction and pattern of change in the
assumed trend rates thereafter, together with the ultimate trend rate(s) and when that rate is expected to be
achieved?

l.

If applicable, the amounts and types of securities of the
employer and related parties included in plan assets,
the approximate amount of future annual benefits of
plan participants covered by insurance contracts, including annuity contracts, issued by the employer or
related parties, and any significant transactions between the employer or related parties and the plan during the period?

m.

The nature and effect of significant nonroutine events,
such as amendments, combinations, divestitures, curtailments, and settlements?

No

N/A
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l 3.

n.

The amounts in accumulated OCI expected to be recognized as components of net periodic benefit cost over
the fiscal year that follows the most recent annual statement of financial position presented, showing separately the net gain or loss, net prior service cost or
credit, and net transition asset or obligation?

o.

The amount and timing of any plan assets expected to
be returned to the employer during the 12 month period, or operating cycle if longer, that follows the most
recent annual statement of financial position presented?

p.

The amount of net periodic benefit cost recognized?
[“Pending Content” in FASB ASC 715-20-50-5]

No

N/A

(Issuers Only) Has the following been disclosed in the entities
interim financial statements that include a statement of income:
a.

b.

The amount of net benefit cost recognized, for each period for which a statement of income is presented,
showing separately each of the following:
i.

The service cost component?

ii.

The interest cost component?

iii.

The expected return on plan assets for the period?

iv.

The gain or loss component?

v.

The prior service cost or credit component?

vi.

The transition asset or obligation component?

vii.

The gain or loss recognized due to a settlement
or curtailment?

The total amount of the employer’s contributions paid,
and expected to be paid, during the current fiscal year,
if significantly different from amounts previously disclosed pursuant to FASB ASC 715-20-50-1(g)? Estimated contributions may be presented in the aggregate
combining all of the following:
i.

Contributions required by funding regulations or
laws?

ii.

Discretionary contributions?

iii.

Noncash contributions?
[FASB ASC 715-20-50-6]
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No
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Practice Tip
With respect to question 4, estimated contributions may be presented in the aggregate combining all of the
following:
●

Contributions required by funding regulations or laws

●

Discretionary contributions

● Noncash contributions
[FASB ASC 715-20-50-7]
l 4. (Nonissuers Only) Has the entity disclosed, in interim periods for
which a complete set of financial statements is presented, the total
amount of the employer’s contributions paid, and expected to be
paid, during the current fiscal year, if significantly different from
amounts previously disclosed pursuant to FASB ASC 715-20-505(f) (question 2A)?
[FASB ASC 715-70-50-1]
Defined Contribution Plans
l 5. Does the entity disclose the amount of cost recognized for defined
contribution pension plans and for other defined contribution
postretirement benefit plans for all periods presented separately
from the amount of cost recognized for defined benefit plans?
[FASB ASC 715-70-50-1]
l 6. Do the disclosures include a description of the nature and effect
of any significant changes during the period affecting comparability, such as a change in the rate of employer contributions, a
business combination, or a divestiture?
[FASB ASC 715-70-50-1]
Multiemployer Plans
l 7. Has the entity disclosed the amount of contributions to multiemployer plans for each annual period for which a statement of income is presented?
[FASB ASC 715-80-50-1]
l 8. If the entity chooses to disclose total contributions to multiemployer plans without disaggregating the amounts attributable to
pension plans and other postretirement benefit plans, do the disclosures include a description of the nature and effect of any
changes affecting comparability, such as a change in the rate of
employer contributions, a business combination, or a divestiture?
[FASB ASC 715-80-50-1]
l 9. If it is either probable or reasonably possible that (a) an entity
would withdraw from the plan under circumstances that would
give rise to an obligation or (b) an entity’s contribution to the fund
would be increased during the remainder of the contract period
to make up a shortfall in the funds necessary to maintain the negotiated level of benefit coverage (a “maintenance of benefits”
clause), has the entity applied the provisions of FASB ASC 450?
[FASB ASC 715-80-50-2]
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No

N/A

Other Matters
l 10. If the matters addressed in paragraphs 69–79 of FASB ASC 71530-55 (Japanese governmental settlement transactions) apply, are
the disclosure requirements of FASB ASC 715-20-50-10 complied
with?
[FASB ASC 715-20-50 par. 9–10]
Medicare Prescription Drug, Improvement, and Modernization
Act
l 11. Until the entity is able to determine whether benefits provided by
its plan are actuarially equivalent, does it disclose the following
in financial statements for interim or annual periods:
a.

The existence of the act?

b.

That measures of the APBO or net periodic postretirement
benefit cost do not reflect any amount associated with the
subsidy because the employer is unable to conclude whether
the benefits provided by the plan are actuarially equivalent
to Medicare Part D under the act?
[FASB ASC 715-60-50-6]

l 12. In interim and annual financial statements for the first period in
which the entity includes the effects of the subsidy in measuring
the APBO and the first period in which the entity includes the
effects of the subsidy in measuring net periodic postretirement
benefit cost, has it disclosed the following:
a.

The reduction in the APBO for the subsidy related to benefits attributed to past service?

b.

The effect of the subsidy on the measurement of net periodic
postretirement benefit cost for the current period? That effect includes (1) any amortization of the actuarial experience
gain in a as a component of the net amortization called for
by paragraphs 29–30 of FASB ASC 715-60-35, (2) the reduction in current period service cost due to the subsidy, and
(3) the resulting reduction in interest cost on the APBO as a
result of the subsidy.

c.

Any other disclosures required by FASB ASC 715-20-50-1(r)?
[FASB ASC 715-60-50-3]

l 13. For purposes of the disclosures required by paragraphs 1(a) and
(f) of FASB ASC 715-20-50, does the entity disclose gross benefit
payments (paid and expected, respectively), including prescription drug benefits, and separately the gross amount of the subsidy
receipts (received and expected, respectively)?
[FASB ASC 715-60-50-4]
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G.

No

N/A

Environmental Remediation Liabilities
Practice Tip

FASB ASC 450-20 provides the primary guidance applicable to disclosures of environmental remediation
loss contingencies. The disclosure requirements of FASB ASC 275-10 also apply to environmental remediation liabilities. Example 1 (FASB ASC 410-30-55-7) illustrates the application of those disclosure requirements.
[FASB ASC 410-30-50 par. 5–6]
.l 1. Has the entity made the following disclosures:
a.

Whether accruals for environmental remediation liabilities
are measured on a discounted basis?
[FASB ASC 410-30-50-4]

b.

With respect to recorded accruals for environmental remediation loss contingencies and assets for third-party recoveries related to environmental remediation obligations: if
any portion of the accrued obligation is discounted, the undiscounted amount of the obligation, and the discount rate
used in the present-value determinations?
[FASB ASC 410-30-50-7]

c.

The policy concerning the timing of recognition of recoveries? (Encouraged, but not required.)
[FASB ASC 410-30-50-8]

d.

Any other additional specific disclosures with respect to environmental remediation loss contingencies that would be
useful to further users’ understanding of the entity’s financial statements. (Encouraged, but not required.)
[FASB ASC 410-30-50-9]

.l 2. Do the financial statements disclose the event, situation, or set of
circumstances that triggered recognition of loss contingencies
that arose out of the reporting entity’s environmental remediation-related obligations? (Encouraged, but not required.)
[FASB ASC 410-30-50-8]
Reasonably Possible Loss Exposures
.l 3. With respect to reasonably possible loss contingencies, including
reasonably possible loss exposures in excess of the amount accrued, are the following disclosed (Encouraged, but not required.):
a.

The estimated time frame of disbursements for recorded
amounts if expenditures are expected to continue over the
long term?

b.

The estimated time frame for realization of recognized
probable recoveries, if realization is not expected in the near
term?

c.

If an estimate of the probable or reasonably possible loss or
range of loss cannot be made, the reasons why it cannot be
made?
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d.

No

N/A

If information about the reasonably possible loss or the recognized and additional reasonably possible loss for an environmental remediation obligation related to an individual
site is relevant to an understanding of the financial position,
cash flows, or results of operations of the entity, the following with respect to the site:
i.

The total amount accrued for the site?

ii.

The nature of any reasonably possible loss contingency or additional loss, and an estimate of the possible loss or the fact that an estimate cannot be made
and the reasons why it cannot be made?

iii.

Whether other potentially responsible parties are involved and the entity’s estimated share of the obligation?

iv.

The status of regulatory proceedings?

v.

The estimated time frame for resolution of the contingency?
[FASB ASC 410-30-50-10]

Probable But Not Reasonably Estimable Losses
.l 4. If the reporting entity’s probable but not reasonably estimable
environmental remediation obligations may be material, are the
nature of the probable contingency (that is, a description of the
remediation obligation) and the fact that a reasonable estimate
cannot currently be made disclosed?
[FASB ASC 450-20-5-5]
.l 5. Is the estimated time frame for resolution of the uncertainty as to
the amount of the loss disclosed? (Encouraged, but not required.)
[FASB ASC 410-30-50-11]
Environmental Remediation Costs Recognized Currently
.l 6. Is the amount of environmental remediation costs recognized in
the income statement disclosed in the following detail: (Encouraged, but not required.)
a.

The amount recognized for environmental remediation loss
contingencies in each period?

b.

The amount of any recovery from third parties that is credited to environmental remediation costs in each period?

c.

The income statement caption in which environmental remediation costs and credits are included?
[FASB ASC 410-30-50-12]

Other Matters
.l 7. Do the financial statements include a contingency conclusion that
addresses the estimated total unrecognized exposure to environmental remediation and other loss contingencies? (Encouraged,
but not required.)
[FASB ASC 410-30-50-14]
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.l 8. Is there a description of the general applicability and impact of
environmental laws and regulations upon their business and
how the existence of such laws and regulations may give rise to
loss contingencies for future environmental remediation? (Encouraged, but not required.)
[FASB ASC 410-30-50-17]
H.

Financial Instruments
Derivative Instruments and Hedging Activities (Including Hybrid Financial Instruments)
Notes: In March 2008, FASB issued Statement No. 161 to enhance the
current disclosure framework in FASB Statement No. 133. This statement has the same scope as FASB Statement No. 133 and, accordingly, applies to all entities.
This statement changes the disclosure requirements for derivative instruments and hedging activities. Entities are required to provide enhanced disclosures about (a) how and why an entity uses derivative
instruments, (b) how derivative instruments and related hedged
items are accounted for under FASB Statement No. 133 and its related
interpretations, and (c) how derivative instruments and related
hedged items affect an entity’s financial position, financial performance, and cash flows.
FASB Statement No. 161 is effective for financial statements issued
for fiscal years and interim periods beginning after November 15,
2008 (that is, January 1, 2009, for entities with calendar year-ends).
Early application is encouraged. This statement encourages but does
not require disclosures for earlier periods presented for comparative
purposes at initial adoption. In years after initial adoption, it requires
comparative disclosures only for periods subsequent to initial adoption.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 161.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should
consider all questions indicated with an “A” reference (for example,
question 1A and question 2A) and should place an “N/A” mark in
questions indicated with a “B” reference. Entities for which the guidance has been implemented should consider all questions indicated
by a “B” reference (for example, question 1B and question 2B) and
place an “N/A” mark by questions indicated with an “A” reference.
Therefore, based upon your entity’s year-end and decision to early
implement or not (if allowed), the following additional questions will
be answered when provided in this section (check one that applies
for your entity):
pppA pppB
Readers can refer to the full text of FASB Statement No. 161 on the
FASB Web site at www.fasb.org.
(continued)
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No

N/A

This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 815-1065-1.

Practice Tips
FASB ASC 815-30-50-2 discusses requirements to report changes in the components of comprehensive income pursuant to FASB ASC 220-10-45-14. Although not-for-profit, business-oriented health care entities are
not subject to the requirements of FASB ASC 220-10, FASB ASC 954-815 requires those entities to separately
disclose the beginning and ending accumulated derivative gain or loss that has been excluded from the
performance indicator (see also paragraphs 4–7 of FASB ASC 954-225-45), the related net change associated
with current period hedging transactions, and the net amount of any reclassifications into the performance
indicator in a manner similar to that described in FASB ASC 815-30-50-2.
Similarly, this FASB ASC 954-815 requires not-for-profit health care entities to provide disclosures that are
analogous to those required by paragraphs 1–3 of FASB ASC 815-30-50 and paragraphs 1–2 of FASB ASC
815-35-50 for for-profit entities, including the disclosure of anticipated reclassifications into the performance
indicator of gains and losses that have been excluded from that measure and reported in accumulated derivative gain or loss as of the reporting date.
[FASB ASC 954-815-50-1]
Note that if the entity has adopted the provisions of FASB Statement No. 161, the not-for-profit health care
entity is not required to provide disclosures analogous to FASB ASC 815-35-50-1 for for-profit entities, as
noted previously.
[“Pending Content” in FASB ASC 954-815-50-1]
.l 1B. (FASB Statement No. 161) Have the following disclosures been
made by the entity with derivative instruments (or nonderivative
instruments that are designated and qualify as hedging instruments pursuant to FASB ASC 815-20-25-58 and FASB ASC 81520-25-66), which enable the users of the financial statements to
understand the following:
a.

How and why an entity uses derivative instruments (or
such nonderivative instruments)?

b.

How derivative instruments (or such nonderivative instruments) and related hedged items are accounted for under
FASB ASC 815?

c.

How derivative instruments (or such nonderivative instruments) and related hedged items affect the entity’s financial
position, performance and cash flows?
[”Pending Content” in FASB ASC 815-10-50-1]

.l 2A. If an entity holds or issues derivative instruments (or nonderivative instruments that are designated and qualify as hedging
instruments pursuant to FASB ASC 815-20-25-58 and FASB ASC
815-20-25-66) have the following disclosures been made for every
annual and interim reporting period for which a statement of financial position and statement of financial performance are presented:
a.

Its objectives for holding or issuing those instruments?
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b.

The context needed to understand those objectives?

c.

Its strategies for achieving those objectives?
[”Pending Content” in FASB ASC 815-10-50-1A]

.l 2B. (FASB Statement No. 161) If an entity holds or issues derivative
instruments (or nonderivative instruments that are designated
and qualify as hedging instruments pursuant to FASB ASC 81520-25-58 and FASB ASC 815-20-25-66) have the following disclosures been made for every annual and interim reporting period
for which a statement of financial position and statement of financial performance are presented:
a.

Its objectives for holding or issuing those instruments?

b.

The context needed to understand those objectives?

c.

Its strategies for achieving those objectives?

d.

Information that would enable users of its financial statements to understand the volume of its activity in those instruments? (An entity should select the format and the specifics of disclosures relating to its volume of such activity
that are most relevant and practicable for its individual
facts and circumstances.)
[”Pending Content” in FASB ASC 815-10-50-1]

.l 3B. (FASB Statement No. 161) Are the disclosures described in question 2B in the context of each instrument’s primary underlying
risk exposure (for example, interest rate, credit, foreign exchange
rate, interest rate and foreign exchange rate, or overall price)?
[”Pending Content” in FASB ASC 815-10-50-1B]
.l 4B. (FASB Statement No. 161) Are the financial instruments described in question 2B distinguished between those used or risk
management purposes and those used for other purposes and is
such information disclosed? Derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments pursuant to FASB ASC 815-20-25-58 and FASB
ASC 815-20-25-66) used for risk management purposes include
those designated as hedging instruments under FASB ASC 81520 as well as those used as economic hedges and for other purposes related to the entity’s risk exposures.
[”Pending Content” in FASB ASC 815-10-50-1B]
.l 5A. Do the disclosures required by FASB ASC 815-10-50-1A (question 2A) distinguish between each of the following (including the
entity’s risk management policy for each):
a.

Fair value hedging instruments?

b.

Cash flow hedging instruments?

c.

Hedges of foreign currency exposure of net investments in
foreign operations?

d.

All other instruments?
[FASB ASC 815-10-50 par. 2–3]

.l 5B. (FASB Statement No. 161) Do the disclosures required by question 2B distinguish between each of the following:
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Yes
a.

N/A

Instruments used for risk management purposes, distinguished between each of the following:

b.
.l 6.

No

i.

Derivative instruments designated as hedging instruments, distinguished between each of the following:
(1) fair value hedging instruments, (2) cash flow hedging instruments, and (3) hedges of foreign currency
exposure of net investments in foreign operations?

ii.

Instruments used as economic hedges and for other
purposes related to the entity’s risk exposure?

Instruments used for other purposes?
[”Pending Content” in FASB ASC 815-10-50-2]

Do the entities disclosures describe the purpose of holding or issuing derivatives which are not designated as hedging instruments?
[“Pending Content” in FASB ASC 815-10-50-4]
Practice Tip

(FASB Statement No. 161) The qualitative disclosures required by FASB ASC 815-10-50-4A(a)–(b), question
7B, should be presented in tabular format except for the information required for hedged items by FASB
ASC 815-10-50-4C(a). Information about hedged items can be presented in a tabular or nontabular format.
[“Pending Content” in FASB ASC 815-10-50-4E]
.l 7B.

(FASB Statement No. 161) For every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented, has the entity disclosed the location and amounts of the gains and losses for
derivative instruments (or nonderivative instruments it holds or
issues that are designated and qualify as hedging instruments
pursuant to FASB ASC 815-20-25-58 and FASB ASC 815-20-2566) reported in the statement of financial performance (or when
applicable, the statement of financial position) (for example,
gains and losses initially recognized in OCI)?
[”Pending Content” in FASB ASC 815-10-50-4A]

.l 8B.

(FASB Statement No. 161) Do the disclosures required by FASB
ASC 815-10-50-A(a), as discussed in question 7B, provide the
following:
a.

The fair value of derivative instruments on a gross basis
(even if the derivative instruments qualify for net presentation in the statement of financial position in accordance
with FASB ASC 210-20 [general hedging activities])?

b.

Separate asset and liability values segregated between derivatives that are designated and qualifying as hedging instruments under FASB ASC 815-20 and those that are not,
and within those two broad categories, by type of derivative contract (for example, interest rate contracts, foreign
exchange contracts, equity contracts, commodity contracts,
credit contracts, and so forth)?
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Yes
c.

.l 9B.

No

N/A

The line item(s) in the statement of financial position in
which the fair value amounts for the above categories of
derivative instruments are included?
[”Pending Content” in FASB ASC 815-10-50-4B]

(FASB Statement No. 161) Are the gains and losses disclosed
pursuant to FASB ASC 815-10-50-4A(b) presented separately for
all of the following by type of contracts:
a.

Derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged
items designated and qualifying in fair value hedges?

b.

The effective portion of gains and losses on derivative instruments designated and qualifying in cash flow hedges
and net investment hedges that was recognized in OCI
during the current period?

c.

The effective portion of gains and losses on derivative instruments designated and qualifying in cash flow hedges
and net investment hedges recorded in accumulated OCI
during the term of the hedging relationship and reclassified into earnings during the current period?

d.

The portion of gains and losses on derivative instruments
designated and qualifying in cash flow hedges and net investment hedges representing (i) the amount of the
hedges’ ineffectiveness and (ii) the amount, if any, excluded from the assessment of hedge effectiveness?

e.

Derivative instruments not designated or qualifying as
hedging instruments under FASB ASC 815-20?
[”Pending Content” in FASB ASC 815-10-50-4C]

.l 10B. (FASB Statement No. 161) Do the disclosures pursuant to question 9B, present information separately by type of derivative
contract (for example, interest rate contracts, foreign exchange
contracts, equity contracts, commodity contracts, credit contracts, and so forth)?
[”Pending Content” in FASB ASC 815-10-50-4D]
.l 11B. (FASB Statement No. 161) Do the disclosures pursuant to question 9B, identify the line item(s) in the statement of financial
performance in which the gains and losses for the categories of
derivative instruments are included?
[”Pending Content” in FASB ASC 815-10-50-4D]
Practice Tip
(FASB Statement No. 161) If the disclosure option in question 12B is elected, the entity should include a
footnote in the required tables referencing the use of alternative disclosures for trading activities.
[“Pending Content” in FASB ASC 815-10-50-4F]
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Yes

No

N/A

.l 12B. (FASB Statement No. 161) If an entity’s policy is to include derivative instruments that are not designated or qualifying as hedging instruments under FASB ASC 815-20 in its trading activities,
and the entity elects to exclude those derivative instruments
from the disclosures pursuant to question 9B, has the entity disclosed the following information:
a.

The gains and losses on its trading activities (including
both derivative and nonderivative instruments) recognized
in the statement of financial performance, separately by
major types of items (such as fixed income/interest rates,
foreign exchange, equity, commodity, and credit)?

b.

The line items in the statement of financial performance in
which trading activities gains and losses are included?

c.

A description of the nature of its trading activities and related risks, and how the entity manages those risks?
[”Pending Content” in FASB ASC 815-10-50-4F]

.l 13B. (FASB Statement No. 161) For every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented, does the entity disclose the following information about derivative instruments it
holds or issues (or nonderivative instruments it holds or issues
that are designated and qualify as hedging instruments pursuant
to FASB ASC 815-20-25-58 and FASB ASC 815-20-25-66) that
have credit-risk-related contingent features and that are in a net
liability position at the end of the reporting period:
a.

The existence and nature of credit-risk-related contingent
features and the circumstances in which the features could
be triggered in derivative instruments that are in a net liability position at the end of the reporting period?

b.

The aggregate fair value amounts of derivative instruments
that contain credit-risk-related contingent features that are
in a net liability position at the end of the reporting period?

c.

The aggregate fair value of assets that are already posted as
collateral at the end of the reporting period and (i) the aggregate fair value of additional assets that would be required to be posted as collateral or (ii) the aggregate fair
value of assets needed to settle the instrument immediately,
if the credit-risk-related contingent features were triggered
at the end of the reporting period?
[”Pending Content” in FASB ASC 815-10-50-4H]

.l 14B. (FASB Statement No. 161) If the disclosures related to derivative
instruments (or nonderivative instruments that are designated
and qualify as hedging instruments pursuant to FASB ASC 81520-25-58 and FASB ASC 815-20-25-66) are presented in more than
a single footnote, does each derivative note cross-reference the
other notes in which derivative-related information is disclosed?
[”Pending Content” in FASB ASC 815-10-50-4I]
Fair Value Hedges
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.l 15A. For each reporting period for which a complete set of financial
statements is presented, does the entity disclose the following for
derivative instruments, as well as nonderivative instruments that
may give rise to foreign currency transaction gains or losses under FASB ASC 830-20, that have been designated and have qualified as fair value hedging instruments and for the related
hedged items:
a.

The net gain or loss recognized in earnings during the reporting period representing (i) the amount of the hedges’
ineffectiveness, (ii) the component of the derivative instruments’ gain or loss, if any, excluded from the assessment of
hedge effectiveness, and (iii) a description of where the net
gain or loss is reported in the statement of income or other
statement of financial performance?

b.

The amount of net gain or loss recognized in earnings when
a hedged firm commitment no longer qualifies as a fair
value hedge?
[FASB ASC 815-25-50-1]

.l 16B. (FASB Statement No. 161) For every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented, does the entity disclose the following for derivative instruments, as well as
nonderivative instruments that may give rise to foreign currency
transaction gains or losses under FASB ASC 830-20, that have
been designated and have qualified as fair value hedging instruments and for the related hedged items:
a.

The net gain or loss recognized in earnings during the reporting period representing (i) the amount of the hedges’
ineffectiveness, (ii) the component of the derivative instruments’ gain or loss, if any, excluded from the assessment of
hedge effectiveness, and (iii) a description of where the net
gain or loss is reported in the statement of income or other
statement of financial performance?

b.

The amount of net gain or loss recognized in earnings when
a hedged firm commitment no longer qualifies as a fair
value hedge?
[”Pending Content” in FASB ASC 815-25-50-1]

Cash Flow Hedges
.l 17A. For every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented, does the entity disclose the following for
derivative instruments that have been designated and have qualified as cash flow hedging instruments and for the related
hedged transactions:
a.

The net gain or loss recognized in earnings during the reporting period representing each of the following:
i.
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Yes
ii.

The component of the derivative instruments’ gain or
loss, if any, excluded from the assessment of hedge
effectiveness?

iii.

A description of where the net gain or loss is reported
in the statement of income or other statement of financial performance?

b.

A description of the transactions or other events that will
result in the reclassification into earnings of gains and
losses that are reported in accumulated OCI, and the estimated net amount of the existing gains or losses at the reporting date that is expected to be reclassified into earnings
within the next 12 months?

c.

The maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for
forecasted transactions excluding those forecasted transactions related to the payment of variable interest on existing
financial instruments?

d.

The amount of gains and losses reclassified into earnings as
a result of the discontinuance of cash flow hedges because
it is probable that the original forecasted transactions will
not occur by the end of the originally specified time period
or within the additional period of time discussed in paragraphs 4–5 of FASB ASC 815-30-40-4?
[FASB ASC 815-30-50-1]

No

N/A

.l 17B. (FASB Statement No. 161) For every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented, does the entity disclose the following for derivative instruments that have been
designated and have qualified as cash flow hedging instruments
and for the related hedged transactions:
a.

A description of the transactions or other events that will
result in the reclassification into earnings of gains and
losses that are reported in accumulated OCI, and the estimated net amount of the existing gains or losses at the reporting date that is expected to be reclassified into earnings
within the next 12 months?

b.

The maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for
forecasted transactions excluding those forecasted transactions related to the payment of variable interest on existing
financial instruments?

c.

The amount of gains and losses reclassified into earnings as
a result of the discontinuance of cash flow hedges because
it is probable that the original forecasted transactions will
not occur by the end of the originally specified time period
or within the additional period of time discussed in paragraphs 4–5 of FASB ASC 815-30-40?
[”Pending Content” in FASB ASC 815-30-50-1]
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Yes
.l 18.

The quantitative disclosures about derivative instruments may
be more useful, and less likely to be perceived to be out of context or otherwise misunderstood, if similar information is disclosed about other financial instruments or nonfinancial assets
and liabilities to which the derivative instruments are related by
activity. Accordingly, in such situations, an entity is encouraged,
but not required, to present a more complete picture of its activities by disclosing that information. Have such disclosures been
made (for every annual and interim reporting period for which
a statement of financial position and statement of financial performance are presented)?
[FASB ASC 815-35-50-2]

.l 19A. Qualitative disclosures about an entity’s objectives and strategies
for using derivative instruments may be more meaningful if such
objectives and strategies are described in the context of an entity’s overall risk management profile. If appropriate, an entity is
encouraged, but not required, to provide such additional qualitative disclosures. Have such disclosures been made (for every
annual and interim reporting period for which a statement of financial position and statement of financial performance are presented)?
[FASB ASC 815-10-50-5]
.l 19B. (FASB Statement No. 161) Qualitative disclosures about an entity’s objectives and strategies for using derivative instruments
may be more meaningful if such objectives and strategies are described in the context of an entity’s overall risk exposures relating to interest rate risk, foreign currency exchange rate risk, commodity price risk, credit risk, and equity price risk. If
appropriate, an entity is encouraged, but not required, to provide such additional qualitative disclosures. Have such disclosures been made (for every annual and interim reporting period
for which a statement of financial position and statement of financial performance are presented)?
[”Pending Content” in FASB ASC 815-10-50-5]
Disclosure About Concentrations of Credit Risk of All Financial Instruments
.l 20.

Is disclosure made of the primary geographic sources of patients?
[“Pending Content” in FASB ASC 825-10-50-20]
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Yes

No

N/A

Practice Tip
FASB ASC 825-10-50 provides guidance on the required disclosures about significant concentrations of
credit risk arising from all financial instruments, including trade accounts receivable. Concentration of credit
risk frequently is an issue because most health care entities generally tend to treat patients from their local
or surrounding communities. It should be noted that concentration of credit risk may be a significant issue
in standalone financial statements issued for a member hospital of a large national multihospital system but
may not be an issue for financial statements prepared for the hospital system. When the individual facilities’
financial statements are consolidated into statements prepared for the entire system, the credit risk is dispersed over a much larger base of health plans, patients, and geographies and, therefore, is not as concentrated.
[FASB ASC 954-310-50-1]
.l 21.

Except as indicated in FASB ASC 825-10-50-22, has the entity disclosed all significant concentrations of credit risk arising from all
financial instruments, whether from an individual counterparty
or groups of counterparties? (Group concentrations of credit risk
exist if a number of counterparties are engaged in similar activities and have similar economic characteristics that would cause
their ability to meet contractual obligations to be similarly affected by changes in economic or other conditions.)
[“Pending Content” in FASB ASC 825-10-50-20]

Notes: In September 2008, FASB issued FSP FAS 133-1 and FIN 45-5,
Disclosures about Credit Derivatives and Certain Guarantees: An Amendment of FASB Statement No. 133 and FASB Interpretation No. 45; and Clarification of the Effective Date of FASB Statement No. 161, to amend current
disclosures by sellers of credit derivatives under FASB Statement No.
161. This FSP applies to credit derivatives within the scope of FASB
Statement No. 133, hybrid instruments that have embedded credit derivatives.
This FSP changes the disclosure requirements related to credit derivatives in that a seller of credit derivatives should disclose information
about its credit derivatives and hybrid instruments that have embedded credit derivatives to enable users of financial statements to assess
their potential effect on its financial position, financial performance,
and cash flows.
This FSP clarifies FASB’s intent that the disclosures required by FASB
Statement No. 161 should be provided for any reporting period (annual or quarterly interim) beginning after November 15, 2008.
The FSP is effective for financial statements issued for fiscal years and
interim periods beginning after November 15, 2008 (that is, January 1,
2009, for entities with calendar year-ends). Early application is encouraged. This statement encourages but does not require disclosures for
earlier periods presented for comparative purposes at initial adoption.
In years after initial adoption, it requires comparative disclosures only
for periods subsequent to initial adoption.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 133-1 and FIN 45-5.
(continued)
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As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions indicated with a “B” reference. Entities for which the guidance
has been implemented should consider all questions indicated by a
“B” reference (for example, question 1B and question 2B) and place an
“N/A” mark by questions indicated with an “A” reference. Therefore,
based upon your entity’s year-end and decision to early implement or
not (if allowed), the following additional questions will be answered
when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 815-1065-2.
Credit Derivatives
.l 21B. (FSP FAS 133-1 and FIN 45-5) Is the following information disclosed by a seller of credit derivative, (as defined in FASB ASC
815-10-50-4J as a guarantor in a guarantee type contract or any
party that provides the credit protection in an option type contract, a credit default swap, or any other credit derivative), even
if the likelihood of the seller’s having to make any payments
under the credit derivative is remote:
a.

b.
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The nature of the credit derivative, including all of the following:
i.

The approximate term of the credit derivative?

ii.

The reasons for entering into the credit derivative?

iii.

The events or circumstances that would require the
seller to perform under the credit derivative?

iv.

The current status (that is, as of the date of the statement of financial position) of the payment/performance risk of the credit derivative?

v.

If the entity uses internal groupings for the purposes of item (iv), how those groupings are determined and used for managing risk?

The maximum potential amount of future payments (undiscounted) that the seller could be required to make under the credit derivative, which should not be reduced by
the effect of any amounts that may possibly be recovered
under recourse or collateralization provisions in the credit
derivative?

No

N/A
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Yes
c.

If the terms of the credit derivative provide for no limitation to the maximum potential future payments under the
credit derivative, is that fact disclosed?

d.

If the seller is unable to develop an estimate of the maximum potential amount of future payments under the
credit derivative, are the reasons why the maximum potential amount cannot be estimated disclosed?

e.

Is the fair value of the credit derivative as of the date of
the statement of financial position disclosed?

f.

The nature of

g.

i.

any recourse provisions that would enable the guarantor to recover from third parties any of the
amounts paid under the guarantee?

ii.

any assets held either as collateral or by third parties that, upon the occurrence of any triggering
event or condition under the guarantee, the guarantor can obtain and liquidate to recover all or a
portion of the amounts paid under the guarantee?

No

N/A

If estimable, the approximate extent to which the proceeds
from liquidation of those assets would be expected to
cover the maximum potential amount of future payments
under the guarantee?
[“Pending Content” in FASB ASC 815-10-50-4J; “Pending
Content” in FASB ASC 815-10-50-4K]

.l 22B. (FSP FAS 133-1 and FIN 45-5) With respect to hybrid instruments that have embedded credit derivatives, has the seller of
the embedded credit derivative disclosed the information required by FASB ASC 815-10-50-4K, question 20, for the entire
hybrid instrument, not just the embedded credit derivatives?
[“Pending Content” in FASB ASC 850-10-50-4L]
.l 23.

Has the entity disclosed its accounting policy for the premium
paid (time value) to acquire an option that is classified as held
to maturity or available for sale, if applicable?
[FASB ASC 815-10-50-9]

Unconditional Purchase Obligations
.l 24.

If the entity has unconditional purchase obligations which are
subject to the requirements of FASB ASC 440 and FASB ASC
815, are the disclosures required by both topics complied with,
including FASB ASC 440-10-50-4?
[FASB ASC 815-10-50-6]

Balance Sheet Offsetting
.l 25.

Is the entity’s policy for offsetting or not offsetting in accordance with FASB ASC 815-10-45-6 disclosed?
[FASB ASC 815-10-50-7]
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Yes

No

N/A

Practice Tip
A reporting entity should make an accounting policy decision to offset fair value amounts pursuant to FASB
ASC 815-10-45-5. The reporting entity’s choice to offset or not must be applied consistently. A reporting
entity should not offset fair value amounts recognized for derivative instruments without offsetting fair
value amounts recognized for the right to reclaim cash collateral or the obligation to return cash collateral.
A reporting entity that makes an accounting policy decision to offset fair value amounts recognized for
derivative instruments pursuant to FASB ASC 815-10-45-5 but determines that the amount recognized for
the right to reclaim cash collateral or the obligation to return cash collateral is not a fair value amount should
continue to offset the derivative instruments.
[FASB ASC 815-10-45-6]
.l 26.

Has the entity disclosed the amounts recognized at the end of
each reporting period for the right to reclaim cash collateral or
the obligation to return cash collateral as follows:
a.

If the entity has made an accounting policy decision to offset fair value amounts it should separately disclose
amounts recognized for the right to reclaim cash collateral
or the obligation to return cash collateral that have been
offset against net derivative positions in accordance with
FASB ASC 815-10-45-5?
Practice Tip

A reporting entity may offset fair value amounts recognized for derivative instruments and fair value
amounts recognized for the right to reclaim cash collateral (a receivable) or the obligation to return cash
collateral (a payable) arising from derivative instrument(s) recognized at fair value executed with the same
counterparty under a master netting arrangement. Solely as it relates to the right to reclaim cash collateral
or the obligation to return cash collateral, fair value amounts include amounts that approximate fair value.
[FASB ASC 815-10-45-5]
b.

Has the entity separately disclosed amounts recognized for
the right to reclaim cash collateral or the obligation to return cash collateral under master netting arrangements that
have not been offset against net derivative instrument positions?

c.

If the entity has made an accounting policy decision to not
offset fair value amounts, have they separately disclosed
the amounts recognized for the right to reclaim cash collateral or the obligation to return cash collateral under master
netting arrangements?
[FASB ASC 815-10-50-8]
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Yes

No

N/A

Certain Hybrid Financial Instruments
Note: In February 2007, FASB issued Statement No. 159, The Fair Value
Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115, which is effective for financial statements issued for fiscal years beginning after November 15, 2007 (that
is, January 1, 2008, for entities with calendar year-ends). Early adoption is permitted as of the beginning of a fiscal year that begins on or
before November 15, 2007, provided the entity also elects to apply the
provisions of FASB Statement No. 157. The choice to adopt early
should be made after issuance of this statement but within 120 days of
the beginning of the fiscal year of adoption, provided the entity has
not yet issued financial statements, including required notes to those
financial statements, for any interim period of the fiscal year of adoption.
This statement applies to all entities, including not-for-profit entities.
Most of the provisions of this guidance apply only to entities that elect
the fair value option. However, the amendment to FASB Statement
No. 115, Accounting for Certain Investments in Debt and Equity Securities,
applies to all entities with available-for-sale and trading securities.
Some requirements apply differently to entities that do not report net
income.
This statement is primarily codified in FASB ASC 825, Financial Instruments.
See part BB, “Fair Value Measurements,” for more information.
.l 27.

If the entity measures hybrid instruments (financial instruments
containing embedded derivatives) at fair value in accordance
with the election and under the practicability exception in FASB
ASC 815-15-30-1 on earnings (or other performance indicators for
entities that do not report earnings), is the aggregate fair value
of those instruments reported separately on the face of the statement of financial position from the aggregate carrying amounts
of assets and liabilities measured using another measurement attribute?
[FASB ASC 815-15-45-1]

.l 28.

For those hybrid financial instruments measured at fair value under the election and under the practicability exception in FASB
ASC 815-15-30-1 on earnings (or other performance indicators for
entities that do not report earnings), has the entity disclosed the
information in paragraphs 28–32 of FASB ASC 825-10-50?
[FASB ASC 815-15-50-1]

.l 29.

Has the entity provided information that will allow users to understand the effect of changes in the fair value of hybrid financial
instruments measured at fair value under the election and under
the practicability exception in FASB ASC 815-15-30-1 on earnings
(or other performance indicators for entities that do not report
earnings)?
[FASB ASC 815-15-50-2]
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.l 30.

For those embedded conversion options previously accounted
for as a derivative instrument under FASB ASC 815-15 (embedded derivatives) which no longer meet the separation criteria has
a description of the principal changes causing the embedded
conversion option to not longer require bifurcation and the
amount of the liability for the conversion option which has been
reclassified to stockholders’ equity been disclosed?
[FASB ASC 815-15-50-3]
Fair Value Hedges

.l 31A. For every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented, does the entity disclose the following for
derivative instruments, as well as nonderivative instruments that
may give rise to foreign currency transaction gains or losses under FASB ASC 830-20, that have been designated and have qualified as fair value hedging instruments and for the related
hedged items:
a.

The net gain or loss recognized in earnings during the reporting period representing (i) the amount of the hedges’
ineffectiveness, (ii) the component of the derivative instruments’ gain or loss, if any, excluded from the assessment of
hedge effectiveness, and (iii) a description of where the net
gain or loss is reported in the statement of income or other
statement of financial performance?

b.

The amount of net gain or loss recognized in earnings when
a hedged firm commitment no longer qualifies as a fair
value hedge?
[FASB ASC 815-25-50-1]

.l 31B. (FASB Statement No. 161) For every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented, does the entity disclose the following for derivative instruments, as well as
nonderivative instruments that may give rise to foreign currency
transaction gains or losses under FASB ASC 830-20, that have
been designated and have qualified as fair value hedging instruments and for the related hedged items:
a.

The net gain or loss recognized in earnings during the reporting period representing (i) the amount of the hedges’
ineffectiveness and (ii) the component of the derivative instruments’ gain or loss, if any, excluded from the assessment of hedge effectiveness?

b.

The amount of net gain or loss recognized in earnings when
a hedged firm commitment no longer qualifies as a fair
value hedge?
[”Pending Content” in FASB ASC 815-25-50-1]
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Cash Flow Hedges
.l 32.

Has the entity displayed, as a separate classification within OCI,
the net gain or loss on any derivative instruments designated
and qualifying as cash flow hedging instruments that are reported in comprehensive income pursuant to FASB ASC 815-2025-65 and FASB ASC 815-30-35-3?
[FASB ASC 815-30-45-1]

.l 33A. For every reporting period for which a statement of financial position and statement of financial performance are presented, does
the entity disclose the following for derivative instruments that
have been designated and have qualified as cash flow hedging
instruments and for the related hedged transactions:
a.

The net gain or loss recognized in earnings during the reporting period representing (i) the amount of the hedges’
ineffectiveness, (ii) the component of the derivative instruments’ gain or loss, if any, excluded from the assessment of
hedge effectiveness, and (iii) a description of where the net
gain or loss is reported in the statement of income or other
statement of financial performance?

b.

A description of the transactions or other events that will
result in the reclassification into earnings of gains and
losses that are reported in accumulated OCI, and the estimated net amount of the existing gains or losses at the reporting date that is expected to be reclassified into earnings
within the next 12 months?

c.

The maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for
forecasted transactions excluding those forecasted transactions related to the payment of variable interest on existing
financial instruments?

d.

The amount of gains and losses reclassified into earnings as
a result of the discontinuance of cash flow hedges because
it is probable that the original forecasted transactions will
not occur by the end of the originally specified time period
or within the additional period of time discussed in paragraphs 4–5 of FASB ASC 815-30-40?
[FASB ASC 815-30-50-1]

.l 33B. (FASB Statement No. 161) For every annual and interim reporting period for which a statement of financial position and statement of financial performance are presented, does the entity disclose the following for derivative instruments that have been
designated and have qualified as cash flow hedging instruments
and for the related hedged transactions:
a.

A description of the transactions or other events that will
result in the reclassification into earnings of gains and
losses that are reported in accumulated OCI, and the estimated net amount of the existing gains or losses at the reporting date that is expected to be reclassified into earnings
within the next 12 months?
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.l 34.

b.

The maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for
forecasted transactions excluding those forecasted transactions related to the payment of variable interest on existing
financial instruments?

c.

The amount of gains and losses reclassified into earnings as
a result of the discontinuance of cash flow hedges because
it is probable that the original forecasted transactions will
not occur by the end of the originally specified time period
or within the additional period of time discussed in paragraphs 4–5 of FASB ASC 815-30-40?
[”Pending Content” in FASB ASC 815-30-50-1]

No

N/A

Has the entity disclosed, as a separate component of OCI, the
beginning and ending accumulated derivative instrument gain
or loss, the related net change associated with current period
hedging transactions, and the net amount of any reclassification
into earnings?
[FASB ASC 815-30-50-2]
Practice Tips

The entity should display as a separate classification within OCI the net gain or loss on derivative instruments designated and qualifying as cash flow hedging instruments that are reported in comprehensive income pursuant to FASB ASC 815-20-25-65 and FASB ASC 815-30-35-3.
[FASB ASC 815-30-45-1]
******
The quantitative disclosures about derivative instruments may be more useful, and less likely to be perceived to be out of context or otherwise misunderstood, if similar information is disclosed about other financial instruments or nonfinancial assets and liabilities to which the derivative instruments are related by
activity. Accordingly, in such situations, an entity is encouraged, but not required, to present a more complete picture of its activities by disclosing that information.
[FASB ASC 815-35-50-2]
Contracts in Entity’s Own Equity
.l 35.

Have changes in the fair value of all contracts classified as assets
or liabilities disclosed, as long as the contracts remain classified
as assets or liabilities?
[FASB ASC 815-40-50-1]

.l 36.

If contracts that are classified as assets or liabilities meet the
FASB ASC glossary definition of a derivative instrument and
meet the criteria under the provisions of FASB ASC 815-10, are
the related disclosures required by FASB ASC 815-10-50, FASB
ASC 815-25-50, FASB ASC 815-30-50, and FASB ASC 815-35-50
disclosed, as detailed in questions preceding?
[FASB ASC 815-40-50-2]
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.l 37.

If contracts within the scope of FASB ASC 815-40 are reclassified
into (or out of) equity during their lives (in whole or in part)
pursuant to the provisions of paragraphs 8–13 of FASB ASC 81540-35, related to reclassification of contracts, is the contract reclassification, the reason for the reclassification and the effect on
the entity’s financial statements disclosed?
[FASB ASC 815-40-50-3]

.l 38.

If the entity partially reclassifies a contract(s) subject to FASB
ASC 815-40, is the accounting policy decision disclosed pursuant
to FASB ASC 235, Notes to the Financial Statements?
[FASB ASC 815-40-50-4]

.l 39.

If the entity has contracts related to their capital structure of the
following nature, have the following disclosures, pursuant to
FASB ASC 505-10-50 (equity disclosures) been displayed?
a.

If the entity has an option or forward contract, has relevant
information including (i) the forward rate, (ii) the option
strike price, (iii) the number of shares to which the contract
is indexed, (iv) the settlement date(s), and (v) the issuers
accounting for the contract (asset, liability, or equity) been
disclosed?

b.

If the entity’s contract(s) provide settlement alternatives,
has the relevant information including (i) who controls the
settlement alternatives and (ii) the maximum number of
shares that could be required to be issued to net share settle
the contract been disclosed?

c.

If the entity’s contract(s) does not have a fixed or determinable maximum number of shares that may be required to
be issued, is the fact that an infinite number may be required to settle the contract(s) disclosed?

d.

For each of the entity’s contract(s) has disclosure been made
of the current fair value for each settlement alternative and
how changes in the price of the issuer’s equity instruments
affect those settlement amounts? (For some issuers, a tabular format may provide the most concise and informative
presentation of these data.)

No

N/A

e.

If the entity has temporary equity (for example redeemable
stock issued by nonpublic entities) have the disclosures required by FASB ASC 505-10-50-11 been made?
[FASB ASC 815-40-50-5]
Weather Derivatives

.l 40.

Weather derivative contracts within the scope of FASB ASC 81545 are financial instruments, therefore, are the existing U.S.
GAAP disclosures for financial instruments such as those required in FASB ASC 825-10-50 included?
[FASB ASC 815-45-50-1]
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Disclosures About Fair Value of Financial Instruments
Notes: In April 2009, FASB issued FSP 107-1 and APB 28-1 to require
disclosures about fair value of financial instruments for interim reporting periods of publicly traded entities as well as in annual financial statements. This FSP also amends APB Opinion No. 28 to require
those disclosures in summarized financial information at interim reporting periods. This FSP applies to all financial instruments within
the scope of FASB Statement No. 107 held by publicly traded companies, as defined by APB Opinion No. 28.
FSP FAS 107-1 and APB 28-1 is effective for interim reporting periods
ending after June 15, 2009 (that is, December 31, 2009, for entities with
calendar year-ends), with early adoption permitted for periods ending
after March 19, 2009. An entity may early adopt this FSP only if it also
elects to early adopt FSP FAS 157-4 and FSP FAS 115-2 and FAS 1242. This FSP does not require disclosures for earlier periods presented
for comparative purposes at initial adoptions. In periods after initial
adoption, this FSP requires comparative disclosures only for periods
ending after initial adoption.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 107-1 and APB 28-1.
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 825-1065-1.

Practice Tips
For interim reporting periods, the disclosure guidance in FASB ASC 825-10-50 applies to all entities but is
optional for those entities that do not meet the FASB ASC definition of a publicly traded company.
[“Pending Content” in FASB ASC 825-10-50-2A]
******
U.S. GAAP requires disclosure of or subsequent measurement at fair value for many classes of financial
instruments. Those requirements are not superseded or modified by FASB ASC 825-10-50.
FASB ASC 825-10-50-13 does not prohibit an entity from disclosing separately the estimated fair value of
any of its nonfinancial intangible and tangible assets and nonfinancial liabilities.
FASB ASC 825-10-50-14 does not require separate disclosure of trade receivables and payables if the carrying
amount approximates fair value.
[FASB ASC 825-10-50 par. 9 and 13–14]
******
The disclosure about fair values of financial instruments is optional (for annual reporting periods) for reporting entities that
●

are nonpublic entities as defined in the FASB ASC glossary,

●

have total assets of less than $100 million on the date of the financial statements, and
(continued)
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●

have no instrument that, in whole or in part, is accounted for as a derivative instrument under FASB
ASC 815, Derivatives and Hedging, other than commitments related to the origination of mortgage
loans to be held for sale during the reporting period.
[“Pending Content” in FASB ASC 825-10-50-3]
This criterion should be applied to the most recent year presented in comparative financial statements to
determine the applicability of FASB ASC 825-10-50.
[FASB ASC 825-10-50-4]
******
The following table clarifies the requirements for disclosures if prior periods are presented in comparative
financial statements.
If Disclosures for the
Current Period Are:

And Disclosures for
Prior Periods Were:

Then Disclosures for
Prior Periods Presented in
Comparative Statements Are:

Optional

Optional

Optional

Optional

Required

Optional

Required

Optional

Optional

Required

Required

Required
[FASB ASC 825-10-50 par. 5–7]
.l 41.

Has the entity disclosed, either in the body of the financial statements or in the accompanying notes, the fair value of financial
instruments for which it is practicable to estimate fair value, the
method(s), significant assumptions used to estimate the fair
value of the financial instruments and a description of the
changes in the method(s) and significant assumptions used, if
any, during the period?
[“Pending Content” in FASB ASC 825-10-50-10]

.l 42.

Has the fair value disclosed in the notes been presented together
with the related carrying amount in a form that makes it clear
whether the fair value and carrying amount represent assets or
liabilities and how the carrying amounts relate to what is reported in the statement of financial position?
[FASB ASC 825-10-50-11]

.l 43.

If fair value information is disclosed in more than a single note,
does one of the notes include a summary table of the fair value
and related carrying amounts, and does the note cross-reference
to the location(s) of the remaining required disclosures?
[FASB ASC 825-10-50-12]

FSP §11,100.01

174

Health Care Entities

Yes
.l 44.

In disclosing the fair value of a financial instrument, has the entity taken care not to net that fair value with the fair value of
other financial instruments—even if those financial instruments
are of the same class or are otherwise considered to be related,
for example, by a risk management strategy—except to the extent that the offsetting of carrying amounts in the statement of
financial position is permitted under the general principle in
FASB ASC 210-20-45-1, or the exceptions for master netting arrangements in FASB ASC 815-10-45-5 and for amounts related to
certain repurchase and reverse repurchase agreements in paragraphs 11–17 of FASB ASC 210-25-45?
[FASB ASC 825-10-50-15]

.l 45.

If it is not practicable (see paragraphs 16–19 of FASB ASC 82510-50 for definition of practicable in this context) to estimate the
fair value of a financial instrument or a class of financial instruments, are the following disclosed:
a.

Information pertinent to estimating the fair value of that financial instrument or class of financial instruments, such as
the carrying amount, effective interest rate, and maturity?

b.

The reasons why it is not practicable to estimate fair value?
[FASB ASC 825-10-50-16]

Notes: In May 2009, FASB Statement No. 163, Accounting for Financial
Guarantee Insurance Contracts, an Interpretation of FASB Statement No. 60,
was released to amend FASB Statement No. 107 to eliminate inconsistencies in the recognition and measurement of claim liabilities. This
statement clarifies how FASB Statement No. 60 applies to financial
guarantee insurance contracts, including the recognition and measurement of premium revenue and claim liabilities. This statement also requires expanded disclosures about financial guarantee insurance contracts.
This statement applies to financial guarantee insurance (and reinsurance) contracts issued by enterprises that are included within the
scope of paragraph 6 of FASB Statement No. 60 and that are not accounted for as derivative instruments.
FASB Statement No. 163 is effective for financial statements issued for
fiscal years beginning after December 15, 2008 (that is, January 1, 2009,
for entities with calendar year-ends), and interim periods within those
fiscal years. However, many of the disclosure requirements are effective for the first period (including interim periods) beginning after issuance.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 163.
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 944-2065-1.
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Practice Tips
Fair value disclosures are required for all financial instruments, whether recognized or not recognized in the
statement of financial position, except that the disclosures about fair value in paragraphs 10–16 of FASB
ASC 825-10-50 are not required for several classes of financial instruments (see FASB ASC 825-10-50-8).
[FASB ASC 825-10-50-8]
******
(FASB Statement No. 163) Fair value disclosures are required for all financial instruments, whether recognized or not recognized in the statement of financial position, except that the disclosures about fair value in
paragraphs 10–16 of FASB ASC 825-10-50 are not required for several classes of financial instruments (see
“Pending Content” in FASB ASC 825-10-50-8).
[“Pending Content” in FASB ASC 825-10-50-8]
Disclosure About Concentrations of Credit Risk of All Financial Instruments
Practice Tip
The disclosure requirements of FASB ASC 825-10-50-21 do not apply to the following financial instruments,
whether written or held:
●

The financial instruments described in FASB ASC 825-10-50-8(a), (c), (e), and (f), except for reinsurance receivables and prepaid reinsurance premiums.

●

Financial instruments of a pension plan, including plan assets, when subject to the accounting and
reporting requirements of FASB ASC 715, Compensation—Retirement Benefits (financial instruments
of a pension plan, other than the obligations for pension benefits, if subject to the accounting and
reporting requirements of FASB ASC 960, Plan Accounting—Defined Benefit Pension Plans, are subject
to the requirements of paragraphs 20–21 of FASB ASC 825-10-50).
[FASB ASC 825-10-50-22]
.l 46. Has the entity made the following disclosures about each significant concentration:
a.

Information about the (shared) activity, region, or economic
characteristic that identifies the concentration? Possible
shared characteristics on which significant concentrations
may be determined include, but are not limited to (i) borrowers subject to significant payment increases, (ii) loans
with terms that permit negative amortization, and (iii) loans
with high loan-to-value ratios.

b.

The maximum amount of loss due to credit risk that, based
on the gross fair value of the financial instrument, the entity
would incur if parties to the financial instruments that
make up the concentration failed completely to perform according to the terms of the contracts and the collateral or
other security, if any, for the amount due proved to be of
no value to the entity?
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c.

The entity’s policy of requiring collateral or other security
to support financial instruments subject to credit risk, information about the entity’s access to that collateral or other
security, and the nature and a brief description of the collateral or other security supporting those financial instruments?

d.

The entity’s policy of entering into master netting arrangements to mitigate the credit risk of financial instruments,
information about the arrangements for which the entity is
a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity’s maximum amount of loss due to credit
risk?
[FASB ASC 825-10-50-21; FASB ASC 958-320-50-4]

No

N/A

.l 47. Has the entity disclosed quantitative information, such as those
listed below, about the market risks of financial instruments that
is consistent with the way it manages or adjusts those risks? (Encouraged, but not required.)
a.

More details about current positions and perhaps activity
during the period?

b.

The hypothetical effects on comprehensive income (or net
assets), or annual income, of several possible changes in
market prices?

c.

A gap analysis of interest rate repricing or maturity dates?

d.

The duration of the financial instruments?

e.

The entity’s value at risk from derivatives and from other
positions at the end of the reporting period and the average
value at risk during the year?
[FASB ASC 825-10-50-23]

.l 48. Are gains and losses (realized and unrealized) on all derivative
instruments within the scope of FASB ASC 815, shown net when
recognized in the income statement, whether or not settled physically, if the derivative instruments are held for trading purposes?
[FASB ASC 815-10-45-9]
Practice Tip
The preceding disclosures are incremental to the disclosures that may be required under other applicable
U.S. GAAP and are required even if the likelihood of the issuer having to make any payments under the
arrangement is remote.
[FASB ASC 825-20-50-2]

FSP §11,100.01

177

Financial Statements and Notes Checklist

Yes

No

N/A

Disclosures About Certain Financial Instruments With Characteristics of Both Liabilities and Equity
Notes: In November 2003, FASB issued FSP FAS 150-3, Effective Date,
Disclosures, and Transition for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable
Noncontrolling Interests under FASB Statement No. 150, to clarify and
defer specific implementation of the provisions of FASB Statement No.
150, Accounting for Certain Financial Instruments with Characteristics of
both Liabilities and Equity.
FASB Statement No. 150 as issued is effective for mandatorily redeemable financial instruments of nonpublic entities for the first fiscal period beginning after December 15, 2003. For mandatorily redeemable
instruments of other entities, FASB Statement No. 150 as issued is effective for financial instruments entered into or modified after May 31,
2003, and for all other instruments for interim periods beginning after
June 15, 2003.
FSP FAS 150-3 deferred the effective date for mandatorily redeemable
financial instruments issued by nonpublic entities that are not SEC
registrants, as follows:
a.

For instruments that are mandatorily redeemable on fixed
dates for amounts that either are fixed or are determined by
reference to an interest rate index, currency index, or another
external index, the classification, measurement, and disclosure
provisions of FASB ASC 480-10-50 were effective for fiscal
periods beginning after December 15, 2004.

b.

For all other financial instruments that are mandatorily redeemable, the classification, measurement, and disclosure provisions of FASB ASC 480-10-50 are deferred indefinitely pending further FASB action.

Note that the effective dates for entities that are not nonpublic and are
not SEC registrants differ and that early adoption for instruments
within the scope of this deferral is prohibited during the deferral period. Readers should review this FSP or the relevant transition guidance to understand the various effective dates of FASB Statement No.
150, as discussed in FASB ASC 480-10-65-1.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 150-3.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions indicated with a “B” reference. Entities for which the guidance
has been implemented should consider all questions indicated by a
“B” reference (for example, question 1B and question 2B) and place an
“N/A” mark by questions indicated with an “A” reference. Therefore,
based upon your entity’s year-end and decision to early implement or
(continued)
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not (if allowed), the following additional questions will be answered
when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web
site at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 480-1065-1.
.l 49B. (FSP FAS 150-3) For items within the scope of FASB ASC 480-10,
are they presented as liabilities (or assets in some circumstances),
and are those items not presented between the liabilities section
and the equity section of the statement of financial position?
[”Pending Content” in FASB ASC 480-10-45-1]
.l 50B. (FSP FAS 150-3) For issuers of financial instruments with the
scope of FASB ASC 480-10:
a.

Are the nature and terms of the financial instruments and
the rights and obligations embodied in those instruments
disclosed?

b.

Does that disclosure include information about settlement
alternatives, if any, in the contract and identify the entity
that controls the settlement alternatives?
[”Pending Content” in FASB ASC 480-10-50-1]

.l 51B. (FSP FAS 150-3) For all outstanding financial instruments within
the scope of FASB ASC 480-10 and for each settlement alternative, does the entity disclose
a.

the amount that would be paid, or the number of shares
that would be issued and their fair value, determined under the conditions specified in the contract if the settlement
were to occur at the reporting date?

b.

how changes in the fair value of the issuer’s equity shares
would affect those settlement amounts (for example, “the
issuer is obligated to issue an additional x shares or pay an
additional y dollars in cash for each $1 decrease in the fair
value of one share”)?

c.

the maximum amount that the issuer could be required to
pay to redeem the instrument by physical settlement, if applicable?

d.

the maximum number of shares that could be required to
be issued, if applicable?

e.

that a contract does not limit the amount that the issuer
could be required to pay or the number of shares that the
issuer could be required to issue, if applicable?
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for a forward contract or an option indexed to the issuer’s
equity shares, the forward price or option strike price, the
number of issuer’s shares to which the contract is indexed,
and the settlement date or dates of the contract, as applicable?
[”Pending Content” in FASB ASC 480-10-50-2]

.l 52B. (FSP FAS 150-3) If the entity has no equity instruments outstanding but has financial instruments in the form of shares, all of
which are mandatorily redeemable financial instruments,
a.

are they classified as liabilities?

b.

are they described in the statement of financial position as
“shares subject to mandatory redemption”?

c.

are payments to holders of such instruments and related
accruals presented separately from payments to and interest due to other creditors in statements of cash flows and
income?
[”Pending Content” in FASB ASC 480-10-45-2]

.l 53B. (FSP FAS 150-3) Do the entities referred to in question 49B disclose the components of the liability that would otherwise be related to shareholders’ interest and OCI, if any, subject to the redemption feature (for example, par value and other paid-in
amounts of mandatorily redeemable instruments should be disclosed separately from the amount of retained earnings or accumulated deficit)?
[”Pending Content” in FASB ASC 480-10-50-4]
.l 54B. (FSP FAS 150-3) Is the cumulative transition adjustment and any
subsequent adjustments reported as an excess of liabilities over
assets (a deficit) and changes thereto even though the mandatorily redeemable shares are reported as a liability?
[”Pending Content” in FASB ASC 480-10-45-2A]
.l 55B. (FSP FAS 150-3) Are unconditional mandatorily redeemable financial instruments classified as liabilities if those instruments
are mandatorily redeemable on fixed dates unless the redemption is required to occur only upon the liquidation or termination
of the reporting entity? (Note: A mandatorily redeemable financial instrument is conditional if the obligation depends upon the
occurrence of an event not certain to occur. Death is not uncertain of occurrence; thus, death is not a condition.)
[”Pending Content” in FASB ASC 480-10-25 par. 4–5]
.l 56B. (FSP FAS 150-3) Are financial instruments, other than an outstanding share, that, at inception, (a) embodies an obligation to
repurchase the issuer’s equity shares or is indexed to such an
obligation, and (b) requires or may require the issuer to settle the
obligation by transferring assets, classified as liabilities (or assets
in some circumstances)?
[”Pending Content” in FASB ASC 480-10-25-8]
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.l 57B. (FSP FAS 150-3) Are financial instruments that embody an unconditional obligation, or financial instruments other than an
outstanding share that embodies a conditional obligation, that
the issuer must or may settle by issuing a variable number of its
equity shares, classified as liabilities (or assets in some circumstances) if, at inception, the monetary value of the obligation is
based solely or predominantly on any one of the following:
a.

A fixed monetary amount known at inception (for example,
a payable settable with a variable number of the issuer’s
equity shares)?

b.

Variations in something other than the fair value of the issuer’s equity shares (for example, a financial instrument indexed to the Standard and Poor’s S&P 500 Index and settleable with a variable number of the issuer’s equity shares)?

c.

Variations inversely related to changes in the fair value of
the issuer’s equity shares (for example, a written put option
that could be net share settled)?
[”Pending Content” in FASB ASC 480-10-25-14]

.l 58.

Has the entity disclosed information about the pertinent rights
and privileges of the various securities outstanding, including
mandatory redemption requirements, in summary form?
[FASB ASC 505-10-50-3]

.l 59.

Has the entity disclosed the amount of redemption requirements
for all issues of stock that are redeemable at fixed or determinable prices on fixed or determinable dates in each of the next five
years?
[FASB ASC 505-10-50-11]

I.

Guarantees
Notes: In September 2008, FASB issued FSP FAS 133-1 and FIN 45-5
to amend disclosures related to the current status of the payment/
performance risk of a guarantee under FASB Interpretation No. 45,
Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others—an interpretation
of FASB Statements No. 5, 57 and 107 and rescission of FASB Interpretation No. 34. This FSP applies guarantees within the scope of FASB
Interpretation No. 45.
This FSP also amends paragraph 13(a) of FASB Interpretation No. 45
to require disclosure of the current status of the payment/performance risk of the guarantee.
The FSP is effective for financial statements issued for fiscal years
and interim periods beginning after November 15, 2008 (that is, January 1, 2009, for entities with calendar year-ends). Early application
is encouraged. This statement encourages but does not require disclosures for earlier periods presented for comparative purposes at
initial adoption. In years after initial adoption, it requires comparative disclosures only for periods subsequent to initial adoption.
(continued)
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Yes

No

N/A

This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 133-1 and FIN 45-5.
As determined by the effective date or early implementation decision, entities for which this guidance has not been implemented
should consider all questions indicated with an “A” reference (for
example, question 1A and question 2A) and should place an “N/A”
mark in questions indicated with a “B” reference. Entities for which
the guidance has been implemented should consider all questions
indicated by a “B” reference (for example, question 1B and question
2B) and place an “N/A” mark by questions indicated with an “A”
reference. Therefore, based upon your entity’s year-end and decision
to early implement or not (if allowed), the following additional
questions will be answered when provided in this section (check one
that applies for your entity):
pppA pppB
Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition
and open effective date information discussed in FASB ASC 815-1065-2.

Practice Tip
An entity should disclose certain loss contingencies even though the possibility of loss may be remote. The
common characteristic of those contingencies is a guarantee that provides a right to proceed against an
outside party in the event that the guarantor is called on to satisfy the guarantee. Examples include the
following:
a.

Guarantees of indebtedness of others, including indirect guarantees of indebtedness of others

b.

Obligations of commercial banks under standby letters of credit

c.

Guarantees to repurchase receivables (or, in some cases, to repurchase the related property) that
have been sold or otherwise assigned

d.

Other agreements that in substance have the same guarantee characteristic

The disclosure should include the nature and amount of the guarantee. Consideration should be given to
disclosing, if estimable, the value of any recovery that could be expected to result, such as from the guarantor’s right to proceed against an outside party.
[FASB ASC 460-10-50 par. 2–3 ]
.l 1A. Is the following information disclosed by a guarantor about
each guarantee, or each group of similar guarantees, even if the
likelihood of the guarantor’s having to make any payments under the guarantee is remote:
a.

The nature of the guarantee, including the approximate
term, how the guarantee arose, and the events or circumstances that would require the guarantor to perform under
the guarantee?
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Yes
b.

The maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee?

c.

If the terms of the guarantee provide for no limitation to
the maximum potential future payments under the guarantee, is that fact disclosed?

d.

If the guarantor is unable to develop an estimate of the
maximum potential amount of future payments under its
guarantee, are the reasons why the maximum potential
amount cannot be estimated disclosed?

e.

The current carrying amount of the liability, if any, for the
guarantor’s obligations under the guarantee, including the
amount, if any, recognized under FASB ASC 450-20-30, regardless of whether the guarantee is freestanding or embedded in another contract?

f.

The nature of

g.

i.

any recourse provisions that would enable the guarantor to recover from third parties any of the
amounts paid under the guarantee?

ii.

any assets held either as collateral or by third parties
that, upon the occurrence of any triggering event or
condition under the guarantee, the guarantor can obtain and liquidate to recover all or a portion of the
amounts paid under the guarantee?

If estimable, the approximate extent to which the proceeds
from liquidation of those assets would be expected to
cover the maximum potential amount of future payments
under the guarantee?
[FASB ASC 460-10-50-4]

.l 1B. (FSP FAS 133-1 and FIN 45-5) Is the following information disclosed by a guarantor about each guarantee, or each group of
similar guarantees, even if the likelihood of the guarantor’s
having to make any payments under the guarantee is remote:
a.

b.
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The nature of the guarantee, including all of the following:
i.

The approximate term of the guarantee?

ii.

How the guarantee arose?

iii.

The events or circumstances that would require the
guarantor to perform under the guarantee?

iv.

The current status (that is, as of the date of the statement of financial position) of the payment/performance risk of the guarantee?

v.

If the entity uses internal groupings for the purposes
of item (iv), how those groupings are determined
and used for managing risk?

The maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee?

No

N/A
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Yes
c.

If the terms of the guarantee provide for no limitation to
the maximum potential future payments under the guarantee, is that fact disclosed?

d.

If the guarantor is unable to develop an estimate of the
maximum potential amount of future payments under its
guarantee, are the reasons why the maximum potential
amount cannot be estimated disclosed?

e.

The current carrying amount of the liability, if any, for the
guarantor’s obligations under the guarantee, including the
amount, if any, recognized under FASB ASC 450-20-30, regardless of whether the guarantee is freestanding or embedded in another contract?

f.

The nature of

g.

i.

any recourse provisions that would enable the guarantor to recover from third parties any of the
amounts paid under the guarantee?

ii.

any assets held either as collateral or by third parties
that, upon the occurrence of any triggering event or
condition under the guarantee, the guarantor can obtain and liquidate to recover all or a portion of the
amounts paid under the guarantee?

No

N/A

If estimable, the approximate extent to which the proceeds
from liquidation of those assets would be expected to
cover the maximum potential amount of future payments
under the guarantee?
[FASB ASC 460-10-50-4]

.l 2.

Are the disclosure requirements in paragraphs 4–6 of FASB
ASC 460-10-50 applied to all minimum revenue guarantees in
financial statements of interim or annual periods?
[FASB ASC 460-10-50 par. 4–6]

.l 3.

For product warranties and other guarantee contracts required
to be disclosed by FASB ASC 460-10-15-9, is the following information disclosed:
a.

The information required to be disclosed in question 1A,
except that a guarantor is not required to disclose the maximum potential amount of future payments in question
1B?

b.

The guarantor’s accounting policy and methodology used
in determining its liability for product warranties (including any liability associated with extended warranties)?

c.

A tabular reconciliation of the changes in the guarantor’s
aggregate product warranty liability for the reporting period?

d.

Does the tabular reconciliation present
i.

the beginning balance of the aggregate product warranty liability?
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Yes

.l 4.

J.

ii.

the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty?

iii.

the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, and the aggregate changes in the liability
for accruals related to preexisting warranties, including adjustments related to changes in estimates?

iv.

the ending balance of the aggregate product warranty liability?
[FASB ASC 460-10-50-8]

Are the disclosure requirements in paragraphs 30–35 of FASB
ASC 460-10-55 for intellectual property infringement indemnifications complied with?
[FASB ASC 460-10-55 par. 30–35]

Foreign Currency Matters
Foreign Currency Transactions

.l 1.

If not disclosed in the financial statements, as discussed in
FASB ASC 830-20-45-2, is the aggregate transaction gain or loss
included in determining net income for the period disclosed in
the notes to the financial statements?
[FASB ASC 830-20-50-1]

.l 2.

If significant rate changes have occurred after the date of the
financial statements, are the effects on unsettled balances related to foreign currency transactions disclosed?
[FASB ASC 830-20-50-2]

.l 3.

Has management supplemented the preceding disclosures with
an analysis and discussion of the effects of rate changes on the
reported results of operations? This type of disclosure might include the mathematical effects of translating revenue and expenses at rates that are different from those used in a preceding
period as well as the economic effects of rate changes, such as
the effects on selling prices, sales volume, and cost structures.
The purpose is to assist financial report users in understanding
the broader economic implications of rate changes and to compare recent results with those of prior periods. (Encouraged but
not required.)
[FASB ASC 830-20-50-3]
Foreign Currency Translations

.l 4.

Has an analysis of the changes during the period in the accumulated amount of translation adjustments reported in equity
been disclosed either in a separate financial statement, as a part
of the statement of changes in equity or in the notes to the financial statements? (See FASB ASC 830-30-45-50 for minimum
disclosure requirements.)
[FASB ASC 830-30-50-1]
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Yes
.l 5.

If significant rate changes have occurred after the date of the
financial statements, are the effects on unsettled balances related to foreign currency transactions disclosed?
[FASB ASC 830-30-50-2]

.l 6.

Are any foreign earnings reported beyond amounts received in
the United States disclosed, if significant?
[FASB ASC 280-10-50-41]

K.

No

N/A

Long-Lived Assets and Disposal Groups to Be Disposed Of

Reporting Discontinued Operations
.l 1.

Are the results of operations of a component of an entity (as that
phrase is defined in FASB ASC glossary) that either has been
disposed of or is classified as held for sale under the requirements of FASB ASC 360-10-45-9, reported in discontinued operations in accordance with FASB ASC 205-20-45-3 if both of the
following conditions are met:
a.

The operations and cash flows of the component have
been (or will be) eliminated from the ongoing operations
of the entity as a result of the disposal transaction?

b.

The entity will not have any significant continuing involvement in the operations of the component after the
disposal transaction?
[FASB ASC 205-20-45-1]

.l 2.

In a period in which a component of an entity either has been
disposed of or is classified as held for sale, does the income
statement for current and prior periods report the results of operations of the component, including any gain or loss recognized in accordance with FASB ASC 360-10-35-40 and 360-1040-5, in discontinued operations?
[FASB ASC 205-20-45-3]

.l 3.

Are the results of operations of a component classified as held
for sale reported in discontinued operations in the period(s) in
which they occur?
[FASB ASC 205-20-45-3]

.l 4.

Are the results of discontinued operations, less applicable income taxes (benefit), reported as a separate component of income before extraordinary items and the cumulative effect of
accounting changes (if applicable)?
[FASB ASC 205-20-45-3]

.l 5.

Is the gain or loss recognized on the disposal disclosed either
on the face of the income statement or in the notes to the financial statements?
[FASB ASC 205-20-45-3]

.l 6.

Are adjustments to amounts previously reported in discontinued operations that are directly related to the disposal of a component of an entity in a prior period classified separately in the
current period in discontinued operations?
[FASB ASC 205-20-50-5]
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Yes
.l 7.

Are the nature and amount of such adjustments (as discussed
in question 6) disclosed?
[FASB ASC 205-20-45-4]

.l 8.

Has interest expense on debt assumed by the buyer and interest
on debt that is required to be repaid as a result of a disposal
transaction allocated to discontinued operations? (The allocation to discontinued operations of other consolidated interest
that is not directly attributable to or related to other operations
of the entity is permitted, but not required.)
[FASB ASC 205-20-45 par. 6–7]

No

N/A

Reporting Disposal Gains or Losses in Continuing Operations
.l 9.

Is a gain or loss that is recognized on the sale of a long-lived
asset (disposal group) that is not a component of an entity included in income from continuing operations before income
taxes in the income statement?
[FASB ASC 360-10-45-5]

.l 10.

If a subtotal such as “income from operations” is presented,
does it include the amounts of those gains or losses considered
in question 9?
[FASB ASC 360-10-45-5]

Reporting a Long-Lived Asset or Disposal Group Sold or Classified as
Held for Sale
Practice Tip
A long-lived asset (disposal group) to be sold shall be classified as held for sale in the period in which all of
the criteria at FASB ASC 360-10-45-9 are met.
[FASB ASC 360-10-45-9]
.l 11. Is the following information disclosed in the notes to the financial statements that cover the period in which a long-lived asset
(disposal group) either has been sold or is classified as held for
sale:
a.

A description of the facts and circumstances leading to the
expected disposal, the expected manner and timing of that
disposal, and, if not separately presented on the face of the
statement, the carrying amount(s) of the major classes of
assets and liabilities included as part of a disposal group?

b.

The gain or loss recognized in accordance with FASB ASC
360-10-35-40 and FASB ASC 360-10-40-5 and if not separately presented on the face of the income statement, the
caption in the income statement that include that gain or
loss?

c.

If applicable, amounts of revenue and pretax profit or loss
reported in discontinued operations?

d.

If applicable, the segment in which the long-lived asset
(disposal group) is reported under FASB ASC 280?
[FASB ASC 205-20-50-1]
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Yes

No

N/A

.l 12. Are the major classes of assets and liabilities that are classified
as held for sale separately disclosed either on the face of the
statement of financial position or in the notes to financial statements?
[FASB ASC 205-20-50-2]
.l 13. If either paragraph 44 or 45 of FASB ASC 360-10-35 applies, is a
description of the facts and circumstances leading to the decision
to change the plan to sell the long-lived asset (disposal group)
and its effect on the results of operations for the period and any
prior periods presented disclosed in the notes to the financial
statements that include the period of that decision?
[FASB ASC 205-20-50-3]
.l 14. For each discontinued operation that generates continuing cash
flows, has the following been disclosed:
a.

The nature of the activities that give rise to continuing cash
flows?

b.

The period of time continuing cash flows are expected to
be generated?

c.

The principal factors used to conclude that the expected
continuing cash flows are not direct cash flows of the disposed component?
[FASB ASC 205-20-50-4]

.l 15. For each discontinued operation in which the ongoing entity
will engage in a continuation of activities with the disposed
component after its disposal and for which the amounts presented in continuing operations after the disposal transaction include a continuation of revenues and expenses that were intraentity transactions (eliminated in consolidated financial
statements) before the disposal transaction, have intra-entity
amounts before the disposal transaction been disclosed for all
periods presented? Further have the types of continuing involvement, if any, that the entity will have after the disposal
transaction been disclosed? (That information should be disclosed in the period in which operations are initially classified
as discontinued.)
[FASB ASC 205-20-50-6]
.l 16. If the criteria of FASB ASC 360-10-45-9 are met (and thus a longlived asset is classified as held for sale) after the balance sheet
date but before issuance of the financial statements, does the
long-lived asset continue to be classified as held and used in
those financial statements when issued and is the information
required by FASB ASC 205-20-50-1(a) (question 11) disclosed in
the notes to the financial statements?
[FASB ASC 360-10-45-13]
.l 17. Is a long-lived asset that is classified as held for sale presented
separately in the statement of financial position?
[FASB ASC 360-10-45-14]
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Yes

No

N/A

.l 18. Are the assets and liabilities of a disposal group that is classified
as held for sale presented separately in the asset and liability
sections, respectively, of the statement of financial position?
[FASB ASC 205-20-45-10]
.l 19. Are those assets and liabilities considered in question 18 not offset and presented as a single amount?
[FASB ASC 205-20-45-10]
.l 20. If a long-lived asset is to be disposed of other than by sale, does
it continue to be classified as held and used until it is disposed
of?
[FASB ASC 360-10-45-15]
Practice Tip
If circumstances arise that previously were considered unlikely and, as a result, an entity decides not to sell
a long-lived asset (disposal group) previously classified as held for sale, the asset (disposal group) should
be reclassified as held and used.
[FASB ASC 360-10-45-6]
L.

Impaired Loans

.l 1. Is the following information about loans that meet the definition
of impaired loans in paragraphs 16–17 of FASB ASC 310-10-35
disclosed as of the date of each balance sheet presented:
a.

The total recorded investment in the impaired loans?

b.

The amount of that recorded investment for which there is
a related allowance for credit losses determined in accordance with FASB ASC 310-10-35 and the amount of that allowance?

c.

The amount of that recorded investment for which there is
no related allowance for credit losses determined in accordance with FASB ASC 310-10-35?
[FASB ASC 310-10-50-15]

.l 2. Is the policy for recognizing interest income on impaired loans,
including how cash receipts are handled, disclosed?
[FASB ASC 310-10-50-15]
.l 3. Are the following disclosures made for each period for which an
income statement is presented:
a.

The average recorded investment in the impaired loans during the period?
[FASB ASC 310-10-50-15]

b.

The related amount of interest income recognized during
the time within the period that the loans were considered
impaired?
[FASB ASC 310-10-50-15]

c.

Unless not practicable, the amount of interest income recognized using a cash-basis method of accounting during the
time within the period that the loans were impaired?
[FASB ASC 310-10-50-15]
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Yes
d.

No

N/A

Activity in the total allowance for credit losses related to
loans, including the balance in the allowance for credit
losses account at the beginning and end of each period, additions charged to operations, direct write-downs charged
against the allowance, and recoveries of amounts previously charged off?
[FASB ASC 310-10-50-12]
Practice Tip

Information about impaired loans that have been restructured in a troubled debt restructuring involving a
modification of terms need not be included in the disclosures required by questions 1 and 3(a)–(c) in years
after the restructuring if (a) the restructuring agreement specifies an interest rate equal to or greater than the
rate that the creditor was willing to accept at the time of the restructuring for a new loan with comparable
risk and (b) the loan is not impaired based on the terms specified in the restructuring agreement. That
exception must be applied consistently for questions 1 and 3(a)–(c) to all loans restructured in a troubled
debt restructuring that meet the specified criteria.
.l 4. Has the amount of write-down and recorded investment of a loan
modified in a troubled debt restructuring been disclosed in the
year of writedown?
[FASB ASC 310-40-50-4]
.l 5. In years after a restructuring, are loans that are restructured in a
troubled debt restructuring into 2 (or more) loan agreements considered separately when assessing the applicability of the disclosures in FASB ASC 310-10-50-15(a) and FASB ASC 310-10-5015(c) (questions 1 and 3(a)–(c))?
[FASB ASC 310-40-50-5]
M.

Impairment of Long-Lived Assets to Be Held and Used

.l 1. Is an impairment loss recognized for a long-lived asset (asset
group) to be held and used included in income from continuing
operations before income taxes in the income statement? If a subtotal such as income from operations is presented, does it include
the amount of the loss?
[FASB ASC 360-10-45-4]
.l 2. Is the following information disclosed in the notes to the financial
statements that include the period in which an impairment loss
is recognized:
a.

A description of the impaired long-lived asset (asset group)
and the facts and circumstances leading to the impairment?

b.

If not separately presented on the face of the statement, the
amount of the impairment loss and the caption in the income statement that includes the loss?

c.

The method or methods for determining fair value (whether
based on a quoted market price, prices for similar assets, or
another valuation technique)?

d.

If applicable, the segment in which the impaired long-lived
asset (asset group) is reported under FASB ASC 280?
[FASB ASC 360-10-50-2]
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Yes
.l 3. If the occurrence of a significant event or circumstance at any
time during the assessment period results in an expectation that
the criteria for reporting discontinued operations in FASB ASC
205-20-45-1 will be met by the end of the assessment period, is
the component’s operations presented as discontinued operations?
[FASB ASC 205-20-55-22]
.l 4. Is the following information disclosed in the notes to the financial
statements for each discontinued operation that generates continuing cash flows:

N.

a.

The nature of the activities that give rise to continuing cash
flows?

b.

The period of time continuing cash flows are expected to be
generated?

c.

The principal factors used to conclude that the expected
continuing cash flows are not direct cash flows of the disposed component?

d.

Additionally, for each discontinued operation in which the
ongoing entity will engage in a “continuation of activities”
with the disposed component after its disposal and for
which the amounts presented in continuing operations after
the disposal transaction include a continuation of revenues
and expenses that were intra-entity transactions before the
disposal transaction, are those intra-entity amounts before
the disposal transaction disclosed for all periods for comparability purposes?

e.

Are the types of continuing involvement, if any, that the entity will have after the disposal transaction disclosed in the
period in which the operations are initially classified as discontinued?
[FASB ASC 205-20-55 par. 9–12]

Leases—Lessors

.l 1. For leasing transactions with related parties, are the nature and
extent of the transaction disclosed?
[FASB ASC 840-10-50-1]
.l 2. If leasing, exclusive of leveraged leasing, is a significant part of
the lessor’s business activities in terms of revenue, net income, or
assets, is a general description of the lessor’s leasing arrangements disclosed?
[FASB ASC 840-10-50-4]
.l 3. For sales-type and direct financing leases, do disclosures include
a.
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Yes
i.

Future minimum lease payments to be received, with
separate deductions for (a) amounts representing executory costs, including any profit thereon, included
in minimum lease payments and (b) the accumulated
allowances for uncollectible minimum lease payments
receivable?

ii.

The unguaranteed residual values accruing to the
benefit of the lessor?

iii.

For direct financing leases only, initial direct costs?

iv.

Unearned income?

b.

future minimum lease payments to be received for each of
the five succeeding fiscal years as of the latest balance sheet
presented?

c.

total contingent rentals included in income for each period
for which an income statement is presented?
[FASB ASC 840-30-50-4]

No

N/A

.l 4. For operating leases, do disclosures include
a.

the cost and carrying amount (if different) of property on
lease or held for leasing by major classes of property according to nature and function, and the amount of accumulated
depreciation in total as of the latest balance-sheet date?

b.

minimum future rentals on noncancelable leases as of the
latest balance-sheet date presented, in the aggregate and for
each of the five succeeding fiscal years?

c.

total contingent rentals included in income for each period
for which an income statement is presented?
[FASB ASC 840-20-50-4]

.l 5. For investments in leveraged leases, do disclosures include
a.

in the balance sheet, the amount of deferred taxes presented
separately from the remainder of the net investment?
[FASB ASC 840-30-45-5]

b.

in the income statement or the notes thereto, separate presentation (from each other) of pretax income from the leveraged lease, the tax effect of pretax income, and the
amount of investment tax credit recognized as income during the period?
[FASB ASC 840-30-45-5]

c.

when leveraged leasing is a significant part of the lessor’s
business activities in terms of revenue, net income, or assets,
the components of the net investment balance in leveraged
leases in the notes to the financial statements?
[FASB ASC 840-30-45-5]
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Yes
.l 6. If accounting for the effect on leveraged leases of the change in
tax rates results in a significant variation from the customary relationship between income tax expense and pretax accounting income and the reason for that variation is not otherwise apparent,
has the entity disclosed the reason for that variation?
[FASB ASC 840-30-50-6]
.l 7. For contingent rental income

O.

a.

has disclosure been made of the lessor’s accounting policy
for contingent rental income?

b.

if the lessor accrues contingent rental income prior to the
lessee’s achievement of the specified target (provided
achievement of that target is considered probable), has disclosure been made of the impact on rental income as if the
lessor’s accounting policy was to defer contingent rental income until the specified target is met?
[FASB ASC 840-10-50-5]

Leases—Lessees

.l 1. For leasing transactions with related parties, are the nature and
extent of transactions disclosed?
[FASB ASC 840-10-50-1]
.l 2. For capital leases, do disclosures include
a.

the gross amounts of assets recorded as of each balancesheet date presented by major classes according to nature or
function? (Note: This information may be combined with
comparable information for owned assets.)
[FASB ASC 840-30-50-1]

b.

future minimum lease payments as of the latest balance
sheet presented in the aggregate and for each of the five
succeeding fiscal years with separate deductions from the
total for the amount representing executory costs, including
any profit thereon, included in the minimum lease payments and for the amount of imputed interest necessary to
reduce net minimum lease payments to present value?
[FASB ASC 840-30-50-1]

c.

total of future minimum sublease rentals to be received in
the future under noncancelable subleases as of the latest balance-sheet date?
[FASB ASC 840-30-50-1]

d.

total contingent rentals actually incurred for each period for
which an income statement is presented?
[FASB ASC 840-30-50-1]

e.

are the following separately identified in the balance sheet
or in the notes to the financial statements:
i.
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No

N/A
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Yes
ii.
f.

No

N/A

The related obligations under the lease?
[FASB ASC 840-30-45-2]

amortization expense, unless it is included in depreciation
expense and that fact is disclosed?
[FASB ASC 840-30-45-3]

.l 3. For operating leases that have initial or remaining noncancelable
lease terms in excess of one year, do disclosures include
a.

future minimum rental payments required as of the latest
balance sheet presented, in the aggregate, and for each of
the five succeeding fiscal years?

b.

total of future minimum rentals under noncancelable subleases as of the date of the latest balance sheet presented?
[FASB ASC 840-20-50-2]

.l 4. For all operating leases
a.

do disclosures include rental expense for each period for
which an income statement is presented?

b.

are separate amounts presented for
i.

minimum rentals?

ii.

contingent rentals?

iii.

sublease rentals?
[FASB ASC 840-20-50-1]

.l 5. Do disclosures include a general description of the lessee’s leasing arrangements including but not limited to
a.

the basis on which contingent rental payments are determined?

b.

the existence and terms of renewal or purchase options or
escalation clauses?

c.

restrictions imposed by lease agreements, such as those concerning dividends, additional debt, or further leasing?
[FASB ASC 840-10-50-2]

.l 6. If there is a modification of lease terms and the increase in lease
payments is a termination penalty, is the accounting policy disclosed in accordance with FASB ASC 235?
[FASB ASC 840-20-55-6]
.l 7. Do the financial statements of a seller-lessee include a description
of the terms of the sale-leaseback transaction including future
commitments, obligations, provisions, or circumstances that require or result in the seller-lessee’s continuing involvement?
[FASB ASC 840-40-50-1]
.l 8. If a sale-leaseback transaction is accounted for using the deposit
method or as a financing arrangement, are the following disclosures made:
a.

The obligation for future minimum lease payments as of the
date of the latest balance sheet presented in the aggregate
and for each of the five succeeding fiscal years?

FSP §11,100.01

194

Health Care Entities

Yes
b.

P.

No

N/A

The total of minimum sublease rentals, if any, to be received
in the future under noncancelable subleases in the aggregate and for each of the five succeeding fiscal years?
[FASB ASC 840-40-50-2]

Nonmonetary Transactions

.l 1. Do disclosures for nonmonetary transactions during the period
include
a.

nature of the transactions?

b.

basis of accounting for the assets transferred?

c.

gains or losses recognized on the transfers?
[FASB ASC 845-10-50-1]

.l 2. Has disclosure been made, in each period’s financial statements,
of the amount of gross operating revenue recognized as a result
of nonmonetary transactions (see FASB ASC 505-50)?
[FASB ASC 845-10-50-2]
Practice Tip
Examples 1–3 in paragraphs 11–26 of FASB ASC 845-10-55 discuss issues that develop when an entity sells
inventory to another entity from which it also purchases inventory to be sold in the same line of business.
The inventory purchase and sales transactions may be pursuant to a single arrangement or separate arrangements, and the inventory purchased or sold may be in the form of raw materials, work-in-process (WIP), or
finished goods.
.l 3. If nonmonetary exchanges of inventory within the same line of
business are recognized at fair value, is the classification of inventory as raw materials, WIP, and finished goods for purposes of
FASB ASC 845-10 the same classification that an entity uses for external financial reporting purposes?
[FASB ASC 845-10-45-1]
.l 4. If nonmonetary exchanges of inventory within the same line of
business are recognized at fair value, does an entity disclose the
amount of revenue and costs (or gains and losses) associated with
those inventory exchanges recognized at fair value?
[FASB ASC 845-10-50-3]
Q.

Postemployment Benefits

.l 1. If an obligation for postemployment benefits (for example, salary
continuation, supplemental unemployment benefits, severance benefits, disability related benefits, job training and counseling, and
continuation of health and insurance coverage [paragraphs 4–6 of
FASB ASC 712-10-05]) has not been accrued because the amount
cannot be reasonably estimated, is that fact disclosed in the financial
statements?
[FASB ASC 712-10-50-2]
R.

Related-Party Transactions and Economic Dependency

.l 1. For related-party transactions, do disclosures include
a.
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Yes
b.

No

N/A

for each period for which an income statement is presented
i.

a description of the transaction, including transactions to
which no amounts or nominal amounts were ascribed?

ii.

other information deemed necessary to an understanding
of the effects of the transaction on the financial statements?

iii.

the dollar amount of transactions?

iv.

the effect of any changes in the method of establishing
the terms from that used in the preceding period?

c.

amounts due from or to related parties as of the date of each
balance sheet presented and, if not otherwise apparent, the
terms and manner of settlement?

d.

if the entity is a member of a group that files a consolidated
tax return, have the following been disclosed in its separately
issued financial statements:
i.

The aggregate amount of current and deferred tax expense for each statement of earnings presented and the
amount of any tax-related balances due to or from affiliates as of the date of each statement of financial position
presented?

ii.

The principal provisions of the method by which the consolidated amount of current and deferred tax expense is
allocated to members of the group and the nature and
effect of any changes in that method (and in determining
related balances to or from affiliates) during the years for
which the preceding disclosures are presented?
[FASB ASC 850-10-50-1; FASB ASC 740-10-50-17]

.l 2. Have notes or accounts receivable from officers, employees, or affiliated entities been shown separately and have not been included
under a general heading (such as notes receivable or accounts receivable)?
[FASB ASC 850-10-50-2]
.l 3. If representations about transactions with related parties are made,
do they avoid the implication that the related party transactions
were consummated at arm’s length, or if such implications are
made, can they be substantiated?
[FASB ASC 850-10-50-5]
.l 4. If (a) the reporting entity and one or more other enterprises are under common ownership or management control and (b) the existence of the control could result in operating results or financial position of the reporting entity being significantly different from that
if the enterprise were autonomous, is the nature of the control relationships disclosed (even if there are no transactions between the
enterprises)?
[FASB ASC 850-10-50-6]
.l 5. Are the nature and extent of leasing transactions with related parties appropriately disclosed?
[FASB ASC 840-10-50-1]
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Yes
.l 6. Are combined financial statements considered for entities under
common control?
[FASB ASC 810-10-55-1B]
.l 7. If consolidated financial statements are presented and they include
a controlled not-for-profit organization, are the following disclosed:
a.

Restrictions made by entities outside of the reporting entity on
distributions from the controlled not-for-profit organization to
the reporting entity?

b.

Any resulting unavailability of the net assets of the controlled
not-for-profit organization for use by the reporting entity?
[FASB ASC 958-810-50-1]

Note: In May 2008, FASB issued FSP SOP 94-3-1 and AAG HCO-1, Omnibus Changes to Consolidation and Equity Method Guidance for Not-forProfit Organizations, which makes several changes to the guidance on
consolidation and the equity method of accounting in SOP 94-3, and
the AICPA Audit and Accounting Guide Health Care Entities. This FSP
●

eliminates the temporary control exception to consolidation
that currently exists for certain relationships between not-forprofit organizations and makes two related changes:
— Amends the definition of majority voting interest in the
board of another entity in SOP 94-3 and Audit and Accounting Guide Health Care Entities
— Conforms the categorization of sole corporate membership
in SOP 94-3 to that in Audit and Accounting Guide Health
Care Entities

●

confirms the continued applicability to not-for-profit organizations of the consensus guidance on consolidation of specialpurpose entity (SPE) lessors in the following EITF issues:
— No. 90-15, “Impact of Nonsubstantive Lessors, Residual
Value Guarantees, and Other Provisions in Leasing Transactions”
— No. 96-21, “Implementation Issues in Accounting for Leasing Transactions involving Special-Purpose Entities”
— No. 97-1, “Implementation Issues in Accounting for Lease
Transactions, including Those involving Special-Purpose
Entities”

●

requires that not-for-profit organizations apply the guidance in
— AICPA Statement of Position 78-9, Accounting for Investments in Real Estate Ventures (AICPA, Technical Practice
Aids, ACC sec. 10,240), on the equity method of accounting
to their non controlling interests in for-profit real estate
partnerships, limited liability companies (LLCs), and similar entities unless those investments are reported at fair
value, where permitted
(continued)
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— FSP SOP 78-9-1, Interaction of AICPA Statement of Position
78-9 and EITF Issue No. 04-5, to help determine whether
their
inter
ests in for-profit partnerships, LLCs, and similar entities
are controlling interests or noncontrolling interests
— EITF Issue No. 03-16, “Accounting for Investments in Limited Liability Companies,” to determine whether an LLC
should be viewed as similar to a partnership, as opposed
to a corporation, for purposes of determining whether noncontrolling interests in an LLC or a similar entity should be
accounted for in accordance with SOP 78-9 and related
guidance.
The provisions of this FSP are effective for fiscal years ending after June
15, 2008 (that is, December 31, 2008, for entities with calendar yearends).
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS SOP 94-3-1 and AAG HCO-1.
Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and
open effective date information discussed in FASB ASC 958-810-65-1.
.l 8. If, as described in FASB ASC 958-810-25-4, the not-for-profit entity
(the reporting entity) controls a related but separate not-for-profit
through a form other than majority ownership interest, sole corporate membership, or majority voting interest in the board of the
other entity and has an economic interest in that other not-forprofit, has the reporting entity disclosed all of the following information if it does not present consolidated financial statements:
a.

Identification of the other not-for-profit and the nature of its
relationship with the reporting entity that results in control?

b.

Summarized financial data of the other not-for-profit, which
shall include the following information:

c.

i.

Total assets, liabilities, net assets, revenue, and expenses?

ii.

Total assets, liabilities, net assets, revenue, and expenses?
Resources that are held for the benefit of the reporting
entity or that are under its control?
[FASB ASC 850-10-50-1; FASB ASC 740-10-50-17]

The disclosures required by paragraphs 1–6 of FASB ASC 85010-50-?
[“Pending Content” in FASB ASC 958-810-50-2]
Practice Tip

In some cases, aggregation of similar transactions by type of related party may be appropriate. Sometimes,
the effect of the relationship between the parties may be so pervasive that disclosure of the relationship
alone will be sufficient. If necessary to the understanding of the relationship, the name of the related party
should be disclosed.
(continued)
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Yes

No

N/A

Further, it is not necessary to duplicate disclosures in a set of separate financial statements that is presented
in the financial report of another entity (the primary reporting entity) if those separate financial statements
also are consolidated or combined in a complete set of financial statements and both sets of financial statements are presented in the same financial report.
[FASB ASC 810-10-50 par. 3–4]
S.

Research and Development Arrangements
1.

2.

T.

If the reporting entity accounts for its obligations under research
and development arrangements as contracts to perform research
and development for others in accordance with FASB ASC 730-20,
are the following disclosed:
a.

The terms of significant agreements under the research and
development arrangements (including royalty arrangements,
purchase provisions, license agreements, and commitments to
provide additional funding) as of the date of each balance
sheet presented?

b.

The amount of compensation earned and costs incurred under
such contracts for each period for which an income statement
is presented?
[FASB ASC 730-20-50-1]

If the reporting entity is a party to more than one research and
development arrangement, has separate disclosure of each arrangement been made if such separate disclosure is necessary to
understand the effects on the financial statements? (Aggregation of
similar arrangements by type may be appropriate.)
[FASB ASC 730-20-50-3]

Exit or Disposal Activities

.l 1.

Is the following information disclosed in notes to the financial
statements that include the period in which an exit or disposal activity is initiated and any subsequent period until the activity is
completed:
a.

A description of the exit or disposal activity, including the
facts and circumstances leading to the expected activity and
the expected completion date?

b.

For each major type of cost associated with the activity (for
example, one-time termination benefits, contract termination
costs, and other associated costs)
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i.

the total amount expected to be incurred in connection
with the activity, the amount incurred in the period, and
the cumulative amount incurred to date?

ii.

a reconciliation of the beginning and ending liability balances showing separately the changes during the period
attributable to costs incurred and charged to expense,
costs paid or otherwise settled, and any adjustments to
the liability with an explanation of the reason(s) therefore?
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Yes
c.

The line item(s) in the income statement in which the costs in
item (b) are aggregated?

d.

For each reportable segment, as defined in FASB ASC 280-1050-10

e.

i.

the total amount of costs expected to be incurred in connection with the activity?

ii.

the amount incurred in the period?

iii.

the cumulative amount incurred to date, net of any adjustments to the liability with an explanation of the reason(s) why?

N/A

If a liability for a cost associated with the activity is not recognized because fair value cannot be reasonably estimated,
that fact and the reasons why?
[FASB ASC 420-10-50-1]

.l 2.

Are costs associated with an exit or disposal activity that involves
a discontinued operation included in the results of discontinued
operations in accordance with FASB ASC 205-20-45?
[FASB ASC 420-10-45-2]

.l 3.

Are costs associated with an exit or disposal activity that does not
involve a discontinued operation included in income from continuing operations before income taxes, for example, in a subtotal
such as “income from operations”?
[FASB ASC 420-10-45-3]

.l 4.

Are costs associated with an exit or disposal activity that does not
involve a discontinued operation included in income from continuing operations in the statement of activities?
[FASB ASC 420-10-45-3]

.l 5.

If an event or circumstance occurs that discharges or removes an
entity’s responsibility to settle a liability for a cost associated with
an exit or disposal activity recognized in a prior period, is the liability reversed?
[FASB ASC 420-10-40-1]

.l 6.

Are the related costs reversed through the same line item(s) in the
income statement used when those costs were recognized initially?
[FASB ASC 420-10-40-1]

U.

No

Segment Reporting
Note: The guidance in the FASB ASC 280 applies to all public entities,
with certain exceptions as follows. Entities other than public entities are
also encouraged to provide the disclosures described in FASB ASC 28010.
(continued)
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Yes

No

N/A

The guidance in FASB ASC 280-10 does not apply to the following entities:
●

Parent entities, subsidiaries, joint ventures, or investees accounted for by the equity method if those entities’ separate
company statements also are consolidated or combined in a
complete set of financial statements and both the separate company statements and the consolidated or combined statements
are included in the same financial report. However, FASB ASC
280-10 does apply to those entities if they are public entities and
their financial statements are issued separately.

●

Not-for-profit entities (regardless of whether the entity meets
the definition of a public entity as defined in the preceding list
item).

●

Nonpublic entities.
[FASB ASC 280-10-15 par. 2–3]

Practice Tips
A public entity should report separately information about each operating segment that meets both of the
following criteria:
●

Has been identified in accordance with FASB ASC 280-10-50-1 and paragraphs 3–9 of FASB ASC
280-10-50 or results from aggregating 2 or more of those segments in accordance with the following
paragraph

●

Exceeds the quantitative thresholds in FASB ASC 280-10-50-12

Public entities are encouraged to report information about segments that do not meet the quantitative
thresholds if management believes that it is material.
Paragraphs 13–18 of FASB ASC 280-10-50 specify other situations in which separate information about an
operating segment should be reported. FASB ASC 280-10-55-26 and examples 1–2 (see paragraphs 27–45 of
FASB ASC 280-10-55) illustrate how to apply the main provisions in this section for identifying reportable
operating segments.
A public entity should report separately information about an operating segment that meets any of the
following quantitative thresholds:
●

Its reported revenue, including both sales to external customers and intersegment sales or transfers,
is 10 percent or more of the combined revenue, internal and external, of all operating segments.

●

The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute
amount, of either
— the combined reported profit of all operating segments that did not report a loss or
— the combined reported loss of all operating segments that did report a loss.

●

Its assets are 10 percent or more of the combined assets of all operating segments.

Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and
separately disclosed, if management believes that information about the segment would be useful to readers
of the financial statements.
[FASB ASC 280-10-50 par. 10 and 12–19]
(continued)
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Yes

No

N/A

If total of external revenue reported by operating segments constitutes less than 75 percent of total consolidated revenue, additional operating segments should be identified as reportable segments (even if they do
not meet the criteria in FASB ASC 280-10-50-12) until at least 75 percent of total consolidated revenue is
included in reportable segments.
[FASB ASC 280-10-50-14]
If management judges an operating segment identified as a reportable segment in the immediately preceding period to be of continuing significance, information about that segment should continue to be reported
separately in the current period even if it no longer meets the criteria for reportability in FASB ASC 280-1050-12.
[FASB ASC 280-10-50-16]
l 1. (Issuers Only) Have the following disclosures been made for each
period for which an income statement is presented:
a.

Factors used to identify the public entity’s reportable segments,
including the basis of organization (for example, whether management has chosen to organize the reporting entity around
differences in products and services, geographic areas, regulatory environments, or a combination of factors and whether
operating segments have been aggregated)?

b.

Types of products and services from which each reportable
segment derives its revenues?
[FASB ASC 280-10-50-21]

l 2. (Issuers Only) Are the factors used to identify the reporting entity’s
reportable segments, including the basis of organization (for example, whether management has chosen to organize the reporting entity around differences in products and services, geographic areas,
regulatory environments, or a combination of factors and whether
operating segments have been aggregated) disclosed?
[FASB ASC 280-10-50-21]
3. (Issuers Only) Has a measure of profit or loss and total assets been
reported for each reportable segment?
[FASB ASC 280-10-50-22]
l 4. (Issuers Only) If the following specified amounts (a) are included in
the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the
chief operating decision maker, even if not included in that measure
of segment profit or loss, are they disclosed for each reportable segment:
a.

Revenues from external customers?

b.

Revenues from transactions with other operating segments of
the reporting entity?

c.

Interest revenue?

d.

Interest expense?

e.

Depreciation, depletion, and amortization expense?

f.

Unusual items as described in FASB ASC 225-20-45-16?
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Yes
g.

Equity in the net income of investees accounted for by the equity method?

h.

Income tax expense or benefit?

i.

Extraordinary items?

j.

Significant noncash items other than depreciation, depletion,
and amortization expense?
[FASB ASC 280-10-50-22]

No

N/A

l 5. (Issuers Only) Unless a segment has no or immaterial financial operations, has the entity reported interest revenue separately from interest expense for each reportable segment (unless a majority of the
segment’s revenues are from interest and the chief operating decision maker relies primarily on net interest revenue to assess the performance of the segment and make decisions about resources to be
allocated to the segment)? (In that situation, a public entity may report that segment’s interest revenue net of its interest expense and
disclose that it has done so.)
[FASB ASC 280-10-50 par. 22–24]
l 6. (Issuers Only) If the following specified amounts are (a) included in
the determination of segment assets reviewed by the chief operating
decision maker or (b) are otherwise regularly provided to the chief
operating decision maker, even if not included in that measure of
segment assets, are they disclosed for each reportable segment:
a.

The amount of investment in equity method investees?

b.

Total expenditures for additions to long-lived assets other than
any of the following: financial instruments, long term customer
relationships of a financial institution, mortgage and other
servicing rights, deferred policy acquisition costs, or deferred
tax assets?
[FASB ASC 280-10-50-25]
Practice Tips

If no asset information is provided for a reportable segment, that fact and the reason therefore should be
disclosed.
[FASB ASC 280-10-50-26]
Reconciliations of balance sheet amounts for reportable segments to consolidated balance sheet amounts are
required only for each year for which a balance sheet is presented. Previously reported information for prior
periods should be restated as described in paragraphs 34–35 of FASB ASC 380-10-50.
[FASB ASC 280-10-50-20]
l 7. (Issuers Only) Is an explanation of the measurements of segment
profit or loss and segment assets that discloses the following for
each reportable segment provided:
a.
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Yes
b.

The nature of any differences between the reporting entity’s
consolidated income before taxes, extraordinary items, discontinued operations, and the cumulative effect of changes in accounting principle?

c.

The nature of any differences between the measurements of the
reportable segments’ assets and the reporting entity’s consolidated assets?

d.

The nature of any changes from prior periods in the measurement methods used to determine reported segment profit or
loss and the effect, if any, of those changes on the measure of
segment profit or loss?

e.

The nature and effect of any asymmetrical allocations to segments?
[FASB ASC 280-10-50-29]

No

N/A

l 8. (Issuers Only) Are reconciliations of the totals of the reportable segments’ revenues, measures of profit or loss, assets, and every other
significant item of information disclosed to corresponding consolidated amounts presented with all significant reconciling items separately identified and described?
[FASB ASC 280-10-50 par. 30–31]
l 9. (Issuers Only) Has the following information about each reportable
segment in condensed financial statements of interim periods been
disclosed for current quarter and year-to-date amounts:
a.

Revenues from external customers?

b.

Intersegment revenues?

c.

A measure of segment profit or loss?

d.

Total assets for which there has been a material change from
the amount disclosed in the last annual report?

e.

A description of differences from the last annual report in the
basis of segmentation or in the basis of measurement of segment profit or loss?

f.

A reconciliation of the total of the reportable segments’ measures of profit or loss to the public entity’s consolidated income
before income taxes, extraordinary items, and discontinued operations? If a public entity allocates items such as income taxes
and extraordinary items to segments, the public entity may
choose to reconcile the total of the segments’ measures of profit
or loss to consolidated income after those items. Significant reconciling items should be separately identified and described in
that reconciliation.
[FASB ASC 280-10-50 par. 32–33]

l 10. (Issuers Only) If the reporting entity changes the structure of its internal organization in a manner that changes the composition of its
reportable segments, is the corresponding information for prior periods restated and is the fact that the corresponding items of segment
information for earlier periods have been restated disclosed?
[FASB ASC 280-10-50-34]
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Yes
l 11. (Issuers Only) If the reporting entity changes the structure of its internal organization in a manner that changes the composition of its
reportable segments and the corresponding information for prior
periods is not restated, does disclosure in the year in which the
change occurs include segment information for the current period
under both the old basis and the new basis?
[FASB ASC 280-10-50-35]
l 12. (Issuers Only) For all reporting entities subject to FASB ASC 280-10,
including those that have a single reportable segment, are the following enterprise-wide items disclosed:
a.

Revenues from external customers for each product and service
or each group of similar products and services unless it is impracticable to do so?
[FASB ASC 280-10-50-40]

b.

The following geographic information unless it is impracticable
to do so:

c.

i.

Revenues from external customers (a) attributed to the
reporting entity’s country of domicile and (b) attributed
to all foreign countries in total from which the reporting
entity derives revenue?

ii.

Revenues from external customers attributed to an individual foreign country, if material?

iii.

The basis for attributing revenues from external customers to individual countries?

iv.

Long-lived assets other than financial instruments, long
term customer relationships of a financial institution,
mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets (a) located in the
reporting entity’s country of domicile and (b) located in
all foreign countries in total in which the reporting entity
holds assets?

v.

Long-lived assets as described above in an individual
foreign country, if material?
[FASB ASC 280-10-50-41]

Information about the extent of the reporting entity’s reliance
on its major customers, including the following:
i.
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If revenues from transactions with any single customer
amount to 10 percent or more of the reporting entity’s
revenues, that fact, the total amount of revenues from
each such customer, and the identity of the segment or
segments reporting the revenue?
[FASB ASC 280-10-50-42]

No

N/A
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Yes
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N/A

Practice Tip
When providing information about major customers pursuant to FASB ASC 280-10-50-42, an insuring entity
should not be considered the customer of a health care facility. The fact that an insuring entity is a paying
agent for the patient does not make the insuring entity the customer of the health care facility because the
insuring entity does not decide which services to purchase and from which health care facility to purchase
the services. The latter two factors are important in determining the customer.
[FASB ASC 280-10-50-20]
l 13. (Issuers Only) If the information described in questions 12(a)–(b)
has not been disclosed because it is impracticable, is that fact disclosed?
[FASB ASC 280-10-50 par. 40–41]
V.

Stock Compensation Plans

l 1. If the entity has one or more share-based payment arrangements,
does it disclose information that enables users of the financial statements to understand
a.

the nature and terms of such arrangements that existed during
the period and the potential effects of those arrangements on
shareholders?

b.

the effect of compensation cost arising from share-based payment arrangements on the income statement?

c.

the method of estimating the fair value of the goods or services
received, or the fair value of the equity instruments granted (or
offered to grant), during the period?

d.

the cash flow effects resulting from share-based payment arrangements?
[FASB ASC 718-10-50-1]

l 2. If the entity acquires goods or services other than employee services
in share-based payment transactions, does it provide disclosures
similar to those in question 1 required by FASB ASC 718-10-50-1
and FASB ASC 718-10-50-2 to the extent that those disclosures are
important to an understanding of the effects of those transactions
on the financial statements?
[FASB ASC 505-50-50-1]
l 3. Has the following, at a minimum, been disclosed with regards to
stock-based compensation:
a.

A description of the share-based payment arrangement(s), including the general terms of awards under the arrangement(s),
such as
i.

the requisite service period(s) and any other substantive
conditions (including those related to vesting)?

ii.

the maximum contractual term of equity (or liability)
share options or similar instruments?

iii.

the number of shares authorized for awards of equity
share options or other equity instruments?

FSP §11,100.01

206

Health Care Entities

Yes
b.

The method it uses for measuring compensation cost from
share-based payment arrangements with employees?

c.

For the most recent year for which an income statement is provided, both of the following:

d.

e.

f.

i.

The number and weighted-average exercise prices (or
conversion ratios) (1) shares outstanding at the beginning
of the year, (2) shares outstanding at the end of the year,
(3) shares exercisable or convertible at the end of the
year, and (4) those during the year that were granted, exercised or converted, forfeited and expired?

ii.

The number and weighted-average grant-date fair value
(or calculated value for a nonpublic entity that uses that
method or intrinsic value for awards measured pursuant
to FASB ASC 718-10-30-21) of equity instruments not
specified in (c)(i), for (1) equity instruments nonvested at
the beginning of the year, (2) nonvested at the end of the
year, and (3) those during the year that were granted,
vested and forfeited?

For each year for which an income statement is provided
i.

the weighted average grant-date fair values (or calculated value for a nonpublic entity that uses that method
or intrinsic value for awards measured at that value pursuant to FASB ASC 718-10-30-21 and FASB ASC 718-1030-22) of equity options or other equity instruments
granted during the year?

ii.

the total intrinsic value of options exercised (or share
units converted), share-based liabilities paid, and the total fair value of shares vested during the year?

For fully vested share options (or share units) and share options expected to vest at the dated of the latest statement of
financial position
i.

the number, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term of options (or share units) outstanding?

ii.

the number, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term of options (or share units) currently
exercisable (or convertible)?

For each year for which an income statement is presented, both
of the following (an entity that uses the intrinsic value method
pursuant to FASB ASC 718-10-30-21 and FASB ASC 718-10-3022 is not required to disclose the following information for
awards accounted for under that method):
i.
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N/A
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Yes
ii.

N/A

A description of the significant assumptions used during
the year to estimate the fair value (or calculated value) of
share-based compensation awards, including (if applicable)
(1)

expected term of share options and similar instruments, including a discussion of the method used
to incorporate the contractual term of the instruments and employees’ expected exercise and postvesting employment termination behavior into the
fair value (or calculated value) of the instrument?

(2)

expected volatility of the entity’s shares and the
method used to estimate it? An entity that uses a
method that employs different volatilities during
the contractual term should disclose the range of
expected volatilities used and the weighted-average expected volatility. A nonpublic entity that
uses the calculated value method should disclose
the reasons why it is not practicable for it to estimate the expected volatility of its share price, the
appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility
using that index.

(3)

expected dividends? An entity that uses a method
that employs different dividend rates during the
contractual term should disclose the range of expected dividends used and the weighted-average
expected dividends.

(4)

risk-free rate(s)? An entity that uses a method that
employs different risk-free rates should disclose the
range of risk-free rates used.

(5)

discount for post-vesting restrictions and the
method for estimating it?

g.

An entity that grants equity or liability instruments under multiple share-based payment arrangements with employees
should provide the information specified in questions 3(a)–(f)
separately for different types of awards to the extent that the
differences in the characteristics of the awards make separate
disclosure important to an understanding of the entity’s use of
share-based compensation.

h.

For each year for which an income statement is presented, both
of the following:
i.

No

Total compensation cost for share-based payment arrangements (including recognized in income as well as
the total recognized tax benefit related thereto and capitalized as part of the cost of an asset)?

FSP §11,100.01

208

Health Care Entities

Yes
ii.

No

N/A

A description of the significant modifications, including
the terms of the modifications, the number of employees
affected, and the total incremental compensation cost resulting from the modifications?

i.

As of the latest balance sheet date presented, the total compensation cost related to nonvested awards not yet recognized and
the weighted-average period over which it is expected to be
recognized?

j.

If not separately disclosed elsewhere, the amount of cash received from exercise of share options and similar instruments
granted under share-based payment arrangements and the tax
benefit realized from stock options exercised during the annual
period?

k.

If not separately disclosed elsewhere, the amount of cash used
to settle equity instruments granted under share-based payment arrangements?

l.

Description of the entity’s policy, if any, for issuing shares
upon share option exercise (or share unit conversion), including the source of those shares (that is, new shares or treasury
shares). If as a result of its policy, an entity expects to repurchase shares in the following annual period, the entity should
disclose an estimate of the amount (or a range, if more appropriate) of shares to be repurchased during that period?
[FASB ASC 718-10-50-2]
Practice Tip

Question 3 indicates the minimum information needed to achieve those objectives and illustrate how the
disclosure requirements might be satisfied. In some circumstances, an entity may need to disclose information beyond that listed to achieve the disclosure objectives.
[FASB ASC 718-10-50-2]
l 4. Has the entity disclosed the nature of any changes in their accounting policy for income tax benefits of dividends on share-based-payment awards resulting in the adoption of the requirements in FASB
ASC 718-740-45-8 through FASB ASC 718-740-45-12?
[FASB ASC 718-740-50-1]
l 5. Have additional disclosures been made, as necessary, that would be
useful to investors and creditors, such as a range of values calculated on the basis of different assumptions, provided that the supplemental information is reasonable and does not lessen the prominence and credibility of the information required by FASB ASC
718-10-50?
[FASB ASC 718-10-50-4]
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Yes
W.

No

N/A

Subsequent Events
Notes: In May 2009, FASB issued Statement No. 165, Subsequent Events,
to establish principles and requirements for subsequent events. In particular, this statement sets forth
a.

the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in
the financial statements.

b.

the circumstances under which an entity should recognize
events or transactions occurring after the balance sheet date in
its financial statements.

c.

the disclosures that an entity should make about events or
transactions that occurred after the balance sheet date.

This statement should be applied to the accounting for and disclosure
of subsequent events not addressed in other applicable U.S. GAAP.
This statement moved the type I and type II subsequent event guidance
from GAAS into U.S. GAAP and added disclosures that an entity
should make about events or transactions that occurred after the balance sheet date.
This statement is effective for interim or annual financial periods ending after June 15, 2009 (that is, December 31, 2009, for entities with calendar year-ends), and should be applied prospectively.
This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 165.
Readers can refer to the full text of the statement on the FASB Web site
at www.fasb.org.
.l 1. Has the entity disclosed (in both originally issued financial statements and any reissued financial statements) the date through
which subsequent events have been evaluated, as well as whether
that date is the date the financial statements were issued or the date
the financial statements were available to be issued?
[FASB ASC 855-10-50-1; FASB ASC 855-10-50-4]
.l 2. For nonrecognized subsequent events that are of such a nature that
they must be disclosed to keep the financial statements from being
misleading, has the entity disclosed
a.

the nature of the event?

b.

an estimate of its financial effect, or a statement that such an
estimate cannot be made?
[FASB ASC 855-10-50-2]

.l 3. For nonrecognized subsequent events, has the entity considered
supplementing the historical financial statements with pro forma financial data, including the presentation of pro forma statements
(usually a balance sheet only, in columnar form on the face of the
historical statements)?
[FASB ASC 855-10-50-3]
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Yes
X.

Accounting for Servicing of Financial Assets
Notes: In December 2008, FASB issued FSP FAS 140-4 and FIN 46(R)-8
to amend FASB Statement No. 140 and to require public entities to provide additional disclosures about transfers of financial assets. It also
amends FASB Interpretation No. 46 (revised December 2003) to require
public enterprises, including sponsors that have a variable interest in a
VIE, to provide additional disclosures about their involvement with
VIEs. Additionally, this FSP requires certain disclosures to be provided
by a public enterprise that is (a) a sponsor of a QSPE that holds a variable interest in the QSPE but was not the transferor (nontransferor) of
financial assets to the QSPE and (b) a servicer of a QSPE that holds a
significant variable interest in the QSPE but was not the transferor
(nontransferor) of financial assets to the QSPE. The disclosures required
by this FSP are intended to provide greater transparency to financial
statement users about a transferor’s continuing involvement with
transferred financial assets and an enterprise’s involvement with VIEs
and QSPEs.
This FSP applies to public entities that are subject to the disclosure requirements of FASB Statement No. 140 and public enterprises that are
subject to the disclosure requirements of FASB Interpretation No. 46(R)
as amended by this FSP.
This FSP is effective for the first reporting period (interim or annual)
ending after December 15, 2008 (that is, December 31, 2008, for entities
with calendar year-ends), with earlier application encouraged. This FSP
applies to each annual and interim reporting period thereafter. An entity (enterprise) is encouraged, but not required, to disclose comparative information in periods earlier than the effective date for disclosures
that were not previously required for public entities (enterprises) by
FASB Statement No. 140 and FASB Interpretation No. 46(R). In periods
after initial adoption, comparative disclosures for those disclosures that
were not previously required for public entities (enterprises) by FASB
Statement No. 140 and FASB Interpretation No. 46(R) are required only
for periods subsequent to the effective date.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 140-4 and FIN 46(R)-8.
Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and
open effective date information discussed in FASB ASC 860-10-65-2.
Readers should be aware that this FSP was superseded by FASB Statement No. 166 and FASB Statement No. 167. Both FASB Statement No.
167 and FASB Statement No. 166 are effective as of the beginning of
each reporting entity’s first annual reporting period that begins after
November 15, 2009 (that is, January 1, 2010, for entities with calendar
year-ends), for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter. Earlier
application is prohibited.
(continued)

FSP §11,100.01

No

N/A

211

Financial Statements and Notes Checklist

No

Yes

N/A

This checklist has not been updated to include the presentation and
disclosure requirements of FASB Statement No. 166 nor FASB Statement No. 167.
Readers can refer to the full texts of these statements on the FASB Web
site at www.fasb.org.

Practice Tip
(Issuers Only) The principal objectives of the public-entity disclosure requirements of FASB ASC 860-10-50
are to provide financial statement users with an understanding of all of the following:
●

A transferor’s continuing involvement with financial assets that it has transferred in a securitization
or asset-backed financing arrangement

●

The nature of any restrictions on assets reported by an entity in its statement of financial position
that relate to a transferred financial asset, including the carrying amounts of such assets

●

How servicing assets and servicing liabilities are reported under FASB ASC 860-50

●

For securitization or asset-backed financing arrangements accounted for as sales if a transferor has
continuing involvement with the transferred financial assets and transfers of financial assets accounted for as secured borrowings, how the transfer of financial assets affects an entity’s financial
position, financial performance, and cash flows

The entity should consider these objectives in providing the required public-entity disclosures required by
FASB ASC 860. The disclosures should be presented in a manner that clearly and fully explains to financial
statements users the risks related to the transferred financial assets and any restrictions on the assets of the
entity.
Public-entity disclosures required by FASB ASC 860 may be reported in the aggregate for similar transfers
if separate reporting of each transfer would not provide more useful information to financial statement
users. A transferor should distinguish between transfers that are accounted for as secured borrowings and
transfers that are accounted for as sales. A transferor should further distinguish between transfers to QSPE
accounted for as sales and all other transfers accounted for as sales. In determining whether to aggregate
the disclosures for multiple transfers, the reporting entity should consider quantitative and qualitative information about the characteristics of the transferred financial assets.
The entity should determine, in light of the facts and circumstances, how much detail it must provide to
satisfy the public-entity disclosure requirements of FASB ASC 860, how much emphasis it places on different
aspects of the requirements, and how it aggregates information for assets with different risk characteristics.
[“Pending Content” in FASB ASC 860-10-50 par. 2–6]
Collateral
.l 1.

(Nonissuers Only) Is the policy for requiring collateral or other security disclosed if the reporting entity has entered into repurchase
agreements or securities lending transactions?
[FASB ASC 860-30-50-1]

.l 2.

(Nonissuers Only) If the entity has pledged any of its assets as collateral that are not reclassified and separately reported in the statement of financial position pursuant to FASB ASC 860-30-25-5(a), is
the carrying amount and classification of those assets as of the date
of the latest statement of financial position presented?
[FASB ASC 860-30-50-1]
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Yes
.l 3.

(Nonissuers Only) If the entity has accepted collateral that it is permitted by contract or custom to sell or repledge, is the fair value (as
of the date of each statement of financial position presented) of that
collateral and of the portion of that collateral that it has sold or repledged disclosed?
[FASB ASC 860-30-50-1]

.l 4.

If debt was considered to be extinguished by in-substance defeasance under the provisions of FASB Statement No. 76, Extinguishment of Debt, prior to the effective date of FASB Statement No. 125,
Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities, do the disclosures include a general description of the transaction and the amount of debt that is considered
extinguished at the end of the period so long as that debt remains
outstanding?
[FASB ASC 470-50-50-1]

.l 5.

(Nonissuers Only) If the entity sets aside assets solely for the purpose of satisfying scheduled payments of a specific obligation, is
disclosure made of the nature of restrictions placed on those assets?
[“Pending Content” in FASB ASC 860-30-50-2]

.l 6.

(Issuers Only) Has the following been disclosed regarding collateral:

.l 7.

a.

The policy for requiring collateral or other security disclosed
if the reporting entity has entered into repurchase agreements
or securities lending transactions?

b.

If the entity has pledged any assets as collateral, the carrying
amount, and classification of those assets and associated liabilities as of the date of the latest statement of financial position presented, including qualitative information about the relationship(s) between those assets and associated liabilities?

c.

If the entity has accepted collateral that is permitted by contract or custom to sell or repledge, the following:
i.

The fair value, as of the date of each statement of financial position presented of that collateral?

ii.

The fair value, as of the date of each statement of financial position presented of the portion of that collateral
that it has sold or repledged?

iii.

Information about the sources and uses of that collateral?
[“Pending Content” in FASB ASC 860-30-50-4]

If it is not practicable to estimate the fair value of certain assets obtained or liabilities incurred in transfers of financial assets during
the period, are those items and the reasons why it is not practicable
to estimate fair value described in the notes to the financial statements?
[FASB ASC 860-10-50-1]
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Yes

No

N/A

Servicing Assets and Servicing Liabilities
.l 8.

.l 9.

For all servicing assets and servicing liabilities, are the following
disclosures made:
a.

Management’s basis for determining its classes of servicing
assets and servicing liabilities?

b.

A description of the risks inherent in servicing assets and
servicing liabilities and, if applicable, the instruments used to
mitigate the income statement effect of changes in fair value
of the servicing assets and servicing liabilities? (Disclosure of
quantitative information about the instruments used to manage the risks inherent in servicing assets and servicing liabilities, including the fair value of those instruments at the beginning and end of the period, is encouraged but not required.)

c.

The amount of contractually specified servicing fees (as defined in the FASB ASC glossary), late fees, and ancillary fees
earned for each period for which results of operations are presented, including a description of where each amount is reported in the statement of income?
[FASB ASC 860-50-50-2]

For servicing assets and servicing liabilities subsequently measured
at fair value, are the following disclosures made:
a.

For each class of servicing assets and servicing liabilities, the
activity in the balance of servicing assets and the activity in
the balance of servicing liabilities (including a description of
where changes in fair value are reported in the statement of
income for each period for which results of operations are
presented), including, but not limited to, the following:
i.

The beginning and ending balances?

ii.

Additions (through purchases of servicing assets, assumptions of servicing obligations, and servicing obligations that result from transfers of financial assets)?

iii.

Disposals?

iv.

Changes in the fair value during the period resulting
from changes in valuation inputs or assumptions used
in the valuation model?

v.

Changes in the fair value during the period resulting
from other changes in fair value and a description of
those changes?

vi.

Other changes that affect the balance and a description
of those changes?
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Yes
b.

A description of the valuation techniques or other methods
used to estimate the fair value of servicing assets and servicing liabilities? If a valuation model is used, the description
should include the methodology and model validation procedures, as well as quantitative and qualitative information
about the assumptions used in the valuation model (for example, discount rates and prepayment speeds). (An entity
that provides quantitative information about the instruments
used to manage the risks inherent in the servicing assets and
servicing liabilities, the entity is also encouraged, but not required, to disclose a description of the valuation techniques,
as well as quantitative and qualitative information about the
assumptions used to estimate the fair value of those instruments.)
[FASB ASC 860-50-50-3]

.l 10. For servicing assets and servicing liabilities subsequently amortized
in proportion to and over the period of estimated net servicing income or loss and assessed for impairment or increased obligation:
a.

b.
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For each class of servicing assets and servicing liabilities, the
activity in the balance of servicing assets and the activity in
the balance of servicing liabilities (including a description of
where changes in the carrying amount are reported in the
statement of income for each period for which results of operations are presented), including, but not limited to, the following:
i.

The beginning and ending balances?

ii.

Additions (through purchases of servicing assets, assumption of servicing obligations, and servicing obligations that result from transfers of financial assets)?

iii.

Disposals?

iv.

Amortization?

v.

Application of valuation allowance to adjust carrying
value of servicing assets?

vi.

Other-than-temporary impairments?

vii.

Other changes that affect the balance and a description
of those changes?

For each class of servicing assets and servicing liabilities, the
fair value of recognized servicing assets and servicing liabilities at the beginning and end of the period if it is practicable
to estimate the value?

No

N/A
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Yes
c.

A description of the valuation techniques or other methods
used to estimate fair value of the servicing assets and servicing liabilities? If a valuation model is used, the description
should include the methodology and model validation procedures, as well as quantitative and qualitative information
about the assumptions used in the valuation model (for example, discount rates and prepayment speeds). (An entity
that provides quantitative information about the instrument
used to manage the risks inherent in the servicing assets and
servicing liabilities, the entity is also encouraged, but not required, to disclose a description of the valuation techniques as
well as quantitative and qualitative information about the assumptions used to estimate the fair value of those instruments.)

d.

The risk characteristics of the underlying financial assets used
to stratify recognized servicing assets for purposes of measuring impairment in accordance with FASB ASC 860-50-35-9?

e.

The activity by class in any valuation allowance for impairment of recognized servicing assets—including beginning and
ending balances, aggregate additions charged and recoveries
credited to operations, and aggregate write-downs charged
against the allowance—for each period for which results of
operations are presented?
[FASB ASC 860-50-50-4]

No

N/A

Practice Tip
The entity should report recognized servicing assets and servicing liabilities that are subsequently measured
using the fair value measurement method in a manner that separates those carrying amounts on the face of
the statement of financial position from the carrying amounts for separately recognized servicing assets and
servicing liabilities that are subsequently measured using the amortization method.
To accomplish that separate reporting, the entity may do either of the following:
●

Display separate line items for the amounts that are subsequently measured using the fair value
measurement method and amounts that are subsequently measured using the amortization method

●

Present the aggregate of those amounts that are subsequently measured at fair value and those
amounts that are subsequently measured using the amortization method and disclose parenthetically the amount that is subsequently measured at fair value that is included in the aggregate
amount
[FASB ASC 860-50-45 par. 1–2]
11. If the entity (public or nonpublic) has elected, under FASB ASC
860-50-35-3(d), to subsequently measure a class of servicing assets
and servicing liabilities at fair value at the beginning of the fiscal
year, has the amount of the cumulative-effect adjustment to retained earnings been separately disclosed?
[FASB ASC 860-50-50-5]
12. (Issuers Only) Have the following disclosures been made for all
servicing assets and servicing liabilities:
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Yes
a.

Management’s basis for determining its classes of servicing
assets and servicing liabilities?

b.

A description of the risks inherent in servicing assets and
servicing liabilities?

c.

If applicable, a description of the instruments used to mitigate the income statement effect of changes in fair value of
the servicing assets and servicing liabilities?

d.

The amount of contractually specified servicing fees, late fees,
and ancillary fees earned for each period for which results of
operations are presented, including a description of where
each amount is reported in the statement of income?

e.

Quantitative and qualitative information about the assumptions used to estimate the fair value?
[“Pending Content” in FASB ASC 860-50-50-7]

13. (Issuers Only) Have the following disclosures been made for all
servicing assets and servicing liabilities subsequently measured at
fair value:
a.

For each class of servicing assets and servicing liabilities, the
activity in the balance of servicing assets and the activity in
the balance of servicing liabilities (including a description of
where changes in fair value are reported in the statement of
income for each period for which results of operations are
presented), including, but not limited to, all of the following:
i.

The beginning and ending balances?

ii.

Additions (through purchases of servicing assets, assumption of servicing obligations, and servicing obligations that result from transfers of financial assets)?

iii.

Disposals?

iv.

Changes in fair value during the period resulting from

v.

(1)

changes in valuation inputs or assumptions used in
the valuation models?

(2)

other changes in fair value and a description of
those changes?

Other changes that affect the balance and a description
of those changes?
[“Pending Content” in FASB ASC 860-50-50-8]

14. (Issuers Only) Have the following disclosures been made for all
servicing assets and servicing liabilities subsequently amortized in
proportion to and over the period of estimated net servicing income or loss:
a.
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For each class of servicing assets and servicing liabilities, the
activity in the balance of servicing assets and the activity in
the balance of servicing liabilities (including a description of
where changes in the carrying amount are reported in the
statement of income for each period for which results of operations are presented), including, but not limited to, the following:

No

N/A
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Yes
i.

The beginning and ending balances?

ii.

Additions (through purchases of servicing assets, assumption of servicing obligations, and servicing obligations that result from transfers of financial assets)?

iii.

Disposals?

iv.

Amortization?

v.

Application of valuation allowance to adjust carrying
value of servicing assets?

vi.

Other-than-temporary impairments?

No

N/A

vii. Other changes that affect the balance and a description
of those changes?
b.

For each class of servicing assets and servicing liabilities, the
fair value of recognized servicing assets and servicing liabilities at the beginning and end of the period if it is practicable
to estimate the value?

c.

The risk characteristics of the underlying financial assets
used to stratify recognized servicing assets for purposes of
measuring impairment in accordance with the guidance in
paragraphs 9–14 of FASB ASC 860-50-35?

d.

For each period for which results of operations are presented,
the activity by class in any valuation allowance for impairment of recognized servicing assets, including (a) beginning
and ending balances, (b) aggregate additions charged and recoveries credited to operations, and (c) aggregate writedowns charged against the allowance?
[“Pending Content” in FASB ASC 860-50-50-9]

Securitized Financial Assets Accounted for as a Sale
15. If the entity has securitized financial assets during any period presented and accounts for that transfer as a sale, are the following
items disclosed for each major asset type (for example, mortgage
loans, credit card receivables, and automobile loans):
a.

Its accounting policies for initially measuring the interests
that continue to be held by the transferor, if any, and servicing assets or servicing liabilities, if any, including the methodology (whether quoted market price, prices based on sales
of similar assets and liabilities, or prices based on valuation
techniques) used in determining their fair value?

b.

The characteristics of securitizations (a description of the
transferor’s continuing involvement with the transferred assets, including, but not limited to, servicing, recourse, and restrictions on interests that continue to be held by the transferor) and the gain or loss from sale of financial assets in
securitizations?
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Yes

No

N/A

Practice Tip
With regard to question 15(c) following, if an entity has made multiple securitizations of the same major
asset type during a period, it may disclose the range of assumptions.
[FASB ASC 860-20-50-3]
c.

The key assumptions used in measuring the fair value of interests that continue to be held by the transferor and servicing
assets or servicing liabilities, if any, at the time of securitization (including, at a minimum, quantitative information about
discount rates, expected prepayments including the expected
weighted-average life of prepayable financial assets, and anticipated credit losses, if applicable)?

d.

Cash flows between the securitization special purpose entity
and the transferor, unless reported separately elsewhere in the
financial statements or notes (including proceeds from new
securitizations, proceeds from collections reinvested in revolving-period securitizations, purchases of delinquent or
foreclosed loans, servicing fees, and cash flows received on
interests that continue to be held by the transferor)?
[FASB ASC 860-20-50-3]

16. (Issuers Only) Has the entity disclosed, for each income statement
presented, the following related to securitization or asset-backed
financing arrangements accounted for as sales:
a.

Its accounting policies for subsequently measuring those interests, if any?

b.

The characteristics of the transfer including a description of
the transferor’s continuing involvement with the transferred
financial assets and the gain or loss from the sale of transferred assets?

c.

Cash flows between a transferee and the transferor, including
proceeds from new transfers, proceeds from collections reinvested in revolving-period transfers, purchases of previously
transferred financial assets, servicing fees, and cash flows received on interests that continue to be held by the transferor?
[“Pending Content” in FASB ASC 860-20-50-8]

Interests in Financial Assets That Continue to be Held by the Transferor
.l 17. If the entity has interest that continues to be held by the transferor
in financial assets that it has securitized or servicing assets or servicing liabilities relating to assets that it has securitized, at the date
of the latest statement of financial position presented, are the following items disclosed for each major asset type (for example,
mortgage loans, credit card receivables, and automobile loans):
a.
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prices based on valuation techniques) used in determining
their fair value?
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Yes
b.

The key assumptions used in subsequently measuring the fair
value of those interests (including, at a minimum, quantitative
information about discount rates, expected prepayments including the expected weighted-average life of prepayable financial assets, and anticipated credit losses, including expected static pool losses, if applicable)?

c.

A sensitivity analysis or stress test showing the hypothetical
effect on the fair value of those interests (including any servicing assets or servicing liabilities) of two or more unfavorable
variations from the expected levels for each key assumption
that is reported under item (b) independently from any
change in another key assumption, and a description of the
objectives, methodology, and limitations of the sensitivity
analysis or stress test?

No

N/A

Practice Tip
With regard to question 17(d) following, this question excludes securitized assets that an entity continues to
service but with which it has no other continuing involvement.
[FASB ASC 860-20-50-4]
d.

l 18.

For the securitized assets and any other financial assets
that it manages together with them,
i.

the total principal amount outstanding, the portion that has been derecognized, and the portion
that continues to be recognized in each category
reported in the statement of financial position, at
the end of the period?

ii.

delinquencies at the end of the period?

iii.

credit losses, net of recoveries, during the period?
[FASB ASC 860-20-50-4]

(Issuers Only) Have the following disclosures been made, in
each statement of financial position presented, related to securitization or asset-backed financing arrangements accounted for sales if the transferor has continuing involvement:
a.

Qualitative and quantitative information about the
transferor’s continuing involvement with transferred financial assets that provides financial statement users
with sufficient information to assess the reasons for the
continuing involvement and the risks related to the
transferred financial assets to which the transferor continues to be exposed after the transfer and the extent
that the transferor’s risk profile has changed as a result
of the transfer (including, but not limited to, credit risk,
interest rate risk, and other risks), including the following:
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Yes
i.

The nature, purpose, size, and activities of special-purpose entities used to facilitate a transfer
of financial assets, if applicable, including how
the special-purpose entities are financed?

ii.

The total principal amount outstanding, the portion that has been derecognized, and the portion
that continues to be recognized in each category
reported in the statement of financial position, at
the end of the period?

iii.

The terms of any arrangements that could require the transferor to provide financial support
(for example, liquidity arrangements and obligations to purchase assets) to the transferee or its
beneficial interest holders, including a description of any events or circumstances that could expose the transferor to loss. All available evidence
should be considered, including, but not limited
to all of the following: (1) explicit written arrangements, (2) communications between the
transferor and the transferee or its beneficial interest holders, and (3) unwritten arrangements
customary to similar transfers?

iv.

Whether the transferor has provided financial or
other support during the periods presented that
it was not previously contractually required to
provide to the transferee or its beneficial interest
holders, including—when the transferor assisted
the transferee or its beneficial interest holders in
obtaining support—both the type and amount of
support and the primary reasons for the support?

No

N/A

Practice Tip
(Issuers Only) The entity also is encouraged to disclose information about any liquidity arrangements, guarantees, or other commitments by third parties related to the transferred financial assets that may affect the
fair value or risk of interest that continues to be held by the transferor.
[“Pending Content” in FASB ASC 860-20-50-9]
b.

The accounting policies for subsequently measuring assets or
liabilities that relate to the continuing involvement?

c.

The key inputs and assumptions used in measuring the fair
value of assets or liabilities that relate to the transferor’s continuing involvement including, at a minimum, (1) quantitative information about discount rates, (2) expected prepayments, including the expected weighted-average life of prepayable
financial assets, and (3) anticipated credit losses, including expected static pool losses?
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Practice Tip
(Issuers Only) If the entity has aggregated multiple transfers during a period in accordance, it may disclose
the range of assumptions for each aggregated group provided it does not obscure important information.
[“Pending Content” in FASB ASC 860-20-50-9]
d.

For interests that continue to be held by the transferor in financial assets, both of the following:
i.

A sensitivity analysis or stress test showing the hypothetical effect on the fair value of those interests, including
any servicing assets or servicing liabilities, of two or more
unfavorable variations from the expected levels for each
key assumption that is reported under item (c), independently from any change in another key assumption?

ii.

A description of the objectives, methodology, and limitations of the sensitivity analysis or stress test?
Practice Tip

(Issuers Only) The information in question 18(e) following should be separated between assets that have
been derecognized and assets that continue to be recognized in the statement of financial position. This
information is intended to provide financial statement users with an understanding of the risks inherent in
the transferred financial assets as well as in other financial assets and liabilities that it manages together with
transferred financial assets. In determining the information that should be disclosed, an entity should consider other U.S. GAAP disclosure requirements applicable to the transferred financial asset.
[“Pending Content” in FASB ASC 860-20-50-9]
e.

Y.

Information about the asset quality of transferred financial assets and any other financial assets that it manages together
with them.
[“Pending Content” in FASB ASC 860-20-50-9]

Troubled Debt Restructurings—Creditors

.l 1. Is the amount of commitments, if any, to lend additional funds to
debtors owing receivables whose terms have been modified in troubled debt restructurings disclosed either in the body of the financial
statements or in the notes thereto as of the date of each balance sheet
presented?
[FASB ASC 310-40-50-1]
Practice Tip
For Restructurings in Fiscal Years Beginning Before December 16, 1994. Per “Pending Content” in FASB ASC
105-10-70-2(d), an entity may continue to account for “grandfathered” loans (restructured in a troubled debt
restructuring before the effective date of FASB Statement No. 114, Accounting by Creditors for Impairment of a
Loan, described in paragraph 24 of FASB Statement No. 118, Accounting by Creditors for Impairment of a
Loan—Income Recognition and Disclosures) in accordance with the provisions of FASB Statement No. 15 prior
to its amendment by FASB Statement No. 118.
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For Restructurings in Fiscal Years Beginning Before December 16, 1994
.l 2. For outstanding “grandfathered” receivables whose terms have
been modified in troubled debt restructurings, are the following disclosed by major category either in the body of the financial statements or the notes thereto as of the date of each balance sheet presented:
a.

The aggregate recorded investment?

b.

The gross interest income that would have been recorded in the
period then ended if those receivables had been current in accordance with their original terms and had been outstanding
throughout the period or since origination?

c.

The amount of interest income on those receivables that was
included in net income for the period?
[SFAS 15 par. 40a]

(See part H, “Financial Instruments,” and part L, “Impaired Loans,”
for possible additional disclosure requirements.)
Z.

Troubled Debt Restructurings—Debtors

.l 1. For a troubled debt restructuring occurring during the current period, do disclosures include
a.

a description of the principal changes in terms, the major features of settlement, or both?

b.

aggregate gain on restructuring of payables?

c.

aggregate net gain or loss on transfers of assets recognized during the period?

d.

per-share amount of the aggregate gain on restructuring of
payables?
[FASB ASC 470-60-50-1]

.l 2. For periods after a troubled debt restructuring, do disclosures include
a.

the extent to which amounts contingently payable are included
in the carrying amount of restructured payables pursuant to
the provisions of FASB ASC 470-60-35-7?

b.

if required by paragraphs 1–6 and 9–10 of FASB ASC 450-2050, total amounts contingently payable on restructured payables and conditions under which those amounts would become
payable or forgiven?
[FASB ASC 470-60-50-2]
Practice Tip

A troubled debt restructuring of a short term obligation after the date of a debtor’s balance sheet but before
that balance sheet is issued or is available to be issued may affect the classification of that obligation in
accordance with FASB ASC 470-10.
[FASB ASC 470-60-45-2A]
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AA. Asset Retirement Obligations
.l 1. Does the entity disclose the following information about its asset
retirement obligations:
a.

A general description of the asset retirement obligations and
the associated long-lived assets?

b.

The fair value of assets that are legally restricted for purposes
of settling asset retirement obligations?

c.

A reconciliation of the beginning and ending aggregate carrying amount of asset retirement obligations showing separately
the changes attributable to (1) liabilities incurred in the current
period, (2) liabilities settled in the current period, (3) accretion
expense, and (4) revisions in estimated cash flows, whenever
there is a significant change in one or more of those four components during the reporting period?
[FASB ASC 410-20-50-1]

.l 2. If the fair value of an asset retirement obligation cannot be reasonably estimated, is that fact and the reasons therefore disclosed?
[FASB ASC 410-20-50-2]
.l 3. Is, on a pro forma basis, in the footnotes to the financial statements,
for the beginning of the earliest period presented and at the end of
all periods presented during the year of adoption, the amount of
liability for asset retirement obligations as if FASB ASC 410-20 had
been applied during all periods affected presented? (These pro
forma amounts should be measured using the information, assumptions, and interest rates used to measure the obligation recognized upon adoption of the provisions of FASB ASC 410-20.)
[FASB ASC 410-20]
Practice Tip
For environmental asset retirement obligations under the requirements of FASB ASC 410-30, see part G,
“Environmental Remediation Liabilities,” in the “Other Financial Statement Disclosures” section of this
checklist.
BB.

Fair Value Measurements
Notes: In February 2007, FASB issued Statement No. 159, primarily
codified in FASB ASC 825, which was effective for financial statements
issued for fiscal years beginning after November 15, 2007.
This statement applies to all entities, including not-for-profit entities.
Most of the provisions of this statement apply only to entities that elect
the fair value option. However, the amendment to FASB Statement No.
115 applies to all entities with available-for-sale and trading securities.
Some requirements apply differently to entities that do not report net
income.
The statement permits an organization to irrevocably elect fair value
as the initial and subsequent measurement attribute for certain finan(continued)
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cial assets and financial liabilities on a contract-by-contract basis, with
changes in fair value recognized in earnings (or another performance
indicator if the business entity does not report earnings) at each subsequent reporting date. The provisions of this statement need not be
applied to immaterial items.
******
In September 2006, FASB issued Statement No. 157, codified in FASB
ASC 820, Fair Value Measurements and Disclosures, which was effective
for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. However,
FSP FAS 157-2, Effective Date of FASB Statement No. 157, delayed the
effective date of FASB Statement No. 157 for all nonfinancial assets and
nonfinancial liabilities, except those that are recognized or disclosed at
fair value in the financial statements on a recurring basis (at least annually), to fiscal years beginning after November 15, 2008 (that is, January 1, 2009, for entities with calendar year-ends), and interim periods
within those fiscal years for items within the scope of this FSP. This
FSP does not apply to entities that have issued interim or annual financial statements that include the application of the measurement and
disclosure provisions of FASB Statement No. 157.
FASB Statement No. 157 establishes a single definition of fair value and
a framework for measuring fair value in U.S. GAAP and also expands
disclosures about fair value measurements. The statement applies under other accounting pronouncements that require or permit fair value
measurements because FASB previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this statement does not require any new fair value
measurements, but the application of it will change current practice.
However, FSP FAS 157-1, Application of FASB Statement No. 157 to FASB
Statement No. 13 and Other Accounting Pronouncements That Address Fair
Value Measurements for Purposes of Lease Classification or Measurement under Statement 13, established that FASB Statement No. 157 does not apply under FASB Statement No. 13, Accounting for Leases, and other accounting pronouncements that address fair value measurements for
purposes of lease classification or measurement under FASB Statement
No. 13. This scope exception does not apply to assets acquired and
liabilities assumed in a business combination that are required to be
measured at fair value under FASB Statement No. 141 or FASB Statement No. 141(R), regardless of whether those assets and liabilities are
related to leases.
FASB Statement No. 157 retains the exchange price notion already established within U.S. GAAP but clarifies, among other matters, that
fair value is the price that would be received to sell the asset or paid
to transfer the liability (that is, an exit price) and not the price that
would be paid to acquire the asset or paid to transfer the liability (that
is, an entry price). Additionally, the statement establishes a fair value
hierarchy that prioritizes the inputs to valuation techniques used to
measure fair value into 3 broad levels.
(continued)
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This checklist has been updated to include the presentation and disclosure requirements of FASB Statement No. 157 and FSP FAS 157-2.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions indicated with a “B” reference. Entities for which the guidance
has been implemented should consider all questions indicated by a “B”
reference (for example, question 1B and question 2B) and place an “N/
A” mark by questions indicated with an “A” reference. Therefore,
based upon your entity’s year-end and decision to early implement or
not (if allowed), the following additional questions will be answered
when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web site
at www.fasb.org.
******
In September, 2008, FASB issued EITF Issue No. 08-5, “Issuer’s Accounting for Liabilities Measured at Fair Values with a Third-Party
Credit Enhancement,” to determine an issuer’s unit of accounting for a
liability issued with an inseparable third-party credit enhancement
when it is measured or disclosed at fair value on a recurring basis and
to amend the required disclosures. This issue applies to liabilities issued with an inseparable third-party credit enhancement (for example,
debt that is issued with a contractual third-party guarantee) when they
are measured or disclosed at fair value on a recurring basis.
This EITF issue states that the issuer of a liability with a third-party
credit enhancement that is inseparable from the liability should not include the effect of the credit enhancement in the fair value measurement of the liability. For example, in determining the fair value of debt
with a third-party guarantee, the issuer would consider its own credit
standing and not that of the third-party guarantor. Further, this issue
requires an issuer disclose the existence of a third-party credit enhancement on its issued liability that is within the scope of this issue.
This EITF issue is effective on a prospective basis in the first reporting
period beginning on or after December 15, 2008 (that is, January 1,
2009, for entities with calendar year-ends). The effect of initially applying the guidance in this Issue should be included in the change in fair
value in the period of adoption. Earlier application is permitted.
The EITF reached a consensus that in the period of adoption an entity
should disclose the valuation technique(s) used to measure the fair
value of liabilities in the scope of this issue and include a discussion of
changes, if any, from the valuation techniques used to measure those
liabilities in prior periods.
This checklist has been updated to include the presentation and disclosure requirements of EITF Issue No. 08-5.
(continued)
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As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions indicated with a “B” reference. Entities for which the guidance
has been implemented should consider all questions indicated by a “B”
reference (for example, question 1B and question 2B) and place an “N/
A” mark by questions indicated with an “A” reference. Therefore,
based upon your entity’s year-end and decision to early implement or
not (if allowed), the following additional questions will be answered
when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web site
at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and
open effective date information discussed in FASB ASC 820-10-65-3.
******
In April, 2009, FSP FAS 157-4, Determining Fair Value When the Volume
and Level of Activity for the Asset or Liability Have Significantly Decreased
and Identifying Transactions That Are Not Orderly, was released to provide additional guidance for estimating fair value in accordance with
FASB Statement No. 157 when the volume and level of activity for the
asset or liability have significantly decreased and to provide guidance
on identifying circumstances that indicate a transaction is not orderly.
Further, this FSP superseded FSP FAS 157-3, Determining the Fair Value
of a Financial Asset When the Market for That Asset Is Not Active.
This FSP is effective for interim and annual reporting periods ending
after June 15, 2009 (that is, December 31, 2009, for entities with calendar year-ends), and should be applied prospectively. This FSP does not
require disclosures for earlier periods presented for comparative purposes at initial adoption. In periods after initial adoption, this FSP requires comparative disclosures only for periods ending after initial
adoption.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 157-4.
Readers can refer to the full text of the FSP on the FASB Web site at
www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and
open effective date information discussed in FASB ASC 820-10-65-4.
******
In September 2009, FASB issued ASU No. 2009-012, Fair Value Measurements and Disclosures.
The amendments in this ASU apply to all reporting entities that hold
an investment that is required or permitted to be measured or dis(continued)
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closed at fair value on a recurring or nonrecurring basis and, as of the
reporting entity’s measurement date, if the investment meets both of
the following criteria:
a.

The investment does not have a readily determinable fair
value.

b.

The investment is in an entity that has all of the attributes
specified in FASB ASC 946-10-15-2 (those attributes include investment activity, unit ownership, pooling of funds, and reporting entity) or, if one or more of the attributes in FASB ASC
946-10-15-2 are not present, is an entity for which it is industry
practice to issue financial statements using guidance that is
consistent with the measurement principles in FASB ASC 946.

This ASU provides amendments to FASB ASC 820 for the fair value
measurement of investments in certain entities that calculate net asset
value per share (or its equivalent). Further, this ASU requires disclosures by major category of investment about the attributes of investments within the scope of the amendments in the update.
The amendments in this ASU are effective for interim and annual periods ending after December 15, 2009 (that is, December 31, 2009, for
entities with calendar year-ends). Early application is permitted in financial statements for earlier interim and annual periods what have
not been issued. (If an entity elects to early adopt ASU No. 2009-012,
the entity is permitted to defer the adoption of the disclosure provisions of FASB 820-10-50-6A until periods ending after December 15,
2009.
This checklist has been updated to include the presentation and disclosure requirements of ASU No. 2009-012.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions indicated with a “B” reference. Entities for which the guidance
has been implemented should consider all questions indicated by a “B”
reference (for example, question 1B and question 2B) and place an “N/
A” mark by questions indicated with an “A” reference. Therefore,
based upon your entity’s year-end and decision to early implement or
not (if allowed), the following additional questions will be answered
when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the ASU on the FASB Web site at
www.fasb.org.
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.l 1. For assets and liabilities that are measured at fair value on a recurring basis in periods subsequent to initial recognition (for example,
trading securities), the reporting entity should disclose information
that enables users of its financial statements to assess the inputs
used to develop those measurements and for recurring fair value
measurements using significant unobservable inputs (level 3), the
effect of the measurements on earnings (or changes in net assets) for
the period. To meet that objective, the reporting entity should disclose the following information for each interim and annual period
(except as otherwise specified) separately for each major category of
assets and liabilities:
a.

The fair value measurements at the reporting date?

b.

The level within the fair value hierarchy in which the fair value
measurements in their entirety fall, segregating fair value
measurements using quoted prices in active markets for identical assets or liabilities (level 1), significant other observable
inputs (level 2), and significant unobservable inputs (level 3)?

c.

For fair value measurements using significant unobservable inputs (level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following (may be presented net):
i.

Total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of where
those gains or losses included in earnings (or changes in
net assets) are reported in the statement of income (or
activities)?

ii.

Purchases, sales, issuances, and settlements (net)?

iii.

Transfers in and out, or both, of level 3 (for example,
transfers due to changes in the observability of significant inputs)?

d.

The amount of the total gains or losses for the period in question 1(c)(1) included in earnings (or changes in net assets) that
are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting
date and a description of where those unrealized gains or
losses are reported in the statement of income (or activities)?

e.

The inputs and valuation technique(s) used to measure fair
value and a discussion of changes in valuation techniques and
related inputs, if any, during the period?
[FASB ASC 820-10-50 par. 1 and 3; “Pending Content” in FASB
ASC 820-10-50-2]
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Practice Tip
(EITF Issue No. 08-05) With regards to question 2B following, FASB ASC 820-10-35-18A states that, for the
issuer, the unit of accounting for a liability measured or disclosed at fair value does not include the thirdparty credit enhancement.
[“Pending Content” in FASB ASC 820-10-50-4A]
.l 2B. (EITF Issue No. 08-05) For a liability having the characteristics set
forth in FASB ASC 820-10-25-1, has the entity disclosed the existence of a third-party credit enhancement on its issued liability, if
such an enhancement exists?
[“Pending Content” in FASB ASC 820-10-50-4A]
.l 3.

Are the quantitative disclosures required by FASB ASC 820-10-50
presented using a tabular format?
[FASB ASC 820-10-50-8]

.l 4A. If the entity has not voluntarily applied the guidance of FASB ASC
820 in interim or annual financial statements to the nonfinancial assets and nonfinancial liabilities as discussed in FASB ASC 820-1015-1A, have disclosures been made (a) that the entity has not applied the guidance of FASB ASC 820 to such nonfinancial assets and
nonfinancial liabilities and (b) to detail each major category of assets
and liabilities that are recognized or disclosed at fair value for
which the entity has not voluntarily applied the guidance in FASB
ASC 820?
[FASB ASC 820-10-50-8A]
4B. (FSP FAS 157-2) [Not used. The preceding item has been removed
due to the effective date of FSP FAS 157-2.]
.l 5.

Is the fair value information disclosed under FASB ASC 820-10-50
and the fair value information disclosed as required by other FASB
ASC topics (for example, FASB ASC 825-10-50) combined in the
periods in which those disclosures are required, if practicable? (Encouraged, but not required.)
[FASB ASC 820-10-50-9]

.l 6.

Is information about other similar measurements (for example, inventories measured at market value under FASB ASC 330, Inventory) disclosed, if practicable? (Encouraged, but not required.)
[FASB ASC 820-10-50-9]

.l 7.

If the organization reports assets and liabilities at fair value pursuant to the fair value option in FASB ASC 825, has it either (a) presented the aggregate of fair value and non-fair-value amounts in
the same line item in the statement of financial position and parenthetically disclosed the amount measured at fair value included in
the aggregate amount or (b) presented 2 separate line items to display the fair value and non-fair-value carrying amounts of similar
assets and liabilities?
[FASB ASC 825-10-45 par. 1–2]
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Practice Tip
The principal objectives of the disclosures required by paragraphs 28–32 of FASB ASC 825-10-50 (questions
8–11 that follow) are to facilitate (a) comparisons between entities that choose different measurement attributes for similar assets and liabilities and (b) comparisons between assets and liabilities in the financial statements of an entity that selects different measurement attributes for similar assets and liabilities.
The disclosure requirements are expected to result in the following:
●

Information to enable users of its financial statements to understand management’s reasons for electing or partially electing the fair value option

●

Information to enable users to understand how changes in fair values affect earnings for the period

●

The same information about certain items (such as equity investments and nonperforming loans)
that would have been disclosed if the fair value option had not been elected

●

Information to enable users to understand the differences between fair values and contractual cash
flows for certain items

To meet those objectives, the disclosures described in questions 8–11 are required for items measured at fair
value under the option in FASB ASC 825-10 and the fair value option for hybrid instruments in FASB ASC
815-15-25-4. Those disclosures are not required for securities classified as trading securities under FASB ASC
320, life settlement contracts measured at fair value pursuant to FASB ASC 325-30, or servicing rights measured at fair value pursuant to FASB ASC 860-50. Guidance therein includes disclosure requirements not
affected by FASB ASC 825-10.
Entities should provide the disclosures in questions 8–11 in both interim and annual financial statements.
These disclosure requirements do not eliminate disclosure requirements otherwise required by U.S. GAAP,
including other disclosure requirements relating to fair value measurement. Entities are encouraged but are
not required to present the disclosures required by FASB ASC 825-10 in combination with related fair value
information required to be disclosed by other FASB ASC topics.
[FASB ASC 825-10-50 par. 24–27]
.l 8. As of each date for which a statement of financial position is presented, has the organization disclosed the following information
about items measured at fair value under the option in FASB ASC
825:
a.

Management’s reasons for electing a fair value option for each
eligible item or group of similar eligible items?

b.

The following information if the fair value option is elected for
some but not all eligible items within a group of similar eligible items:

c.
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i.

A description of those similar items and the reasons for
partial election?

ii.

Information to enable users to understand how the group
of similar items relates to individual line items on the
statement of financial position?

The following information for each line item in the statement
of financial position that includes an item or items for which
the fair value option has been elected:
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d.

e.

f.

i.

Information to enable users to understand how each line
item in the statement of financial position relates to major
categories of assets and liabilities presented in accordance
with the fair value disclosure requirements in FASB ASC
820?

ii.

The aggregate carrying amount of items included in each
line item in the statement of financial position that are not
eligible for the fair value option, if any?

N/A

The difference between the aggregate fair value and the aggregate unpaid principal balance of
i.

Loans and long term receivables (other than securities
subject to FASB ASC 320) that have contractual principal
amounts and for which the fair value option has been
elected?

ii.

Long term debt instruments that have contractual principal amounts and for which the fair value option has been
elected?

For loans held as assets for which the fair value option has
been elected
i.

The aggregate fair value of loans that are 90 days or more
past due?

ii.

If the entity’s policy is to recognize interest income separately from other changes in fair value, the aggregate fair
value of loans in nonaccrual status?

iii.

The difference between the aggregate fair value and the
aggregate unpaid principal balance for loans that are 90
days or more past due, in nonaccrual status, or both?

The information required by FASB ASC 323-10-50-3 (equity
method and joint venture investments) for investments that
would have been accounted for under the equity method if the
entity had not chosen to apply the fair value option?
[FASB ASC 825-10-50-28]
Practice Tip

Per FASB ASC 825-10-50-29, the disclosure in FASB ASC 825-10-50-28(f), question 8 applies to investments
in common stock, investments in in-substance common stock, and other investments (for example, partnerships and certain limited liability corporations) that both
a.

would otherwise be required to be accounted for under the equity method under other U.S. GAAP,
and

b.

would be required to satisfy the disclosure requirements of FASB ASC 323-10-50-3.

When applying this item, an entity should apply the guidance from paragraphs 2 and 3(a)–(c) of FASB ASC
323-10-50.
[FASB ASC 825-10-50-29]
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.l 9.

As of each period for which an interim or annual income statement
is presented, has the entity disclosed the following information
about items measured at fair value under the option in FASB ASC
825:
a.

For each line item in the statement of financial position, the
amounts of gains and losses from fair value changes during the
period included in earnings and in an intermediate measure of
operations, if one is presented, and in which line in the income
statement those gains and losses are reported? (An entity may
meet this requirement by disclosing amounts of gains and
losses that include amounts of gains and losses for other items
measured at fair value, such as items required to be measured
at fair value.)

b.

A description of how interest and dividends are measured and
where they are reported in the income statement?

c.

For loans and other receivables held as assets, (1) the estimated
amount of gains or losses included in earnings during the period attributable to changes in instrument-specific credit risk
and (2) how the gains or losses attributable to changes in instrument-specific credit risk were determined?

d.

For liabilities with fair values that have been significantly affected during the reporting period by changes in the instrument-specific credit risk, (1) the estimated amount of gains and
losses from fair value changes included in earnings that are
attributable to changes in the instrument-specific credit risk, (2)
qualitative information about the reasons for those changes,
and (3) how the gains and losses attributable to changes in instrument-specific credit risk were determined?
[FASB ASC 825-10-50-30]

.l 10. In its annual period only, has the entity disclosed the methods and
significant assumptions used to estimate the fair value of items for
which the fair value option has been elected?
[FASB ASC 825-10-50-31]
.l 11. If an entity elects the fair value option at a remeasurement event,
has it disclosed the following for the period of the election:
a.

Qualitative information about the nature of the event?

b.

Quantitative information by line item in the statement of financial position indicating which line items in the income statement include the effect of initially electing the fair value option
for an item?
[FASB ASC 825-10-50-32]
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Practice Tip
(ASU No. 2009-012) ASU No. 2009-012 changes the definition of major category, as used in the questions
12–13 following, to be defined as a major security type as described in FASB ASC 320-15-50-1B, even if the
equity securities or debt securities are not within the scope of FASB ASC 320-10 and, for a reporting entity
within the scope of FASB ASC 942, Financial Services–Depository and Lending, as described in FASB ASC 942320-50-2.
[“Pending Content” in FASB ASC 820-10-50-2; “Pending Content” in FASB ASC 820-10-50-5]
.l 12. For assets and liabilities that are measured at fair value on a recurring basis in periods subsequent to initial recognition (for example,
trading securities), the reporting entity should disclose information
that enables users of its financial statements to assess the inputs
used to develop those measurements and for recurring fair value
measurements using significant unobservable inputs (level 3), the
effect of the measurements on earnings (or changes in net assets)
for the period. To meet that objective, the reporting entity should
disclose the following information for each interim and annual period (except as otherwise specified) separately for each major category of assets and liabilities:
a.

The fair value measurements at the reporting date?

b.

The level within the fair value hierarchy in which the fair
value measurements in their entirety fall, segregating fair
value measurements using quoted prices in active markets for
identical assets or liabilities (level 1), significant other observable inputs (level 2), and significant unobservable inputs
(level 3)?

c.

For fair value measurements using significant unobservable
inputs (level 3), a reconciliation of the beginning and ending
balances, separately presenting changes during the period attributable to the following (may be presented net):

d.

i.

Total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of
where those gains or losses included in earnings (or
changes in net assets) are reported in the statement of
income (or activities)?

ii.

Purchases, sales, issuances, and settlements (net)?

iii.

Transfers in and out, or both, of level 3 (for example,
transfers due to changes in the observability of significant inputs)?

The amount of the total gains or losses for the period in question 12(c)(1) included in earnings (or changes in net assets)
that are attributable to the change in unrealized gains or
losses relating to those assets and liabilities still held at the
reporting date and a description of where those unrealized
gains or losses are reported in the statement of income (or
activities)?
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Yes
e.

The inputs and valuation technique(s) used to measure fair
value and a discussion of changes in valuation techniques, if
any, during the period?
[“Pending Content” in FASB ASC 820-10-50-2; FASB ASC
820-10-50-3]

.l 13. For assets and liabilities that are measured at fair value on a nonrecurring basis in periods subsequent to initial recognition (for example, impaired assets), the reporting entity should disclose information that enables users of its financial statements to assess the
inputs used to develop those measurements? To meet that objective, the reporting entity should disclose the following information
for each interim and annual period (except as otherwise specified)
separately for each major category of assets and liabilities:
a.

The fair value measurements recorded during the period and
the reasons for the measurements?

b.

The level within the fair value hierarchy in which the fair
value measurements in their entirety fall, segregating fair
value measurements using quoted prices in active markets for
identical assets or liabilities (level 1), significant other observable inputs (level 2), and significant unobservable inputs
(level 3)?

c.

For fair value measurements using significant unobservable
inputs (level 3), a description of the inputs and the information used to develop the inputs?

d.

The inputs and valuation technique(s) used to measure fair
value and a discussion of changes, if any, in the valuation
technique(s) used to measure similar assets and/or liabilities
in prior periods?
[“Pending Content” in FASB ASC 820-10-50-5]

.l 14B. (ASU No. 2009-012) For investments that are within the scope of
paragraphs 4–5 of FASB ASC 820-10-15 and that are measured at
fair value (on a recurring or nonrecurring basis), has the entity disclosed information that enables that users of its financial statements to understand the nature and risks of the investments and
whether the investments are probable of being sold at amounts different from net asset value (or its equivalent)? (See FASB ASC 82010-50-6A for example disclosures.)
[“Pending Content” in FASB ASC 820-10-50-6A]
.l 15B. (EITF Issue No. 08-5) For a liability having the characteristics set
forth in FASB ASC 820-10-25-1, has the entity disclosed the existence of the third-party credit enhancement on its issued liability?
(Note: FASB ASC 820-10-35-18A states that, for the issuer, the
unity of accounting for a liability measured or disclosed at fair
value does not include the third-party credit enhancement.)
[“Pending Content” in FASB ASC 820-10-50-4A]
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Yes

No

N/A

Practice Tip
The disclosure provisions in FASB ASC 250 for a change in accounting estimate are not required for revisions resulting from a change in a valuation technique of its application.
[FASB ASC 820-10-50-7]

Notes: In December 2008, FASB issued FSP FAS 132(R)-1 to provide
guidance on an employer’s disclosures about plan assets of a defined
benefit pension or other postretirement plan. One objective is to disclose
information about fair value measurements of plan assets that would be
similar to the disclosures required by FASB Statement No. 157.
The disclosures about plan assets required by this FSP should be provided for fiscal years ending after December 15, 2009 (that is, December
31, 2009, for entities with calendar year-ends). Upon initial application,
the provisions of this FSP are not required for earlier periods presented
for comparative purposes. Earlier application is permitted.
This FSP also includes a technical amendment to FASB Statement No.
132(R) that requires a nonpublic entity to disclose net periodic benefit
cost for each annual period for which a statement of income is presented.
This amendment was effective upon issuance.
This checklist has been updated to include the presentation and disclosure requirements of FSP FAS 132(R)-1.
As determined by the effective date or early implementation decision,
entities for which this guidance has not been implemented should consider all questions indicated with an “A” reference (for example, question 1A and question 2A) and should place an “N/A” mark in questions
indicated with a “B” reference. Entities for which the guidance has been
implemented should consider all questions indicated by a “B” reference
(for example, question 1B and question 2B) and place an “N/A” mark
by questions indicated with an “A” reference. Therefore, based upon
your entity’s year-end and decision to early implement or not (if allowed), the following additional questions will be answered when provided in this section (check one that applies for your entity):
pppA pppB
Readers can refer to the full text of the statement on the FASB Web site
at www.fasb.org.
This guidance is labeled as "Pending Content" due to the transition and
open effective date information discussed in FASB ASC 715-20-65-2.
16B.

(FSP FAS 132(R)-1) Plan assets of a defined pension or other postretirement plan that are accounted for under FASB ASC 715 are
not subject to the disclosure requirements in paragraphs 1–9 of
FASB ASC 820-10-50 but are subject to disclosure requirements
under FASB ASC 715-20-50-1(d)(iv) and FASB ASC 715-20-505(c)(iv). Have the proper disclosures been made under the listed
paragraphs of FASB ASC 715?
[“Pending Content” in FASB ASC 820-10-50-10]
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Yes

VIII.

No

N/A

Continuing Care Retirement Communities
Practice Tip

Health care entities, including not-for-profit, business-oriented health care entities, should classify assets and
liabilities as current and noncurrent as discussed in FASB ASC 210-10-45. However, rather than presenting
a classified balance sheet, a continuing care retirement community instead may sequence assets according
to their nearness of conversion to cash and may sequence liabilities according to the nearness of the maturity
and resulting use of cash.
[FASB ASC 954-210-45-1]
A.

Refundable Advance Fees
1.

Has the method of accounting for advance fees, the method
of calculating the obligation to provide future services and
use of facilities, and the refund policy for refundable fees
been disclosed?
[FASB ASC 954-430-50-1]

.l 2.

Has the gross amount of contractual refund obligations under
existing contracts and the continuing care retirement community’s refund policy disclosed in the notes to the financial
statements?
[FASB ASC 954-430-50-2]
Practice Tip

With regards to the preceding question, those amounts refunded should be disclosed in the statement of
cash flows as a financing transaction.
[FASB ASC 954-430-50-2]
.l 3. If any portion of an advance fee is refundable, is the method of amortization of that liability disclosed in the noted to the financial statements?
[FASB ASC 954-430-50-3]
.l 4. Is the amortization method for deferred revenue disclosed?
[FASB ASC 954-430-50-4]
B.

Obligations to Provide Future Services and Use of Facilities to Current Residents

.l 1. Do the notes to the financial statements of the continuing care retirement community include the carrying amount of the liability to provide future services and the use of facilities related to continuingcare contracts presented at present value (if not separately disclosed
in the balance sheet/statement of financial position) and the interest
rate used to discount that liability?
[FASB ASC 954-440-50-1]
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Yes
C.

No

N/A

Other

.l 1. Do the notes to the financial statements of the continuing care retirement community include a description of the continuing care retirement community and the nature of the related continuing-care contracts entered into by the continuing care retirement community?
[FASB ASC 954-440-50-1]
.l 2. Do the notes to the financial statements of the continuing care retirement community include the statutory escrow or similar requirements?
[FASB ASC 954-440-50-1]
.l 3. Do the notes to the financial statements of the continuing care retirement community include the refund policy of the continuing care
retirement community and the general amount of refund obligation
under existing contracts?
[FASB ASC 954-440-50-1]

IX.

OMB Circular A-133 Presentation Requirements

1.

Does the schedule of expenditures of federal awards disclose the basis of
accounting and the significant accounting policies used in preparing the
schedule?
[AAG-SLA 7.09]

2.

Did the auditee prepare a schedule of expenditures of federal awards for
the period covered by the auditee’s financial statements that, at a minimum:

3.

a.

Lists individual federal programs by federal agency?

b.

Include, for federal awards received as a subrecipient, the name of the
pass-through entity and the identifying number assigned by the passthrough entity?

c.

Provide the total federal awards expended for each individual federal
program and the Catalog of Federal Domestic Assistance (CFDA)
number or other identifying number when the CFDA information is
not available?

d.

Include notes that describe the significant accounting policies used in
preparing the schedule?

e.

For federal awards received as a pass-through entity, identify, to the
extent practical, the total amount provided to subrecipients from each
federal program?

f.

Include, in either the schedule or a note to the schedule, the value of
federal awards expended in the form of noncash assistance, the
amount of insurance in effect during the year, and loans or loan guarantees outstanding at year end?
[AAG-SLA 7.10]

If nonfederal data are presented in the schedule of expenditures of federal
awards:
a.

Are the nonfederal data segregated and clearly designated as nonfederal?

FSP §11,100.01

238

Health Care Entities

Yes
b.

4.

Is the title of the schedule modified to indicate that nonfederal awards
are included?
[AAG-SLA 7.14]

If the auditee is unable to obtain the CFDA number, does the schedule
include
a.

a statement that the CFDA number is not available?

b.

if available, other identifying numbers?
[AAG-SLA 7.15]
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FSP Section 11,200
Auditors’ Reports Checklist
.01 This section of the checklist has been developed primarily to address the requirements most likely
to be encountered when reporting on financial statements of health care entities in accordance with generally
accepted auditing standards (GAAS) as issued by the Auditing Standards Board (ASB), a senior technical
committee of the AICPA. Certain key differences in reporting requirements between audits conducted in
accordance with GAAS and audits conducted in accordance with the rules and standards of the Public
Company Accounting Oversight Board (PCAOB) are identified in bold text throughout this section of the
checklist. However, the differences identified are not intended to be all inclusive, and readers should seek
appropriate guidance for a comprehensive source of reporting requirements associated with audits conducted in accordance with the rules and standards of the PCAOB.
.02 This section does not contain all requirements for reports required to be issued in audits in accordance with Government Auditing Standards (Yellow Book), with the audit requirements of Office of Management and Budget Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations (Single
Audits), or PCAOB professional standards.
Yes
1.

Is each financial statement audited specifically identified in the introductory paragraph of the auditor’s report?
[AU 508.06]

2.

Do the titles of the financial statements referred to in the introductory
paragraph of the auditor’s report match the titles of the financial
statements presented?
[Common Practice]

3.

Do the dates of the financial statements referred to in the introductory
paragraph of the auditor’s report match the dates of the financial
statements presented?
[Common Practice]

4.

Is the report appropriately addressed?
[AU 508.09]

No

N/A

Practice Tip
Interpretation No. 17, “Clarification in the Audit Report of the Extent of Testing of Internal Control Over
Financial Reporting in Accordance With Generally Accepted Auditing Standards,” of AU section 508, Reports on Audited Financial Statements (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .85–.88), provides language that may be added to the auditor’s standard report on the financial statements of a nonissuer
to clarify differences between a GAAS audit and an audit conducted in accordance with the standards of
the PCAOB. Interpretation No. 18, “References to PCAOB Standards in an Audit Report on a Nonissuer,”
of AU section 508 (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .89–.92) explains how the auditor
should report if engaged to also follow PCAOB auditing standards in the audit of a nonissuer.
5.

Does the independent auditor’s report include the following elements:
a.

A title that includes the word independent?
[AU 508.08a]
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Yes
b.

The titles of each financial statement in the introductory paragraph of the report?
[AU 508.06]

c.

If the financial statements include a separate statement of
changes in stockholders’ equity accounts, it is identified in the
introductory paragraph of the report?
[AU 508.06]

d.

A statement that the financial statements are the responsibility
of management and that the auditor’s responsibility is to express an opinion on the financial statements based on his or her
audit?
[AU 508.08c]

e.

For audits conducted in accordance with GAAS in the United
States, a statement that the audit was conducted in accordance
with GAAS and an identification of the country of origin of
those standards (for example, auditing standards generally accepted in the United States of America or U.S. GAAS)?
[AU 508.08d]

f.

(Audits of Issuers Only) A statement that the audit was conducted in accordance with the standards of the Public Company
Accounting Oversight Board (United States)?
[PCAOB Auditing Standard 1 par. 3]

g.

A statement that those standards require that the auditor plan
and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement?
[AU 508.08e]

h.

A statement that an audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements; assessing the accounting principles used and
significant estimates made by management; and evaluating the
overall financial statement presentation?
[AU 508.08f]

i.

A statement that the auditor believes that his or her audit provides a reasonable basis for his or her opinion?
[AU 508.08g]

j.

When the auditor reports on financial statements presented in
conformity with U.S. generally accepted accounting principles
(GAAP), an opinion concerning whether the financial statements present fairly, in all material respects, the financial position of the reporting entity as of the balance sheet date and the
results of its operations and its cash flows for the period then
ended in conformity with GAAP? The opinion should include
an identification of the United States of America as the country
of origin of those accounting principles.
[AU 508.08h]
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Yes

No

N/A

Notes: Interpretation No. 19, “Financial Statements Prepared in Conformity
With International Financial Reporting Standards as Issued by the International Accounting Standards Board,” of AU section 508 (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .93–.97) provides that, when the
auditor of a nonissuer reports on financial statements prepared in conformity with International Financial Reporting Standards (IFRSs), the auditor
would refer, in the auditor’s report, to the IFRSs rather than U.S. GAAP.
When an auditor of a nonissuer reports on financial statements presented
in conformity with both the IFRSs as issued by the International Accounting Standards Board (IASB) and a jurisdictional variation of the IFRSs, the
auditor would refer, in the auditor’s report, to both the IFRSs and the IFRSs
as endorsed by [insert name of endorsing country or economic union].
When an auditor of a nonissuer reports on financial statements presented
in conformity with a jurisdictional variation of the IFRSs such that the entity’s financial statements do not contain an explicit and unreserved statement of compliance with the IFRSs as issued by the IASB, paragraphs
.14–.15 of AU section 534, Reporting on Financial Statements Prepared for Use
in Other Countries (AICPA, Professional Standards, vol. 1), and paragraphs
.35–.60 of AU section 508 (AICPA, Professional Standards, vol. 1) apply to
financial statements prepared for more than limited distribution in the
United States.
k.

When the auditor reports on financial statements presented in
conformity with the IFRSs, an opinion concerning whether the
financial statements present fairly, in all material respects, the
financial position of the reporting entity as of the balance sheet
date and the results of its operations and its cash flows for the
period then ended in conformity with the IFRSs as issued by the
IASB?
[AU 9508.93–.97]

l.

When the auditor reports on financial statements presented both
in conformity with the IFRSs and a jurisdictional variant of the
IFRSs, an opinion concerning whether the financial statements
present fairly, in all material respects, the financial position of
the reporting entity as of the balance sheet date and the results
of its operations and its cash flows for the period then ended in
conformity with the IFRSs as issued by the IASB and with the
IFRSs as endorsed by [insert name of endorsing country or economic
union]?
[AU 9508.93–.97]
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Yes
m.

When the auditor reports on financial statements presented in
conformity with a jurisdictional variation of the IFRSs such that
the entity’s financial statements do not contain an explicit and
unreserved statement of compliance with the IFRSs as issued by
the IASB, a variation of the standard report that reflects the
guidance in paragraphs .14–.15 of AU section 534 and paragraphs .35–.60 of AU section 508 (AICPA, Professional Standards,
vol. 1) for financial statements prepared for more than limited
distribution in the United States?
[AU 9508.93–.97]

n.

The manual or printed signature of the auditor’s firm?
[AU 508.08i]

o.

The date of the audit report?
[AU 508.08j; AU 530.05]

No

N/A

Practice Tip
The independent auditor has 2 methods available for dating the report when a subsequent event disclosed
in the financial statements occurs after the original date of the auditor’s report but before the issuance of the
related financial statements. The auditor may use "dual dating" (for example, "February 16, 20pp, except for
Note pp, for which the date is March 1, 20pp,") or may date the report as of the later date. In the former
instance, the responsibility for events occurring subsequent to the original report date is limited to the specific event referred to in the note (or otherwise disclosed). In the latter instance, the independent auditor’s
responsibility for subsequent events extends to the date of the report, and, accordingly, the procedures outlined in paragraph .12 of AU section 560, Subsequent Events (AICPA, Professional Standards, vol. 1), generally
should be extended to that date.
6.

7.

Does the reporting language conform with the auditor’s standard report on
a.

financial statements of a single year or period?

b.

comparative financial statements?
[AU 508.08]

Does the report include appropriate language for the following situations:
a.

Only one basic financial statement is presented and there are no
scope limitations?
[AU 508.33–.34]

b.

Audited and unaudited financial statements are presented in
comparative form?
[AU 504.15–.17]

c.

Different opinions are expressed on comparative financial statements?
[AU 508.05]
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No

N/A

Note: Interpretation No. 14, “Reporting on Audits Conducted in Accordance With Auditing Standards Generally Accepted in the United States of
America and in Accordance With International Standards on Auditing,” of
AU section 508 (AICPA, Professional Standards, vol. 1, AU sec. 9508 par.
.56–.59) provides that, when the audit of a nonissuer is conducted both in
accordance with standards generally accepted in the United States of
America and in accordance with the International Standards on Auditing
(ISAs), the auditor may so indicate in the auditor’s report. To determine
whether an audit was conducted in accordance with the ISAs, it is necessary to consider the text of the ISAs in their entirety, including the basic
principles and essential procedures together with the related guidance included in the ISAs.

Practice Tip
If the audit of financial statements to be used in the United States was conducted in accordance with auditing standards generally accepted in the United States of America and ISAs as issued by the International
Auditing and Assurance Standards Board, in their entirety, although not required, has the auditor considered indicating in the auditor‘s report that the audit was also conducted in accordance with ISA as allowed.
[AU 9508.57–.59]
8.

Is the reporting form, content, and timing of paragraphs .20–.30 of
AU section 325A, Communicating Internal Control Related Matters Identified in an Audit (AICPA, Professional Standards, vol. 1), followed when
communicating matters related to an organization’s internal control
over financial reporting identified in an audit of financial statements?
[AU 325A.20–.30]

Note: Auditors are required to communicate control deficiencies identified
during an audit that are significant deficiencies or material weaknesses as
defined by AU section 325A, including significant deficiencies or material
weaknesses that were communicated in previous audits and have not yet
been remediated. Those control deficiencies must be communicated in
writing to management and those charged with governance. In October
2008, the ASB issued Statement on Auditing Standards (SAS) No. 115, Communicating Internal Control Related Matters Identified in an Audit (AICPA, Professional Standards, vol. 1, AU sec. 325), to eliminate differences within the
AICPA’s Audit and Attest Standards resulting from the issuance of Statement on Standards for Attestation Engagements (SSAE) No. 15, An Examination of an Entity’s Internal Control Over Financial Reporting That Is Integrated
With an Audit of Its Financial Statements (AICPA, Professional Standards, vol.
1, AT sec. 501). SAS No. 115 supersedes SAS No. 112 and revises the information in AU section 325A. SAS No. 115 is effective for audits of financial
statements for periods ending on or after December 15, 2009. Earlier application is permitted. Due to the issuance of SAS No. 115, the content of SAS
No. 112 has been moved to AU section 325A of Professional Standards until
the effective date of SAS No. 115.
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Yes
9.

10.

If a subsequent event disclosed in the financial statements occurs after
the original date of the independent auditor’s report but before the
issuance of the related financial statements, has the auditor followed
one of the following two methods available for dating the report:
a.

Dual dating, in which the independent auditor’s responsibility
for events occurring subsequent to the original report date is
limited to the specific event referred to in an explanatory note
in the report (or otherwise disclosed)?

b.

Dating the report as of the later date, in which the independent
auditor’s responsibility for subsequent events extends to the
date of the report?
[AU 530.03–.05]

(Audits of Issuers Only) If the auditor obtains knowledge about a
subsequent event that
a.

b.

11.

materially and adversely affects the effectiveness of the entity’s
internal control over financial reporting as of the date specified
in the assessment, has the auditor either
i.

issued an adverse opinion on internal control over financial reporting (and followed the direction in paragraph C2
of PCAOB Auditing Standard No. 5 if management’s assessment states that internal control over financial reporting is effective)?

ii.

disclaimed an opinion if the auditor is unable to determine
the effect of the subsequent event on the effectiveness of
the entity’s internal control over financial reporting?

relates to conditions that did not exist at the date specified in
the assessment but arose subsequent to that date and before issuance of the auditor’s report, and the subsequent event has a
material effect on the entity’s internal control over financial reporting, has the auditor included in his or her report an explanatory paragraph describing the event and its effects or directed
the reader’s attention to the event and its effects as disclosed in
management’s report?
[PCAOB Auditing Standard No. 5 par. .96–.97]

If the accountant is not independent, has he or she followed one of
the two reporting alternatives available:
a.

Disclaiming the opinion with respect to the financial statements
and specifically stating that he or she is not independent?

b.

Issuing a compilation report in accordance with Statements on
Standards for Accounting and Review Services (SSARSs) indicating the lack of independence (nonpublic entities only)?
[AU 504.05 and .09–.10; AR 100.21 and .48]
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Yes

No

N/A

Note: The Accounting and Review Services Committee (ARSC) issued
an exposure draft that would revise the standards for compilation
and review engagements. Significant changes to SSARSs include the
following:
●

The introduction of new terms, such as review evidence and
review risk, to the review literature to harmonize with international review standards.

●

A discussion of materiality in the context of a review engagement.

●

A requirement that an accountant document the establishment of an understanding with management through a written communication (that is, an engagement letter) regarding
the services to be performed.

●

The establishment of enhanced documentation requirements
for compilation and review engagements.

●

The ability for an accountant to include a general description
in the accountant’s compilation report regarding the reason(s)
for an independence impairment.

ARSC voted to issue these revisions as a final standard, SSARS No.
19, Compilation and Review Engagements (AICPA, Professional Standards,
vol. 2). The standard is expected to be issued in December 2009. The
effective date is for compilations and reviews of financial statements
for periods beginning on or after December 15, 2010. Early application would be permitted with respect to permitting an accountant to
disclose the reasons for a lack of independence in a compilation report.
12.

If the opinion is based in part on the report of another auditor,
a.

does the introductory paragraph of the standard report disclose
the fact that the opinion is based, in part, on the report of other
auditors?

b.

does the opinion paragraph include a reference to the report of
the other auditor?
[AU 508.11a, .12, and .13]

13.

If, to prevent the financial statements from being misleading because
of unusual circumstances, the financial statements contain a departure from an accounting principle promulgated by a body designated
by the AICPA Council to establish such principles, does the report
include, in a separate paragraph or paragraphs, the information required by the rule?
[AU 508.11b and .15]

14.

If the auditor uses the work of a specialist in performing an audit,
have they added an optional explanatory paragraph?
[AU 336.16]
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No

N/A

Note: Reference to and identification of the specialist may be added if
the auditor believes such a reference will facilitate an understanding
of the reason for the explanatory paragraph.
[AU 336.16]
15.

If there is substantial doubt about the entity’s ability to continue as a
going concern for a reasonable period of time, not to exceed one year
beyond the date of the financial statements being audited,
a.

does the report include an explanatory paragraph, following the
opinion paragraph, to reflect that conclusion?

b.

is that conclusion expressed through the use of the phrase “substantial doubt about its (the entity’s) ability to continue as a going concern” or similar wording that includes the terms substantial doubt and going concern?
[AU 508.11c; AU 341.12]
Practice Tip

In evaluating whether there is substantial doubt about the entity’s ability to continue as a going concern, the
auditor’s evaluation is based on his or her knowledge of relevant conditions that exist at or have occurred
prior to the date of the auditor’s report. If, after considering identified conditions and events and management’s
plans, the auditor concludes that substantial doubt about the entity’s ability to continue as a going concern
for a reasonable period of time remains, the audit report should include an explanatory paragraph to reflect
that conclusion.
In a going concern paragraph, the auditor should not use conditional language in expressing a conclusion
concerning the existence of substantial doubt about the entity’s ability to continue as a going concern. See
paragraph .13 of AU section 341, The Auditor’s Consideration of an Entity’s Ability to Continue as a Going Concern (AICPA, Professional Standards, vol. 1), for an example.
16.

Is the report dated no earlier than the date on which the auditor has
obtained sufficient appropriate audit evidence to support the auditor’s opinion on the financial statements?
[AU 530.01]

17.

(Audits of Issuers Only) Is the report dated no earlier than the date
on which the auditor has obtained sufficient competent evidence to
support the auditor‘s opinion on the financial statements?
[PCAOB Auditing Standard No. 5 par. 89]

18.

(Audits of Issuers Only) When performing an integrated audit of financial statements and internal control over financial reporting, are
the auditor’s reports on the entity’s financial statements and on internal control over financial reporting dated the same?
[PCAOB Auditing Standard No. 5 par. 89]

19.

(Audits of Issuers Only) Prior to the report release date, among other
matters, has the auditor obtained sufficient evidence to support the
representations in the auditor’s reports?
[PCAOB Auditing Standard No. 3 par. 15]
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Practice Tip
Changes in Accounting Estimates
Paragraph .15 of AU section 420, Consistency of Application of Generally Accepted Accounting Principles (AICPA,
Professional Standards, vol. 1), clarifies that the change in an accounting estimate that does not include a
change in accounting principle does not require an explanatory paragraph in the auditor’s report. However,
an accounting change of this type having a material effect on the financial statements may require disclosure
in a note to the financial statements.
Changes in Classification
Paragraph .17 of AU section 420 clarifies that changes in classification from the prior year’s financial statements are usually not of sufficient importance to necessitate disclosure; however, material changes in classification should be indicated and explained in the financial statements or notes.
Error Corrections
Paragraph .16 of AU section 420 states that the correction of an error in previously issued financial statements resulting from mathematical mistakes, oversight, or misuse of facts that existed at the time the financial statements were originally prepared does not involve the consistency standard if no element of accounting principles or their application is included. Accordingly, the independent auditor need not recognize the
correction in his report. However, if the independent auditor had previously reported on the financial statements containing the error, the auditor has concluded, based on the considerations in paragraph .05 of AU
section 561, Subsequent Discovery of Facts Existing at the Date of the Auditor’s Report (AICPA, Professional Standards, vol. 1), that action should be taken to prevent future reliance on his report, and the issuance of financial statements accompanied by the auditor’s report for a subsequent period is imminent, the auditor should
disclose the revision in such statements instead of reissuing the earlier statements.

Notes: For audits of issuers, certain circumstances, although not affecting
the auditor’s unqualified opinion, may require that the auditor add explanatory language to the standard report as described in paragraphs .11–.19 of
AU section 508, Reports on Audited Financial Statements (AICPA, PCAOB
Standards and Related Rules, Interim Standards).
Other circumstances may require a departure from an unqualified opinion,
either in the form of a qualified opinion, an adverse opinion, or a disclaimed opinion as described in paragraphs .20–.63 of AU section 508
(AICPA, PCAOB Standards and Related Rules, Interim Standards).
For special reporting situations relating to the auditor’s report on internal
control over financial reporting, refer to appendix C, Special Reporting Situations, of Auditing Standard No. 5.
******
PCAOB Auditing Standard No. 6, Evaluating Consistency of Financial Statements (AICPA, PCAOB Standards and Related Rules, Auditing Standards),
updated the auditor’s responsibilities to evaluate and report on the consistency of an entity’s financial statements and align the auditor’s responsibilities with Financial Accounting Standards Board (FASB) Statement No. 154,
Accounting Changes and Error Corrections.
One significant difference in terminology between FASB Statement No. 154
(which is codified in FASB Accounting Standards Codification (ASC) 250,
(continued)
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Accounting Changes and Error Corrections) and Auditing Standard No. 6 is
the use of the term error in the FASB standard whereas the PCAOB standard uses the term misstatement and specifically states that the meaning is
the same for purposes of the PCAOB Auditing Standards. Auditing Standard No. 6 also establishes that the auditor’s report should indicate
whether an adjustment to previously issued financial statements results
from a change in accounting principle or the correction of a misstatement.
Auditing Standard No. 6 contains numerous amendments to AU section
508 (AICPA, PCAOB Standards and Related Rules, Interim Standards) and
other interim PCAOB Auditing Standards. If Auditing Standard No. 6 is
applicable to issuers’ financial statements, answer questions 21–22; otherwise, skip questions 21–22. For more information and for the full text of
the auditing standard, refer to the PCAOB Web site at www.pcaob.org.
Also refer to the Securities and Exchange Commission (SEC) Web site at
www.sec.gov.
20.

21.

If there has been a material change between periods in accounting
principles or in the method of their application, including a change
from an accounting principle that is not generally accepted to one that
is generally accepted and a change in accounting principle that is inseparable from the effect of a change in estimate, that has a material
effect on the comparability of the reporting entity’s financial statements,
a.

does the report include an explanatory paragraph, following the
opinion paragraph that refers to the change?

b.

does the explanatory paragraph identify the nature of the
change and refer the reader to the note to the financial statements that discusses the change in detail?
[AU 508.05–.06 and .12–.13]

c.

if the change in the accounting principle is a change in reporting
entity that did not result from a transaction or an event, is an
explanatory paragraph included in the auditor’s report? (Note:
A change in the reporting entity resulting from a transaction or
event, such the creation, cessation, or complete or partial purchase or disposition of a subsidiary or other business unit, does
not require that an explanatory paragraph about consistency be
included in the auditor’s report.)
[AU 420.08]

(Audits of Issuers Only) If there has been a change in accounting
principle that has a material effect on the financial statements, including a change in the method of applying an accounting principle, a
change in estimate effected by a change in accounting principle, and
a change in classification that represents a change in accounting principle, and meets the four criteria established in paragraph 7 of
PCAOB Auditing Standard No. 6,
a.

does the report include an explanatory paragraph, following the
opinion paragraph, in the year of the change and in subsequent
years until the new accounting principle is applied in all periods
presented?
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22.

23.

24.

b.

does the explanatory paragraph identify the nature of the
change and include a reference to the note disclosure describing
the change?

c.

if the change in the accounting principle is a change in reporting
entity that did not result from a transaction or an event, is an
explanatory paragraph included in the auditor’s report? (Note:
A change in the reporting entity resulting from a transaction or
event, such the creation, cessation, or complete or partial purchase or disposition of a subsidiary or other business unit, does
not require recognition in the auditor’s report.)
[PCAOB Auditing Standard No. 6 par. 4–8 and 11]

No

N/A

(Audits of Issuers Only) If there has been a correction of a material
misstatement in previously issued financial statements, including a
change from an accounting principle that is not generally accepted to
one that is generally accepted and a change in classification that represents the correction of a material misstatement, does the auditor’s
report contain an explanatory paragraph, following the opinion paragraph, that includes
a.

a statement that the previously issued financial statements have
been restated for the correction of a misstatement in the respective period?

b.

a reference to the entity’s disclosure of the correction of the misstatement?
[PCAOB Auditing Standard No. 6 par. 5 and 9–11]

In an updated report on the individual financial statements of one or
more prior periods presented on a comparative basis with those of
the current period, if the opinion is different from the opinion previously expressed on the financial statements of a prior period,
a.

does the report include an explanatory paragraph, preceding the
opinion paragraph that discloses all of the substantive reasons
for the different opinion?

b.

does the explanatory paragraph disclose
i.

the date of the auditor’s previous report?

ii.

the type of opinion previously expressed?

iii.

the circumstances or events that caused the auditor to express a different opinion?

iv.

that the auditor’s updated opinion on the financial statements of the prior period is different from his or her previous opinion on those statements?
[AU 508.11e and .69]

If financial statements of a prior period (presented for comparative
purposes) have been audited by a predecessor auditor whose report
is not presented,
a.

does the introductory paragraph of the report indicate
i.

that the financial statements of the prior period were audited by another auditor?

ii.

the date of the predecessor auditor’s report?
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b.

25.

iii.

the type of report issued by the predecessor auditor?

iv.

if the report was other than a standard report, the substantive reasons therefore, including a description of the nature
of and reasons for the explanatory paragraph added to the
predecessor’s report or his or her opinion qualification?

if the financial statements have been restated, does the introductory paragraph indicate that the predecessor auditor reported
on the financial statements of the prior period before restatement?
[AU 508.11e and .74]

Is an explanatory paragraph (or other explanatory language) added
to the standard auditor’s report if
a.

the auditor wishes to clarify that an audit performed in accordance with GAAS does not require the same level of testing and
reporting on internal control over financial reporting as an audit
of an issuer when Section 404(b) of the Sarbanes-Oxley Act is
applicable? (Note: Not required—Interpretation No. 17 of AU
section 508 [AICPA, Professional Standards, vol. 1] provides an
example report.)
[AU 9508.85–.88]

b.

the audit is conducted in accordance with both GAAS and the
PCAOB’s Auditing Standards as allowed by Interpretation No.
18 of AU section 508 (AICPA, Professional Standards, vol. 1)?
(Note: Not required—Interpretation No. 18 of AU section 508
[AICPA, Professional Standards, vol. 1] provides an example report.)
[AU 9508.89–.92]

26.

Is an explanatory paragraph (or other explanatory language) added
to the standard auditor’s report if the prior period’s financial statements are audited by a predecessor auditor who has ceased operations?
[AU 9508.60–.75]

27.

If selected quarterly financial data required by SEC Regulation S-K
has been omitted or has not been reviewed, does the report include
an additional paragraph stating that fact?
[AU 508.11f; AU 722.50]

Note: In February 2009, the ASB issued SAS No. 116, Interim Financial Information (AICPA, Professional Standards, vol. 1, AU sec. 722). SAS No. 116
amends AU section 722 to accommodate reviews of interim financial information of nonissuers, including companies offering securities pursuant to
SEC Rule 144A or participating in private equity exchanges. SAS No. 116
is effective for audits of financial statements for periods beginning on or
after December 15, 2009. Earlier application is permitted.
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28.

If other information in a document containing audited financial statements is materially inconsistent with information appearing in the financial statements, has it been determined whether the financial
statements, the auditor’s report, or both require revision?
[AU 508.11h; AU 550.04]

29.

If the auditor decides to emphasize a matter regarding the financial
statements in the report, is the matter being emphasized disclosed in
the financial statements’ and is the explanatory information presented
in a separate paragraph that avoids use of phrases such as “with the
foregoing (following) explanation”?
[AU 508.11 and .19; AU 9410.18; AU 9342.03]

30.

If it has not been possible to conduct the audit in accordance with
GAAS or to apply all of the procedures considered necessary in the
circumstances, has consideration been given to the need to issue a
qualified opinion or to disclaim an opinion?
[AU 508.22]

31.

If a qualified opinion is to be expressed because of a scope limitation,
a.

are all of the substantive reasons for the qualification disclosed
in one or more explanatory paragraphs preceding the opinion
paragraph?

b.

does the qualified opinion include the word except or exception
in a phrase such as except for or with the exception of?

c.

is the situation described and referred to in both the scope and
opinion paragraphs?

d.

does the wording in the opinion paragraph indicate that the
qualification pertains to the possible effects on the financial
statements and not to the scope limitation itself?
[AU 508.22–.32; AU 318.76]

No

N/A

Practice Tip
Scope limitations can be imposed by the client or by circumstances such as the timing of the auditor’s work,
the inability to obtain sufficient appropriate audit evidence, or an inadequacy in the accounting records.
Sufficient appropriate audit evidence includes, among other things, management having asserted responsibility for the final financial statements. As provided in Technical Questions and Answers (TIS) section
9100.06, “The Effect of Obtaining the Management Representation Letter on Dating the Auditor’s Report”
(AICPA, Technical Practice Aids), the auditor will need to have the signed management representation letter
in hand prior to releasing the auditor’s report because management’s refusal to furnish written representations constitutes a limitation on the scope of the audit sufficient to preclude an unqualified opinion.
In circumstances in which the auditor is unable to obtain sufficient appropriate audit evidence to support
management’s assertions about the nature of a matter involving an uncertainty and its presentation or disclosure in the financial statements, the auditor should consider the need to express a qualified opinion or to
disclaim an opinion because of a scope limitation.
It also includes situations in which the auditor’s only evidence of the existence, valuation, or both, of (a)
investments without readily determinable fair value, or (b) interests held in trust by a third-party trustee, is
receiving confirmation from a third party for those assets.
(continued)
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In circumstances in which the auditor is unable to audit the existence or measurement of interests in investments in securities and interests in trusts, the auditor should consider whether that scope limitation requires
the auditor to either qualify his or her opinion or to disclaim an opinion, as discussed in paragraphs .22–.26
of AU section 508 (AICPA, Professional Standards, vol. 1); Interpretation No. 1, “Auditing Interests in Trusts
Held by a Third-Party Trustee and Reported at Fair Value,” of AU section 328, Auditing Fair Value Measurements and Disclosures (AICPA, Professional Standards, vol. 1, AU sec. 9328 par. .01–.04); and Interpretation No.
1, “Auditing Investments in Securities Where a Readily Determinable Fair Value Does Not Exist,” of AU
section 332, Auditing Derivative Instruments, Hedging Activities, and Investments in Securities (AICPA, Professional Standards, vol. 1, AU sec. 9332 par. .01–.04).
32.

33.

Is a qualified opinion or disclaimer of opinion expressed if the auditor’s understanding of internal control raises doubts about the auditability of an entity’s financial statements, such as
a.

concerns about the integrity of an entity’s management cause
the auditor to conclude that the risk of management misrepresentation in the financial statements is such that an audit cannot
be conducted?

b.

concerns about the condition and reliability of an entity’s records cause the auditor to conclude that it is unlikely that sufficient appropriate audit evidence will be available to support an
unqualified opinion on the financial statements?
[AU 314.109]

If, in the auditor’s judgment, the two-way communication between
the auditor and those charged with governance as described in AU
section 380 is not adequate and the situation cannot be resolved,
thereby prohibiting the auditor from obtaining all the audit evidence
required to form an opinion on the financial statements, has the auditor considered the following:
a.

Modifying the audit opinion on the basis of a scope limitation?

b.

Obtaining legal advice about the consequences of different
courses of action?

c.

Communicating with an appropriate third party (for example, a
regulator)?

d.

Withdrawing from the engagement?
[AU 380.63]

34.

If, in the auditor’s judgment, significant difficulties in dealing with
management such as those described in AU section 380, have been
encountered, has the auditor considered modifying the audit opinion
on the basis of a scope limitation?
[AU 380.39]

35.

If an opinion is disclaimed because of a scope limitation,
a.

are all of the substantive reasons for the disclaimer stated in a
separate paragraph or paragraphs?

b.

does the report state that the scope of the audit was not sufficient to warrant the expression of an opinion?
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c.

does the report avoid identifying procedures that were performed?

d.

is the scope paragraph omitted?

e.

if there are reservations about fair presentation of the financial
statements in conformity with GAAP, are they described in the
report?
[AU 508.62–.63]

No

N/A

Note: Consult the Topical Index to AICPA Professional Standards under
“Scope of Audit—Limitations” for additional references to specific types of
scope limitations that could result in either a qualified or disclaimer of
opinion.
36.

If the financial statements are materially affected by a departure from
GAAP (including, for example, inadequate disclosure, inappropriate
accounting principles, and unreasonable accounting estimates), has
the auditor issued a qualified opinion or an adverse opinion?
[AU 508.35]

37.

If a qualified opinion is to be expressed because of a GAAP departure,

38.

39.

a.

are all of the substantive reasons that have led to the conclusion
that there is a departure from GAAP disclosed in one or more
separate explanatory paragraphs preceding the opinion paragraph?

b.

does the qualified opinion include the word except or exception
in a phrase such as except for or with the exception of and a reference to the explanatory paragraph?

c.

does the explanatory paragraph disclose the principle effects of
the departure on financial position, results of operations, and
cash flows, if practicable, or state that the effects are not reasonably determinable?
[AU 508.21 and AU 508.37–.39]

If an adverse opinion is to be expressed because of a GAAP departure,
a.

are all of the substantive reasons for the adverse opinion disclosed in one or more separate explanatory paragraphs preceding the opinion paragraph?

b.

does the explanatory paragraph disclose the principle effects of
the departure on financial position, results of operations, and
cash flows, if practicable, or state that the effects are not reasonably determinable?

c.

state that the financial statements do not present fairly the financial position, or results of operations or cash flows in conformity
with GAAP?
[AU 508.58–.59]

If essential data concerning an impending change in GAAP and the
future resulting restatement are not disclosed, has the auditor issued
a qualified or adverse opinion?
[AU 9410.15]
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40.

No

N/A

If the auditor concludes that an illegal act has a material effect on the
financial statements and the act has not been properly accounted for
or disclosed, has the auditor issued a qualified or adverse opinion
(depending on the materiality effect on the financial statements taken
as a whole)?
[AU 317.18]

Note: Consult the Topical Index to AICPA Professional Standards under “Departures From Standard Report” for additional information.
Readers may also wish to refer to TIS section 1400.31, “GAAP Departure
for FASB ASC 810” (AICPA, Technical Practice Aids), for assistance in determining the implications on the auditors report if the reporting entity does
not consolidate a variable interest entity.

Practice Tip
Reporting on financial statements prepared in conformity with an other comprehensive basis of accounting
(OCBOA) is addressed in AU section 623, Special Reports (AICPA, Professional Standards, vol. 1). For purposes
of that section, a comprehensive basis of accounting other than GAAP is one of the following:
a.

A basis of accounting that the reporting entity uses to comply with the requirements or financial
reporting provisions of a governmental regulatory agency to whose jurisdiction the entity is subject.
An example is a basis of accounting insurance companies use pursuant to the rules of a state insurance commission.

b.

A basis of accounting that the reporting entity uses or expects to use to file its income tax return for
the period covered by the financial statements.

c.

The cash receipts and disbursements basis of accounting, and modifications of the cash basis having
substantial support, such as recording depreciation on fixed assets or accruing income taxes.

d.

A definite set of criteria having substantial support that is applied to all material items appearing in
financial statements, such as the price-level basis of accounting.

In considering whether the financial statements (including the accompanying notes) include all informative
disclosures that are appropriate for the basis of accounting used, paragraph .09 of AU section 623 states that
the auditor should apply essentially the same criteria to financial statements prepared on an other comprehensive basis of accounting as he or she does to financial statements prepared in conformity with GAAP.
41.

When reporting on financial statements prepared in conformity with
a comprehensive basis of accounting other than GAAP, as defined in
paragraph .04 of AU section 623, does the independent auditor’s report include the following elements (for audits prepared in conformity with GAAS):
a.

A title that includes the word independent?
[AU 623.05a]

b.

A paragraph that states that
i.
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ii.

c.

d.

No

N/A

the financial statements are the responsibility of the entity’s management and that the auditor is responsible for
expressing an opinion on the financial statements based on
the audit?
[AU 623.05b]

A paragraph that states that
i.

the audit was conducted in accordance with GAAS with
specific identification of the United States of America as
the country of origin of those standards?

ii.

those standards require that the auditor plan and perform
the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement?

iii.

an audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements; assessing the accounting principles used and significant estimates made by management; and evaluating the
overall financial statement presentation?

iv.

the auditor believes that his or her audit provides a reasonable basis for the opinion?
[AU 623.05c]

A paragraph that states
i.

the basis of presentation and refers to the note to the financial statements that describes the basis?

ii.

that the basis of presentation is a comprehensive basis of
accounting other than GAAP?
[AU 623.05d]

e.

A paragraph that expresses the auditor’s opinion (or disclaims
an opinion) on whether the financial statements are presented
fairly, in all material respects, in conformity with the basis of
accounting described?
[AU 623.05e]

f.

If the financial statements are prepared in conformity with the
requirements or financial reporting provisions of a governmental regulatory agency, a separate paragraph at the end of the
report stating that the report is intended solely for the information and use of those within the entity and the regulatory agencies to whose jurisdiction the entity is subject, and is not intended to be and should not be used by anyone other than these
specified parties?
[AU 623.05f]

g.

The manual or printed signature of the auditor’s firm?
[AU 623.05g]

h.

The date of the audit report?
[AU 623.05h]
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42.

When the financial statements are prepared in conformity with the
requirements or financial reporting provisions of a governmental regulatory agency and the financial statements and reports will be used
by parties or distributed by the entity to parties other than the regulatory agencies to whose jurisdiction the entity is subject, has the standard form of report been modified as appropriate because of the departures from GAAP and has an additional paragraph been added to
express an opinion on whether the financial statements are presented
in conformity with the regulatory basis of accounting? (Note: Interpretation 15, “Auditor Reports on Regulatory Accounting or Presentation When the Regulated Entity Distributes the Financial Statements
to Parties Other Than the Regulatory Agency Either Voluntarily or
Upon Specific Request,” of AU section 623 [AICPA, Professional Standards, vol. 1, AU sec. 9623 par. .96–.98] provides an example report.)
[AU 544.04; AU 9623.96–.98]

43.

If certain other information, including supplementary information required by GAAP, contained in annual reports and other client-prepared documents described in paragraph .02 of AU section 550, Other
Information in Documents Containing Audited Financial Statements
(AICPA, Professional Standards, vol. 1), that contain audited financial
statements has been subjected to auditing procedures applied in the
audit of the basic financial statements, does the auditor express an
opinion on whether the information is fairly stated in all material respects in relation to those financial statements taken as a whole in the
auditor’s report and does the report describe clearly the character of
the auditor’s work and the degree of responsibility the auditor is taking?
[AU 550.07; AU 558.09]

44.

If other information contained in annual reports and other client-prepared documents described in AU section 550 paragraph .02 that contain audited financial statements is materially inconsistent with information appearing in the financial statements, has it been determined
whether the financial statements, the auditor’s report, or both require
revision?
[AU 508.11h; AU 550.04]

45.

If other information contained in annual reports and other client-prepared documents described in AU section 550 paragraph .02 that contain audited financial statements is materially inconsistent with information appearing in the financial statements, and the auditor has
determined that neither the financial statements nor the auditor’s report require revision, has the auditor either
a.

requested that the client revise the other information to eliminate the material consistency?

b.

considered other actions such as revising the audit report to include an explanatory paragraph describing the material inconsistency, withholding the use of the audit report in the document, and withdrawing from the engagement?
[AU 550.04]
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46.

47.

No

N/A

If information accompanies the basic financial statements and auditor’s report in an auditor-submitted document, is it accompanied by
a report that
a.

states that the audit was performed for the purpose of forming
an opinion on the basic financial statements taken as a whole?

b.

specifically identifies the accompanying information?

c.

states that the accompanying information is presented for purposes of additional analysis and is not a required part of the
basic financial statements?

d.

includes either an opinion on whether the accompanying information is fairly stated in all material respects in relation to the
basic financial statements taken as a whole or a disclaimer of
opinion (depending on whether the information was subjected
to the auditing procedures applied in the audit of the basic financial statements)?
[AU 551.05–.06]

If information accompanying the basic financial statements and auditor’s report in an auditor-submitted document is materially misstated in relation to the basic financial statements taken as a whole,
has the auditor either
a.

requested that the client revise the accompanying information
to eliminate the material misstatement?

b.

considered other actions such as modifying the audit report to
describe the misstatement or refusing to include the accompanying information in the auditor-submitted document?
[AU 551.09]

48.

When the basic financial statements are accompanied by supplementary information required by GAAP and such supplementary information has not been audited as part of the basic financial statements,
does the auditor’s report exclude any language that refers to the supplementary information or the limited procedures applied (except in
the circumstances described in AU section 558 paragraph .08)?
[AU 558.08]

49.

When the basic financial statements are accompanied by supplementary information required by GAAP and such supplementary information has been audited as part of the basic financial statements, has
the audit report been expanded in accordance with AU section 550
paragraph .07?
[AU 558.09]
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50.

If supplementary information required by GAAP has been omitted,
the presentation of such information departs materially from prescribed guidelines, the auditor is unable to complete prescribed procedures with respect to such information, or the auditor is unable to
remove substantial doubt about whether the supplementary information conforms to prescribed guidelines, does the report include an
additional paragraph stating that fact?
[AU 558.08]
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Auditors’ Reports Checklist for Audits
Performed in Accordance With
Government Auditing Standards and
OMB Circular A-133
.01 Government Auditing Standards (also referred to as the Yellow Book), issued by the Comptroller General of the United States of the U.S. Government Accountability Office (GAO; formerly U.S. General Accounting Office), applies to the audits of governmental entities, programs, activities, and functions, and of
governmental assistance administered by contractors, not-for-profit organizations, and other nongovernmental entities, when required by statute or other mandates or when auditors hold themselves out as following those standards.1 The Single Audit Act Amendments of 1996 (the Single Audit Act) and Office of Management and Budget (OMB) Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations,
require a single or program-specific audit for entities that expend $500,000 or more of federal awards in a
fiscal year. The Single Audit Act Amendments of 1996 requires single audits and program-specific audits of
federal awards to be performed in accordance with Government Auditing Standards. Similarly, Government
Auditing Standards requires the use of its standards when auditing compliance with regulations relating to
federal award expenditures and other governmental financial assistance in conjunction with or as a byproduct of a financial statement audit.
.02 This checklist has 2 parts. Part I is for auditor’s reports on financial statement audits performed in
accordance with Government Auditing Standards. (This checklist does not address the performance auditing
or attestation standards of Government Auditing Standards. It also does not address types of financial audits
other than financial statement audits, except for Circular A-133 audits.) Part II contains the additional requirements for auditor’s reports on audits performed in accordance with the Single Audit Act Amendments
of 1996 and Circular A-133. For audits performed in accordance with Circular A-133, both parts I and II of
this checklist must be completed. Illustrative auditor’s reports on financial statement audits performed in
accordance with Government Auditing Standards and illustrative auditor’s reports and an illustrative schedule
of findings and questioned costs for Circular A-133 audits are in the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits.
.03 The OMB issues an annual Circular A-133 compliance supplement for conducting single audits. That
supplement is available from the Government Printing Office by calling (202) 512-1800 and on the OMB’s
Web site at www.whitehouse.gov/omb/grants/grantspcirculars.html. The AICPA issues the annual Audit
Risk Alert Government Auditing Standards and Circular A-133 Audits Developments, as a complement to the
Audit Guide Government Auditing Standards and Circular A-133 Audits. The AICPA has also issued the
related practice aid Auditing Recipients of Federal Awards: Practical Guidance for Applying OMB Circular A-133,
Audits of States, Local Governments, and Non-Profit Organizations (product no. 006621).

1
As discussed in paragraph 4.26 of the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits (the guide),
paragraph 5.06 of Government Auditing Standards (GAS) acknowledges that an auditee may need a financial statement audit for purposes
other than to comply with a requirement calling for an audit in accordance with GAS. For example, the auditee may need a financial
statement audit to issue bonds. In that case, GAS permits auditors to issue a separate report on the financial statements conforming only
to the requirements of generally accepted auditing standards (GAAS). The information contained in this checklist is based on the GAS
July 2007 revision, which is effective for audits of periods beginning on or after January 1, 2008.
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.04 The Public Company Accounting Oversight Board (PCAOB) establishes standards for audits of issuers, as that term is defined by the Sarbanes-Oxley Act of 2002, or whose audit is prescribed by the rules of
the Securities and Exchange Commission. Other entities are referred to as nonissuers. Because not-for-profit
organizations are nonissuers, this checklist does not address PCAOB standards. However, although not
common, the auditor may be engaged to audit and report on the effectiveness of an not-for-profit organization’s internal control over financial reporting in accordance with PCAOB auditing standards. In those
cases, the auditor should modify this checklist considering the guidance in PCAOB standards, the GAO
Internet Notice at www.gao.gov/govaud/ybk01.htm titled Guidance on Complying with Government Auditing Standards Reporting Requirements for the Report on Internal Control for Audits of Certain Entities Subject to
the Requirements of the Sarbanes-Oxley Act of 2002 and Government Auditing Standards, and Interpretation
No. 18, “Reference to PCAOB Standards in an Audit Report on a Nonissuer,” of AU section 508, Reports on
Audited Financial Statements (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .89–.92), as well as the
discussion in the notice to readers and appendix A to chapter 4 of the AICPA Audit Guide Government
Auditing Standards and Circular A-133 Audits.
.05 This checklist has been updated for the revisions to OMB Circular A-133 published in the Federal
Register on June 26, 2007, that changes the reporting requirements on internal control deficiencies over compliance to be consistent with the control deficiency definitions of AU section 325A, Communicating Internal
Control Related Matters Identified in an Audit (AICPA, Professional Standards, vol. 1). Interpretation No. 1,
“Communicating Deficiencies in Internal Control Over Compliance in an Office of Management and Budget
(OMB) Circular A-133 Audit,” of AU section 325, Communicating Internal Control Related Matters Identified in
an Audit (AICPA, Professional Standards, vol. 1, AU sec. 9325 par. .01–.04), provides guidance on implementing these reporting requirements.
.06 Explanation of References:
A-133 5

OMB Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations (June 2007 Revision)

GAS 5

GAO 2007 revision to Government Auditing Standards, as amended through
Amendment No. 3, Independence

AU 5

Reference to section number in AICPA Professional Standards (vol. 1)

AAG 5

AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits (with conforming changes as of October 1, 2009)

.07 Checklist Questionnaire:
Yes

No

N/A

Part I—Reports on Audits Performed in Accordance With
Government Auditing Standards
1.

In a financial statement audit performed in accordance with Government Auditing Standards, has the auditor issued the following
reports:2
a.

2

A report on the entity’s financial statements that provides an
opinion or disclaimer of opinion on the financial statements?
[GAS 5.03; AAG 4.04 and .22]

There is no provision in GAS that requires the auditee to prepare financial statements in accordance with accounting principles
generally accepted in the United States of America (GAAP). If an auditee prepares financial statements in conformity with comprehensive
bases of accounting other than GAAP, known as other comprehensive bases of accounting, or OCBOA, the auditor still is required to
express or disclaim an opinion and should follow the reporting guidance in AU section 623, Special Reports (AICPA, Professional Standards,
vol. 1) (GAS paragraph 5.03 footnote 62 and paragraph 4.22h of the guide).
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Yes
b.

No
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N/A

A report on internal control over financial reporting and on
compliance with laws, regulations, and provisions of contracts or grant agreements based on an audit of financial
statements performed in accordance with Government Auditing Standards?
[GAS 5.07; AAG 4.04, .08, and .27]

Report on the Financial Statements
2.

In addition to the elements listed in the checklist for the auditor’s
report on the financial statements in FSP section 11,200, does the
auditor’s report on the financial statements contain
a.

a statement that the audit was conducted in accordance with
the standards applicable to financial audits contained in
Government Auditing Standards, issued by the Comptroller
General of the United States?3
[GAS 5.05; AAG 4.05a, .22d, and .24]

b.

a statement or a reference to a separate report on internal
control over financial reporting and on compliance with certain provisions of laws, regulations, contracts, and grant
agreements and other matters prepared in accordance with
Government Auditing Standards,4 which includes
i.

a description of the scope of testing of internal control
over financial reporting and compliance with laws,
regulations, and provisions of contracts or grant agreements and the results of that testing, and a statement
as to whether the tests performed provided sufficient
appropriate evidence to support an opinion on the internal control over financial reporting or on compliance with laws, regulations, and provisions of contracts or grant agreements?5

ii.

if a separate report is issued, a reference to the separate
report is included in the report on the financial statements and a statement that the separate report is an
integral part of an audit performed in accordance with
Government Auditing Standards and should be considered in assessing the results of the audit?
[GAS 5.08–.09; AAG 4.05b and .22i]

3
When personal, external, and organizational impairments to independence exist, a government auditor who cannot decline to perform the work because of a legislative requirement or for other reasons should report the impairment in the scope section of the auditor’s
report (GAS paragraph 3.05 and paragraph 4.22d of the guide).
4
If the reporting on internal control over financial reporting and on compliance and other matters is included in the report on the
financial statements, the reference to the separate report is not required. The guide recommends separate reporting (paragraphs 4.05b
and 4.21i of the guide).
5

Paragraph 5.08 of the guide permits, but does not require, an opinion on internal control over financial reporting or on compliance if
sufficient work was performed. This statement should be modified if the auditor is providing an opinion on internal control over financial
reporting or on compliance in the GAS report (paragraphs 4.05b and 4.22i of the guide).
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Yes
3.

If the auditor does not follow an applicable standard of Government Auditing Standards, does the scope section of the report disclose the standard that was not followed, the reasons therefore,
and how not following the standard affected, or could have affected, the results of the audit?
[GAS 1.12b; AAG 4.25]

4.

If a material organizational unit is not required to have an audit
in accordance with Government Auditing Standards, has the scope
paragraph of the report on the financial statements been modified
to indicate the portion of the entity that was not audited in accordance with Government Auditing Standards?
[AAG 4.39–.40]

No

N/A

Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit Performed in Accordance
With Government Auditing Standards

6

5.

Does the auditor’s report on internal control over financial reporting and on compliance and other matters conform to the standard
report language illustrated in the guide?
[AAG examples 4-3 and 4–5]

6.

Does the auditor’s report on internal control over financial reporting and on compliance and other matters contain
a.

a statement that the auditor has audited the financial statements of the auditee and a reference to the auditor’s report
on the financial statements, including a description of any
departure from the standard report (for example, a qualified
opinion, a modification as to consistency because of a
change in accounting principle, or a reference to the report
of other auditors)?
[AAG 4.28a and examples 4-3 and 4–5]

b.

a statement that the audit was conducted in accordance with
GAAS (with an identification of the United States of America as the country of origin of those standards) and with the
standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General
of the United States?6

c.

a statement that in planning and performing the audit, the
auditor considered the auditee’s internal control over financial reporting in order to determine the auditing procedures
for the purpose of expressing an opinion on the financial
statements and not to provide an opinion on the internal
control over financial reporting; and accordingly, do not express an opinion on the effectiveness of the entity’s internal
control over financial reporting?7

See footnote 3 (GAS paragraph 3.06 and paragraph 4.28b of the guide).

7

Paragraph 5.08 of the guide permits, but does not require, an opinion on internal control over financial reporting or on compliance if
sufficient work was performed. This statement should be modified if the auditor is providing an opinion on internal control over financial
reporting (paragraph 4.28c of the guide).
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d.

the definition of control deficiency and significant deficiency? If
applicable, a statement that deficiencies were identified that
are considered to be significant deficiencies in internal control over financial reporting?

e.

a statement that the auditor’s consideration of internal control over financial reporting would not necessarily identify
all deficiencies in internal control that might be significant
deficiencies or material weaknesses. If significant deficiencies are identified, a statement that certain deficiencies in internal control over financial reporting were identified that
the auditor considers to be significant deficiencies?

f.

if applicable, a description of the significant deficiencies
identified (including the views of responsible officials and
their planned corrective action) or a reference to a separate
schedule in which the significant deficiencies, views of responsible officials, and their planned corrective action are
described?8

g.

the definition of a material weakness?

h.

if no significant deficiencies are identified, a statement that
no material weaknesses were identified. If significant deficiencies are identified, a statement that the auditor’s consideration of internal control over financial reporting would
not necessarily identify all deficiencies in the internal control
that might be significant deficiencies and a statement about
whether the auditor believes any of the significant deficiencies identified are material weaknesses and, if they are, that
identifies which significant deficiencies are considered material weaknesses?9(If there are no reportable conditions
noted, a statement is made that no material weaknesses
were noted.)

i.

a statement that as part of obtaining reasonable assurance
about whether the auditee’s financial statements are free of
material misstatement, the auditor performed tests of the
auditee’s compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance
with which could have a direct and material effect on the
determination of financial statement amounts?

j.

a statement that providing an opinion on compliance with
those provisions was not an objective of the audit and that,
accordingly, the auditor does not express such an opinion?10

No

263
N/A

8

For an audit in accordance with Circular A-133, all findings, including those required to be reported under GAS, should be included
in the schedule of findings and questioned costs. Therefore, for such audits, this report should refer to the schedule of findings and
questioned costs. See the questions about that schedule in part II of this checklist (paragraphs 4.28f and 13.17 of the guide).
9
In reporting significant deficiencies, the auditor should identify those that are individually or in the aggregate material weaknesses
(GAS paragraph 5.13 and paragraph 4.09 of the guide).
10

Paragraph 5.08 of the guide permits, but does not require, an opinion on internal control over financial reporting or on compliance
if sufficient work was performed. This statement should be modified if the auditor is providing an opinion on compliance (paragraph
4.28 of the guide).
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11

k.

a statement that notes whether the results of tests disclosed
instances of noncompliance or other matters (certain fraud
and abuse) that are required to be reported under Government Auditing Standards and, if they are, describes the instances of noncompliance and other matters (including the
views of responsible officials and their planned corrective
action) or refers to the separate schedule in which the noncompliance and other matters, views of responsible officials,
and their planned corrective action are described?11
[AAG 4.26]

l.

if applicable, a statement that the auditor did not audit the
auditee’s response and, accordingly, expresses no opinion
on it?
[AAG 4.28]

m.

if applicable, a statement that additional matters were communicated to the auditee in a management letter?
[AAG 4.28l, .37, table 1, and examples 4-3 and 4-5]

n.

a separate paragraph at the end of the report stating that the
report is intended solely for the information and use of the
management, [identify the body or individuals charged with governance], others within the entity, and [identify any specified
legislative or regulatory body]12 and is not intended to be and
should not be used by anyone other than these specified
parties?13

o.

the manual or printed signature of the auditor’s firm?

p.

the date of the auditor’s report?
[AAG 4.28]

7.

Does the report carry the same date as the report on the financial
statements?
[AAG 4.28o]

8.

If a material operating unit or organizational component is not
required to have an audit in accordance with Government Auditing
Standards, has the scope paragraph of the report been modified to
indicate the portion of the entity that was not audited in accordance with Government Auditing Standards?
[AAG 4.39–.40 ]

9.

If certain pertinent information is prohibited from public disclosure or is excluded from a report due to the confidential or sensitive nature of the information (as it may be by federal, state, or
local laws or regulations), does the auditor’s report state that certain information has been omitted and the reason or other circumstance that makes the omission necessary?
[GAS 5.39; AAG 4.05g]

No

N/A

See footnote 27 of the guide.

12

For an audit in accordance with A-133, this reference should include federal awarding agencies and, if applicable, pass-through
entities (paragraphs 4.28m and 13.17 of the guide).
13
This paragraph conforms to AU section 532, Restricting the Use of an Auditor’s Report (AICPA, Professional Standards, vol. 1). See AU
section 532 for additional guidance on restricted-use reports (paragraph 4.28m of the guide).
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10.

Does the language in the compliance and other matters section of
the report refer to findings that do or may include fraud and
abuse? (That language should appear in all reports, even if the
report does not describe or refer to findings of fraud or abuse or
even if the only findings of fraud or abuse are described in or
referred to from the section on internal control over financial reporting.)
[AAG 4.31]

11.

Are findings that relate to both internal control over financial reporting and to compliance reported in or referred to from both
the section of the report concerning internal control over financial
reporting and in the section of the report concerning compliance
and other matters? (The reporting in one section of the report or
schedule may be in summary form with a reference to a detailed
reporting in the other section.)
[AAG 4.30]

12.

Are findings of fraud and abuse reported in or referred to from
the compliance and other matters section of the report, unless the
primary nature of the finding is a significant deficiency in internal
control? (Auditors should present or refer to findings of fraud and
abuse that represent significant deficiencies in internal control in
the internal control section.)
[AAG 4.31]

13.

Do the reported findings include all identified deficiencies in internal control over financial reporting considered to be significant
deficiencies (identifying those considered to be material weaknesses) and all fraud and illegal acts (unless inconsequential),14
and material violations of provisions of contracts or grant agreements and material abuse that has occurred or is likely to have
occurred?15
[GAS 5.10; AAG 4.05c, .09, .16–.17 and .29 and 13.33]

14.

Does each finding include a reference number? (For example,
findings identified and reported in the audit of fiscal year 20X1
could be assigned reference numbers 20X1-1, 20X1-2, and so
forth.)
[AAG 4.34]

15.

Do the reported findings place the findings in proper perspective
(or context) by describing the nature and extent of the issues reported and the work performed that resulted in the finding? (The
identified instances should be related to the population or the
number of cases examined and be quantified in terms of dollar
value or other measures, if appropriate.)
[GAS 5.22; AAG 4.32]

No

265
N/A

14
In an audit conducted in accordance with A-133, the auditor should apply a financial statement materiality consideration in reporting
in the GAS report fraud and illegal acts involving federal awards that are subject to A-133 reporting. That is because those findings
already are reported in the A-133 report and reporting findings that are not material to the financial statements again in the GAS report
would be unnecessarily duplicative (paragraphs 4.16 and 13.15 and 13.33 of the guide).
15

GAS requires this reporting even if the auditor disclaims an opinion on the financial statements. GAS also provides reporting
requirements for other findings of internal control deficiencies, fraud, illegal acts, violations of provisions of contracts or grants agreements, and abuse; see questions 18–19.
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a.

No

N/A

When reporting instances of fraud, illegal acts, violations of
provisions of contracts or grant agreements, or abuse, are
the results projected? (If the results cannot be projected, auditors should limit their conclusions appropriately.)
[GAS 5.22; AAG 4.32]

16.

To the extent possible and to achieve audit objectives, do the reported findings present criteria, condition, cause, effect or potential effect, and recommendation?
[GAS 4.14–.18 and 5.21; AAG 4.33]

17.

Does the auditor’s report include the views of responsible officials
concerning the findings, conclusions, and recommendations, as
well as planned corrective actions?16, 17
[GAS 5.32; AAG 4.05f and .35]
a.

If the auditor receives, in writing, the views of responsible
officials, is a copy of the officials’ written comments or a
summary of the comments received included in the auditor’s report?18

b.

Does the auditor’s report include an evaluation of the comments, as appropriate?

c.

If the entity’s views oppose the report’s findings, conclusions, or recommendations, and are not, in the auditor’s
opinion, valid—or if the planned corrective actions do not
adequately address the auditor’s recommendations—does
the report state reasons for disagreeing with the comments
or planned corrective actions?

d.

If the audited entity refused to provide comments or is unable to provide comments within a reasonable period of
time, does the auditor’s report state that the audited entity
did not provide comments?
[GAS 5.34–.38; AAG 4.35]

Other Reporting and Communication Considerations
18.

Does the management letter communicate the following unless
clearly inconsequential—deficiencies in internal control that are
not significant deficiencies, immaterial violations of provisions of
contracts or grant agreements, and immaterial abuse?19
[GAS 5.16; AAG 4.19 and .37]

16
In an audit in accordance with A-133, the auditee is required to submit a corrective action plan. For those audits, depending on the
status of the development of the corrective action plan at the time the auditor’s reports are released, the auditor may be able to refer to
the corrective action plan to satisfy as the required presentation of the auditee’s views and planned corrective actions. See the questions
about the reporting of auditee views and the corrective action plan in part II of this checklist (paragraph 4.35 of the guide).
17

The auditor is required to extend a reasonable effort to obtain and report auditee views and planned corrective actions. GAS does
not require the auditor to delay or withhold the release of the report if the auditee does not provide the necessary information on a timely
basis. If, however, the auditee does not provide the necessary information by the time the report is released, the report should indicate
that the audited entity did not provide comments (paragraph 4.36 of the guide).
18
When the responsible officials provide oral comments only, auditors should prepare a summary of the oral comments and provide
a copy of the summary to the responsible officials to verify that the comments are accurately stated.
19
Generally, GAS requires the auditor to evaluate findings for the purpose of communication in the management letter based on their
consequence to the financial statements or other financial data significant to the audit objectives. In an audit in accordance with A-133,
however, the auditor should evaluate findings involving federal awards for the purpose of that communication based only on their
(continued)
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a.

Are the management letter discussions worded so that readers can distinguish those matters that are required to be included by GAAS or Government Auditing Standards from
matters that are recommendations for improvements or information about “best practices”?
[AAG 4.38]

b.

Does the management letter not include personal identification or other potentially sensitive matters?
[AAG 4.49]

19.

Has the auditor used professional judgment to determine whether
and how to communicate to auditee officials deficiencies in internal control, fraud, illegal acts, violations of provisions of contracts
or grant agreements, and abuse that are less than material but
more than inconsequential?20
[GAS 5.16; AAG 4.37]

20.

Has the auditor reported known or likely fraud, illegal acts, violations of provisions of contracts or grant agreements, and abuse
directly to parties outside of the auditee in the situations required
by Government Auditing Standards, even if the auditor has resigned
or been dismissed from the audit?
[GAS 5.18–.20; AAG 4.20]

21.

In addition to the communications required by GAAS, has the auditor communicated the following information regarding his or
her planned work and reporting related to testing internal control
over financial reporting and compliance with laws, regulations,
and provisions of contracts or grant agreements, preferably in a
writing such as the engagement letter, to those charged with governance of the audited entity and to the individuals contracting
for or requesting the audit during the planning stages of the audit:
a.

The auditor’s responsibilities for testing and reporting on internal control over financial reporting and on compliance
with laws, regulations, and provisions of contracts or grant
agreements?

b.

The nature of any additional testing of internal control and
compliance required by laws, regulations, and provisions of
contracts or grant agreements or otherwise requested, and
whether the auditor is planning on providing an opinion on
internal control over financial reporting or on compliance
with laws, regulations, and provisions of contracts or grant
agreements?

c.

A contrasting of the responsibilities in questions 21 a–b with
other audits of internal control and compliance?

No

267
N/A

consequence to the financial statements. Further, the auditor should not communicate such findings in the management letter if they are
otherwise reported as audit findings in accordance with A-133 (paragraphs 4.37 and 13.25 of the guide).
20
GAAS require that whenever the auditor has determined that there is evidence that fraud may exist, the auditor should bring that
matter to the attention of an appropriate level of management, even if the matter might be considered inconsequential (paragraph .79 of
AU section 316, Consideration of Fraud in a Financial Statement Audit [AICPA, Professional Standards, vol. 1], and paragraphs 4.12 and 4.37
of the guide).
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d.

Potential restrictions on the auditor’s reports?

e.

Additional relevant topics, such as the auditor’s fieldwork
and reporting responsibilities for fraud and abuse?
[GAS 4.06–.07]

22.

If an audit is terminated before it is complete, is the reason for
terminating the audit communicated to auditee management, the
entity requesting the audit, and other appropriate officials, preferably in writing?
[GAS 4.08; AAG 2.30]

23.

If the auditor is
a.

a government auditor, does the auditor submit the auditor’s
reports to the appropriate officials of the audited entity, appropriate officials of the organizations requiring or arranging for the audits (unless legal restrictions prevent it), and
other officials who have legal oversight authority or who
may be responsible for acting on audit findings and recommendations and to others authorized to receive such reports?

b.

a nongovernment auditor, does the auditor clarify report
distribution responsibilities with the party contracting for
the audit and follow the agreements reached?
[GAS 5.44; AAG 4.05g]

24.

Unless the report is restricted by law or regulation, or contains
privileged and confidential information, does the auditor clarify
that copies are made available for public inspection? (That clarification should be made in the engagement letter and may also be
made in correspondence that transmits the reports to the auditee
and other recipients.)
[GAS 5.44; AAG 4.05h]

25.

If the auditor is reporting on restated financial statements, did the
auditor’s report include an explanatory paragraph in the reissued
or updated auditor’s report that included
a.

a statement disclosing that the previously-issued financial
statements have been restated?

b.

a statement that the previously-issued report (referred to by
report date) is not to be relied upon (because previously issued financial statements were materially misstated) and is
being replaced by the auditor’s report on the restated financial statements?

c.

a reference to the notes to the restated financial statements
that discusses the restatement?

d.

if applicable, a reference to the report on internal control
containing a discussion of any significant deficiency identified related to the failure to prevent or detect the misstatement and any management corrective action taken?
[GAS 5.29]
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Yes
26.

If the auditor is reporting on restated financial statements and if
management fails to include the appropriate disclosures related
to the restatement, are the omitted disclosures included in the auditor’s report?
[GAS 5.28c and .30]

27.

Has the auditor notified those charged with governance if the entity’s management (a) does not act in an appropriate time frame
after new information was available to determine the financial
statement effects of the new information and take the necessary
steps to timely inform those who are likely to rely on the financial
statements and the related auditor’s reports of the situation or (b)
does not restate with reasonable timeliness the financial statements under circumstances in which auditors believe they need
to be restated?
[GAS 5.31]

No
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N/A

Part II—Reports on Audits Performed in Accordance With A-133
1.

In an audit performed in accordance with A-133, has the auditor
issued the following reports in addition to those in part I of this
checklist:21
a.

A report on the supplementary schedule of expenditures of
federal awards that provides an opinion (or disclaimer of
opinion) as to whether the schedule is presented fairly in all
material respects in relation to the financial statements taken
as a whole?

b.

A report on compliance with requirements applicable to
each major program and on internal control over compliance in accordance with A-133 that provides an opinion (or
disclaimer of opinion) as to whether the audited entity complied with laws, regulations, and the provisions of contracts
or grant agreements which could have a direct and material
effect on each major program, and, where applicable, a reference to the separate schedule of findings and questioned
costs?

c.

A schedule of findings and questioned costs?
[A-133 sec. 505; AAG 13.06]

Report on the Supplementary Schedule of Expenditures of Federal
Awards
2.

Is the report on the schedule (a) included in the auditor’s report
on the financial statements, (b) included in the report on compliance with requirements applicable to each major program and on
internal control over compliance in accordance with A-133, or (c)
issued as a stand-alone report?
[AAG 13.11, .14, .24, and .28]

21
Because of the requirements of GAS, the auditor also has other reporting and communication responsibilities in an A-133 audit. See
the questions in the section titled “Other Reporting and Communication Considerations” in part I of this checklist.
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3.

If the report on the financial statements refers to the work of other
auditors, has the auditor considered the need to refer to the major
federal programs audited by other auditors in the report on the
schedule?
[AAG 13.29]

4.

If the report on the schedule is included in the auditor’s report on
the financial statements or in the A-133 report on compliance and
on internal control over compliance, does it

5.

a.

conform to the standard report language illustrated in the
guide?
[AAG 13.13 and example 13-1]

b.

identify the schedule of expenditures of federal awards as
accompanying supplementary information by descriptive title or by page number of the document?

c.

contain a statement that the audit was conducted for the
purpose of forming an opinion on the basic financial statements taken as a whole and that the schedule is presented
for purposes of additional analysis and is not a required part
of the financial statements?
[AAG 13.11 and example 13-1]

d.

contain an opinion or a disclaimer of opinion as to whether
the Schedule is fairly stated, in all material respects, in relation to the financial statements taken as a whole?
[AAG 13.09, .11, and example 13-1]

e.

carry the same date as the report on the financial statements,
even if that requires a dual date on the A-133 report on compliance and on internal control over compliance?
[AAG 13.26–.28]

f.

consider the effect of any modifications to this report?
[AAG 13.12]

If the report on the schedule is issued as a stand-alone report, is
the guidance AU section 508 followed in issuing that report?
a.

Does the report carry the same date as the A-133 report on
compliance and on internal control over compliance?
[AAG 13.28]

Report on Compliance With Requirements Applicable to Each Major
Program and on Internal Control Over Compliance in Accordance
With A-133
6.

Does the report conform to the standard report language illustrated in the guide?
[AAG examples 13-1–13-5]

7.

Does the report contain the following elements:
a.
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No

N/A
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Yes
b.

A statement that the auditee’s major programs are identified
in the summary of the auditor’s results section of the accompanying schedule of findings and questioned costs?

c.

A statement that compliance with the requirements of laws,
regulations, contracts, and grants applicable to each of the
auditee’s major federal programs is the responsibility of the
auditee’s management, and that the auditor’s responsibility
is to express an opinion on the auditee’s compliance based
on the audit?

d.

A statement that the audit of compliance was conducted in
accordance with GAAS (with an identification of the United
States of America as the country of origin of those standards), the standards applicable to financial audits contained in Government Auditing Standards issued by the
Comptroller General of the United States, and A-133?

e.

A statement that those standards and A-133 require that the
auditor plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of
compliance requirements that could have a direct and material effect on a major federal program occurred?

f.

A statement that an audit includes examining, on a test basis, evidence about the auditee’s compliance with those requirements and performing such other procedures as the auditor considered necessary in the circumstances?

g.

A statement that the auditor believes that the audit provides
a reasonable basis for the auditor’s opinion?

h.

A statement that the audit does not provide a legal determination of the auditee’s compliance with those requirements?

i.

If instances of noncompliance are noted that result in an
opinion modification, a reference to a description in the accompanying schedule of findings and questioned costs, including
i.

the reference number(s) of the finding(s)?

ii.

an identification of the type(s) of compliance requirements and related major program(s)?

iii.

a statement that compliance with such requirements is
necessary, in the auditor’s opinion, for the auditee to
comply with the requirements applicable to the program(s)?

j.

An opinion on whether the auditee complied, in all material
respects, with the types of compliance requirements that are
applicable to each of its major federal programs?

k.

If applicable, a statement that the results of the auditing procedures disclosed instances of noncompliance that are required to be reported in accordance with A-133 and a reference to the schedule of findings and questioned costs in
which they are described?

No
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Yes
l.

A statement that the auditee’s management is responsible
for establishing and maintaining effective internal control
over compliance with the requirements of laws, regulations,
contracts, and grants applicable to federal programs?

m.

A statement that in planning and performing the audit, the
auditor considered the auditee’s internal control over compliance with requirements that could have a direct and material effect on a major federal program, to determine the
auditing procedures for the purpose of expressing an opinion on compliance but not for the purpose of expressing an
opinion on the effectiveness of internal control over compliance?

n.

The definition of control deficiency and significant deficiency. If
applicable, a statement that deficiencies were identified that
are considered to be significant deficiencies in internal control over compliance?

o.

If applicable, a reference to a description of the significant
deficiencies identified in the accompanying schedule of findings and questioned costs, including the reference number
of the finding(s)?

p.

If no significant deficiencies are identified, a statement that
the auditor’s consideration of internal control over compliance would not necessarily disclose all matters in internal
control that might be significant deficiencies or material
weaknesses; if significant deficiencies are identified, a statement that the auditor’s consideration of internal control over
compliance would not necessarily disclose all matters in the
internal control that might be significant deficiencies or material weaknesses and a statement that certain deficiencies
were identified that are considered to be significant deficiencies (and, if applicable, material weaknesses)?

q.

The definition of a material weakness?

r.

If applicable, a statement about whether the auditor believes
any of the significant deficiencies identified are material
weaknesses and, if they are, a reference to a description of
the material weaknesses in the schedule of findings and
questioned costs, including the reference number of the
finding(s)? (If there are no significant deficiencies identified,
a statement should be made that no material weaknesses
were identified.)

s.

If applicable, a statement that the auditee’s response to findings identified in the audit are described in the accompanying schedule of findings and questioned costs, and that the
auditor did not audit the auditee’s response and, accordingly, expresses no opinion on it?

FSP §11,300.07
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Yes
t.

A separate paragraph at the end of the report stating that
the report is intended solely for the information and use of
[identify the body or individuals charged with governance], others
within the entity, [identify the specified legislative or regulatory
body], federal awarding agencies, and (if applicable) passthrough entities and is not intended to be and should not be
used by anyone other than these specified parties?22

u.

The manual or printed signature of the auditor’s firm?

v.

The date of the auditor’s report?
[AAG 13.23]

8.

If the audit of the auditee’s compliance with requirements applicable to a major program detects material instances of noncompliance with those requirements, does the auditor’s report express a
qualified or adverse opinion?
[AAG 13.19]

9.

Have scope limitations on the auditor’s testing of the auditee’s
compliance with laws, regulations, and the provisions of contracts
or grant agreements been considered in the opinion on compliance with requirements applicable to each major program?
[AAG 13.20–.22]

10.

Have the cumulative effects of all instances of noncompliance
with federal programs and scope limitations been considered in
the opinion on the financial statements?
[AAG 13.19–.20 ]

11.

If there are abuse findings reported in the federal awards section
of the schedule of findings and questioned costs that do not otherwise meet the A-133 requirements for reporting as findings, has
the auditor considered the need to modify the report on compliance and on internal control over compliance?
[AAG 13.36]

12.

Is the report dated the same as or later than the date of the auditor’s report on the financial statements?
a.

22

No

273
N/A

If the report is dated later than the date of the auditor’s report on the financial statements, have appropriate subsequent events procedures been performed?
[AAG 13.27]

13.

If the audit of federal awards does not encompass the entirety of
the auditee’s operations expending federal awards, are the operations that are not included identified in a separate paragraph following the first paragraph of the report?
[AAG 13.30]

14.

If the report on the financial statements refers to the work of other
auditors, has the auditor considered the need to refer to the major
federal programs audited by other auditors in the report on compliance and on internal control over compliance?
[AAG 13.29]

See footnote 17 (paragraph 13.23t of the guide).
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Schedule of Findings and Questioned Costs
15.

Does the report conform to the standard report language illustrated in the guide?
[AAG example 13-6]

16.

Is the report presented even if there are no findings to report? (In
a situation in which there are no findings or questioned costs, the
auditor should prepare the summary of auditor’s results section
of the schedule and either omit the other sections or include them,
indicating that no matters were reported.)
[AAG 13.40]

17.

Does the report contain the following three sections:

18.

a.

A summary of the auditor’s results?

b.

Findings related to the financial statements that are required
to be reported in accordance with Government Auditing Standards? (See the questions about those findings in part I of
this checklist.)

c.

Findings and questioned costs for federal awards?
[AAG 13.31]

Does the summary of auditor’s results include
a.

the type of report the auditor issued on the financial statements of the auditee (that is, unqualified opinion, qualified
opinion, adverse opinion, or disclaimer of opinion)?

b.

where applicable, a statement that significant deficiencies in
internal control were disclosed by the audit of the financial
statements and whether any such deficiencies were material
weaknesses?

c.

a statement on whether the audit disclosed any noncompliance that is material to the financial statements?

d.

where applicable, a statement that significant deficiencies in
the internal control over major programs were disclosed by
the audit and whether any such deficiencies were material
weaknesses?

e.

the type of report the auditor issued on compliance for major programs (that is, unqualified opinion, qualified opinion,
adverse opinion, or disclaimer of opinion)? (If the audit report for one or more major programs is other than unqualified, indicate the type of report issued for each program.)

f.

a statement on whether the audit disclosed any audit findings that the auditor is required to report under A-133? (See
the following question 20.)

g.

an identification of major programs?

h.

the dollar threshold used to distinguish between type A and
type B programs?

i.

a statement on whether the auditee qualified as a low-risk
auditee?
[AAG 13.32a]
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Yes
19.

If there are abuse findings reported in the federal awards section
of the schedule of findings and questioned costs that do not otherwise meet the A-133 requirements for reporting as findings, has
the auditor considered the need to modify the summary of the
auditor’s results?
[AAG 13.36]

20.

Are the following reported as audit findings related to federal
awards:

21.

a.

Significant deficiencies and material weaknesses in internal
control over major programs? (The auditor should identify
significant deficiencies that are individually or cumulatively
material weaknesses.)

b.

Material noncompliance with the provisions of laws, regulations, contracts, or grant agreements related to a major
program?

c.

Known questioned costs that are greater than $10,000 for a
type of compliance requirement for a major program?

d.

Known questioned costs when likely questioned costs are
greater than $10,000 for a type of compliance requirement
for a major program?

e.

Known questioned costs that are greater than $10,000 for
programs that are not audited as major?

f.

The circumstances concerning why the auditor’s report on
compliance for major programs is other than an unqualified
opinion, if not otherwise reported as an audit finding?

g.

Known fraud affecting a federal award, if not otherwise reported as an audit finding? (An audit finding is not required
if the fraud was reported outside the entity as required by
GAS.)
[A-133 sec. 510(a); AAG 13.35]

h.

Instances of material misrepresentation by the auditee of the
status of any prior audit findings?
[A-133 sec. 510(a); AAG 13.35 and .42]

i.

Abuse involving federal awards that is material to a major
program?
[AAG 13.36]

No

275
N/A

Does the audit finding detail include
a.

a reference number? (For example, findings identified and
reported in the audit of fiscal year 20X1 would be assigned
reference numbers 20X1-1, 20X1-2, and so forth.)
[A-133 sec. 510(c); AAG 13.39]
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Yes
b.

identification of the federal program and specific federal
award, including the Catalog of Federal Domestic Assistance title and number, federal award number and year,
name of the federal agency, and name of the applicable
pass-through entity?23

c.

the criteria or specific requirement upon which the audit
finding is based, including the statutory, regulatory, or other
citation?

d.

the condition found, including facts that support the deficiency identified in the audit finding?

e.

identification of questioned costs and how they were computed?

f.

information to provide a proper perspective for judging the
prevalence and consequences of the audit findings?24

g.

the possible asserted effect to provide sufficient information
to the auditee and federal agency, or pass-through entity in
the case of a subrecipient, to permit them to determine the
cause and effect to facilitate prompt and proper corrective
action?

h.

recommendations to prevent future occurrences of the deficiency?
[A-133 sec. 510(b); AAG 13.37]

22.

Do the audit findings related to federal awards also meet the presentation requirements of Government Auditing Standards? (See the
questions about those presentation requirements in part I of this
checklist.)
[AAG 13.38]

23.

Are audit findings that relate to federal awards

24.

a.

and that relate to the same issue presented as one finding?

b.

organized by federal agency or pass-through entity, where
practical?
[A-133 sec. 505(d)(3)(i); AAG 13.32c]

No

N/A

Are audit findings that relate to both the financial statements and
the federal awards reported in both sections of the schedule? (An
alternative is to report the finding in one section of the schedule
in summary form, with a reference to a detailed reporting in the
other section of the schedule.)
[A-133 sec. 505(d)(3)(ii); AAG 13.32c]

23
When information such as the Catalog of Federal Domestic Assistance (CFDA) title and number or the federal award number is not
available, the auditor should provide the best information available to describe the federal award (chapter 7 of the guide discusses an
alternative for presentation if a CFDA number is not available) (A-133 section 510(b)(1) and paragraph 13.37a of the guide).
24
Where appropriate, the instances identified should be related to the universe and the number of cases examined and be quantified
in terms of the dollar value (A-133 section 510(b)(5) and paragraph 13.37e of the guide).

FSP §11,300.07

Auditors’ Reports Checklist for Audits Performed in Accordance With GAS & OMB Circular A-133

Yes
25.

Are findings of abuse involving federal awards presented in the
compliance section of the schedule, unless the primary nature of
the finding is a significant deficiency in internal control? (Auditors should present findings of abuse that represent significant
deficiencies in internal control in the internal control section.)
[AAG 13.36]

26.

Do the findings report the views of responsible officials concerning the findings, conclusions, and recommendations, as well as
planned corrective actions, as required by Government Auditing
Standards, or refer to the corrective action plan, depending on the
status of the development of the corrective action plan at the time
the auditor’s reports are released?25
[AAG 13.34 and .38]
a.

27.

No

277
N/A

If the auditee’s comments oppose the report’s findings, conclusions, or recommendations, and are not, in the auditors’
opinion, valid—or if the planned corrective actions do not
adequately address the auditors’ recommendations—does
the federal awards section of the schedule of findings and
questioned costs state the auditor’s reasons for disagreeing
with the comments or planned corrective actions?
[A-133 sec. 510(b)(8); AAG 13.38]

Do the audit report and any attached or referenced schedules not
include names, Social Security numbers, other personal identification, or other potentially sensitive matters?
[AAG 13.51]

Data Collection Form26

25

28.

Has the auditor completed the appropriate parts of the data collection form?

29.

Has the auditor signed the form and dated it as of the date on
which the auditor completes and signs the form?
[AAG 13.45]

30.

Does the information on the data collection form agree to the information in the auditor’s reports and the summary of auditor’s
results in the schedule of findings and questioned costs?
[Federal Audit Clearinghouse, Data Collection Form, No. SF-SAC]

See footnote 17.

26

The data collection form and related instructions are available from the Federal Audit Clearinghouse’s (FAC’s) home page at
http://harvester.census.gov/sac. The form number is SF-SAC. The FAC requires electronic submission of the data collection form via an
online Internet Data Entry System. The Office of Management and Budget periodically revises the data collection form and its accompanying instructions. Auditors should exercise caution to make sure they complete the version of the form and instructions that applies to
the fiscal year audited (paragraph 13.46 of the guide).
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Yes

No

N/A

Practice Tip
When an auditee expends federal awards under only one federal program (excluding research and development) and the federal program’s laws, regulations, or grant agreements do not require a financial statement
audit of the auditee, the auditee may elect to have a program-specific audit. A program-specific audit may not
be elected for research and development unless all federal awards expended were received from the same
federal agency (or the same federal agency and the same pass-through entity) and that federal agency (or passthrough entity, in the case of a subrecipient) approves a program-specific audit in advance.
[A-133 sec. 200(c); AAG 14.02]
Program-Specific Audits
31.

If a program-specific audit guide is available and current with regard to the program’s compliance requirements, has the auditor
issued the reports required by the guide?
[A-133 sec. 235(a); AAG 14.04]

32.

If a program-specific audit guide is not available or not current with
regard to the program’s compliance requirements, has the auditor
issued the following reports:27, 28

33.

a.

A report on the federal program’s financial statements that
provides an opinion or disclaimer of opinion on the financial
statements?

b.

A report on compliance with requirements applicable to the
federal program and on the internal control over compliance
in accordance with the program-specific audit option under
A-133?

c.

A schedule of findings and questioned costs for the program?
[A-133 sec. 235(b)(4); AAG 14.07–.09]

Do the reports conform to the standard report language illustrated
in the guide?
[AAG examples 13-1–13-6 and 14-1–14-2]

27
If the financial statement(s) of the program present only the activity of the federal program, the auditor is not required to issue a
separate report to meet the reporting requirements of GAS. However, if the financial statement(s) of the federal program present more
than the program’s activity the auditor should issue a separate GAS report and modify it so that it refers only to the financial statement(s)
of the federal program (paragraph 14.10 of the guide).
28

See footnote 21.
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Illustrative Financial Statements
.01 The following illustrative auditor’s reports and financial statements demonstrate one form of currently acceptable practice. The illustrative financial statements in this section are reproduced from the 2009
AICPA Audit and Accounting Guide Health Care Entities, with conforming changes as of August 1, 2009.
The illustrative financial statements are intended to provide sample financial statement formats and disclosures, and are not intended to provide all financial statement formats and disclosures, or all of the disclosures covered in the financial statement checklist. Other forms of financial statements are acceptable. More
or less detail should appear either in the financial statements or in the notes, depending on the circumstances.
.02 Governmental health care entities are required to follow the accounting and reporting requirements
of the Governmental Accounting Standards Board (GASB). GASB pronouncements may require governmental health care entities to present information beyond or different from that presented by not-for-profit
and investor-owned entities.
.03 Certain disclosures required by Securities and Exchange Commission (SEC) rules and regulations
are not presented in the illustrative financial statements. Furthermore, the illustrative financial statements
do not include all disclosures and presentation items promulgated.
Note: The illustrative financial statements and notes included in this checklist have been updated to reflect Financial Accounting Standards Board (FASB) Accounting Standards Codificatione (ASC). However,
in FASB’s notice to constituents, it suggests the use of plain English in financial statement footnotes to
describe broad FASB ASC topic references. FASB suggests a reference similar to “as required by the Derivatives and Hedging topic of the FASB Accounting Standards Codification.” Entities might consider revising
their financial statement references to reflect this plain English referencing, rather than the use of specific
FASB ASC references. We have provided these detailed references in the 2009 editions as a learning tool
to familiarize constituents with FASB ASC.
.04 This section contains illustrative financial statements, prepared using the illustrative financial statements in the AICPA Audit and Accounting Guide Health Care Entities (with conforming changes as of August 1, 2009), for the following types of health care organizations:
a.

Not-for-profit hospital

b.

Governmental hospital authority

c.

Nursing home

d.

Continuing care retirement community

e.

Home health agency

f.

Health maintenance organization

g.

Ambulatory care organization
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NOT-FOR-PROFIT HOSPITAL
.05
Sample Not-for-Profit Hospital
Balance Sheets*
December 31, 20X7 and 20X6
(in thousands)
20X7
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Assets limited as to use
Patient accounts receivable, net of allowance for
doubtful accounts of $2,500 in 20X7 and $2,400 in
20X6
Other current assets
Total current assets

20X6

$4,758
15,836
970

$5,877
10,740
1,300

15,100
2,670

14,194
2,856

39,334

34,967
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7
Interest in net assets of Sample Hospital Foundation1
Assets limited as to use:
Internally designated for capital acquisition
Held by trustee

20X6
510

462

12,000
6,949

12,500
7,341

18,949
(970)

19,841
(1,300)

17,979

18,541

4,680
320
51,038
1,185

4,680
520
50,492
908

$115,046

$110,570

$1,470
5,818
2,143
1,969

$1,750
5,382
1,942
2,114

Total current liabilities

11,400

11,188

Long-term debt, net of current portion
Other liabilities

23,144
3,953

24,014
3,166

38,497

38,368

70,846
2,115
3,588

66,199
2,470
3,533

Less amount required to meet current obligations
Long-term investments
Long-term investments restricted for capital acquisition
Property and equipment, net
Other assets
Total assets
Liabilities and Net Assets
Current liabilities:
Current portion of long-term debt
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities

Total liabilities
Net assets:
Unrestricted
Temporarily restricted
Permanently restricted
Total net assets
Total liabilities and net assets

76,549

72,202

$115,046

$110,570

See accompanying notes to financial statements.

1
These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation
that is based on the particular fact pattern described in note 11 to the illustrative financial statements and the following additional facts:

●

Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it
can determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the hospital to imply
a time restriction on amounts held by the Foundation.

●

Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the hospital
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified
as unrestricted in the hospital’s financial statements.

●

The hospital’s policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues
are recognized.

Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in
paragraph 10.32 for contributions restricted to property acquisitions. The AICPA has released Technical Question and Answer (TIS)
sections 6400.36–.42 (AICPA, Technical Practice Aids), that address recognition of the interests in the net assets of financially interrelated
organizations and the classification of the changes in those interests.
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.06
FORMAT A
Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7
Unrestricted revenues, gains and other support:
Net patient service revenue
Premium revenue
Other revenue
Net assets released from restrictions used for
operations
Total revenues, gains and other support
Expenses:
Operating expenses
Depreciation and amortization
Interest
Provision for bad debts
Other
Total expenses
Operating income
Other income:
Investment income
Other expense:
Loss from extinguishment of debt
Excess of revenues over expenses
Change in net unrealized gains and losses on other
than trading securities
Net assets released from restrictions used for
purchase
of property and equipment
Change in interest in net assets of Sample Hospital
Foundation2
Transfers to parent
Increase in unrestricted net assets
See accompanying notes to financial statements.

2

See footnote 1.
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20X6

$85,156
11,150
2,601

$78,942
10,950
5,212

300
99,207

95,104

88,521
4,782
1,752
1,000
2,000

80,585
4,280
1,825
1,300
1,300

98,055

89,290

1,152

5,814

3,900

3,025

(500)
4,552

8,839

300

375

200
283
(688)
$4,647

536
(3,051)
$6,699
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.07
FORMAT B
Sample Not-for-Profit Hospital
Statements of Operations
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X6

20X7
Unrestricted revenues, gains and other support:
Net patient service revenue
Premium revenue
Other, primarily investment income
Net assets released from restrictions used for
operations
Total revenues, gains and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Depreciation and amortization
Interest
Allowance for bad debts
Loss from extinguishment of debt
Other
Total expenses
Excess of revenues, gains, and other support over
expenses
Change in net unrealized gains and losses on other than
trading securities
Net assets released from restrictions used for purchase
of property and equipment
Change in interest in net assets of Sample Hospital
Foundation3
Transfers to parent
Increase in unrestricted net assets

$85,156
11,150
6,501

$78,942
10,950
8,237

300
103,107

98,129

53,900
26,532
8,089
4,782
1,752
1,000
500
2,000

49,938
22,121
8,526
4,280
1,825
1,300

98,555

89,290

4,552

8,839

300

375

200

—

283
(688)
$4,647

1,300

536
(3,051)
$6,699

See accompanying notes to financial statements.

3

See footnote 1.
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.08
Sample Not-for-Profit Hospital
Statements of Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X6

20X7
Unrestricted net assets:
Excess of revenues over expenses
Net unrealized gains on investments, other than
trading securities
Change in interest in net assets of Sample Hospital
Foundation4
Transfer to parent
Net assets released from restrictions used for
purchase
of property and equipment
Increase in unrestricted net assets

$8,839

300

375

283
(688)

536
(3,051)

200
4,647

6,699

Temporarily restricted net assets:
Contributions for charity care
Net realized and unrealized gains on investments
Net assets released from restrictions

140
5
(500)

996
8

Increase (decrease) in temporarily restricted net
assets

(355)

1,004

Permanently restricted net assets:
Contributions for endowment funds
Net realized and unrealized gains on investments

50
5

411
2

Increase in permanently restricted net assets

55

413

4,347
72,202

8,116
64,086

$76,549

$72,202

Increase in net assets
Net assets, beginning of year
Net assets, end of year
See accompanying notes to financial statements.

4

$4,552

See footnote 1.
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.09
Sample Not-for-Profit Hospital
Statements of Cash Flows (Indirect Method)
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X6

20X7
Cash flows from operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by operating activities:
Loss from extinguishment of debt
Depreciation and amortization
Net realized and unrealized gains on investments,
other than trading
Undistributed portion of change in interest in net
assets of Sample Hospital Foundation
Transfers to parent
Allowance for bad debts
Restricted contributions and investment income
received
(Increase) decrease in:
Patient accounts receivable
Trading securities
Other current assets
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Proceeds from sale of investments
Purchase of investments
Capital expenditures
Net cash used in investing activities

$4,347

$8,116

500
4,782

4,280

(450)

(575)

(48)
688
1,000

(51)
3,051
1,300

(290)

(413)

(1,906)
215
186
(277)

(2,036)
(2,481)
(190)

436
201
(145)
787

679
305
(257)
(128)

10,026

11,600

45,100
(48,869)
(4,728)

50,650
(52,800)
(5,860)

(8,497)

(8,010)
(continued)
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20X7
Cash flows from financing activities:
Transfer to parent
Proceeds from restricted contributions and restricted
investment income
Payments on long-term debt
Payments on capital lease obligations
Proceeds from issuance of long-term debt

20X6

(688)

(3,051)

290
(24,700)
(150)
22,600

413
(804)
(100)
500

(2,648)

(3,042)

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of year

(1,119)
5,877

548
5,329

Cash and cash equivalents, end of year

$4,758

$5,877

Net cash used in financing activities

Supplemental Disclosures of Cash Flow Information:
The hospital entered into capital lease obligations in the amount of $600,000 for new
equipment in 20X7.
Cash paid for interest (net of amount capitalized) in 20X7 and 20X6 was $1,780,000 and
$1,856,000, respectively.
See accompanying notes to financial statements.
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.10
Sample Not-For-Profit Hospital
Notes to Financial Statements†
December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies5

Organization. The Sample Not-for-Profit Hospital (the hospital), located in Tulsa, Oklahoma, is a not-forprofit acute care hospital. The hospital provides inpatient, outpatient and emergency care services for residents of northeastern Oklahoma. Admitting physicians are primarily practitioners in the local area. The
hospital was incorporated in Oklahoma in 20X1 and is affiliated with the Sample Health System.
Use of estimates. The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include certain investments in highly liquid debt
instruments with original maturities of three months or less.
The hospital routinely invests its surplus operating funds in money market mutual funds. These funds
generally invest in highly liquid U.S. government and agency obligations.
Investments. Investments in equity securities with readily determinable fair values and all investments
in debt securities are measured at fair value in the balance sheet. Investment income or loss (including
realized gains and losses on investments, interest and dividends) is included in the excess of revenues over
expenses unless the income or loss is restricted by donor or law. Unrealized gains and losses on investments
are excluded from the excess of revenues over expenses unless the investments are trading securities.
Assets limited as to use. Assets limited as to use primarily include assets held by trustees under indenture
agreements and designated assets set aside by the Board of Trustees for future capital improvements, over
which the Board retains control and may at its discretion subsequently use for other purposes. Amounts
required to meet current liabilities of the hospital have been reclassified in the balance sheet at December
31, 20X7 and 20X6.

†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
5
FASB ASC 310-10-50 provides guidance on accounting policy disclosures for loans, trade receivables, and doubtful accounts that
should be included in the summary of significant accounting policies.
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Property and equipment. Property and equipment acquisitions are recorded at cost. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed using the straightline method. Equipment under capital lease obligations is amortized on the straight-line method over the
shorter period of the lease term or the estimated useful life of the equipment. Such amortization is included
in depreciation and amortization in the financial statements. Interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those
assets.
Gifts of long-lived assets such as land, buildings, or equipment are reported as unrestricted support,
and are excluded from the excess of revenues over expenses, unless explicit donor stipulations specify how
the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the
assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are
reported as restricted support. Absent explicit donor stipulations about how long those long-lived assets
must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived
assets are placed in service.
‡

Temporarily and permanently restricted net assets. Temporarily restricted net assets are those whose use by
the hospital has been limited by donors to a specific time period or purpose. Permanently restricted net
assets have been restricted by donors to be maintained by the hospital in perpetuity.
Excess of revenues over expenses. The statement of operations includes excess of revenues over expenses.
Changes in unrestricted net assets which are excluded from excess of revenues over expenses, consistent
with industry practice, include unrealized gains and losses on investments other than trading securities,
permanent transfers of assets to and from affiliates for other than goods and services, and contributions of
long-lived assets (including assets acquired using contributions which by donor restriction were to be used
for the purposes of acquiring such assets).
Net patient service revenue. The hospital has agreements with third-party payors that provide for payments to the hospital at amounts different from its established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments.
Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party
payors, and others for services rendered, including estimated retroactive adjustments under reimbursement
agreements with third-party payors. Retroactive adjustments are accrued on an estimated basis in the period
the related services are rendered and adjusted in future periods as final settlements are determined.
Premium revenue. The hospital has agreements with various health maintenance organizations (HMOs)
to provide medical services to subscribing participants. Under these agreements, the hospital receives
monthly capitation payments based on the number of each HMO’s participants, regardless of services actually performed by the hospital. In addition, the HMOs make fee-for-service payments to the hospital for
certain covered services based upon discounted fee schedules.
Charity care. The hospital provides care to patients who meet certain criteria under its charity care policy
without charge or at amounts less than its established rates. Because the hospital does not pursue collection
of amounts determined to qualify as charity care, they are not reported as revenue.
Donor-restricted gifts. Unconditional promises to give cash and other assets to the hospital are reported
at fair value at the date the promise is received. Conditional promises to give and indications of intentions
to give are reported at fair value at the date the gift is received. The gifts are reported as either temporarily
‡
In August 2008, FASB issued FASB Staff Position (FSP) FAS 117-1, Endowments of Not-for-Profit Organizations: Net Asset Classification of
Funds Subject to an Enacted Version of the Uniform Prudent Management of Institutional Funds Act, and Enhanced Disclosures for All Endowment
Funds, and has codified the FSP primarily in FASB ASC 958-205. FSP FAS 117-1 is effective for fiscal years ending after December 15,
2008. Earlier application is permitted provided that annual financial statements for that fiscal year have not been previously issued. FSP
FAS 117-1 provides guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit entity that is subject
to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA). The FSP also improves
disclosures about a not-for-profit entity’s endowment funds (both donor-restricted endowment funds and board-designated endowment
funds), whether or not the not-for-profit entity is subject to an enacted version of the UPMIFA. Paragraphs 16–17 of the FSP discuss the
display of the reclassification upon implementation of the guidance and the reinstatement of purpose restrictions on unappropriated net
appreciation if the not-for-profit entity is subject to an enacted version of the UPMIFA.
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or permanently restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose
restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and
reported in the statement of operations as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions
in the accompanying financial statements.
Estimated malpractice costs. The provision for estimated medical malpractice claims includes estimates of
the ultimate costs for both reported claims and claims incurred but not reported.
Income taxes. The hospital is a not-for-profit corporation and has been recognized as tax-exempt pursuant
to Section 501(c)(3) of the Internal Revenue Code.
2.

Net Patient Service Revenue

The hospital has agreements with third-party payors that provide for payments to the hospital at
amounts different from its established rates. A summary of the payment arrangements with major thirdparty payors follows:
●

Medicare. Inpatient acute care services and outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Inpatient nonacute services and
defined capital and medical education costs related to Medicare beneficiaries are paid based on a
cost reimbursement methodology. The hospital is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by the hospital
and audits thereof by the Medicare fiscal intermediary. Beginning in 20X3, the hospital claimed
Medicare payments based on an interpretation of certain "disproportionate share" rules. The intermediary disagreed and declined to pay the excess reimbursement claimed under that interpretation.
Through 1996, the hospital has not included the claimed excess in net patient revenues pending
resolution of the matter. In 20X7, the intermediary accepted the claims and paid the outstanding
claims, including $950,000 applicable to 20X6 and $300,000 applicable to 20X5 and prior, which has
been included in 20X7 net revenues.

●

Medicaid. Inpatient and outpatient services rendered to Medicaid program beneficiaries are reimbursed under a cost reimbursement methodology. The hospital is reimbursed at a tentative rate with
final settlement determined after submission of annual cost reports by the hospital and audits
thereof by the Medicaid fiscal intermediary.

Revenue from the Medicare and Medicaid programs accounted for approximately XX percent and XX
percent, respectively, of the hospital’s net patient revenue for the year ended 20X7, and XX percent and XX
percent, respectively, of the hospital’s net patient revenue, for the year ended 20X6. Laws and regulations
governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a
result, there is at least a reasonable possibility that recorded estimates will change by a material amount in
the near term. The 20X6 net patient service revenue increased approximately $XXX due to removal of allowances previously estimated that are no longer necessary as a result of final settlements and years that are no
longer subject to audits, reviews, and investigations. The 20X7 net patient service revenue decreased approximately $XXX due to prior-year retroactive adjustments in excess of amounts previously estimated.
The hospital also has entered into payment agreements with certain commercial insurance carriers,
health maintenance organizations, and preferred provider organizations. The basis for payment to the hospital under these agreements includes prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.
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Investments

Assets Limited as to Use
The composition of assets limited as to use at December 31, 20X7 and 20X6, is set forth in the following
table. Investments are stated at fair value.
Internally designated for capital acquisition:
Cash
U.S. Treasury obligations
Interest receivable
Held by trustee under indenture agreement:
Cash and short-term investments
U.S. Treasury obligation
Interest receivable

20X7

20X6

$545,000
11,435,000
20,000

$350,000
12,115,000
35,000

12,000,000

12,500,000

352,000
6,505,000
92,000

260,000
7,007,000
74,000

6,949,000

7,341,000

$18,949,000

$19,841,000

Other Investments
Other investments, stated at fair value, at December 31, 20X7 and 20X6, include:
Trading:
U.S. Corporate Bonds
Other
U.S. Treasury obligations
Interest receivable
Less:
Long-term investments
Long-term investments restricted for capital
acquisitions
Short-term investments

20X7

20X6

$1,260,000

$1,475,000

$19,266,000
310,000

$14,233,000
232,000

20,836,000

15,940,000

4,680,000

4,680,000

320,000

520,000

$15,836,000

$10,740,000

Investment income and gains for assets limited as to use, cash equivalents, and other investments are
comprised of the following for the years ending December 31, 20X7 and 20X6:
20X7
Income:
Interest income
Realized gains on sales of securities
Unrealized gains on trading securities
Other Changes in Unrestricted Net Assets:
Unrealized gains on other than trading securities
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20X6

$3,585,000
150,000
165,000

$2,725,000
200,000
100,000

$3,900,000

$3,025,000

$300,000

$375,000

291

Illustrative Financial Statements

4.

Property and Equipment
A summary of property and equipment at December 31, 20X7 and 20X6, follows:
20X7

20X6

Land
Land improvements
Buildings and improvements
Equipment
Equipment under capital lease obligations

$3,000,000
472,000
46,852,000
29,190,000
2,851,000

$3,000,000
472,000
46,636,000
26,260,000
2,752,000

Less accumulated depreciation and amortization

82,365,000
34,928,000

79,120,000
30,661,000

Construction in progress

47,437,000
3,601,000

48,459,000
2,033,000

$51,038,000

$50,492,000

Property and equipment, net

Depreciation expense for the years ended December 31, 20X7 and 20X6 amounted to approximately
$4,782,000 and $4,280,000. Accumulated amortization for equipment under capital lease obligations was
$689,000 and $453,000 at December 31, 20X7 and 20X6, respectively. Construction contracts of approximately
$7,885,000 exist for the remodeling of Hospital facilities. At December 31, 20X7, the remaining commitment
on these contracts approximated $4,625,000.
5.

Long-Term Debt
A summary of long-term debt and capital lease obligations at December 31, 20X7 and 20X6, follows:
20X7
7.25 percent 20X7 Tax-Exempt Revenue Bonds, principal
maturing in varying annual amounts, due November
1, 20XX, collateralized by a pledge of the hospital’s
gross receipts
8.50 percent 20X2 Tax-Exempt Revenue Bonds, principal
maturing in varying annual amounts, due June 1,
20XX
7.75 percent mortgage loan, principal maturing in
varying annual amounts, due January 20XX,
collateralized by a mortgage on certain property and
equipment
7.75 percent note payable, payable in monthly
installments of $12,000, including interest, due March
20XX, unsecured
Capital lease obligations, at varying rates of imputed
interest from 6.8 percent to 9.3 percent collateralized
by leased equipment
Less current portion

20X6

$21,479,000

$22,016,000

2,010,000

2,127,000

125,000

671,000

1,000,000

950,000

24,614,000
1,470,000

25,764,000
1,750,000

$23,144,000

$24,014,000

Under the terms of the 20X7 and 20X2 revenue bond indentures, the hospital is required to maintain
certain deposits with a trustee. Such deposits are included with assets limited as to use. The revenue note
indenture also places limits on the incurrence of additional borrowings and requires that the hospital satisfy
certain measures of financial performance as long as the notes are outstanding.
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Scheduled principal repayments on long-term debt and payments on capital lease obligations are as
follows:
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2
Thereafter

Long-Term Debt

Capital Leases
Obligations

$970,000
912,000
983,000
1,060,000
1,143,000
18,546,000

$550,000
260,000
260,000
45,000
—
—

$23,614,000

1,115,000

Less amount representing interest under capital
leases obligations

115,000
$1,000,000

A summary of interest cost and investment income on borrowed funds held by the trustee under the
20X7 and 20X2 revenue bond indentures during the years ended December 31, 20X7 and 20X6, follows:
20X7
Interest cost:
Capitalized
Charged to operations
Total
Investment income:
Capitalized
Credited to other revenue
Total
6.

20X6

$740,000
1,752,000

$700,000
1,825,000

$2,492,000

$2,525,000

$505,000
330,000

$663,000
386,000

$835,000

$1,049,000

Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets are available for the following purposes or periods at December 31,
20X7 and 20X6:
Health care services
Purchase of equipment
Indigent care
Health education
For periods after December 31, 20X9

20X7

20X6

$320,000
840,000
350,000
605,000

$520,000
950,000
400,000
600,000

$2,115,000

$2,470,000

Permanently restricted net assets at December 31, 20X7 and 20X6, are restricted to:
Investments to be held in perpetuity, the income from
which is expendable to support health care services
(reported as operating income)
Endowment requiring income to be added to original
gift until fund value is $1,500,000
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$2,923,000

615,000

610,000

$3,588,000

$3,533,000
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During 20X7, net assets were released from donor restrictions by incurring expenses satisfying the restricted
purposes of indigent care and health care education in the amounts of $250,000 and $50,000, respectively.
7.

Medical Malpractice Claims

The hospital purchases professional and general liability insurance to cover medical malpractice claims.
There are known claims and incidents that may result in the assertion of additional claims, as well as claims
from unknown incidents that may be asserted arising from services provided to patients. The hospital has
employed independent actuaries to estimate the ultimate costs, if any, of the settlement of such claims.
Accrued malpractice losses have been discounted at 7 percent and in management’s opinion provide an
adequate reserve for loss contingencies.
On March 15, 20X7, a patient filed a suit against the hospital for malpractice during care received as an
inpatient. The hospital believes it has meritorious defenses against the suit; however, the ultimate resolution
of the matter could result in a loss. The patient has claimed $16 million in actual damages. Under state law,
punitive damages are determined at trial. The hospital maintains insurance coverage for malpractice claims.
The coverage does not include punitive damages awards. Trial is scheduled to occur within the next year.
8.

Pension Plan and Other Postretirement Benefit Plans6, 7

[The following two paragraphs are encouraged but not required.]
The hospital has a defined benefit pension plan covering substantially all of its employees. The plan
benefits are based on years of service and the employees’ compensation during the last five years of covered
employment. Contributions are intended to provide not only for benefits attributed to service to date but
also for those expected to be earned in the future.
The hospital also sponsors two defined benefit postretirement plans that cover both salaried and nonsalaried employees. One plan provides medical and dental benefits, and the other provides for the payment
of life insurance premiums. The postretirement health care plan is contributory, with retiree contributions
adjusted annually; the life insurance plan is noncontributory. The accounting for the health care plan anticipates future cost-sharing changes to the written plan that are consistent with the hospital’s expressed intent
to increase retiree contributions each year to 50 percent of the excess of the expected general inflation rate
over 6 percent. Beginning in 20X7, the hospital adopted a funding policy for its postretirement health care
plan similar to its funding policy for its life insurance plan—an amount equal to a level percentage of the
employees’ salaries is contributed to the plan annually. For 20X7, that percentage was 4.25, and the aggregate contribution for both plans was $34,000. The hospital uses a December 31 measurement date for its
plans.

6

This note to the financial statements illustrates the financial statement disclosures about pension and postretirement benefit plans for
a public entity. Readers should refer to FASB ASC 715-20-50 when considering disclosure requirements for nonpublic entities.
FASB Statement No. 158, Employers’ Accounting for Defined Benefit Pension and Other Postretirement Plans—an amendment of FASB
Statements No. 87, 88, 106, and 132(R), as amended, is incorporated in FASB ASC 715, Compensation—Retirement Benefits, subject to the
effective date and transition guidance in FASB ASC 715-20-65-1. An employer with publicly traded equity securities shall initially apply
the requirement to recognize the funded status of a benefit plan and the disclosure requirements as of the end of the fiscal year ending
after December 15, 2006. An employer without publicly traded equity securities shall initially apply the requirement to recognize the
funded status of a benefit plan and the disclosure requirements as of the end of the fiscal year ending after June 15, 2007. An employer
without publicly traded equity securities shall provide the disclosures in paragraph 14 in the notes to the financial statements for a fiscal
year ending after December 15, 2006, but before June 16, 2007 unless it has applied the recognition provisions of this statement in
preparing those financial statements; the requirement to measure plan assets and benefit obligations as of the date of the employer’s fiscal
year-end statement of financial position shall be effective for fiscal years ending after December 15, 2008.
7
Readers may also need to consider the accounting and disclosure requirements of the “Medicare Prescription Drug, Improvement
and Modernization Act” subsections of FASB ASC 715-60 when an employer provides postretirement prescription drug coverage.
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The following table sets forth the changes in benefit obligations, changes in plan assets and components
of net periodic benefit cost for both the pension plan and the other postretirement benefit plans:
Other Benefits

Pension Benefits
20X7
Change in benefit obligation:
Benefit obligation at beginning of year
Service cost
Interest cost
Plan participants’ contributions
Actuarial gain
Benefits paid

20X6

$500
15
44
34

(1,410)

10,920

9,710

610

585

Change in plan assets:
Fair value of plan assets at beginning of
year
Actual return on plan assets
Employer contribution
Plan participants’ contributions
Benefits paid

9,800
759
866

9,610
810
790
(1,410)

89
4
39
34
(66)

40
4
19
34
(8)

Fair value of plan assets at end of year

11,050

9,800

100

89
(496)
(40)
19
470
—
($47)

Funded status
Unrecognized net actuarial gain
Unrecognized prior service cost
Unrecognized transition obligation
Unrecognized transition asset
Prepaid (accrued) benefit cost

(20)
(375)

(375)

$9,700
770
650

20X6

$585
14
50
34
(7)
(66)

Benefit obligation at end of year

$9,710
905
700

20X7

130
(30)
50

90
(40)
55

(15)

(20)

(510)
(30)
16
445
—

$85

($79)

$135

(8)

The accumulated benefit obligation for the defined benefit pension plan was $XXX and $XXX at December
31, 20X7, and 20X6, respectively.
Pension Benefits
20X7
Components of net periodic benefit cost:
Service cost
Interest cost
Expected return on plan assets
Amortization of prior service cost
Recognized net actuarial (gain)
Amortization of transition obligation
Amortization of transition asset

Other Benefits

20X6

20X7

$905
700
(784)
5
(5)

$770
650
(769)
7
(2)

(5)

(1)

20X6

$14
50
(6)
3
(15)
25
—

$15
44
(3)
2
(1)
25
—

Net periodic benefit cost

$816

$655

$71

$82

Additional Information
Assumptions
Weighted-average assumptions used to
determine benefit obligations at
December 31
Discount rate
Rate of compensation increase

7.00%
6.00%

7.00%
6.00%

7.00%

7.00%
(continued)
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Pension Benefits
20X7
Weighted-average assumptions used to
determine net periodic benefit cost for
years ended December 31
Discount rate
Expected long-term return on plan assets
Rate of compensation increase

Other Benefits

20X6

7.00%
8.00%
6.00%

20X7

7.00%
8.00%
6.00%

20X6

7.00%
6.60%

7.00%
6.60%

(Entity specific narrative description of the basis used to determine the overall expected long-term rate of
return on assets, as described in FASB ASC 715-20-50-1(d)(3) would be included here.)
20X6

20X7

Assumed health care cost trend rates at December 31
Health care cost trend rate assumed for next year
Rate to which the cost trend rate is assumed to decline
(the ultimate trend rate)
Year that the rate reaches the ultimate trend rate

7%

7%

5%
20Y2

5%
20Y2

Assumed health care cost trend rates have a significant effect on the amounts reported for the health care
plans. A one-percentage-point change in assumed health care cost trend rates would have the following
effects:
1-PercentagePoint Decrease

1-PercentagePoint Increase
Effect on total of service and interest cost
Effect on postretirement benefit obligation

$13
73

($11)
(67)

Plan Assets
The composition of plan assets at December 31, 20X7, and 20X6, is as follows:
Pension Benefits
20X7

Other Benefits

20X6

20X7

20X6

Asset Category

XX%

XX%

XX%

XX%

Equity securities
Debt securities
Real estate
Other
Total

XX
XX
XX
XX
100%

XX
XX
XX
XX
100%

XX
XX
XX
XX
100%

XX
XX
XX
XX
100%

(Entity specific narrative description of investment policies and strategies for plan assets, including
weighted-average target asset allocations [if used as part of those policies and strategies] as described in
FASB ASC 715-10-50-1(d)(2), would be included here.)
Cash Flows
Contributions
The hospital expects to contribute $XXX to its pension plan and $XXX to its other postretirement benefit
plan in 20X8.
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Estimated Future Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are expected to be
paid:
Other
Benefits

Pension
Benefits
20X8
20X9
20Y0
20Y1
20Y2
Years 20Y3–20Y7
9.

$XXX
XXX
XXX
XXX
XXX
XXX

$XXX
XXX
XXX
XXX
XXX
XXX

Concentrations of Credit Risk

The hospital grants credit without collateral to its patients, most of whom are local residents and are
insured under third-party payor agreements. The mix of receivables from patients and third-party payors at
December 31, 20X7 and 20X6, was as follows:
20X6

20X7
Medicare
Medicaid
Blue Cross
Other third-party payors
Patients

10.

51%
17
18
7
7

53%
14
17
9
7

100%

100%

Commitments and Contingencies

Operating leases. The hospital leases various equipment and facilities under operating leases expiring at
various dates through April 20Y2. Total rental expense in 20X7 and 20X6 for all operating leases was approximately $859,000 and $770,000, respectively.
The following is a schedule by year of future minimum lease payments under operating leases as of
December 31, 20X7, that have initial or remaining lease terms in excess of one year.
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2

Amount
$517,000
506,000
459,000
375,000
343,000

Litigation. The hospital is involved in litigation and regulatory investigations arising in the course of
business. After consultation with legal counsel, management estimates that these matters will be resolved
without material adverse effect on the hospital’s future financial position or results from operations.
Allowance for doubtful accounts. Beginning in 20X5, the hospital has provided care under an agreement
with Associated HMO. The HMO currently owes the hospital $950,000, substantially all of which is overdue.
The hospital has notified the HMO that further services under the contract cannot be provided without
payment on the outstanding balance. The HMO has assured the hospital that additional funds are being
obtained in order to pay the overdue balance and continue service under the agreement, however, if the
HMO is unable to make payments, additional allowances for bad debts would need to be accrued.
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11.

Related Party Transactions

During the years ended December 31, 20X7 and 20X6, the hospital contributed capital to Sample Health
System, an affiliate with some board members in common with the hospital, in the amounts of $688,000 and
$3,051,000, respectively.
The Sample Hospital Foundation (the Foundation), which is controlled by Sample Health System, was
established to solicit contributions from the general public solely for the funding of capital acquisitions by
the hospital. Funds are distributed to the hospital as determined by the Foundation’s Board of Directors. A
summary of the foundation’s assets, liabilities, net assets, results of operations, and changes in net assets
follows. The hospital’s interest in the net assets of the Foundation is reported as a noncurrent asset in the
balance sheets.
At December 31,
20X7

20X6

$521,000

$472,000

11,000
510,000

10,000
462,000

Total liabilities and net assets

$521,000

$472,000

Support and revenue

$269,000

$535,000

235,000
13,000

485,000
16,000

248,000

501,000

21,000
27,000
462,000

34,000
17,000
411,000

$510,000

$462,000

Assets principally cash and cash equivalents
Liabilities
Unrestricted net assets

Expenses
Distributions to Sample Hospital for property
acquisitions
Other
Total expenses
Excess of support and revenue over expenses
Other changes in net assets
Unrestricted net assets, beginning of year
Unrestricted net assets, end of year

Liabilities include $10,000 payable at the end of each year to Sample Hospital. These amounts were paid
after the end of each year.
12.

Functional Expenses

The hospital provides general health care services to residents within its geographic location. Expenses
related to providing these services are as follows (in thousands):
At December 31,
20X7
Health care services
General and administrative

13.

20X6

$86,000
12,055

$78,647
10,643

$98,055

$89,290

Fair Value of Financial Instruments

The following methods and assumptions were used by the hospital in estimating the fair value of its
financial instruments:
Cash and cash equivalents: The carrying amount reported in the balance sheet for cash and cash
equivalents approximates its fair value.
Investments: Fair values, which are the amounts reported in the balance sheet, are based on
quoted market prices, if available, or estimated using quoted market prices for similar securities.
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Assets limited as to use: These assets consist primarily of cash and short-term investments and
interest receivable. The carrying amount reported in the balance sheet is fair value.
Accounts payable and accrued expenses: The carrying amount reported in the balance sheet for
accounts payable and accrued expenses approximates its fair value.
Estimated third-party payor settlements: The carrying amount reported in the balance sheet for
estimated third-party payor settlements approximates its fair value.
Long-term debt: Fair values of the hospital’s revenue notes are based on current traded value.
The fair value of the hospital’s remaining long-term debt is estimated using discounted cash
flow analyses, based on the hospital’s current incremental borrowing rates for similar types of
borrowing arrangements.
The carrying amounts and fair values of the hospital’s financial instruments at December 31,
20X7 and 20X6, are as follows (In thousands):
20X6

20X7
Carrying
Amount
Cash and cash equivalents
Short-term investments
Assets limited as to use
Long-term investments
Long-term investments restricted for capital acquisition
Accounts payable and accrued expenses
Estimated third-party payor settlements
Long-term debt
14.

$4,758
15,836
18,949
4,680
320
5,818
2,143
24,614

Fair
Value
$4,758
15,836
18,949
4,680
320
5,818
2,143
23,980

Carrying
Amount
$5,877
10,740
19,841
4,680
520
5,382
1,942
25,764

Fair
Value
$5,877
10,740
19,841
4,680
520
5,382
1,942
24,918

Promises to Contribute

At December 31, 20X7, the hospital had received $1,500,000 of conditional promises to contribute to the
building of a new facility for outpatient services. These contributions will be recorded as temporarily restricted support when received. The hospital had no material outstanding unconditional promises of support at December 31, 20X7.
15.

Charity Care

The amount of charges foregone for services and supplies furnished under the hospital’s charity care
policy aggregated approximately $4,500,000 and $4,100,000 in 20X7 and 20X6, respectively.
Subsequent Event\

16.

On February 9, 20X8, the hospital signed a contract in the amount of $1,050,000 for the purchase of
certain real estate.
\

In May 2009, FASB issued Statement No. 165, Subsequent Events, which establishes general standards of accounting for and disclosure
of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. This statement
sets forth
a.

the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions
that may occur for potential recognition or disclosure in the financial statements.

b.

the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its
financial statements.

c.

the disclosures that an entity should make about events or transactions that occurred after the balance sheet date.

FASB Statement No. 165 introduces the concept of financial statements being available to be issued. It also requires disclosure of the
date through which an entity has evaluated subsequent events and the basis for that date (that is, whether that date represents the date
the financial statements were issued or were available for issue).
FASB Statement No. 165 is effective for interim or annual financial periods ending after June 15, 2009. For additional information
please visit the FASB Web site at www.fasb.org.
FASB Statement No. 165 has been codified in FASB ASC 855, Subsequent Events.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A GOVERNMENTAL
HOSPITAL AUTHORITY
.11
Sample Governmental Hospital Authority
A Component Unit of Feeling County, State of Union
Balance Sheets8
December 31, 20X7 and 20X6
(in thousands)
20X7
Assets
Current assets:
Cash and cash equivalents
Short term investments
Patient accounts receivable, net of estimated
uncollectibles of $2,125 (20X7) and $2,040 (20X6)
Supplies and other current assets

20X6

$7,136
3,142

$7,557
3,423

19,834
2,270

16,727
2,428

32,382

30,135

15,000
2,605
1,945

15,000
1,327
2,005

1,124
3,003
385

1,078
2,919
229

Total current assets
Noncurrent cash and investments:
Internally designated for capital acquisitions
Other long term investments
Held by trustee for debt service
Restricted by contributors and grantors for capital
acquisitions and research
Principal of permanent endowments
Delinquent property taxes
Capital Assets:
Land
Depreciable capital assets, net of accumulated
depreciation

3,590

3,590

39,792

39,328

Total capital assets, net of accumulated depreciation
Other assets

43,382
1,056

42,918
936

$100,882

$96,547

$1,250
4,945
1,822
1,673

$1,488
4,575
1,651
1,797

9,690

9,511
(continued)

Total assets
Liabilities and Net Assets
Current liabilities:
Current maturities of long term debt
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities
Total current liabilities

8

GASB Statement No. 34, Basic Financial Statements—and Management’s Discussion and Analysis—for State and Local Governments, paragraphs 97–99 provide guidance on the statement of net assets or balance sheet. Governmental health care entities that are special-purpose
governments engaged only in business-type activities may use either a balance sheet format—assets equal liabilities plus net assets/
equity—or a net assets format—assets less liabilities equal net assets/equity. Assets and liabilities are required to be presented in a
classified format.
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20X7
Long term debt, net of current maturities
Other long term liabilities
Total liabilities
Net Assets:
Invested in capital assets net of related debt
Restricted:
For debt service
Expendable for capital acquisitions
Expendable for research
Expendable for specific operating activities
Nonexpendable permanent endowments
Unrestricted

20X6
19,672
3,361

20,412
2,690

32,723

32,613

22,460

21,018

1,945
733
781
331
3,003
38,906

2,005
628
899
573
2,919
35,892

68,159

63,934

$100,882

$96,547

9

Total net assets
Total liabilities and net assets
See accompanying notes to financial statements.

9
Either the term net assets or equity may be used to refer to the difference between assets and liabilities. Regardless of the label, net
assets/equity is required to be reported in three broad components: (a) invested in capital assets, net of related debt; (b) restricted, and (c)
unrestricted. When permanent endowments are reported in restricted net assets, two additional components—expendable and nonexpendable—are required, as discussed in paragraph 35 of GASB Statement No. 34.
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.12
Sample Governmental Hospital Authority
A Component Unit of Feeling County, State of Union
Statements of Revenues, Expenses, and Changes in Net Assets10
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7
Operating revenues:
Net patient service revenue (net of provision for bad
debts of $859 in 20X7 and $938 in 20X6)
Premium revenue
Other

20X6

$43,305
9,876
3,416

$43,736
13,058
3,248

Total operating revenues

56,597

60,042

Operating expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Other supplies
Depreciation and amortization

46,845
12,746
7,030
10,314
4,065

43,235
7,986
7,382
11,166
3,638

Total operating expenses

81,000

74,407

(24,403)

(13,365)

23,895
5,653
(1,489)
170
(425)

15,309
5,304
(1,552)
853
—

27,804

19,914

3,401

6,549

824
—

2,560
351

$4,225
63,934

$9,460
54,474

$68,159

$63,934

Operating loss
Nonoperating revenues (expenses):
Property taxes
Investment income
Interest expense
Noncapital grants and contributions
Other
Total nonoperating revenues (expenses)
Excess of revenues over expenses before capital
grants, contributions, and additions to
permanent endowments
Capital grants and contributions
Additions to permanent endowments
Increase in net assets
Net assets beginning of the year
Net assets end of the year
See accompanying notes to financial statements.

10

GASB Statement No. 34 paragraph 101 requires proprietary funds and special purpose governments engaged only in business-type
activities to present an operating statement that uses an “all-inclusive” format, presenting all changes in both restricted and unrestricted
net assets and presenting a final total, “Increase (decrease) in net assets/equity.” Either the term net assets or equity may be used to refer
to the difference between assets and liabilities. Regardless of the label, net assets/equity is required to be reported in three broad
components: (a) invested in capital assets, net of related debt; (b) restricted, and (c) unrestricted. When permanent endowments are
reported in restricted net assets, two additional components—expendable and nonexpendable—are required, as discussed in paragraph
35 of GASB Statement No. 34.
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.13
Sample Governmental Hospital Authority
A Component Unit of Feeling County, State of Union
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6
(in thousands)
20X7

20X6

Cash flows from operating activities:
Receipts from and on behalf of patients
Payments to suppliers and contractors
Payments to employees
Other receipts and payments, net

$50,074
(30,029)
(46,955)
4,591

$54,680
(26,634)
(43,460)
3,597

Net cash provided by operating activities

(22,319)

(11,817)

Cash flows from noncapital financing activities:
Property taxes
Noncapital grants and contributions
Contributions to permanent endowments
Other

20,739
170
—
(425)

12,224
853
351
—

Net cash provided by noncapital financing activities

20,484

13,428

Cash flows from capital and related financing activities:
Capital grants and contributions
Property taxes restricted to capital acquisitions
Principal paid on long term debt
Interest paid on long term debt
Purchase of capital assets

824
3,000
(1,488)
(1,489)
(4,019)

2,560
3,000
(1,896)
(1,552)
(4,111)

Net cash used by capital and related financing activities

(3,172)

(1,999)

Cash flows from investing activities:
Interest and dividends on investments
Purchases of investments
Proceeds from sale of investments

2,737
(1,045)
2,327

2,124
(289)
683

4,019

2,518

Net cash provided by investing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Reconciliation of cash and cash equivalents to the
statement of net assets:
Cash and cash equivalents in current assets
Restricted cash and cash equivalents
Total cash and cash equivalents

(988)

2,130

9,101
$8,113

6,971
$9,101

7,136
977

7,557
1,544

$8,113

$9,101
(continued)
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20X7
Reconciliation of operating income (loss) to net cash
provided (used) by operating activities:
Operating loss
Adjustments to reconcile operating income to net cash
flows used in operating activities:
Depreciation and amortization
Provision for bad debts
Changes in:
Patient accounts receivable
Supplies and other current assets
Other assets
Accounts payable, accrued expenses, and other current
Liabilities
Estimated third-party payor settlements
Other liabilities related to operating activities
Net cash used in operating activities

20X6

($24,403)

($13,365)

4,065
859

3,638
938

(3,966)
158
(120)

(2,909)
100
—

246
171
671
($22,319)

(225)
(235)
241
($11,817)

Noncash Investing, Capital, and Financing Activities:
The authority entered into capital lease obligations of $510,000 for new
equipment in 20X7.
The authority held investments at December 31, 20X7, with a fair value of
$XXX. During 20X7, the net increase in the fair value of these investments
was $XXX.
See accompanying notes to financial statements.
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.14
Sample Governmental Hospital Authority
A Component Unit of Feeling County, State of Union
Notes to Financial Statements11
December 31, 20X7 and 20X6 (in thousands)
1.

Description of Reporting Entity and Summary of Significant Accounting Policies

Reporting entity. The Sample Hospital Authority (the authority) is a public corporation. It was created
on January 1, 19XX, by the board of county commissioners of Feeling County, State of Union, to operate,
control, and manage all matters concerning the county’s health care functions. The board of county commissioners appoints the board of trustee members of the authority, and the authority may not issue debt or levy
taxes without the county’s approval. For this reason, the authority is considered to be a component unit of
Feeling County and is included as a discretely presented component unit in the basic financial statements of
the county.
Use of estimates. The preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Enterprise fund accounting. The authority uses enterprise fund accounting. Revenues and expenses are
recognized on the accrual basis using the economic resources measurement focus. Based on GASB Statement
No. 20, as amended, the authority has elected to apply the provisions of all relevant pronouncements of the
FASB, including those issued after November 30, 1989, that do not conflict with or contradict GASB pronouncements.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt instruments with an original maturity of three months or less.
Capital assets. The authority’s capital assets are reported at historical cost. Contributed capital assets are
reported at their estimated fair value at the time of their donation. All capital assets other than land are
depreciated or amortized (in the case of capital leases) using the straight-line method of depreciation using
these asset lives:
Land improvements
Buildings and building improvements
Equipment, computers, and furniture

15–20 years
20–40 years
3–7 years

Costs of borrowing. Except for capital assets acquired through gifts, contributions, or capital grants, interest cost on borrowed funds during the period of construction of capital assets is capitalized as a component
of the cost of acquiring those assets. None of the authority’s interest cost was capitalized in either 20X7 or
20X6.

11
The notes to the financial statements in these illustrative financial statements generally include only disclosures unique to a governmental hospital. The disclosures regarding the accounting policies for the use of estimates and cost of borrowing in note 1 and charity
care in note 5 are not unique to a governmental hospital. Also, the notes to the financial statements include disclosures that are not
required.
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Property taxes. The authority received approximately 29 percent in 20X7 and 19 percent in 20X6 of its
financial support from property taxes. These funds were used as follows:
20X7
Used to support operations
Levied for debt service

$20,895
3,000

20X6
$12,309
3,000

Property taxes are levied by the county on the authority’s behalf on January 1 and are intended to finance
the authority’s activities of the same calendar year. Amounts levied are based on assessed property values
as of the preceding July 1.
Property taxes are considered delinquent on the day following each payment due date.
Grants and contributions. From time to time, the authority receives grants from Feeling County and the
State of Union as well as contributions from individuals and private organizations. Revenues from grants
and contributions (including contributions of capital assets) are recognized when all eligibility requirements,
including time requirements are met. Grants and contributions may be restricted for either specific operating
purposes or for capital purposes. Amounts that are unrestricted or that are restricted to a specific operating
purpose are reported as nonoperating revenues. Amounts restricted to capital acquisitions are reported after
nonoperating revenues and expenses.
Endowments. Endowments are provided to the authority on a voluntary basis by individuals and private
organizations. Permanent endowments require that the principal or corpus of the endowment be retained in
perpetuity. If a donor has not provided specific instructions, Union state law permits the authority’s board
of trustees to authorize for expenditure the net appreciation of the investments of endowment funds, as
discussed in note 2.
Restricted resources. When the authority has both restricted and unrestricted resources available to finance a particular program, it is the authority’s policy to use restricted resources before unrestricted resources.
Net assets. Net assets of the authority are classified in four components. Net assets invested in capital assets
net of related debt consist of capital assets net of accumulated depreciation and reduced by the current balances of any outstanding borrowings used to finance the purchase or construction of those assets. Restricted
expendable net assets are noncapital net assets that must be used for a particular purpose, as specified by
creditors, grantors, or contributors external to the authority, including amounts deposited with trustees as
required by revenue bond indentures, discussed in note 8. Restricted nonexpendable net assets equal the principal portion of permanent endowments. Unrestricted net assets are remaining net assets that do not meet the
definition of invested in capital assets net of related debt or restricted.
Operating revenues and expenses. The authority’s statement of revenues, expenses and changes in net assets distinguishes between operating and nonoperating revenues and expenses. Operating revenues result
from exchange transactions associated with providing health care services—the authority’s principal activity. Nonexchange revenues, including taxes, grants, and contributions received for purposes other than capital asset acquisition, are reported as nonoperating revenues. Operating expenses are all expenses incurred
to provide health care services, other than financing costs.
Compensated absences. The authority’s employees earn vacation days at varying rates depending on years
of service. Vacation time does not accumulate. Generally, any days not used at year-end expire. Employees
also earn sick leave benefits based on varying rates depending on years of service. Employees may accumulate sick leave up to a specified maximum. Employees are not paid for accumulated sick leave if they
leave before retirement. However, employees who retire from the authority may convert accumulated sick
leave to termination payments at varying rates, depending on the employee’s contract. The estimated
amount of sick leave payable as termination payments is reported as a noncurrent liability in both 20X7 and
20X6.
Risk management. The authority is exposed to various risks of loss from torts; theft of, damage to, and
destruction of assets; business interruption; errors and omissions; employee injuries and illnesses; natural
disasters; medical malpractice; and employee health, dental, and accident benefits. Commercial insurance
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coverage is purchased for claims arising from such matters. Settled claims have not exceeded this commercial coverage in any of the three preceding years.
Investments in debt and equity securities. Investments in debt and equity securities are reported at fair
value except for short term highly liquid investments that have a remaining maturity at the time they are
purchased of one year or less. These investments are carried at amortized cost. Interest, dividends, and gains
and losses, both realized and unrealized, on investments in debt and equity securities are included in nonoperating revenue when earned.
2.

Endowments and Restricted Net Assets
Restricted, expendable net assets are available for the following purposes:
20X6

20X7
Program A activities:
Purchase of equipment
Research
General
Program B activities:
Purchase of equipment
Research
General
Program C activities:
General
Buildings and equipment
Research
Total expendable, restricted net assets

$404
553
46

$321
683
63

235
184
79

235
151
110

206
94
44

400
72
65

$1,845

$2,100

Unless the contributor provides specific instructions, Union state law permits the authority’s board of
trustees to authorize for expenditure the net appreciation (realized and unrealized) of the investments in its
endowments. When administering its power to spend net appreciation, the board of trustees is required to
consider the authority’s “long- and short-term needs, present and anticipated financial requirements, expected total return on its investments, price-level trends, and general economic conditions.” Any net appreciation that is spent is required to be spent for the purposes designated by the contributor.
The board of trustees chooses to spend only a portion of the investment income (including changes in
the value of investments) each year. Under the policy established by the board, 5 percent of the average
market value of endowment investments at the end of the previous 3 years has been authorized for expenditure. The authority retains the remaining amount, if any, to be used in future years when the amount
computed using the spending policy exceeds investment income. At December 31, 20X7 and 20X6, net appreciation of $864 and $953, respectively, is available to be spent, of which $402 and $682, respectively, is
reported as restricted expendable net assets, and the balance is in unrestricted net assets.
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Restricted nonexpendable net assets as of December 31, 20X7 and 20X6, represent the principal amounts
of permanent endowments, restricted to investment in perpetuity. Investment earnings from the authority’s
permanent endowments are expendable to support these programs as established by the contributor:
20X6

20X7
Program A activities
Program B activities
Program C activities
Any activities of the authority

3.

$158
176
423
854
1,611

$158
176
423
854
1,611

Endowment requiring income to be added to
original gift until the fund’s value is $2,125

1,392

1,308

Total restricted nonexpendable net assets

3,003

2,919

Designated Net Assets

Of the $40,851 and $37,897 of unrestricted net assets reported in 20X7 and 20X6, respectively, $15,000
has been designated by the authority’s board of trustees for capital acquisitions. Designated funds remain
under the control of the board of trustees, which may at its discretion later use the funds for other purposes.
4.

Deposits and Investments

State law requires collateralization of all deposits with federal depository insurance and other acceptable
collateral in specific amounts. The authority’s bylaws require that all bank balances be insured or collateralized by U.S. government securities held by the pledging financial institution’s trust department in the
name of the authority.
The authority’s investments generally are reported at fair value, as discussed in note 1. At December 31,
20X7 and 20X6, the authority had the following investments and maturities, all of which were held in the
authority’s name by a custodial bank that is an agent of the authority:12
December 31, 20X7
Investment Type
U.S. Treasuries
Federal National Mortgage Association
Government National Mortgage Association
Total

Investment Maturities (in Years)
Carrying
Amount
$21,749
3,580
3,5806
$28,934

U.S. Treasuries
Federal National Mortgage Association
Government National Mortgage Association
Total

$XXX
XXX
XXX
$XXX

1–5
$XXX
XXX
XXX
$XXX

6–10

More
Than 10

$XXX
XXX
XXX
$XXX

$XXX
XXX
XXX
$XXX

Investment Maturities (in Years)

December 31, 20X6
Investment Type

Less
Than 1

Carrying
Amount
$20,039
3,365
3,366
$26,770

Less
Than 1
$XXX
XXX
XXX
$XXX

1–5
$XXX
XXX
XXX
$XXX

6–10
$XXX
XXX
XXX
$XXX

More
Than 10
$XXX
XXX
XXX
$XXX

Interest Rate Risk. The authority does not have a formal investment policy that limits investment maturities as a means of managing its exposure to fair value losses arising from changing interest rates.
Credit Risk. Statutes authorize the authority to invest in obligations of the U.S. Treasury, agencies, and
instrumentalities, commercial paper rated A-1 by Standard & Poor’s Corporation or P-1 by Moody’s Commercial Paper Record, and bankers’ acceptances. However, the authority’s bylaws require that investments
12
This illustrative note presents interest rate information using the segmented time distribution method. Other methods for illustrating
interest rate information are described in paragraph 15 of GASB Statement No. 40, Deposit and Investment Risk Disclosures.
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be made only in U.S. government obligations held by the authority’s third-party agent. As of December 31,
20X7 and 20X6, the authority’s investments in Federal National Mortgage Association were rated AAA by
Standard and Poor’s and Fitch Ratings and Aaa by Moody’s Investor Services.
Concentration of Credit Risk. The authority places no limit on the amount it may invest in any 1 issuer.
More than 5 percent of the authority’s investments at December 31, 20X7 and 20X6 are invested in the
Federal National Mortgage Association. These investments are 12.37 percent and 12.57 percent, respectively,
of the authority’s total investments at December 31, 20X7 and 20X6.
The carrying amounts of deposits and investments are included in the authority’s balance sheets as
follows:
20X7
Carrying amount
Deposits
Investments
Included in the following balance sheet captions
Cash and cash equivalents
Short term investments
Noncurrent cash and investments:
Other long term investments
Restricted by contributors and grantors for
capital acquisitions and research
Internally designated for capital acquisitions
Held by trustee for debt service
Principal of permanent endowments

5.

20X6

$5,021
28,934

$6,539
26,770

$33,955

$33,309

$7,136
3,142

$7,557
3,423

2,605

1,327

1,124
15,000
1,945
3,003

1,078
15,000
2,005
2,919

$33,955

$33,309

Charity Care

Charges excluded from revenue under the authority’s charity care policy were $7,100 and $6,845 for
20X7 and 20X6, respectively.
6.

Accounts Receivable and Payable

Patient accounts receivable and accounts payable (including accrued expenses) reported as current assets and liabilities by the authority at December 31, 20X7 and 20X6 consisted of these amounts:
Patient Accounts Receivable
20X7
Receivable from patients and their insurance carriers
Receivable from Medicare
Receivable from Medicaid
Total patient accounts receivable
Less allowance for uncollectibles amounts
Patient accounts receivable, net
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20X6

$13,976
4,286
3,697
21,959

$11,868
3,002
3,897
18,767

2,125

2,040

$19,834

$16,727
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Accounts Payable and Accrued Expenses
20X7

7.

20X6

Payable to employees (including payroll taxes)
Payable to suppliers
Other

$2,437
2,481
27

$1,970
2,591
14

Total accounts payable and accrued expenses

$4,945

$4,575

Capital Assets

Capital asset additions, retirements, and balances for the years ended December 31, 20X7 and 20X6 were
as follows:
Balance
December 31,
20X6

Additions

Retirements

Balance
December 31,
20X7

$3,590
645
29,265
30,375

—
17
965
3,547

—
—
(810)
(1,860)

$3,590
662
29,420
32,062

Totals at historical cost
Less accumulated depreciation for:
Land improvements
Buildings and improvements
Equipment

$63,875

$4,529

($2,670)

$65,734

(291)
(5,352)
(15,314)

(65)
(582)
(3,418)

—
810
1,860

(356)
(5,124)
(16,872)

Total accumulated depreciation

(20,957)

(4,065)

2,670

(22,352)

Capital assets, net

$42,918

$464

Land
Land improvements
Buildings and improvements
Equipment
13

$0

$43,382

Balance
December 31,
20X5

Additions

Retirements

Balance
December 31,
20X6

$3,590
608
29,187
26,710

—
112
78
3,921

—
(75)
—
(256)

$3,590
645
29,265
30,375

Totals at historical cost
Less accumulated depreciation for:
Land improvements
Buildings and improvements
Equipment

$60,095

$4,111

($331)

$63,875

(309)
(4,826)
(12,515)

(57)
(526)
(3,055)

75
—
256

(291)
(5,352)
(15,314)

Total accumulated depreciation

(17,650)

(3,638)

331

(20,957)

Capital assets, net

$42,445

$473

$0

$42,918

Land
Land improvements
Buildings and improvements
Equipment

13

When present, construction-in-progress should be reported in a separate line in this schedule. (See the GASB staff document
Comprehensive Implementation Guide—2005, item 7.353). Also, GASB Statement No. 34 paragraph 20 requires nondepreciable capital assets
to be shown separately on the face of the balance sheet when these balances are significant.
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Long Term Debt and Other Noncurrent Liabilities
A schedule of changes in the authority’s noncurrent liabilities for 20X7 and 20X6 follows:
Balance
December
31, 20X6

Bonds and Notes Payable:
Revenue notes
Mortgage loan
Note payable
Total long term debt
Capital lease obligations
Other Liabilities:
Compensated absences
Net pension obligation
Total other liabilities
Total noncurrent liabilities

Reductions

Amounts Due
Within 1 Year

$18,714
1,808
570
21,092
808

—
—
—
—
510

($457)
(99)
(464)
(1,020)
(468)

$18,257
1,709
106
20,072
850

$620
99
106
825
425

2,625
65
2,690
$24,590

662
15
677
$1,187

(6)
—
(6)
($1,494)

3,281
80
3,361
$24,283

—
See note 9
—
$1,250

Reductions

Balance
December
31, 20X6

Balance
December
31, 20X5
Bonds and Notes Payable:
Revenue notes
Mortgage loan
Note payable
Total long term debt
Capital lease obligations
Other Liabilities:
Compensated absences
Net pension obligation
Total other liabilities
Total noncurrent liabilities

Additions

Balance
December
31, 20X7

Additions

Amounts Due
Within 1 Year

19,568
1,907
1,045
22,520
1,276

—
—
—
—
—

(854)
(99)
(475)
(1,428)
(468)

18,714
1,808
570
21,092
808

457
99
464
1,020
468

2,400
49
2,449
$26,245

236
16
252
$252

(11)
—
(11)
($1,907)

2,625
65
2,690
$24,590

—
See note 9
—
$1,488

Long term debt. The terms and due dates of the authority’s long term debt, including capital lease obligations, at December 31, 20X7 and 20X6, follow:
●

7.25 percent revenue notes, due November 1, 20Z7, collateralized by a pledge of the authority’s
gross receipts. Thus all operating and nonoperating revenues of the authority are similarly pledged.

●

9.25 percent mortgage loan, due January 20Y4, collateralized by a mortgage on property and equipment with a depreciated cost of $1,530 at December 31, 20X7

●

9.75 percent note payable, due March 20X8, unsecured

●

Capital lease obligations, at varying rates of imputed interest from 9.8 percent to 12.3 percent collateralized by leased equipment with cost of $1,275 at December 31, 20X7

Under the terms of the revenue note indenture, the authority is required to maintain certain deposits
with a trustee. Such deposits are included with restricted cash and investments in the balance sheet. The
revenue note indenture also places limits on the incurrence of additional borrowings and requires that the
authority satisfy certain measures of financial performance as long as the notes are outstanding.
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Scheduled principal and interest repayments on long term debt and payments on capital lease obligations are as follows:
Long Term Debt
Year Ending December 31:
20X8
20X9
20Y0
20Y1
20Y2
20Y3–20Y7
20Y8–20Z2
20Z3–20Z7
Total
9.

Principal

Interest

Capital Lease Obligations
Principal

Interest

$825
775
836
900
972
5,764
4,824
5,176

$53
487
465
448
432
1,769
1,492
1,116

$425
213
212

$58
27
13

$20,072

$6,762

$850

$98

Commitments under Noncancelable Operating Leases

The authority is committed under various noncancelable operating leases, all of which are for equipment
and computers. These expire in various years through 20Y9. Future minimum operating lease payments are
as follows:
Year ending
December 31:
20X8
20X9
20Y0
20Y1
20Y2
20Y3–20Y7
20Y8–20Y9
Total
10.

$3,109
2,898
2,795
2,780
2,575
4,215
1,065
$19,437

Pension Plan14

Plan description. Sample Hospital Pension Plan (SHPP) provides retirement and disability benefits, annual cost-of-living adjustments, and death benefits to plan members and beneficiaries. SHPP is affiliated
with County Employees Pension Plan (CEPP), an agent multiple-employer pension plan administered by
the Union Retirement System. Article 39 of the Regulations of the State of Union assigns the authority to
establish and amend the benefit provisions of the plans that participate in CEPP to the respective employer
entities; for CEPP, that authority rests with the County of Feeling, Union. The Union Retirement System
issues a publicly available financial report that includes financial statements and required supplementary
information for SHPP. That report may be obtained by writing to Union Retirement System, State Government Lane, Anytown, Union 01000 or by calling 1-800-555-PLAN.
Funding policy. The contribution requirements of plan members and the authority are established and
may be amended by the CEPP board of trustees. Plan members are required to contribute 7.8 percent of
their annual covered salary. The authority is required to contribute at an actuarially determined rate; the
current rate for both 20X7 and 20X6 is 11.9 percent of annual covered payroll.

14
The preparer of the financial statements should consider the need for required supplementary information as required by GASB
Statement No. 27, Accounting for Pensions by State and Local Governmental Employers, paragraph 22.
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Annual pension cost and net pension obligation. The authority’s annual pension cost and net pension obligation to SHPP for 20X7 and 20X6 were as follows:
20X6

20X7
Annual required contribution
Interest on net pension obligation
Adjustment to annual required contribution

$26
3
(3)

$23
2
(2)

Annual pension cost
Contributions made

26
(11)

23
(7)

Increase (decrease) in net pension obligation
Net pension obligation beginning of year
Net pension obligation, end of year

15
65
$80

16
49
$65

The annual required contribution for the current year was determined as part of the December 31, 20X6,
actuarial valuation using the entry age actuarial cost method. The actuarial assumptions included (a) 7.5
percent investment rate of return (net of administrative expenses) and (b) projected salary increases ranging
from 5.5 percent to 9.5 percent per year. Both (a) and (b) included an inflation component of 5.5 percent. The
actuarial assumptions also include a 2 percent per year cost-of-living adjustment. The actuarial value of
assets was determined using techniques that smooth the effects of short term volatility in the market value
of investments over a 4 year period. The same actuarial assumptions were used to determine the actuarial
required contributions for 20X6. The unfunded actuarial accrued liability is being amortized as a level percentage of projected payroll on an open basis. The remaining amortization period at December 31, 20X6,
was 23 years.

Fiscal Year Ending
12/31/X5
12/31/X6
12/31/X7
11.

Three-Year Trend Information
Annual Pension Cost
Percentage of APC
(APC)
Contributed
$20
23
26

94%
30
42

Net Pension
Obligation
$49
65
80

Postretirement Plan#

In addition to the pension benefits previously described, the authority provides postretirement health
care benefits, in accordance with the authority’s bylaws, to all employees who retire from the authority on
or after attaining age 60 with at least 15 years of service. Currently 250 retirees (245 in 20X6) meet these
eligibility requirements. The authority reimburses 75 percent of the amount of validated claims for medical,
dental, and hospitalization costs incurred by pre-Medicare retirees and their dependents. The authority also
reimburses a fixed amount of $25 per month for a Medicare supplement for each retiree eligible for Medicare. Expenses for postretirement health care benefits are recognized as retirees report claims and include a
provision for estimated claims incurred but not yet reported to the authority. Expenses of $764 were recognized for postretirement health care in 20X7; expenses recognized in 20X6 were $636. Approximately $64 of
#
In 2004, the GASB issued GASB Statement No. 45 that would supersede or amend previous authoritative guidance on accounting
and financial reporting for an employer’s OPEB expense and related information, including GASB Statement No. 12. GASB Statement
No. 45 requires reporting of the annual cost of OPEB, and the outstanding obligations and commitments related to OPEB in essentially
the same manner as required for pensions in GASB Statement No. 27. Paragraphs 24–25 of GASB Statement No. 45 require disclosures in
the notes to the financial statements for OPEB plans. Conforming changes to modify these illustrative financial statements to reflect the
issuance of GASB Statement No. 45 will be made in a future edition of this checklist.

GASB issued Technical Bulletin 2006-1, Accounting and Financial Reporting by Employers and OPEB Plans for Payments from the Federal
Government Pursuant to the Retiree Drug Subsidy Provisions of Medicare Part D, in June 2006. This Technical Bulletin is effective immediately,
except for portions of answers pertaining specifically to measurement, recognition, or required supplementary information requirements
of GASB Statement Nos. 43, Financial Reporting for Postemployment Benefit Plans Other Than Pension Plans, or 45. Those provisions should
be applied simultaneously with the implementation of GASB Statement Nos. 43 or 45. This Technical Bulletin clarifies the application of
existing standards of accounting and financial reporting to payments that an employer or a defined benefit OPEB plan receives from the
federal government pursuant to the retiree drug subsidy provisions of Medicare Part D, as established in the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003.
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the $128 increase in expenses over the previous year was caused by the addition of dental benefits, effective
July 1, 20X7.
Note: Although not presented in these sample illustrative financial statements, other disclosures required by
GASB pronouncements may be applicable, including the following:
●

Short term debt (GASB Statement No. 38, Recipient Reporting for Certain Shared Nonexchange Revenues—an amendment of GASB Statement No. 33, paragraph 12)

●

Interfund balances and transfers (GASB Statement No. 38 paragraph 14 when a governmental health
care entity reports multiple enterprise funds or is reported as an enterprise fund of a general purpose government.)

●

Segment information (GASB Statement No. 34, as amended, paragraphs 122–123)

●

Violations of finance-related legal or contractual provisions (GASB Statement No. 38 paragraph 9)

●

Risk financing (Requirements for disclosures about claims and judgments and risk financing by
governmental health care entities that retain a portion of risk for claims and judgments (including
malpractice claims and judgments) are provided in GASB Statement No. 10, as amended). Additionally, GASB Statement No. 34 paragraph 119 requires disclosure of certain information about the long
term portion of accrued claims and judgments, if applicable.

Other required disclosures, which may be applicable and would be similar to the disclosures contained in
the notes to the sample illustrative financial statements for a not-for-profit hospital, are not repeated here.
They include the following:
●

Off-Balance Sheet Risk and Concentration of Credit Risk

●

Fair Value of Financial Instruments

●

Commitments and Contingencies

●

Subsequent Events\

●

Net patient service revenue

●

Related party transactions

●

Description of Reporting Entity and Summary of Significant Accounting Policies—Supplies, Net Patient Service Revenue, Charity Care, Premium Revenue

\

In May 2009, FASB issued Statement No. 165, Subsequent Events, which establishes general standards of accounting for and disclosure
of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. This statement
sets forth
a.

the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions
that may occur for potential recognition or disclosure in the financial statements.

b.

the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its
financial statements.

c.

the disclosures that an entity should make about events or transactions that occurred after the balance sheet date.

FASB Statement No. 165 introduces the concept of financial statements being available to be issued. It also requires disclosure of the
date through which an entity has evaluated subsequent events and the basis for that date (that is, whether that date represents the date
the financial statements were issued or were available for issue).
FASB Statement No. 165 is effective for interim or annual financial periods ending after June 15, 2009. For additional information
please visit the FASB Web site at www.fasb.org.
FASB Statement No. 165 has been codified in FASB ASC 855, Subsequent Events.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NURSING HOME
.15
Sample For-Profit Nursing Home, Inc.
Balance Sheets*
December 31, 20X7 and 20X6
20X7
Assets
Current assets:
Cash and cash equivalents
Investments
Assets limited as to use
Patient accounts receivable, net of allowance for
doubtful accounts of $6,700 in 20X7 and $5,300 in
20X6
Estimated third-party payor settlements
Interest receivable
Supplies
Prepaid expenses
Deferred tax asset

20X6

$95,000
150,000
50,000

$129,000

162,000
71,000
7,000
47,000
3,000
12,000

152,000
62,000

597,000

452,000

Assets limited as to use, net of amount required
for current liabilities

173,000

150,000

Property and equipment:
Land
Land improvements

205,000
37,000

205,000
32,000
(continued)

Total current assets

50,000

43,000
2,000
14,000

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7

20X6

Buildings
Furniture, fixtures, and equipment

1,399,000
228,000

1,399,000
189,000

Less accumulated depreciation

1,869,000
210,000

1,825,000
141,000

Property and equipment, net

1,659,000

1,684,000

150,000

127,000

$2,579,000

$2,413,000

$50,000
78,000
175,000
50,000
74,000

$50,000
52,000
188,000
45,000
15,000

427,000

350,000

6,000

14,000

1,700,000

1,750,000

70,000
376,000

70,000
229,000

446,000

299,000

$2,579,000

$2,413,000

Other assets
Total assets
Liabilities and Shareholders’ Equity
Current liabilities:
Current maturities of long-term debt
Accounts payable
Accrued expenses
Deposits from patients
Other current liabilities
Total current liabilities
Deferred tax liability
Long-term debt, net of current maturities
Shareholders’ equity:
Common stock $20 par value; authorized 5,000
shares; issued and outstanding 3,500 shares
Retained earnings
Total shareholders’ equity
Total liabilities and shareholders’ equity
See accompanying notes to financial statements.

FSP §11,400.15

316

Health Care Entities

.16
Sample For-Profit Nursing Home, Inc.
Statements of Income and Retained Earnings
Years Ended December 31, 20X7 and 20X6
20X7
Revenue:
Net patient service revenue
Other revenue
Interest on investments held by trustee

20X6

$2,163,000
67,000
13,000

$1,949,000
22,000
7,000

2,243,000

1,978,000

969,000
511,000
216,000
92,000
69,000
164,000

919,000
499,000
176,000
83,000
57,000
172,000

2,021,000

1,906,000

Operating income
Nonoperating income:
Other interest income

222,000

72,000

Income before provision for income taxes
Provision for income taxes

227,000
80,000

72,000
29,000

Net income
Retained earnings, beginning of year

147,000
229,000

43,000
186,000

$376,000

$229,000

Total revenue
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses

Retained earnings, end of year
See accompanying notes to financial statements.
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.17
Sample For-Profit Nursing Home, Inc.
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6
20X7
Cash flows from operating activities:
Cash received from residents and
third party payors
Cash received from others
Cash paid to employees and suppliers
Interest and dividends received, 10,000
Interest paid
Taxes paid
Deposits received from patients
Deposits refunded to patients
Net cash provided by operating activities
Cash flows from investing activities:
Purchase of investments
Proceeds from sale of property
Capital expenditures
Purchase of assets limited as to use
Net cash used in investing activities

$2,019,000
67,000
(1,679,000)
10,000
(160,000)
(29,000)
35,000
(30,000)
233,000

20X6

$1,796,000
22,000
(1,495,000)
10,000
(170,000)
(30,000)
15,000
(20,000)
128,000

(150,000)
(44,000)
(23,000)

2,000
(79,000)

(217,000)

(77,000)

(50,000)

(50,000)

(50,000)

(50,000)

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year

(34,000)
129,000

1,000
128,000

Cash and cash equivalents, end of year

$95,000

$129,000

$147,000

$43,000

Cash flows from financing activities:
Repayment of long-term debt
Net cash used in financing activities

Reconciliation of net income to net cash provided by
operating activities:
Net income
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation
Provision for bad debts
Loss on sale of property
Change in deferred income taxes
(Increase) decrease in:
Patient accounts receivable
Other current assets
Estimated third-party payor settlements
Interest receivable
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Deposits from patients
Other current liabilities
Net cash provided by operating activities

69,000
92,000
—
(6,000)

57,000
83,000
11,000
(14,000)

(102,000)
(21,000)
(9,000)
(7,000)
(7,000)

(41,000)
(15,000)
(10,000)
(3,000)
(10,000)

13,000
5,000
59,000

43,000
(5,000)
(11,000)

$233,000

$128,000

See accompanying notes to financial statements.
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.18
Sample For-Profit Nursing Home, Inc.
Notes to Financial Statements†
December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies15

Organization. The Sample Nursing Home, Inc. (the Company) was incorporated in New State in 20X1
and operates a 128-bed nursing home in Abacus, New State. A summary of the Company’s significant accounting policies follows:
Use of estimates. The preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt instruments with an original maturity of three months or less, excluding amounts whose use is limited by note
indenture.
Investments. Investments in debt instruments, including assets limited as to use, are classified as held-tomaturity because the Company has the positive intent and ability to hold the securities until maturity. Heldto-maturity securities are carried at cost adjusted for amortization of premiums and accretion of discounts.
Assets limited as to use. Assets deposited with a trustee under terms of the note indenture and assets set
aside by the Board of Directors for capital improvements are classified as assets limited as to use. Amounts
required to meet current liabilities have been reclassified in the balance sheet.
Property and equipment. Property and equipment are recorded at cost. Depreciation is calculated on the
straight-line method over the estimated useful lives of depreciable assets.
Bond issuance costs. Costs incurred in issuing the Series 20X1 bonds are being amortized based on the
effective interest method.
Net patient service revenue. Net patient service revenue is reported at the estimated net realizable amounts
from residents, third-party payors, and others for service rendered.

†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
15

See footnote 5.
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Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions
for estimated third-party payor settlements are provided in the period the related services are rendered.
Differences between the estimated amounts accrued and interim and final settlements are reported in operations in the year of settlement.
Income taxes. The provisions for income taxes are based on amounts estimated to be currently payable
and those deferred because of temporary differences between the financial statement and tax bases of assets
and liabilities. These differences consist principally of bad debts and depreciation.
2.

Assets Limited as to Use
Assets limited as to use include:
Assets held by trustee under the Series 20X1 note indenture agreement at December 31, 20X7 and 20X6.
U.S. Government obligations
Cash
Accrued interest income
Internally designated by the Board of Directors for
capital improvements
Certificate of deposit
Accrued interest

3.

Investments**

4.

Long-Term Debt

20X7

20X6

$150,000
24,000
2,000

$130,000
21,000
2,000

176,000

153,000

$45,000
2,000

$45,000
2,000

47,000

47,000

$223,000

$200,000

20X7

20X6

$1,750,000
50,000

$1,800,000
50,000

$1,700,000

$1,750,000

Long-term debt at December 31, 20X7 and 20X6, was as follows:
9.5 percent bonds payable to the City of Abacus,
maturing $50,000 annually through November 1, 20YY,
with a final maturity of $1 million on November 1,
20YY
Less current maturities

The notes are collateralized by a first mortgage lien on all property and equipment of the Company and
a security interest in all of its receipts. The note indenture requires the maintenance of certain deposits with
a trustee, which are included in assets limited as to use.

**
In reporting disclosures about investments in securities, entities should comply primarily with the requirements of FASB ASC 32010-50. Other disclosure requirements may also be applicable.
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Future maturities of long-term debt as of December 31, 20X7, follow:
Year Ending
December 31,

5.

Amount

20X8
20X9
20Y0
20Y1
20Y2
Thereafter

$50,000
50,000
50,000
50,000
50,000
1,500,000

Total

$1,750,000

Income Taxes
The provisions for income taxes are as follows:††
20X7
Current:
Federal
State
Total current

$72,000
2,000

$15,000

74,000

15,000

6,000

13,000
1,000

6,000
$80,000

14,000
$29,000

Deferred:
Federal
State
Total deferred
Total provision for income taxes

20X6

Deferred income taxes are provided for the temporary differences between the financial reporting basis
and the tax basis of the Company’s assets and liabilities.
For the years ended December 31, 20X7 and 20X6, the effective tax rate approximated the statutory rate
of 34 percent and 40 percent, respectively.
The net current and noncurrent components of deferred income taxes recognized in the balance sheet at
December 31, 20X7 and 20X6, follows:
20X7
Net current assets
Net noncurrent liabilities

20X6

$12,000
6,000

$14,000
14,000

$6,000

$0

††
FASB ASC 740-10 includes guidance from FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of
FASB Statement No. 109. This interpretation is effective for fiscal years beginning after December 15, 2006. The interpretation clarifies the
accounting for uncertainty in income taxes recognized in an organization’s financial statements in accordance with FASB Statement No.
109, Accounting for Income Taxes. This interpretation prescribes a recognition threshold and measurement attribute for the financial
statement recognition, measurement and disclosures of a tax position taken or expected to be taken in a tax return. This interpretation
also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

However, FSP FIN 48-3, Effective Date of FASB Interpretation No. 48 for Certain Nonpublic Enterprises, defers the effective date of that
interpretation to fiscal years beginning after December 15, 2008, for certain nonpublic enterprises as defined by the glossary of FASB ASC
740-10, including nonpublic not-for-profit health care entities. If a nonpublic health care entity decides to defer in accordance with the
FSP, it should disclose that fact and its accounting policy for evaluating uncertain tax positions. Earlier application of FASB Interpretation
No. 48 is permitted. Health care entities that have already adopted the provisions of FASB Interpretation No. 48 are not eligible for the
deferral. This guidance is located in FASB ASC 740-10-15 and 740–10-65. The AICPA has prepared a practice guide to help in understanding the interpretation. The practice guide is available by following the link “Professional Standards and Ethics” at http://tax.aicpa.org/
Resources.
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Management has determined that no valuation allowance related to deferred tax assets is necessary at
December 31, 20X7 and 20X6, respectively.
6.

Concentration in State Medicaid Program

The Company has 100 of its 128 beds designated for care of patients under the state’s Medicaid program.
The current funding of that program is 90 days behind filed claims. The current state budget has no provision for reducing that lag and, while the proposed budget for 20X8 includes additional funding, there is no
assurance that the final budget will include the needed additional funds.
7.

Third Party Rate Adjustments and Revenue

Revenue from the Medicaid program accounted for approximately XX percent for the year ended 20X7,
and XX percent for the year ended 20X6, of the Company’s net patient revenue. Laws and regulations governing the Medicaid program are extremely complex and subject to interpretation. As a result, there is at
least a reasonable possibility that recorded estimates will change by a material amount in the near term. The
20X7 net patient service revenue increased approximately $XXX due to removal of allowances previously
estimated that are no longer necessary as a result of final settlements and years that are no longer subject to
audits, reviews, and investigations. The 20X6 net patient service revenue decreased approximately $XXX
due to prior-year retroactive adjustments in excess of amounts previously estimated.
8.

Risks and Uncertainties Disclosures‡‡

9.

Pension Plan‡‡

10.

Postretirement Benefits‡‡

11.

Fair Values of Financial Instruments‡‡

12.

Concentrations of Credit Risk‡‡

‡‡
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A CONTINUING CARE
RETIREMENT COMMUNITY
.19
Sample Not-for-Profit Continuing Care Retirement Community
Balance Sheets*
December 31, 20X7 and 20X6
20X7
Assets
Current assets:
Cash
Assets limited as to use
Accounts receivable, net of allowance for doubtful
accounts of $4,000 in 20X7 and $5,000 in 20X6
Supplies
Prepaid expenses
Total current assets
Assets limited as to use, net of amount required for
current liabilities
Property and equipment, net
Deferred financing costs, net of accumulated
amortization of $28,000 in 20X7 and $21,000 in 20X6
Total assets

20X6

$375,000
265,000

$330,000
170,000

187,000
40,000
115,000

197,000
21,000
73,000

982,000

791,000

1,865,000
14,893,000

1,583,000
15,280,000

83,000

90,000

$17,823,000

$17,744,000
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7
Liabilities and Net Assets
Liabilities:
Current maturities of long-term debt
Accounts payable
Accrued expenses
Deposits on unoccupied units

20X6

$90,000
180,000
161,000
22,000

$77,000
174,000
178,000
40,000

453,000

469,000

8,871,000
59,000

8,935,000
144,000

88,000
6,304,000

100,000
6,585,000

Total liabilities

15,775,000

16,233,000

Net assets:
Unrestricted
Temporarily restricted
Permanently restricted

1,286,000
311,000
451,000

833,000
294,000
384,000

Total net assets

2,048,000

1,511,000

$17,823,000

$17,744,000

Total current liabilities
Long-term debt, less current maturities
Refundable fees
Estimated obligation to provide future services, in excess
of amounts received or to be received
Deferred revenue from advance fees

Total liabilities and net assets
See accompanying notes to financial statements.

FSP §11,400.19

324

Health Care Entities

.20
Sample Not-for-Profit Continuing Care Retirement Community
Statements of Operations
Years Ended December 31, 20X7 and 20X6
20X7
Revenue, gains, and other support:
Resident services, including amortization of advance
fees of $935,000 in 20X7 and $915,000 in 20X6
Patient revenue from nonresidents
Change in obligation to provide future services
Contributions
Net assets released from restrictions used for
operations
Investment income
Other
Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Depreciation
Interest
Total expenses

$3,946,000
249,000
12,000
54,000

20X6

$3,152,000
275,000
(82,000)
39,000

24,000
29,000
75,000

50,000
30,000
68,000

4,389,000

3,532,000

1,708,000
543,000
291,000
452,000
967,000

1,250,000
742,000
311,000
447,000
955,000

3,961,000

3,705,000

Operating income (loss)
Net assets released from restriction—purchase of
equipment

428,000

(173,000)

25,000

45,000

Increase (decrease) in unrestricted net assets

$453,000

See accompanying notes to financial statements.
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.21
Sample Not-for-Profit Continuing Care Retirement Community
Statements of Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
20X7
Unrestricted net assets:
Operating income (loss)
Net assets released from restriction—purchase of
equipment
Increase (decrease) in unrestricted net assets
Temporarily restricted net assets:
Contributions
Net assets released from restrictions used for
operations
Net assets released from restriction—purchase of
equipment
Investment income
Increase (decrease) in temporarily restricted net
assets
Permanently restricted net assets:
Contributions
Increase in permanently restricted net assets
Increase (decrease) in net assets
Net assets, beginning of year
Net assets, end of year

$428,000

20X6
$(173,000)

25,000

45,000

453,000

(128,000)

40,000

15,000

(24,000)

(50,000)

(25,000)
26,000

(45,000)
15,000

17,000

(65,000)

67,000

52,000

67,000

52,000

537,000
1,511,000
$2,048,000

(141,000)
1,652,000
$1,511,000

See accompanying notes to financial statements.

FSP §11,400.21

326

Health Care Entities

.22
Sample Not-for-Profit Continuing Care Retirement Community
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6
20X7
Cash flows from operating activities:
Cash received from residents and third party payors
Advance fees received
Other receipts from operations
Investment income received
Contributions received
Cash paid to employees and suppliers
Interest paid
Net cash provided by operating activities

$3,252,000
654,000
75,000
68,000
51,000
(2,576,000)
(950,000)

20X6
$2,341,000
857,000
68,000
53,000
44,000
(2,040,000)
(945,000)

574,000

378,000

Cash flows from investing activities:
Purchase of property and equipment

(65,000)

(250,000)

Purchase of assets limited as to use

(377,000)

229,000

Net cash used in investing activities

(442,000)

(21,000)

Cash flows from financing activities:
Permanently restricted funds received
Refunds of deposits and refundable fees
Proceeds from issuance of long-term debt
Principal payments of long-term debt

67,000
(103,000)
26,000
(77,000)

52,000
(52,000)
(307,000)

Net cash used in financing activities

(87,000)

(307,000)

45,000
330,000

50,000
280,000

$375,000

$330,000

$537,000

$(141,000)

654,000
(67,000)
(935,000)
(12,000)
452,000
7,000
3,000

857,000
(52,000)
(915,000)
82,000
447,000
34,000,
3,000

7,000
(61,000)

(33,000)
(4,000)

(11,000)

100,000

Net increase in cash
Cash, beginning of year
Cash, end of year
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net cash
provided by operating activities:
Advance fees received
Restricted net assets received
Amortization of advance fees
Loss (gain) on obligation to provide future services
Depreciation
Amortization of deferred financing costs
Provision for bad debts
(Increase) decrease in:
Accounts receivable
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Net cash provided by operating activities
See accompanying notes to financial statements.
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.23
Sample Not-for-Profit Continuing Care Retirement Community
Notes to Financial Statements16, †
December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies\ \, 17

Organization. The Sample Continuing Care Retirement Community (the CCRC) is a nonprofit organization that principally provides housing, health care, and other related services to residents through the operation of a retirement facility containing 249 apartments and a 78-bed health care facility located in Evergreen Park, Illinois. The CCRC was incorporated in Illinois in 20X1. A summary of significant accounting
policies follows.
Use of estimates. The preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value in the
balance sheet. Investment income (including realized gains and losses on investments, interest, and dividends) is included in operating income (loss) unless restricted by donor or law. Unrealized gains and losses
on investments, if any, are excluded from operating income (loss).
Deferred financing costs. Deferred financing costs are amortized using the effective interest method over
the term of the related financing agreement.
Advance fees. Fees paid by a resident upon entering into a continuing care contract, net of the portion
thereof that is refundable to the resident, are recorded as deferred revenue and are amortized to income
using the straight-line method over the estimated remaining life expectancy of the resident.
Obligation to provide future services. The CCRC annually calculates the present value of the net cost of
future services and the use of facilities to be provided to current residents and compares that amount with

16

Statement of Position (SOP) 00-1, Auditing Health Care Third-Party Revenues and Related Receivables (AICPA, Technical Practice Aids,
AUD sec. 14,360), provides auditors with guidance regarding uncertainties in health care revenue recognition and includes a sample
disclosure in paragraph 37 of the SOP for material differences between an original estimate and subsequent revisions regarding thirdparty payments.
†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
\\

Does not include all disclosures common to all health care entities.

17

See footnote 5.
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the balance of deferred revenue from advance fees. If the present value of the net cost of future services and
the use of facilities exceeds the deferred revenue from advance fees, a liability is recorded (obligation to
provide future services and use of facilities) with the corresponding charge to income. The obligation is
discounted at 9 percent, based on the expected long-term rate of return on government obligations.
Donor restrictions. The CCRC reports gifts of cash and other assets as restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires
(that is, when a stipulated time restriction ends or a purpose restriction is accomplished), temporarily restricted net assets are reclassified as unrestricted net assets and reported in the statement of operations as
net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the
same year as received are reflected as unrestricted contributions in the accompanying financial statements.
The CCRC reports gifts of property and equipment (or other long-lived assets) as unrestricted support
unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets
with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must
be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations
about how long those long-lived assets must be maintained, the CCRC reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service.
Income taxes. The CCRC has been recognized by the IRS as a not-for-profit corporation as described in
Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from federal income taxes pursuant to
Section 501(a) of the IRC.
Property and equipment. Property and equipment are stated at cost. Donated property is recorded at its
estimated fair value at the date of receipt. Depreciation is computed on the straight-line method based on
the following estimated useful lives:
Land improvements
Buildings and improvements
Furniture and equipment

20 years
40 years
5–15 years

Operating income (loss). The statement of operations includes operating income (loss). Changes in unrestricted net assets which are excluded from operating income (loss), consistent with industry practice, include
unrealized gains and losses on investments other than trading securities, permanent transfers of assets to
and from affiliates for other than goods and services, and contributions of long-lived assets (including assets
acquired using contributions which by donor restriction were to be used for the purposes of acquiring such
assets).
2.

Property and Equipment
A summary of property and equipment at December 31, 20X7 and 20X6, follows:
20X7

20X6

Land
Land improvements
Buildings and improvements
Furniture and equipment

$557,000
205,000
14,573,000
752,000

$557,000
203,000
14,564,000
698,000

Less accumulated depreciation

16,087,000
(1,194,000)

16,022,000
(742,000)

$14,893,000
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3.

Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
Purchase of equipment
Charity care

20X7

20X6

$169,000
142,000

$152,000
142,000

$311,000

$294,000

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes
or by occurrence of other events specified by donors:
20X7

4.

20X6

Charity care

$24,000

$50,000

Purchase of equipment

$25,000

$45,000

Permanently Restricted Net Assets

Permanently restricted net assets are restricted to investment in perpetuity, the income from which is
expendable to support:
Charity care
Community activities

5.

20X7

20X6

$168,000
283,000

$168,000
216,000

$451,000

$384,000

20X7

20X6

Long-Term Debt
Long-term debt at December 31, 20X7 and 20X6, is as follows:
10.75 percent mortgage note payable
Notes payable to bank—unsecured
Other
Less current maturities

$8,901,000
34,000
26,000

$8,965,000
14,000
33,000

8,961,000
90,000

9,012,000
77,000

$8,871,000

$8,935,000

The mortgage note is payable in consecutive monthly installments of principal and interest of $85,425 to
May 20XX. The note is collateralized by a first mortgage on property and equipment with a depreciated cost
at December 31, 20X7, of $14,893,000 and by a pledge of all operating revenue.
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As required by the mortgage note agreement, the CCRC established an initial debt service reserve fund
of $1,000,000 at April 15, 20X5. All resident fees received thereafter, net of resident fee refunds and debt
service payments not to exceed $300,000 annually in the first four years and $200,000 annually thereafter,
are to be added to the debt service reserve fund until the total sum of $2,050,000 is accumulated. Since June
1, 20X6, the CCRC has been required to deliver to the trustee $5,500 per month to establish maintenance
reserves until the aggregate of such payments equals a residential unit reserve and a health care center
reserve of $240,000 and $90,000, respectively. At December 31, 20X7 and 20X6, the trustee held investments
aggregating $2,130,000 and $1,753,000, respectively. Such amount has been classified as assets limited as to
use.
Scheduled annual principal maturities of long-term debt for the next five years are as follows:
Year Ending
December 31,

Amount

20X8
20X9
20Y0
20Y1
20Y2
6.

$90,000
90,000
95,000
105,000
105,000

Classification of Expenses
20X7
Program activities
General and administrative

7.

Assets Limited as to Use‡‡

8.

Risks and Uncertainties Disclosures‡‡

9.

Pension Plan‡‡

10.

Postretirement Benefits‡‡

11.

Fair Values of Financial Instruments‡‡

12.

Concentrations of Credit Risk‡‡

13.

Investments‡‡

20X6

3,368,000
593,000

3,135,000
570,000

$3,961,000

$3,705,000

‡‡
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A HOME HEALTH AGENCY
.24
Sample Not-for-Profit Home Health Agency
Balance Sheets*
December 31, 20X7 and 20X6
20X7
Assets
Current assets:
Cash and cash equivalents
Investments
Accounts receivable, net of allowance for doubtful
accounts of $61,000 in 20X7 and $30,000 in 20X6
Other receivables
Total current assets
Investments
Equipment:
Medical and office equipment
Vehicles
Less accumulated depreciation
Equipment, net
Deferred finance charges, net of accumulated
amortization of $15,000 in 20X7 and $10,000 in 20X6
Total assets

20X6

$74,000
147,000

$41,000
137,000

752,000
27,000

476,000
22,000

1,000,000

676,000

100,000

100,000

56,000
50,000

39,000
37,000

106,000
(45,000)

76,000
(24,000)

61,000

52,000

20,000

25,000

$1,181,000

$853,000
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7
Liabilities and Net Assets
Current liabilities:
Current maturities of long-term debt
Accounts payable
Accrued payroll and vacation costs
Estimated third-party payor settlements
Advances from third-party payors
Total current liabilities
Long-term debt, less current maturities
Total liabilities
Net assets:
Unrestricted
Temporarily restricted
Permanently restricted
Total net assets
Total liabilities and net assets
See accompanying notes to financial statements.
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20X6

$13,000
40,000
496,000
28,000
70,000

$13,000
21,000
352,000
31,000
66,000

647,000

483,000

105,000

118,000

752,000

601,000

330,000
9,000
90,000

167,000
5,000
80,000

429,000

252,000

$1,181,000

$853,000
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.25
FORMAT A
Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31, 20X7 and 20X6

Revenue, gains, and other support:
Net patient service revenue
Contributions
Net assets released from restrictions
Investment income
Other revenue
Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses
Excess of revenue over expenses and change in
unrestricted net assets

20X7

20X6

$4,042,000
5,000
5,000
13,000
27,000

$2,687,000
22,000
—
6,000
32,000

4,092,000

2,747,000

2,714,000
1,042,000
90,000
46,000
21,000
16,000

1,835,000
675,000
83,000
21,000
15,000
19,000

3,929,000

2,648,000

$163,000

$99,000

See accompanying notes to financial statements.
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.26
FORMAT B
Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31, 20X7 and 20X6
20X7
Revenue, gains, and other support:
Net patient service revenue
Contributions
Net assets released from restrictions
Other revenue
Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses
Operating income
Other income:
Investment income
Excess of revenue over expenses and change in
unrestricted net assets
See accompanying notes to financial statements.
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20X6

$4,042,000
5,000
5,000
27,000

$2,687,000
22,000
—
32,000

4,079,000

2,741,000

2,714,000
1,042,000
90,000
46,000
21,000
16,000

1,835,000
675,000
83,000
21,000
15,000
19,000

3,929,000

2,648,000

150,000

93,000

13,000

6,000

$163,000

$99,000
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Sample Not-for-Profit Home Health Agency
Statements of Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
20X7
Unrestricted net assets:
Excess of revenue over expenses
Increase in unrestricted net assets
Temporarily restricted net assets:
Contributions
Net assets released from restrictions
Increase in temporarily restricted net assets
Permanently restricted net assets:
Contributions
Increase in permanently restricted net assets
Increase in net assets
Net assets, beginning of year
Net assets, end of year

20X6

$163,000

$99,000

163,000

99,000

9,000
(5,000)

5,000
—

4,000

5,000

10,000

6,000

10,000

6,000

177,000
252,000

110,000
142,000

$429,000

$252,000

See accompanying notes to financial statements.
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.28
Sample Not-for-Profit Home Health Agency
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6

Cash flows from operating activities:
Cash received from patients and third party payors
Other receipts from operations
Cash paid to employees and suppliers
Interest paid
Nonoperating revenue
Net cash provided by operating activities

20X7

20X6

$3,721,000
22,000
(3,679,000)
(11,000)
23,000

$2,542,000
32,000
(2,541,000)
(14,000)
22,000

76,000

41,000

(30,000)
(10,000)

(19,000)
(15,000)

Net cash used in investing activities

(40,000)

(34,000)

Cash flows from financing activities:
Proceeds from contributions restricted for:
Endowment

10,000

6,000

Cash flows from investing activities:
Purchase of equipment
Purchase of investments

Other financing activities:
Payment of long-term debt
Net cash provided by (used in) financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net cash
provided by operating activities:
Increase in permanently restricted net assets
Provision for bad debts
Depreciation
Amortization of deferred financing charges
(Increase) decrease in:
Accounts receivable
Other receivables
Increase (decrease) in:
Accounts payable, accrued payroll, and vacation costs
Estimated third-party payor settlements
Net cash provided by operating activities
See accompanying notes to financial statements.
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(13,000)

—

(3,000)

6,000

33,000
41,000

13,000
28,000

$74,000

$41,000

$177,000

$110,000

(10,000)
46,000
21,000
5,000

(6,000)
21,000
15,000
5,000

(322,000)
(5,000)

(150,000)
4,000

163,000
1,000

38,000
4,000

$76,000

$41,000
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.29
Sample Not-for-Profit Home Health Agency
Notes to Financial Statements†
Years Ended December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies18

Organization. The Sample Home Health Agency (the Agency) was incorporated in 20X0 in New State as
a not-for-profit corporation. The Agency provides health and supportive services to individuals at their
homes, primarily in the New State area.
Use of estimates. The preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt instruments with an original maturity of three months or less.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value in the
balance sheet. Investment income (including realized gains and losses on investments, interest and dividends) is included in excess of revenues over expenses unless restricted by donor or law. Unrealized gains
and losses on investments, if any, are excluded from excess of revenues over expenses.
Equipment. Equipment is recorded at cost. Depreciation is computed using the straight-line method over
the estimated useful lives of the assets.
Deferred financing costs. Deferred financing costs are being amortized using the effective interest method
over the term of the related financing agreement.
Donor restrictions. The Agency reports gifts of cash and other assets as restricted support if they are
received with donor stipulations that limit the use of the donated assets. When a donor restriction expires,
that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted
net assets are reclassified as unrestricted net assets and reported in the statement of operations as net assets
released from restrictions. When long-lived assets are placed in service, thus satisfying purpose restrictions,
the amount is included as a change in net assets, restricted and unrestricted. Donor-restricted contributions

†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
18

See footnote 5.
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whose restrictions are met within the same year as received are reflected as unrestricted contributions in the
accompanying financial statements.
The Agency reports gifts of equipment (or other long-lived assets) as unrestricted support unless explicit
donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit
restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to
acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how
long those long-lived assets must be maintained, the Agency reports expirations of donor restrictions when
the donated or acquired long-lived assets are placed in service.
Net patient service revenue. Net patient service revenue represents the estimated net realizable amounts
from patients, third-party payors, and others for services rendered.
Charity care. The Agency has a policy of providing charity care to patients who are unable to pay. Such
patients are identified based on financial information obtained from the patient and subsequent analysis.
Since the Agency does not expect payment, estimated charges for charity care are not included in revenue.
Income taxes. The Agency has been recognized by the IRS as a not-for-profit corporation as described in
Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from federal income taxes on related
income pursuant to Section 501(a) of the IRC.
Excess of revenue over expenses. The statement of operations includes excess of revenue over expenses.
Changes in unrestricted net assets which are excluded from excess of revenue over expenses, consistent with
industry practice, include unrealized gains and losses on investments other than trading securities, permanent transfers of assets to and from affiliates for other than goods and services, and contributions of longlived assets (including assets acquired using contributions which by donor restriction were to be used for
the purposes of acquiring such assets).
2.

Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
20X7
Charity care
Purchase of equipment

20X6

$—
9,000

$5,000
—

$9,000

$5,000

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes
or by occurrence of other events specified by donors:
20X7
Charity care expenditures
3.

20X6
$—

$5,000

Permanently Restricted Net Assets

Permanently restricted net assets are restricted in perpetuity, the income from which is expendable to
support:
20X7
Program A activities
Any activities of the Agency

4.

20X6

$10,000
80,000

$—
80,000

$90,000

$80,000

Third-Party Rate Adjustments and Revenue

Approximately 38 percent in 20X7 and 37 percent in 20X6 of net patient service revenue was derived
under federal and state third-party reimbursement programs. These revenues are based, in part, on cost
reimbursement principles and are subject to audit and retroactive adjustment by the respective third-party
fiscal intermediaries. Laws and regulations governing these programs are extremely complex and subject to
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interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a
material amount in the near term. The 20X7 net patient service revenue increased approximately $XXX due
to removal of allowances previously estimated that are no longer necessary as a result of final settlements
and years that are no longer subject to audits, reviews, and investigations. The 20X6 net patient service
revenue decreased approximately $XXX due to prior-year retroactive adjustments in excess of amounts previously estimated.
5.

Internally Designated Assets

The Board of Directors has designated investments aggregating $100,000 to be used for future major
capital improvements. Those assets are classified in the balance sheet as long-term investments.
6.

Long-Term Debt
Long-term debt at December 31, 20X7 and 20X6, is as follows:
Note payable to bank, interest at 15 percent,
payable in monthly installments of $2,200
per month, including interest, collateralized
by equipment with a depreciated cost of
$42,000
Less current maturities

20X7

20X6

$118,000
13,000

$131,000
13,000

$105,000

$118,000

Scheduled maturities of long-term debt at December 31, 20X7, are as follows:
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2
Thereafter
Total

Amount
$13,000
13,000
13,000
13,000
13,000
53,000
$118,000
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Classification of Expenses
Program

Expenses incurred for the year
ended December 31, 20X7, were
for:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses

B

General and
Administrative

Total

A

C

$2,714,000
1,042,000
90,000
46,000
21,000
16,000

$1,363,000
511,000
58,000
16,000
5,000
10,000

$699,000
246,000

3,000

—

16,000
3,000

$3,929,000

$1,963,000

$978,000

$648,000

$340,000

$363,000
285,000

$289,000
32,000

30,000

Program
Total
Expenses incurred for the year
ended December 31, 20X6, were
for:
Salaries and benefits
Medical supplies and drugs
Insurance and other
Provision for bad debts
Depreciation
Interest
Total expenses

A

B

General and
Administrative

C

$1,835,000
675,000
83,000
21,000
15,000
19,000

$915,000
335,000
64,000
21,000
6,000
12,000

$463,000
211,000

$216,000
129,000

$241,000

5,000

—

9,000
2,000

$2,648,000

$1,353,000

$679,000

$345,000

$271,000

19,000

(The preparer of the financial statements may wish to include a brief description of the types of programs.)
8.

Charity Care
Charity care represented approximately 3 percent and 4 percent of visits in 20X7 and 20X6, respectively.

9.

Risks and Uncertainties Disclosures‡‡

10.

Pension Plan‡‡

11.

Postretirement Benefits‡‡

12.

Fair Value of Financial Statements‡‡

13.

Concentrations of Credit Risk‡‡

14.

Investments‡‡

‡‡
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A HEALTH MAINTENANCE
ORGANIZATION
.30
Sample Not-for-Profit Health Maintenance Organization
Balance Sheets*
June 30, 20X7 and 20X6
20X7
Assets
Current assets:
Cash and cash equivalents
Premiums receivable, net of allowance for doubtful
accounts of $36,000 in 20X7 and $42,000 in 20X6
Other receivables
Supplies
Prepaid expenses
Total current assets
Property and equipment, net
State guaranty fund deposit
Debt issuance costs, net of accumulated amortization of
$42,000 in 20X7 and $39,000 in 20X6
Total assets

20X6

$2,937,000

$1,021,000

358,000
263,000
190,000
197,000

407,000
261,000
184,000
99,000

3,945,000

1,972,000

5,756,000
150,000

5,626,000
150,000

18,000

21,000

$9,869,000

$7,769,000
(continued)

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7
Liabilities and Net Assets
Current liabilities:
Unsecured 12 percent note payable to a bank
Current maturities of long-term debt
Accounts payable—medical services
Other accounts payable and accrued expenses
Unearned premium revenue

20X6

$—
241,000
2,245,000
829,000
141,000

$44,000
109,000
1,471,000
661,000
202,000

3,456,000

2,487,000

4,295,000

2,382,000

Total liabilities

7,751,000

4,869,000

Net assets—unrestricted

2,118,000

2,900,000

$9,869,000

$7,769,000

Total current liabilities
Long-term debt, less current maturities

Total liabilities and net assets
See accompanying notes to financial statements.
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.31
Sample Not-for-Profit Health Maintenance Organization
Statements of Operations and Changes in Net Assets
Years Ended June 30, 20X7 and 20X6
20X7
Revenue:
Premiums earned
Coinsurance
Interest and other income
Total revenue
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses
Operating income (loss)
Net assets, beginning of year
Net assets, end of year

20X6

$27,682,000
689,000
242,000

$22,500,000
500,000
100,000

28,613,000

23,100,000

16,154,000
8,507,000
3,963,000
19,000
367,000
385,000

13,328,000
5,988,000
2,463,000
20,000
336,000
375,000

29,395,000

22,510,000

(782,000)
2,900,000
$2,118,000

590,000
2,310,000
$2,900,000

See accompanying notes to financial statements.

FSP §11,400.31

344

Health Care Entities

.32
Sample Not-for-Profit Health Maintenance Organization
Statements of Cash Flows
Years Ended June 30, 20X7 and 20X6
20X7
Cash flows from operating activities:
Cash received from premiums, stop-loss insurance
recoveries, and coinsurance
Cash paid to employees and to providers of health
care services
Interest and other income received
Interest paid
Net cash provided by operating activities
Cash flows from investing activities:
Capital expenditures

20X6

$28,969,000

$24,410,000

(28,405,000)
230,000
(382,000)

(22,818,000)
90,000
(372,000)

412,000

1,310,000

(497,000)

(121,000)

Net cash used in investing activities

(497,000)

(121,000)

Cash flows from financing activities:
Proceeds from long-term debt
Principal payments on long-term debt
Principal payments on note payable

2,300,000
(255,000)
(44,000)

—
(1,000,000)
—

2,001,000

(1,000,000)

Net cash provided by (used in) financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net
cash provided by operating activities:
Depreciation and amortization
Provision for bad debts
(Increase) decrease in:
Premiums receivables
Other current assets
Increase (decrease) in:
Accounts payable—medical services
Other accounts payable and accrued expenses
Unearned premium revenue
Net cash provided by operating activities
See accompanying notes to financial statements.
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1,916,000
1,021,000

189,000
832,000

$2,937,000

$1,021,000

$(782,000)

$590,000

370,000
19,000

339,000
20,000

30,000
230,000

64,000
(93,000)

774,000
(168,000)
(61,000)

335,000
(60,000)
115,000

$412,000

$1,310,000
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.33
Sample Not-for-Profit Health Maintenance Organization
Notes to Financial Statements19, †
June 30, 20X7 and 20X6
1.

Organization

The Sample Health Maintenance Organization (the HMO) was incorporated in 20X0 in New State as a
not-for-profit corporation for the purpose of providing comprehensive health care services on a prepaid
basis and for the purpose of establishing and operating organized health maintenance and health care delivery systems.
The HMO has been determined to be a qualified health maintenance organization under Title XIII of the
Public Health Service Act.
2.

Summary of Significant Accounting Policies20

Use of estimates. The preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt instruments with an original maturity of three months or less.
Supplies. Inventories of drugs and other supplies are stated at the lower of cost (first-in, first-out) or
market.
Property and equipment. Property and equipment are recorded at cost. Maintenance and repairs are
charged to expense, and betterments are capitalized. Property and equipment costing approximately
$700,000 was financed by health maintenance organization initial development grants received in 20X1 and
20X2 from the U.S. Department of Health and Human Services (HHS). This property will be owned by the
HMO as long as the equipment and facilities are used for projects related to the objectives of the Public
Health Service Act.

19

See footnote 16.

†

FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.
FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
20

See footnote 5.
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Depreciation is computed using the straight-line method over the estimated useful lives of the related
assets as follows:
Building
Improvements
Data processing and laboratory equipment and
automobiles
Medical equipment
Office equipment

40 years
20–25 years
3–7 years
10 years
5–10 years

Amortization of debt issuance costs. Debt issuance costs are deferred and amortized using the effective
interest method over the term of the related debt.
Health care service cost recognition. The HMO contracts with various health care providers for the provision of certain medical care services to its members. The HMO compensates these providers on a capitation
basis. As part of a cost control incentive program, the HMO retains up to 20 percent of the capitation as a
risk-sharing fund. In the event of hospital utilization in excess of budget, those providers bear the risk to
the extent of 15 percent of the capitation fee. Operating expenses include all amounts incurred by the HMO
under the aforementioned contracts.
The cost of other health care services provided or contracted for is accrued in the period in which it is
provided to a member based in part on estimates, including an accrual for medical services provided but
not reported to the HMO.
Premiums revenue. Membership contracts are on a yearly basis subject to cancellation by the employer
group or the HMO upon 30 days written notice. Premiums are due monthly and are recognized as revenue
during the period in which the HMO is obligated to provide services to members.
Reinsurance (stop-loss insurance). Reinsurance premiums are reported as health care costs, and reinsurance
recoveries are reported as a reduction of related health care costs.
Federal income tax. The HMO is exempt from federal income taxes under Section 501(c)(4) of the Internal
Revenue Code; accordingly, no provision for federal income taxes has been made in the accompanying
financial statements.
3.

Property and Equipment
Property and equipment at June 30, 20X7 and 20X6, consists of the following:
Land
Buildings and improvements
Furniture and equipment
Less accumulated depreciation
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20X7

20X6

$300,000
5,473,000
1,786,000

$300,000
5,459,000
1,303,000

7,559,000
(1,803,000)

7,062,000
(1,436,000)

$5,756,000

$5,626,000

347

Illustrative Financial Statements

4.

Long-Term Debt

Long-term debt is collateralized by assets with a depreciated cost of $4,943,000. A summary of longterm debt at June 30, 20X7 and 20X6, follows.
20X6

20X7
HHS loan, interest at 7.5 percent, payable in monthly
installments of $50,000, including interest
HHS loan, interest at 9.25 percent, payable in monthly
installments of $10,000, including interest
Secured equipment loans, payable in monthly
installments of $15,000, including interest
Less current maturities

$2,020,000

$111,000

1,658,000

1,694,000

858,000

686,000

4,536,000
241,000

2,491,000
109,000

$4,295,000

$2,382,000

Scheduled principal payments on long-term debt are as follows:
Year Ending
December 31,
20X8
20X9
20Y0
20Y1
20Y2

Amount
$241,000
259,000
280,000
800,000
2,956,000
$4,536,000

5.

State Guarantee Fund Deposit

In August 20X4 the state in which the HMO is domiciled enacted legislation specifically governing
HMOs. Under this legislation, the corporation is required to maintain a deposit of $150,000 with the director
of the division of insurance of the state.
6.

Employee Retirement Plan

The HMO has a contributory defined contribution retirement plan covering substantially all employees.
Expense determined in accordance with the plan formula (4 percent to 10 percent of eligible covered compensation) was $354,000 and $275,000 for the years ended June 30, 20X5 and 20X4, respectively.
7.

Stop-Loss Insurance

The HMO entered into a stop-loss insurance agreement with an insurance company to limit its losses on
individual claims. Under the terms of this agreement, the insurance company will reimburse the HMO approximately 25 percent of the cost of each member’s annual hospital services, in excess of a $1,000 deductible, up to a lifetime limitation of $500,000 per member. In the event the HMO ceases operations, (a) plan
benefits will continue for members who are confined in an acute care hospital on the date of insolvency until
their discharge, and (b) plan benefits will continue for any other member until the end of the contract period
for which premiums have been paid.
Stop-loss insurance premiums of approximately $700,000 and $500,000 are included in insurance expense (note 9) in 20X7 and 20X6 respectively. Approximately $600,000 and $400,000 in stop-loss insurance
recoveries are deducted from insurance expense in 20X7 and 20X6, respectively.
Included in other receivables is approximately $50,000 recoverable from insurers.
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Malpractice Claims

Malpractice claims have been asserted against the HMO by various claimants. The claims are in various
stages of processing, and some may ultimately be brought to trial. In the opinion of counsel, the outcome of
these actions will not have a significant effect on the financial position or the operating income of the HMO.
Incidents occurring through June 30, 20X7, may result in the assertion of additional claims. Other claims
may be asserted arising from past services provided. Management believes that these claims, if asserted,
would be settled within the limits of insurance coverage.
9.

Classification of Expenses

Program activities
General and administrative

10.

Risks and Uncertainties Disclosures‡‡

11.

Pension Plan‡‡

12.

Postretirement Benefits‡‡

13.

Fair Value of Financial Instruments‡‡

14.

Concentrations of Credit Risk‡‡

20X7

20X6

26,921,000
2,474,000

20,909,000
1,601,000

$29,395,000

$22,510,000

‡‡
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR AN AMBULATORY CARE
ORGANIZATION
.34
Sample Not-for-Profit Ambulatory Care, Inc.
Balance Sheets*
December 31, 20X7 and 20X6
20X7
Assets
Current assets:
Cash
Patient accounts receivable, net of allowance for
doubtful accounts of $15,000 in 20X7 and $5,000 in
20X6
Estimated retroactive adjustments—third-party
payors
Accounts receivable—other
Supplies
Prepaid expenses and deposits

20X6

$65,000

$76,000

290,000

278,000

19,000
13,000
21,000
5,000

32,000
8,000
18,000
9,000

413,000

421,000

Property and equipment, at cost:
Land
Land improvements
Buildings
Equipment

100,000
322,000
682,000
1,390,000

100,000
322,000
682,000
1,389,000

Less accumulated depreciation

2,494,000
217,000

2,493,000
100,000

Total current assets

*
The fair value option subsections of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 825-10
permit all entities, including not-for-profit organizations, to choose to measure eligible items at fair value at specified election dates.
Notable eligible items include recognized financial assets and financial liabilities (except for those specifically prohibited), written loan
commitments, and rights and obligations under a warranty that is not a financial instrument (because it requires or permits the insurer
to provide goods or services rather than a cash payment) but whose terms permit the insurer to settle by paying a third party to provide
those goods or services. Prohibited recognized financial assets and liabilities include

a.

an investment in a subsidiary that the entity is required to consolidate.

b.

an interest in a variable interest entity that the entity is required to consolidate.

c.

employers and plans’ obligations (or assets representing net overfunded positions) for pension benefits, other postretirement
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements.

d.

financial assets and financial liabilities recognized under leases as defined in FASB ASC 840, Leases, excluding guarantees of a
third-party lease obligation or a contingent obligation arising from a cancelled lease.

e.

deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository institutions.

f.

financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder’s equity (including
temporary equity). An example is a convertible debt security with a noncontingent beneficial conversion feature.

Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a manner
that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another measurement
attribute. To accomplish that, an entity shall either
a.

present the aggregate of fair value and non-fair-value amounts in the same line item in the statement of financial position and
parenthetically disclose the amount measured at fair value included in the aggregate amount, or

b.

present two separate line items to display the fair value and non-fair-value carrying amounts.
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20X7

Property and equipment, net
Other assets:
Advances receivable
Total assets
Liabilities and Net Assets
Current liabilities:
Notes payable
Accounts payable
Accrued payroll, benefits, and taxes
Estimated retroactive adjustments—third-party
payors
Financing advance from third-party payors
Total current liabilities
Guarantee liability
Total liabilities
Net assets—unrestricted
Total liabilities and net assets
See accompanying notes to financial statements.
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20X6

2,277,000

(continued)
2,393,000

14,000

5,000

$2,704,000

$2,819,000

$138,000
42,000
33,000

$144,000
77,000
22,000

30,000
—

24,000
1,000

243,000

268,000

10,000

10,000

253,000

278,000

2,451,000

2,541,000

$2,704,000

$2,819,000
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.35
Sample Not-for-Profit Ambulatory Care, Inc.
Statements of Operations and Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
20X7
Revenue and gains:
Net patient service revenue
Other
Total revenue and gains
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses
Operating loss
Net assets, beginning of year
Net assets, end of year

20X6

$860,000
29,000

$357,000
15,000

889,000

372,000

485,000
189,000
154,000
14,000
117,000
20,000

243,000
66,000
98,000
4,000
100,000
18,000

979,000

529,000

(90,000)
2,541,000

(157,000)
2,698,000

$2,451,000

$2,541,000

See accompanying notes to financial statements.
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.36
Sample Not-for-Profit Ambulatory Care, Inc.
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6
20X7
Cash flows from operating activities:
Cash received from patients and third-party payors
Cash received from others
Interest received
Interest paid
Cash paid to employees and suppliers
Net cash provided by (used in) operating activities

20X6

$866,000
21,000
3,000
(15,000)

$368,000
6,000
11,000
(16,000)

(870,000)

(432,000)

5,000

(63,000)

Cash flows from investing activities:
Purchase of equipment
Advances made to XYZ Affiliate

(1,000)
(9,000)

(4,000)
(5,000)

Net cash used in investing activities

(10,000)

(9,000)

Cash flows from financing activities:
Proceeds from notes payable
Payments on notes payable

—
(6,000)

144,000
—

(6,000)

144,000

Net increase (decrease) in cash
Cash, beginning of year

(11,000)
76,000

72,000
4,000

Cash, end of year

$65,000

$76,000

$(90,000)

$(157,000)

117,000
14,000

100,000
4,000

(12,000)
1,000

(19,000)
(2,000)

(24,000)
(1,000)

10,000
1,000

$5,000

$(63,000)

Net cash provided by (used in) financing activities

Reconciliation of change in net assets to net cash
provided by (used in) operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net cash
provided by (used in) operating activities:
Depreciation
Provision for bad debts
(Increase) decrease in:
Patient accounts receivable
Other current assets
Increase (decrease) in:
Accounts payable and accrued payroll, benefits, and
taxes
Other current liabilities
Net cash provided by (used in) operating activities
See accompanying notes to financial statements.
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.37
Sample Not-for-Profit Ambulatory Care, Inc.
Notes to Financial Statements†
December 31, 20X7 and 20X6
1.

Description of Organization and Summary of Significant Accounting Policies21

Organization. Ambulatory Care, Inc. was incorporated on September 7, 20X3, in New State, to operate
an ambulatory care health facility to treat or prevent injury and disease, to provide funds or to expend funds
to further the treatment or prevention of injury or disease, and to develop and participate in activities designed to promote the general health of the community.
Three area hospitals—ABC Hospital and Health Center, DEF Hospital, and GHI Hospital—entered into
a members’ agreement to develop this ambulatory care center. In accordance with this agreement, each
hospital contributed capital of $947,000 to Ambulatory Care, Inc. Ambulatory Care, Inc. began operations in
October 20X3.
Use of estimates. The preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Supplies. Supplies are stated at the lower of cost (first-in, first-out) or net realizable value.
Depreciation. Depreciation of property and equipment is computed on the straight-line method over the
estimated lives of depreciable assets.
Third-party contractual adjustments. Retroactively calculated third-party contractual adjustments are accrued on an estimated basis in the period the related services are rendered. Net patient service revenue is
adjusted as required in subsequent periods based on final settlements.
Net patient service revenue. Patient service revenue is reported at the estimated net realizable amounts
from patients, third-party payors, and others for services rendered.
Charity care. Ambulatory Care, Inc. has a policy of providing charity care to patients who are unable to
pay. Such patients are identified and related charges are estimated, based on financial information obtained
from the patient and subsequent analysis. Since management does not expect payment for charity care, the
estimated charges are excluded from revenue.

†
FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This guidance applies under other
accounting pronouncements that require or permit fair value measurements, the FASB having previously concluded in those accounting
pronouncements that fair value is the relevant measurement attribute. Accordingly, FASB ASC 820 does not require any new fair value
measurements but the application of it will change current practice.

FASB ASC 820 retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value
is the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, FASB ASC 820 establishes a fair
value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are
quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
measurement date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than
quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for
example, quoted prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability.
Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for
situations in which there is little, if any, market activity. Unobservable inputs shall be developed based on the best information available
in the circumstances, which might include the reporting entity’s own data.
FASB ASC 820-10-50 expands disclosures about the use of fair value to measure assets and liabilities in interim and annual periods
subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings (or
changes in net assets) for the period. Entities are encouraged to combine the fair value information disclosed under this statement with
other required fair value information, including that required by FASB ASC 825-10-50 about financial instruments.
21

See footnote 5.
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Income taxes. Ambulatory Care, Inc. has been recognized by the Internal Revenue Service as a not-forprofit corporation as described in Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from
federal income taxes on related income pursuant to Section 501(a) of the IRC.
2.

Advances Receivable

In May 20X4, Ambulatory Care, Inc. entered into a five-year agreement with XYZ Affiliates (XYZ). Under this agreement, XYZ is to provide emergency medical services as well as charge and bill each patient
treated at Ambulatory Care, Inc. Ambulatory Care, Inc. has guaranteed that XYZ will collect at least $18,000
per month during the term of this agreement. In any month in which XYZ does not collect the minimum
guarantee, Ambulatory Care, Inc. advances funds to XYZ to cover the deficiency. Such advances are to be
repaid to the extent XYZ’s net cash collections exceed the minimum guarantee amount. Management estimates that the advances will be fully recovered in 20X8.
3.

Related-Party Transactions

During 20X3, Ambulatory Care, Inc. entered into a contract with one of the member hospitals (the managing hospital) for the management of the business and affairs of Ambulatory Care, Inc. Under this agreement, Ambulatory Care, Inc. pays $4,000 per month to the managing hospital. The agreement with the
managing hospital was to remain in effect through December 31, 20X5, but has been extended on a monthto-month basis.
In addition, during 20X4 each hospital loaned $48,000 to Ambulatory Care, Inc. in the form of promissory notes at an interest rate of prime rate plus 1 percent (effective rates of 10 percent and 9 percent in 20X7
and 20X6, respectively). Of the total $144,000 liability, $48,000 is payable on demand after November 28,
20X7, to one member hospital, with the remaining portion ($96,000) payable on demand after December 8,
20X6, to the other two member hospitals. During 20X7, Ambulatory Care, Inc. paid $2,000 to each member
hospital, thereby reducing the obligation to $138,000.
4.

Revenue From Contracting Agencies

Ambulatory Care, Inc. participates as a provider of health care services to Blue Cross, Medicare, and
County Indigent Plan patients. Reimbursement for covered services is based on tentative payment rates.
Final reimbursement is determined after submission of annual cost reports and audits thereof by the fiscal
intermediaries. Provisions for estimated reimbursement adjustments are reported in the financial statements
in the period that the services are rendered.
Revenue from the Medicare program accounted for approximately XX percent for the year ended 20X7,
and XX percent for the year ended 20X6, of Ambulatory Care, Inc.’s net patient revenue. Laws and regulations governing the Medicare program are extremely complex and subject to interpretation. As a result, there
is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.
The 20X7 net patient service revenue increased approximately $XXX due to removal of allowances previously estimated that are no longer necessary as a result of final settlements and years that are no longer
subject to audits, reviews, and investigations. The 20X6 net patient service revenue decreased approximately
$XXX due to prior-year retroactive adjustments in excess of amounts previously estimated.
5.

Charity Care

Ambulatory Care, Inc. has a policy of providing charity care to indigent patients in emergency situations. These services, which are excluded from revenues, amounted to $27,000 and $13,000 in 20X7 and 20X6,
respectively, when measured at Ambulatory Care, Inc.’s established rates.

FSP §11,400.37

355

Illustrative Financial Statements

6.

Classification of Expenses
Program
Total

Expenses incurred for the year
ended December 31, 20X7, were
for:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses

A

B

C

General and
Administrative

$485,000
189,000
154,000
14,000
117,000
20,000

$216,000
98,000
79,000
9,000
100,000
9,000

$102,000
43,000
45,000
—
—
—

$121,000
48,000
14,000
5,000
17,000
—

$46,000
—
16,000
—
—
11,000

$979,000

$511,000

$190,000

$205,000

$73,000

Program
Total
Expenses incurred for the year
ended December 31, 20X6, were
for:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses

A

B

C

General and
Administrative

$243,000
66,000
98,000
4,000
100,000
18,000

$111,000
31,000
45,000
—
56,000
7,000

$46,000
15,000
19,000
4,000
—
—

$57,000
20,000
26,000
—
44,000
—

$29,000
—
8,000
—
—
11,000

$529,000

$250,000

$84,000

$147,000

$48,000

(The preparer of the financial statements may wish to include a brief description of the types of programs.)
7.

Risks and Uncertainties Disclosures‡‡

8.

Pension Plan‡‡

9.

Postretirement Benefits‡‡

10.

Fair Value of Financial Instruments‡‡

11.

Concentrations of Credit Risk‡‡

‡‡
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the
not-for-profit hospital and, therefore, are not repeated here.
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Your Opinion Matters
Thank you for selecting this publication for your accounting or auditing needs.
At the AICPA, we strive to provide the most useful publications available to the profession, which have been
produced with the highest quality. Responsiveness to our members and the profession as a whole is our
hallmark. We rely on feedback from our users to continually hone and improve our products.
Please take a few moments to let us know what you think of this edition. Does it meet your needs? Is it written
clearly? Is it comprehensive in its coverage? Is it easy to use? If not, how can we improve it?
Send your feedback by e-mail to A&APublications@aicpa.org.
Please note the name and edition of the publication, answers to the preceding questions, and anything else
you would like to share with us. Your feedback will help us improve subsequent editions and better serve
you.
Do you want to help even more?
Consider participating in a focus or advisory group related to this subject matter. If you are interested in, and
available for, participating in such a group, please be sure to include that information in your e-mail.
Thank you in advance for taking the time to write. We appreciate your feedback!

Additional Publications for Your Financial Reporting Library
Checklists and Illustrative Financial Statements

AICPA publishes a full range of Checklists to help you prepare financial statements and assist you
in determining the adequacy of disclosures in the financial statements you’re auditing.

AICPA Checklists include:

Corporations
Defined Benefit Pension Plans
Defined Contribution Pension Plans
Depository and Lending Institutions
Health and Welfare Benefit Plans
Health Care Entities
Life and Health Insurance
Not-for-Profit Entities
Property & Liability Insurance Entities
State and Local Governments
Supplements to Corporations Checklist
Real Estate and Construction Contractors
Investment Companies

*****
Audit and Accounting Guides

The content and guidance you trust in the AICPA Audit and Accounting Guides
are being updated for FASB Accounting Standards Codification™(ASC).
To help you during this transition, all non-governmental accounting guidance
in the 2009 editions, as applicable, contains FASB ASC references and content.

AICPA Audit and Accounting Industry Guides include:

Airlines
Brokers and Dealers in Securities
Casinos
Construction Contractors
Depository and Lending Institutions: Banks and Savings Institutions, Credit
Unions, Finance Companies, and Mortgage Companies
Employee Benefit Plans
Entities With Oil and Gas Producing Activities
Government Auditing Standards and Circular A-133 Audits
Health Care Entities
Investment Companies
Life & Health Insurance Entities
Not-for-Profit Entities
Property and Liability Insurance Entities
State and Local Governments

Audit and Accounting Guides – General Guides

Analytical Procedures
Audit Sampling
Auditing Derivative Instruments, Hedging Activities, and Investments in Securities
Auditing Revenue in Certain Industries
Assessing and Responding to Audit Risk In a Financial Statement Audit
Prospective Financial Information
Service Organizations: Applying SAS No. 70, as Amended

For complete details on any of the titles listed above
including Table of Contents, Excerpts, and availability
– and to order – visit the AICPA Store
at www.cpa2biz.com/publications. Or call 1-888-777-7077.

AICPA RESOURCE:
Accounting & Auditing Literature
AICPA RESOURCE is a powerful online research tool that gives you access to the most
comprehensive, up-to-date accounting and auditing information available anywhere —
all linked and cross-referenced for easy information retrieval. AICPA RESOURCE includes
the AICPA, FASB Codification and GASB libraries.You’ll find subscriptions to the following:
• AICPA Professional Standards
• AICPA Technical Practice Aids
• AICPA Accounting Trends & Techniques
• AICPA Audit and Accounting Guides
• AICPA Audit Risk Alerts
• AICPA Checklists and Illustrative Financial Statements
• AICPA Audit & Accounting Manual
• FASB Accounting Standards Codification™
• GASB Original Pronouncements
• Codification of Governmental Accounting and Financial Reporting Standards
• GASB Implementation Guides
• GASB’s Comprehensive Topical Index
Search for pertinent information from both databases by keyword and get the
results ranked by relevancy. Print out important AICPA RESOURCE segments
and integrate the literature into your engagements and financial statements.
Available from anywhere you have Internet access, this comprehensive reference
library is packed with the A & A guidance you need — and use — the most. All
libraries are updated with the latest standards and guidance.
AICPA Complete Library with FASB Codification and GASB Library, No. WGLBY12
AICPA Complete Library with FASB Codification, No. WFLBY12
AICPA Complete Library, No. WALBY12
AICPA Accounting Guidance Library featuring the FASB Accounting
Standards Codification™ and AICPA Audit and Accounting Guides, No. WGCXX12
Log onto www.cpa2biz.com/AICPAresource for subscription details.

